
<html lang="en"     class="pb-page"  data-request-id="1f7871a4-277c-4a5d-b4bf-e1f82393a336"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.1c00489;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-12;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor" /></meta><meta name="dc.Creator" content="David L.  McKinzie" /></meta><meta name="dc.Creator" content="Leonard L.  Winneroski" /></meta><meta name="dc.Creator" content="Steven J.  Green" /></meta><meta name="dc.Creator" content="Erik J.  Hembre" /></meta><meta name="dc.Creator" content="Jon A.  Erickson" /></meta><meta name="dc.Creator" content="Brian A.  Willis" /></meta><meta name="dc.Creator" content="Scott A.  Monk" /></meta><meta name="dc.Creator" content="Christopher D.  Aluise" /></meta><meta name="dc.Creator" content="Thomas K.  Baker" /></meta><meta name="dc.Creator" content="Jose E.  Lopez" /></meta><meta name="dc.Creator" content="Jörg  Hendle" /></meta><meta name="dc.Creator" content="James P.  Beck" /></meta><meta name="dc.Creator" content="Richard A.  Brier" /></meta><meta name="dc.Creator" content="Leonard N.  Boggs" /></meta><meta name="dc.Creator" content="Anthony R.  Borders" /></meta><meta name="dc.Creator" content="Patrick J.  Cocke" /></meta><meta name="dc.Creator" content="Pablo  Garcia-Losada" /></meta><meta name="dc.Creator" content="Stephen L.  Lowe" /></meta><meta name="dc.Creator" content="Brian M.  Mathes" /></meta><meta name="dc.Creator" content="Patrick C.  May" /></meta><meta name="dc.Creator" content="Warren J.  Porter" /></meta><meta name="dc.Creator" content="Stephanie L.  Stout" /></meta><meta name="dc.Creator" content="David E.  Timm" /></meta><meta name="dc.Creator" content="Brian M.  Watson" /></meta><meta name="dc.Creator" content="Zhixiang  Yang" /></meta><meta name="dc.Creator" content="Dustin J.  Mergott" /></meta><meta name="dc.Description" content="The beta-site APP cleaving enzyme 1, known as BACE1, has been a widely pursued Alzheimer’s disease drug target owing to its critical role in the production of amyloid-beta. We have previously repor..." /></meta><meta name="Description" content="The beta-site APP cleaving enzyme 1, known as BACE1, has been a widely pursued Alzheimer’s disease drug target owing to its critical role in the production of amyloid-beta. We have previously repor..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 3, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00489" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00489" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00489" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00489" /></link>
        
    
    

<title>Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00489" /></meta><meta property="og:title" content="Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0065.jpeg" /></meta><meta property="og:description" content="The beta-site APP cleaving enzyme 1, known as BACE1, has been a widely pursued Alzheimer’s disease drug target owing to its critical role in the production of amyloid-beta. We have previously reported the clinical development of LY2811376 and LY2886721. LY2811376 advanced to Phase I before development was terminated due to nonclinical retinal toxicity. LY2886721 advanced to Phase II, but development was halted due to abnormally elevated liver enzymes. Herein, we report the discovery and clinical development of LY3202626, a highly potent, CNS-penetrant, and low-dose BACE inhibitor, which successfully addressed these key development challenges." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00489"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00489">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00489&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00489&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00489&amp;href=/doi/10.1021/acs.jmedchem.1c00489" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 8076-8100</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00434" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.1c00843" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">David L. McKinzie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David L. McKinzie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+L.++McKinzie">David L. McKinzie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Leonard L. Winneroski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Leonard L. Winneroski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Leonard+L.++Winneroski">Leonard L. Winneroski</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Steven J. Green</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steven J. Green</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steven+J.++Green">Steven J. Green</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Erik J. Hembre</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Erik J. Hembre</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Erik+J.++Hembre">Erik J. Hembre</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jon A. Erickson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jon A. Erickson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jon+A.++Erickson">Jon A. Erickson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brian A. Willis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian A. Willis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian+A.++Willis">Brian A. Willis</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Scott A. Monk</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Scott A. Monk</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Scott+A.++Monk">Scott A. Monk</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christopher D. Aluise</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher D. Aluise</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+D.++Aluise">Christopher D. Aluise</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas K. Baker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas K. Baker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+K.++Baker">Thomas K. Baker</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jose E. Lopez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jose E. Lopez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jose+E.++Lopez">Jose E. Lopez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jörg Hendle</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jörg Hendle</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=J%C3%B6rg++Hendle">Jörg Hendle</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James P. Beck</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James P. Beck</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+P.++Beck">James P. Beck</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard A. Brier</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard A. Brier</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard+A.++Brier">Richard A. Brier</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Leonard N. Boggs</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Leonard N. Boggs</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div><div class="loa-info-affiliations-info">Department of Biochemistry, University of Utah, Salt Lake City, Utah 84112, United States</div><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Leonard+N.++Boggs">Leonard N. Boggs</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anthony R. Borders</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anthony R. Borders</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anthony+R.++Borders">Anthony R. Borders</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Patrick J. Cocke</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Patrick J. Cocke</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div><div class="loa-info-affiliations-info">Department of Biochemistry, University of Utah, Salt Lake City, Utah 84112, United States</div><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Patrick+J.++Cocke">Patrick J. Cocke</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pablo Garcia-Losada</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pablo Garcia-Losada</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pablo++Garcia-Losada">Pablo Garcia-Losada</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephen L. Lowe</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephen L. Lowe</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephen+L.++Lowe">Stephen L. Lowe</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brian M. Mathes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian M. Mathes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian+M.++Mathes">Brian M. Mathes</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Patrick C. May</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Patrick C. May</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div><div class="loa-info-affiliations-info">Department of Biochemistry, University of Utah, Salt Lake City, Utah 84112, United States</div><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Patrick+C.++May">Patrick C. May</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Warren J. Porter</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Warren J. Porter</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div><div class="loa-info-affiliations-info">Department of Biochemistry, University of Utah, Salt Lake City, Utah 84112, United States</div><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Warren+J.++Porter">Warren J. Porter</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephanie L. Stout</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephanie L. Stout</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephanie+L.++Stout">Stephanie L. Stout</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David E. Timm</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David E. Timm</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+E.++Timm">David E. Timm</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brian M. Watson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian M. Watson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian+M.++Watson">Brian M. Watson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhixiang Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhixiang Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhixiang++Yang">Zhixiang Yang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Dustin J. Mergott</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dustin J. Mergott</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 317-277-2261. Email: <a href="/cdn-cgi/l/email-protection#9cf1f9eefbf3e8e8f8e9dcf0f5f0f0e5b2fff3f1"><span class="__cf_email__" data-cfemail="3e535b4c59514a4a5a4b7e5257525247105d5153">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dustin+J.++Mergott">Dustin J. Mergott</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-1802-0758" title="Orcid link">https://orcid.org/0000-0003-1802-0758</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00489&amp;href=/doi/10.1021%2Facs.jmedchem.1c00489" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 8076–8100</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 3, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 March 2021</li><li><span class="item_label"><b>Published</b> online</span>3 June 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 June 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00489" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00489</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8076%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDavid%2BL.%2BMcKinzie%252C%2BLeonard%2BL.%2BWinneroski%252C%2BSteven%2BJ.%2BGreen%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D12%26contentID%3Dacs.jmedchem.1c00489%26title%3DDiscovery%2Band%2BEarly%2BClinical%2BDevelopment%2Bof%2BLY3202626%252C%2Ba%2BLow-Dose%252C%2BCNS-Penetrant%2BBACE%2BInhibitor%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8100%26publicationDate%3DJune%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00489"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1625</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00489" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;L. McKinzie&quot;},{&quot;first_name&quot;:&quot;Leonard&quot;,&quot;last_name&quot;:&quot;L. Winneroski&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;J. Green&quot;},{&quot;first_name&quot;:&quot;Erik&quot;,&quot;last_name&quot;:&quot;J. Hembre&quot;},{&quot;first_name&quot;:&quot;Jon&quot;,&quot;last_name&quot;:&quot;A. Erickson&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;A. Willis&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;A. Monk&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;D. Aluise&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;K. Baker&quot;},{&quot;first_name&quot;:&quot;Jose&quot;,&quot;last_name&quot;:&quot;E. Lopez&quot;},{&quot;first_name&quot;:&quot;Jörg&quot;,&quot;last_name&quot;:&quot;Hendle&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;P. Beck&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;A. Brier&quot;},{&quot;first_name&quot;:&quot;Leonard&quot;,&quot;last_name&quot;:&quot;N. Boggs&quot;},{&quot;first_name&quot;:&quot;Anthony&quot;,&quot;last_name&quot;:&quot;R. Borders&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;J. Cocke&quot;},{&quot;first_name&quot;:&quot;Pablo&quot;,&quot;last_name&quot;:&quot;Garcia-Losada&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;L. Lowe&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;M. Mathes&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;C. May&quot;},{&quot;first_name&quot;:&quot;Warren&quot;,&quot;last_name&quot;:&quot;J. Porter&quot;},{&quot;first_name&quot;:&quot;Stephanie&quot;,&quot;last_name&quot;:&quot;L. Stout&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;E. Timm&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;M. Watson&quot;},{&quot;first_name&quot;:&quot;Zhixiang&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Dustin&quot;,&quot;last_name&quot;:&quot;J. Mergott&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;8076-8100&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00489&quot;},&quot;abstract&quot;:&quot;The beta-site APP cleaving enzyme 1, known as BACE1, has been a widely pursued Alzheimer’s disease drug target owing to its critical role in the production of amyloid-beta. We have previously reported the clinical development of LY2811376 and LY2886721. LY2811376 advanced to Phase I before development was terminated due to nonclinical retinal toxicity. LY2886721 advanced to Phase II, but development was halted due to abnormally elevated liver enzymes. Herein, we report the discovery and clinical development of LY3202626, a highly potent, CNS-penetrant, and low-dose BACE inhibitor, which successfully addressed these key development challenges.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00489&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00489" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00489&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00489" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00489&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00489" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00489&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00489&amp;href=/doi/10.1021/acs.jmedchem.1c00489" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00489" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00489" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00489%26sid%3Dliteratum%253Aachs%26pmid%3D34081466%26genre%3Darticle%26aulast%3DMcKinzie%26date%3D2021%26atitle%3DDiscovery%2Band%2BEarly%2BClinical%2BDevelopment%2Bof%2BLY3202626%252C%2Ba%2BLow-Dose%252C%2BCNS-Penetrant%2BBACE%2BInhibitor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D12%26spage%3D8076%26epage%3D8100%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291719" title="Redox reactions">Redox reactions</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0065.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0065.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The beta-site APP cleaving enzyme 1, known as BACE1, has been a widely pursued Alzheimer’s disease drug target owing to its critical role in the production of amyloid-beta. We have previously reported the clinical development of LY2811376 and LY2886721. LY2811376 advanced to Phase I before development was terminated due to nonclinical retinal toxicity. LY2886721 advanced to Phase II, but development was halted due to abnormally elevated liver enzymes. Herein, we report the discovery and clinical development of LY3202626, a highly potent, CNS-penetrant, and low-dose BACE inhibitor, which successfully addressed these key development challenges.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26081" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26081" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">It is estimated that over 50 million people worldwide are currently living with dementia. This number is projected to increase to more than 82 million by 2030 and triple to 152 million by 2050.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Alzheimer’s disease is the most common cause of dementia, and this devastating, progressive neurodegenerative disease, for which no disease modifying therapy is available, ultimately leads to death. An abnormal extracellular plaque in the brain, principally composed of amyloid-beta (Aβ), is a pathological hallmark of the disease. Beta-site APP cleaving enzyme 1 (BACE1) is critical to the production of Aβ, and consequently, it has been aggressively targeted for the development of potential Alzheimer’s disease therapies.<a onclick="showRef(event, 'ref2 ref3 ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5 ref6 ref7">(2−7)</a> We have previously reported the discovery and clinical development of LY2811376 and LY2886721 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). LY2811376 was terminated in Phase I due to adverse effects observed in the retinal epithelium of rats upon longer term dosing, believed to be connected to off-target protease activity.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> LY2886721 advanced to Phase II, but development was stopped because liver enzymes were abnormally elevated.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> In order to reduce the risk of drug-induced liver injury, we sought to develop a more potent BACE inhibitor capable of achieving high BACE inhibition at lower clinical doses.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Herein, we report the discovery and Phase I clinical development of LY3202626, a highly potent, CNS-penetrant, and low-dose BACE inhibitor.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Previously reported Lilly BACE inhibitors LY2811376 and LY2886721.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45043" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45043" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We recently described a series of cyclopropyl BACE inhibitors that leveraged a cyclopropyl group as a conformational constraint.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Initial efforts in this series focused on molecules such as <i>cis</i>-fused THF-aminothiazine <b>3</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). While <b>3</b> demonstrated high microsomal stability across species, we struggled to increase potency in this series beyond the ∼1 μM range. Furthermore, <b>3</b> was a weak Pgp substrate and possessed low passive permeability. We subsequently discovered that potency could be increased ∼100× by employing a <i>cis</i>-fused [4,5]-pyrrolidine ring system substituted with a 2-pyrimidine group in compounds <b>4</b> and <b>5</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Data for Cyclopropyl BACE Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0012.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Versus BACE1 IC<sub>50</sub>.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">MDCK cell bidirectional transport assay.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">m = mouse, r = rat, d = dog, h = human.</p></div></div><div></div></div><div class="NLM_p">Compounds <b>4</b> and <b>5</b> both demonstrated significant liabilities. Amide <b>4</b> was a Pgp substrate with an efflux ratio of 15. Compound <b>5</b>, in which the amide was replaced by an ether group, showed lower Pgp efflux and higher passive permeability. However, microsomal stability was poor, and a proof-of-concept study in PDAPP mice resulted in only 37% hippocampal Aβ reduction at a dose of 100 mg/kg. The cyclopropyl side chain also carried additional synthetic complexity that rendered the SAR quite challenging. Thus, we sought to move away from this series due to the aforementioned liabilities.</div><div class="NLM_p">The X-ray crystal structure of compound <b>5</b> is shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. The binding mode highlights the cyclopropyl group in the S1 pocket with the ether chain projecting the methyl cyclopropyl moiety into the S3 pocket, while the pyrrolidine ring system places the pyrimidine ring in the S2′ pocket. As part of our SAR exploration, we evaluated the impact of truncating the cyclopropyl side chain, thereby eliminating the S3-binding group. We prepared compound <b>6</b>, which contains an S1-binding thiophene group in place of the cyclopropyl side chain, to explore the impact of this structural change (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). α-Bromination of acetylthiophene <b>7</b>, followed by displacement of the bromine by diallyl amine, afforded α-amino ketone <b>8</b>. Treatment of <b>8</b> with hydroxylamine hydrochloride afforded the oxime, which when heated in xylenes at 150 °C underwent an intramolecular [3 + 2]-cycloaddition to afford the 5,5-<i>cis</i>-fused pyrrolidine <b>9</b> as a mixture of diastereomers. N–O bond cleavage using Zn powder, followed by treatment with benzoyl isothiocyanate, afforded hydroxythiourea <b>10</b>. Activation of the alcohol using Ghosez’s reagent promoted ring closure to afford the thiazine as a mixture of diastereomers which were separated by chiral HPLC to afford the cyclized product <b>11</b>. Next, deprotection of the <i>N</i>-allyl pyrrolidine followed by reaction with 2-chloropyrimidine afforded compound <b>12</b>. Debromination, followed by hydrolysis of the benzoyl group, afforded compound <b>6</b> after treatment with HCl.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray crystal structure of compound <b>5</b> (green) bound to the BACE1 binding site (amino acid residues labeled in yellow, protease pocket labels in red, hydrogen bonds in dashed yellow lines).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> PDB access code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UWV">6UWV</a>, final model derived by molecular replacement and structure refinement from PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UVV">6UVV</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Bu<sub>4</sub>N–Br<sub>3</sub>, MeOH, CH<sub>2</sub>Cl<sub>2</sub>; (b) diallylamine, K<sub>2</sub>CO<sub>3</sub>, ACN, rt; (c) NH<sub>2</sub>OH–HCl, NaOAc, EtOH, 70 °C; (d) xylenes, 150 °C, 35% yield (4 steps); (e) Zn, AcOH, 40 °C; (f) PhCONSC, bis(trimethylsilyl)trifluoroacetamide, THF, rt, 97% (2 steps); (g) 1-chloro-<i>N</i>,<i>N</i>,2-trimethylpropenylamine, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C for 2 h then warmed to rt, 39%; (h) chiral HPLC to separate mix of <i>cis</i>-fused enantiomers; (i) <i>N</i>,<i>N</i>-dimethylbarbituric acid, Pd(Ph<sub>3</sub>)<sub>4</sub>, CHCl<sub>3</sub>, rt; (j) 2-chloropyrimidine, DIEA, 1,4-dioxane, 110 °C, 69% (2 steps); (k) 10% Pd/C, ammonium formate, EtOH, 40 °C, 87%; (l) methoxylamine hydrochloride, pyridine, EtOH, 55 °C, 40%; (m) 1 M HCl in ether, rt, 100%.</p></p></figure><div class="NLM_p">Interestingly, <b>6</b> demonstrated BACE1 IC<sub>50</sub> = 121 nM along with an exceptionally high LEAN<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> value of 0.33, rendering it more potent than LY2811376 and more LEAN efficient than both LY2811376 and LY2886721 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The X-ray crystal structure of compound <b>6</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) shows the thiophene in the S1 pocket and the pyrimidine in the S2′ pocket. Thiophene <b>6</b> possessed a low Pgp efflux ratio (1.3) and high passive permeability; however, cathepsin D selectivity was significantly decreased compared to that of LY2886721.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Key Data for Compounds <b>1</b>, <b>2</b>, <b>6</b>, <b>15</b>, <b>16</b>, <b>17</b> and <b>18</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>1</b></th><th class="colsep0 rowsep0" align="center"><b>2</b></th><th class="colsep0 rowsep0" align="center"><b>6</b></th><th class="colsep0 rowsep0" align="center"><b>15</b></th><th class="colsep0 rowsep0" align="center"><b>16</b></th><th class="colsep0 rowsep0" align="center"><b>17</b></th><th class="colsep0 rowsep0" align="center"><b>18</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MW</td><td class="colsep0 rowsep0" align="left">320</td><td class="colsep0 rowsep0" align="left">390</td><td class="colsep0 rowsep0" align="left">317</td><td class="colsep0 rowsep0" align="left">335</td><td class="colsep0 rowsep0" align="left">331</td><td class="colsep0 rowsep0" align="left">360</td><td class="colsep0 rowsep0" align="left">336</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>P</i></td><td class="colsep0 rowsep0" align="left">2.9</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PSA</td><td class="colsep0 rowsep0" align="left">85</td><td class="colsep0 rowsep0" align="left">115</td><td class="colsep0 rowsep0" align="left">121</td><td class="colsep0 rowsep0" align="left">121</td><td class="colsep0 rowsep0" align="left">118</td><td class="colsep0 rowsep0" align="left">145</td><td class="colsep0 rowsep0" align="left">80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">p<i>K</i><sub>a</sub></td><td class="colsep0 rowsep0" align="left">8.8</td><td class="colsep0 rowsep0" align="left">7.7</td><td class="colsep0 rowsep0" align="left">7.6</td><td class="colsep0 rowsep0" align="left">7.5</td><td class="colsep0 rowsep0" align="left">7.1</td><td class="colsep0 rowsep0" align="left">6.6</td><td class="colsep0 rowsep0" align="left">6.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BACE1 IC<sub>50</sub><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">239 nM</td><td class="colsep0 rowsep0" align="left">20.3 nM</td><td class="colsep0 rowsep0" align="left">121 nM</td><td class="colsep0 rowsep0" align="left">83.1 nM</td><td class="colsep0 rowsep0" align="left">470 nM</td><td class="colsep0 rowsep0" align="left">110 nM</td><td class="colsep0 rowsep0" align="left">172 nM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LEAN</td><td class="colsep0 rowsep0" align="left">0.29</td><td class="colsep0 rowsep0" align="left">0.29</td><td class="colsep0 rowsep0" align="left">0.33</td><td class="colsep0 rowsep0" align="left">0.32</td><td class="colsep0 rowsep0" align="left">0.28</td><td class="colsep0 rowsep0" align="left">0.29</td><td class="colsep0 rowsep0" align="left">0.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cell IC<sub>50</sub><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">126 nM</td><td class="colsep0 rowsep0" align="left">10.7 nM</td><td class="colsep0 rowsep0" align="left">275 nM</td><td class="colsep0 rowsep0" align="left">324 nM</td><td class="colsep0 rowsep0" align="left">1700 nM</td><td class="colsep0 rowsep0" align="left">1210 nM</td><td class="colsep0 rowsep0" align="left">2460 nM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cathepsin D IC<sub>50</sub>; ratio<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">15 μM; 63×</td><td class="colsep0 rowsep0" align="left">>300 μM; >15,000×</td><td class="colsep0 rowsep0" align="left">40.9 μM; 338×</td><td class="colsep0 rowsep0" align="left">19 μM; 229×</td><td class="colsep0 rowsep0" align="left">83 μM; 177×</td><td class="colsep0 rowsep0" align="left">14 μM; 127×</td><td class="colsep0 rowsep0" align="left">29 μM; 169×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pgp efflux ratio<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">4.0</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">permeability (10<sup>–6</sup> cm/s)</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">55</td><td class="colsep0 rowsep0" align="left">59</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">54</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LysoTracker <i>R</i><sub>max</sub></td><td class="colsep0 rowsep0" align="left">3364</td><td class="colsep0 rowsep0" align="left">7863</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="left">4090</td><td class="colsep0 rowsep0" align="left">59</td><td class="colsep0 rowsep0" align="left">91</td><td class="colsep0 rowsep0" align="left">20</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Data are the means of at least 2 independent experiments.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Cultured primary cortical neuronal cells.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">MDCK cell bidirectional transport.</p></div></div></div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystal structure of compound <b>6</b> (green) bound to the BACE1 binding site (amino acid residues labeled in yellow, protease pocket labels in red, hydrogen bonds in dashed yellow lines). PDB access code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7MYI">7MYI</a>, final model derived by molecular replacement and structure refinement from PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UVV">6UVV</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Previously, development of early BACE1 inhibitors, such as LY2811376 and AMG-8718, was halted due to findings of ocular toxicity in dedicated animal toxicology studies. Both of these compounds induced accumulation of autofluorescent granules in the retinal pigment epithelium of rats that was associated with nonclinical retinal photoreceptor degeneration.<a onclick="showRef(event, 'ref8 ref15'); return false;" href="javascript:void(0);" class="ref ref8 ref15">(8,15)</a> Subsequent research has provided compelling evidence that this ocular toxicity effect was not attributable to BACE1 inhibition, including a study in which LY2811376 induced such effects in BACE1 knockout mice.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Additionally, a comprehensive chemoproteomics study identified cathepsin D (CatD) as the primary enzyme mediating the ocular toxicity.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> CatD is a lysosomal enzyme involved in phagocytosis, thereby facilitating clearance of shed retinal material. Importantly, CatD deficiency in animals and humans is associated with retinal atrophy and visual deficits.<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17−19)</a> In another study by Ellis and colleagues, the conformational dynamics of LY2811376 binding to BACE1 and CatD were evaluated across a pH range reflective of endosomal and lysosomal environments.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> They found that within the pH range that these enzymes were active, LY2811376 interacted more robustly with CatD versus BACE1, suggesting that the pH of the cellular environment may influence the BACE1/CatD selectivity of BACE1 inhibitor compounds.</div><div class="NLM_p">Prior to the aforementioned chemoproteomics study, we hypothesized that increasing CatD selectivity would reduce the risk of retinal toxicity. This hypothesis was initially supported by the improved nonclinical safety profile of LY2886721, which helped enable its progression to a Phase II study. We also reasoned that reducing the p<i>K</i><sub>a</sub> of the aminothiazine moiety would reduce risk of this off-target retinal epithelial toxicity by decreasing lysosomal accumulation of the corresponding BACE inhibitors. We used a LysoTracker assay as a surrogate for accumulation of inhibitors in lysosomes, and these data can be found in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Smaller fluorescence response max (<i>R</i><sub>max</sub>) values are indicative of lower accumulation, whereas larger values suggest extensive lysosomal accumulation. The comparison of <i>R</i><sub>max</sub> values for LY2811376 and LY2886721 indicated that both molecules accumulate in lysosomes, which in turn suggested that this accumulation must be counterbalanced by high CatD selectivity in the case of LY2886721, thereby reducing the risk of retinal epithelial toxicity.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> We sought to achieve a similar risk reduction by employing a less basic aminothiazine group.</div><div class="NLM_p">We evaluated whether the p<i>K</i><sub>a</sub> of the basic aminothiazine group could be reduced by employing more electron-withdrawing S1-binding heterocycles.<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22−24)</a> Compounds <b>15</b>–<b>18</b> were prepared via the routes shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> to explore the impact of p<i>K</i><sub>a</sub> on lysosomal accumulation. We initially explored route 1 for the synthesis of these compounds. In route 1, 2-bromoethylacetate was alkylated with allylamine followed by BOC protection. Hydrolysis of the ester and conversion to the Weinreb amide via the mixed anhydride afforded <b>13</b>. Addition of the desired aryl lithium afforded the corresponding ketone, which when treated with paramethoxybenzyl hydroxylamine in the presence of Ti(OEt)<sub>4</sub> and DIEA, underwent a nitrone cycloaddition to afford the fused 5,5 ring system. Following removal of the paramethoxybenzyl group, an analogous sequence, as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, was used to convert the tetrahydroisoxazole to the desired aminothiazine. We also explored route 2, which moved the diversification of the aryl S1 SAR closer to the end of the route compared to route 1. Route 2 started with isooxazoline <b>14</b>, which was prepared from the cyclization of the known benzyl <i>N</i>-[2-(hydroxyimino)ethyl]-<i>N</i>-2-propen-1-ylcarbamate. Addition of aryl Grignard reagents to <b>14</b> in the presence of BF<sub>3</sub>-etherate afforded the tetrahydroisoxazole, which then underwent ring opening to the amino alcohol followed by conversion to the thiourea. Ring closure and CBZ deprotection afforded the fused NH-pyrrolidine. Treatment of the fused NH-pyrrolidine with 2-chloro-4-fluoropyrimidine, followed by hydrolysis of the benzoyl group, completed the synthesis. Compounds <b>16</b> and <b>18</b> were prepared via route 1, whereas compounds <b>15</b> and <b>17</b> were prepared by route 2.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>15</b>–<b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, NaI, Et<sub>3</sub>N, DMF; (b) (Boc)<sub>2</sub>O, Et<sub>3</sub>N, EtOH; (c) NaOH, MeOH (d) Piv-Cl, HN(Me)OMe-HCl, Et<sub>3</sub>N, THF; (e) ArLi, THF, −40 °C; (f) Ti(OEt)<sub>4</sub>, DIPEA, toluene, reflux; (g) TFA; CH<sub>2</sub>Cl<sub>2</sub>, rt; (h) 2-chloro-4-fluoropyrimidine, DIEA, NMP, 100 °C; (i) TFA, 60 °C; (j) Zn, AcOH; (k) PhCONSC, THF then CDI rt to reflux; (l) LiOH, MeOH; (m) HCl, CH<sub>2</sub>Cl<sub>2</sub>/Et<sub>2</sub>O; (n) BF<sub>3</sub>-Et<sub>2</sub>O, ArMgBr, CH<sub>2</sub>Cl<sub>2</sub>/THF, −50 °C; (o) Zn, AcOH; (p) PhCONSC, THF; (q) 1-chloro-<i>N</i>,<i>N</i>,2-trimethylpropenylamine, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (r) TMS-I, ACN; (s) 2-chloro-4-fluoropyrimidine, DIEA, NMP, 100 °C; (t) LiOH, MeOH; (u) HCl, CH<sub>2</sub>Cl<sub>2</sub>/Et<sub>2</sub>O.</p></p></figure><div class="NLM_p">Compared to S1-thiophene <b>15</b>, introduction of polar atoms or substituents in the S1-binding group resulted in loss of potency but selectivity similar to that of cathepsin D (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). These structural changes did lower the log <i>P</i> and p<i>K</i><sub>a</sub> of compounds <b>16</b>–<b>18</b>. Interestingly, similar to observations involving the association of p<i>K</i><sub>a</sub> and log <i>P</i> with phospholipidosis, we discovered that both p<i>K</i><sub>a</sub> and log <i>P</i> appeared to play an important role in lysosomal accumulation as judged by the LysoTracker <i>R</i><sub>max</sub> values (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Compound <b>16</b>, which showed a modest p<i>K</i><sub>a</sub> reduction (−0.4) but a significant log <i>P</i> reduction (−1.6) relative to that of compound <b>15</b>, demonstrated a substantial decrease in LysoTracker <i>R</i><sub>max</sub>. Compound <b>18</b>, in which the S1-isothiazole group imparted significant reduction of both p<i>K</i><sub>a</sub> and log <i>P</i> relative to that of <b>15</b>, demonstrated the lowest <i>R</i><sub>max</sub> value. An X-ray crystal structure (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) of compound <b>18</b> shows the thiazole group bound in the S1 pocket of the BACE1 enzyme.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystal structure of compound <b>18</b> (green) bound to the BACE1 binding site. (amino acid residues labeled in yellow, protease pocket labels in red, hydrogen bonds in dashed yellow lines). PDB access code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7MYR">7MYR</a>, final model derived by molecular replacement and structure refinement from PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UVV">6UVV</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Beyond its low LysoTracker <i>R</i><sub>max</sub> value, isothiazole <b>18</b> possessed many other favorable properties, including low Pgp efflux, high passive permeability, and free equilibration across the plasma/CNS barrier (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Compound <b>18</b> also possessed suitable PK properties in rats and dogs (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). However, isothiazole <b>18</b> was about 14-fold less potent in cultured primary cortical neuronal cells (IC<sub>50</sub> = 2460 nM) than in the BACE1 biochemical assay (IC<sub>50</sub> = 172 nM) (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). As low p<i>K</i><sub>a</sub> can reduce cellular potency by limiting compound accumulation within the endosomal environment to interact with BACE1,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> it is notable that <b>18</b> had the lowest p<i>K</i><sub>a</sub> (6.4) of the compounds in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. We sought to investigate this apparent enzyme–cell potency disconnect using a cannulated dog CSF model to measure reduction of CSF Aβ. After a single oral dose of 3 mg/kg of compound <b>18</b>, CSF Aβ 1–<i>x</i> levels were reduced  ∼40–45% relative to baseline at 6 and 9 h. By 24 h, CSF Aβ 1–<i>x</i> levels were back to near baseline values. Data from this study indicated that the in vivo potency in dogs (IC<sub>50</sub> = 276 nM) was closer to the BACE1 biochemical IC<sub>50</sub> than the cell IC<sub>50</sub>. These data also suggested that isothiazole <b>18</b> freely crossed the blood–brain barrier, consistent with the absence of Pgp efflux and high passive permeability (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Unfortunately, a human dose projection indicated a QD dose >300 mg would be required to enable time-averaged CSF Aβ reduction of 70% at a steady state. Thus, isothiazole <b>18</b> did not meet our primary goal for this effort, which was to deliver a BACE inhibitor with a significantly lower dose than LY2886721.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Key Data for LY2886721 (<b>2</b>) and Isothiazole <b>18</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0013.gif" alt="" id="fx2" /></img><div></div></div><div class="NLM_p">As part of our chemistry efforts, we also sought to explore amides such as <b>20</b>–<b>22</b> which, in addition to engaging the S1 and S2′ pockets, could also bind within the S3 pocket and potentially increase BACE1 potency relative to LY2886721. We also wanted to explore whether this S3 pocket binding could increase selectivity against cathepsin D for amides <b>20</b>–<b>22</b> compared to that with compound <b>18</b>.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> However, we recognized the high molecular weight and polar surface area of these compounds would likely decrease brain penetration. Nevertheless, we elected to explore compounds <b>20</b>–<b>22</b> and make data-driven decisions regarding their strengths and weaknesses. Compounds <b>20</b>–<b>22</b> were prepared in one step from diamine <b>19</b> and the corresponding acid chloride as described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>20</b>–<b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Ar–COCl, ACN/EtOH, 50 °C.</p></p></figure><div class="NLM_p">Amides <b>20</b>–<b>22</b> displayed potency at least 25-fold greater than that of LY2886721 with high LEAN values, indicating that the addition of heavy atoms efficiently translated to higher BACE1 potency (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The X-ray structure of compound <b>22</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) showed that the methoxypyrazine group filled the S3 pocket of the BACE enzyme. Compounds <b>20</b>–<b>22</b> were not selective over the BACE2 enzyme but were highly selective over CatD, with ratios ranging from 105,000 to 220,000. Compound <b>20</b> displayed similar potency between the BACE1 enzyme and the PDAPP neuronal cell culture assay, whereas compounds <b>21</b>–<b>22</b> showed a slight increase in cellular potency. We deprioritized compound <b>20</b> as it had the lowest selectivity against the hERG channel (299-fold) compared to <b>21</b> and <b>22</b>. We initially favored difluoropyridine carboxamide <b>21</b> due to its modest CatD potency (IC<sub>50</sub> = 169 μM) and exceptional selectivity (220,000-fold) over CatD. However, compound <b>21</b> was also a weak Pgp substrate and demonstrated low CNS penetration in mice and dogs (mouse brain kpu,u and dog CSF/free plasma values of 0.05 and 0.2, respectively). Upon further study of methoxypyrazine carboxamide <b>22</b>, we were surprised to find that <b>22</b> was freely CNS-penetrant in both mouse and dog models, with mouse brain kpu,u and dog CSF/free plasma values of 1.0 and 0.9, respectively. Given the high MW and polar surface area of compound <b>22</b>, it is not clear why <b>22</b> displays free CNS penetration. The MW and polar surface area are well outside the range that is often cited for CNS-penetrant molecules.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> No single variable, such as intramolecular hydrogen bonding or lipophilicity, is sufficient to explain this observation.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Key Data for Compounds <b>20</b>, <b>21</b>, and LY3202626 (<b>22</b>)<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0069.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0070.gif" alt="" id="GRAPHIC-d7e1675-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Data are the means of at least 2 independent experiments.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Cultured primary cortical neuronal cells.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Percent turnover in hepatic microsomes in 30 min; h = human; r = rat; m = mouse; d = dog.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">MDCK cell bidirectional transport.</p></div></div><div></div></div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray crystal structure of compound <b>22</b> (green) bound to the BACE1 binding site. (amino acid residues labeled in yellow, protease pocket labels in red, hydrogen bonds in dashed yellow lines). PDB access code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7MYU">7MYU</a>, final model derived by molecular replacement and structure refinement from PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UVV">6UVV</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The aforementioned CNS/free plasma ratio for compound <b>22</b> was obtained as part of a central pharmacology study conducted in intrathecally cannulated dogs. CSF and blood were collected at baseline and select time points, after orally dosing 1.5 mg/kg compound <b>22</b>, to assess compound exposure as well as pharmacodynamic responses. Robust decreases in plasma and CSF levels of Aβ 1–<i>x</i> (approximately an 80% reduction at nadir) were observed (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Parallel changes of similar magnitude were observed in CSF Aβ 1–40 and Aβ 1–42 (data not shown). The plasma free concentrations of compound <b>22</b> exceeded the BACE1 IC<sub>50</sub> by ∼30 to 1.7-fold from 0.5 to 12 h postdose, respectively. As indicated above, CSF concentrations of <b>22</b> were similar to free compound in plasma, indicating good permeability across the blood–brain barrier. The dog in vivo IC<sub>50</sub> was 0.097 nM, which was about 3-fold more potent than the cellular BACE1 IC<sub>50</sub>. This shift was observed for compounds <b>20</b> and <b>21</b> but not observed with LY2886721. The reason for this difference is not clear.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Plasma and CSF Aβ 1–<i>x</i> response in beagle dog to 1.5 mg/kg oral dose of LY3202626 (<b>22</b>). Value of **<i>p</i> < 0.01 vs baseline for CSF 6, 12, and 24 h time points [ANOVA; <i>F</i>(5,28) = 9.40, <i>p</i> < 0.001; Dunnett posthoc comparisons] and #<i>p</i> < 0.01 vs baseline for all plasma time points [ANOVA; <i>F</i>(9,49) =43.93, <i>p</i> < 0.0001; Dunnett posthoc comparison]. Data are means ± SE from 5 to 6 dogs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Data from this dog study were used to develop a PK/PD model describing plasma and CSF PK as well as CSF PD. Changes in CSF Aβ were described using an indirect response model driven by drug concentration in the CSF, and this model was used to estimate an in vivo IC<sub>50</sub> value. Human clearance was predicted with simple allometry, utilizing clearance from rats and dogs (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). It was assumed that the CSF/free plasma ratio and in vivo IC<sub>50</sub> values in dogs would reflect the CNS penetration and potency in humans. These assumptions were used to project the daily doses that would reduce CSF Aβ at a steady state (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Compound <b>22</b> was projected to reduce CSF Aβ by 70% at a clinical daily dose of 1.3 mg (90% CI: 0.46, 4.7 mg).</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Relationship between total daily dose and change in CSF Aβ for LY3202626 (<b>22</b>). Light blue region represents the 90% confidence interval of the relationship. Vertical bars represent point estimate for doses projected to produce 50, 70, and 90% CSF Aβ reduction. Colored horizontal bars represent the 90% confidence interval around these point estimates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The combination of a low projected dose, low projected steady-state exposure for 70% time-averaged Aβ reduction, and free CNS penetration led us to prioritize LY3202626 (<b>22</b>) for clinical development. After successfully completing nonclinical safety testing, LY3202626 was advanced into a combined Phase I single and multiple ascending dose study to explore how its nonclinical properties would translate to clinical performance.</div><div class="NLM_p">The pharmacokinetics and pharmacodynamics of LY3202626 were evaluated in a clinical trial (NCT02323334).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The clinical trial was a randomized, placebo-controlled, subject- and investigator-blind study conducted at a single site following ethical review board approval. The trial was conducted in compliance with the Declaration of Helsinki and the International Conference on Harmonisation/Good Clinical Practice Guidelines. The trial was composed of a single ascending dose phase exploring doses from 0.1 to 45 mg, a phase where single doses of 1.6, 10, and 26 mg were followed by 36 h of serial CSF collection, and a multiple dose phase where daily doses of 1, 6, or 26 mg were administered for 14 days. Based upon serial CSF sampling following single dose administration into healthy participants (<i>n</i> = 5/cohort, except for the 10 mg dose group, where 2 additional subjects were included due to sample collection issues), plasma/CSF LY3202626 concentration ratios ranged between 0.0278 and 0.0428, similar to the measured in vitro plasma free fraction value of 0.041. This suggests that unbound drug concentrations were equivalent in CSF and plasma, indicating free penetration across the blood–brain barrier.</div><div class="NLM_p">Data from the human serial CSF cohort were used to fit a PK/PD model. Pharmacokinetics were described using a three-compartment model, with one of the compartments representing CSF concentrations. An indirect response model was used to estimate the in vivo potency of LY3202626 against BACE1. The model estimated IC<sub>50</sub> for LY3202626 was 0.0712 ng/mL (0.13 nM), generally consistent with the in vivo value of 0.097 nM estimated using data from the dog study. The model projected doses to achieve 70 and 90% CSF Aβ reduction at a steady state were within the confidence interval of the values projected from dog data, demonstrating the reliability of the dog model to predict the degree of blood–brain barrier penetration as well as the in vivo IC<sub>50</sub> (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Projected and Observed Pharmacokinetic and Pharmacodynamic Parameters for LY3202626 (<b>22</b>)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">human PK/PD projections based on nonclinical data</th><th class="colsep0 rowsep0" align="center">observed clinical value</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CSF/free plasma ratio</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human oral clearance</td><td class="colsep0 rowsep0" align="left">19 L/h (90% CI: 7.1, 51.2)</td><td class="colsep0 rowsep0" align="left">26 L/h</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vivo IC<sub>50</sub></td><td class="colsep0 rowsep0" align="left">0.097 nM</td><td class="colsep0 rowsep0" align="left">0.130 nM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">projected human dose for 70% CSF Aβ reduction</td><td class="colsep0 rowsep0" align="left">1.3 mg (90% CI: 0.46, 4.7)</td><td class="colsep0 rowsep0" align="left">2.4 mg</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">projected human dose for 90% CSF Aβ reduction</td><td class="colsep0 rowsep0" align="left">4.9 mg (90% CI: 1.5, 17)</td><td class="colsep0 rowsep0" align="left">9.2 mg</td></tr></tbody></table></div></div><div class="NLM_p">Based on the information obtained from the serial CSF collections following single dose administration, doses of 1, 6, and 26 mg were administered daily for 14 days in healthy subjects (<i>n</i> = 9/cohort). These doses led to Aβ 1–40 reductions of 50.1, 75.7, and 93.7, and 46.7, 73.1, and 94.6% in Aβ 1–42 at each of the three doses, respectively (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). This effect was consistent with predictions made using the model-estimated in vivo IC<sub>50</sub> value. Overall, the preclinical data enabled accurate human PK/PD projections.</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Change in human CSF Aβ concentrations following daily LY3202626 (<b>22</b>) Administration. Concentrations of CSF Aβ<sub>1–40</sub> (○) and Aβ<sub>1–42</sub> (Δ) were measured at baseline and after 14 days of LY3202626 administration. If the post-treatment Aβ concentration was below detectable limits, a value of one-half the lower limit of quantification was used in the calculation, and the value was plotted in red to denote this. Nine healthy subjects were included in each cohort.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07835" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07835" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We have described two new series of BACE inhibitors. One series, exemplified by compound <b>18</b>, achieved nM potency and free CNS penetration. While this series appeared to have reduced risk for retinal toxicity owing to its lower p<i>K</i><sub>a</sub> and log <i>P</i> values relative to those of other BACE inhibitors, its projected human dose of >300 mg did not meet our low-dose criteria for mitigating the risk of elevated liver enzymes observed with LY2886721. We also felt that high CatD selectivity was a more optimal approach to reducing retinal toxicity risk. The other series, exemplified by compounds <b>20</b>–<b>22</b>, demonstrated pM potency and >100,000-fold selectivity against CatD. Whereas compounds <b>20</b> and <b>21</b> displayed low CNS penetration, LY3202626 displayed free CNS penetration in mice and dogs, thus allowing its high BACE1 enzymatic and cellular potency (IC<sub>50</sub> = 615 and 275 pM, respectively) to translate to a low projected human dose of 1.3 mg for steady-state CSF levels targeting an Aβ 1–40 reduction of 70%. Human exposure and dose projections proved to be accurate, with Phase I data indicating that a dose of 2.4 mg would reduce Aβ 1–40 by 70% at a steady state.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Remarkably, a dose of 9.2 mg was projected to reduce Aβ 1–40 by >90% at a steady state. LY3202626 advanced to a Phase II clinical study (NCT02791191) in patients with mild Alzheimer’s disease, evaluating doses of 3 and 12 mg of LY3202626 administered daily. While LY3202626 was well tolerated, with similar numbers of treatment emergent adverse reported in the placebo and 12 mg arms, an interim analysis of efficacy data did not demonstrate a meaningful benefit to participants. Based on this analysis, as well as reports of other BACE inhibitors failing to slow disease progression (including cognitive worsening in some studies) despite similar levels of Aβ reduction, a decision was made to stop the Phase II study.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_p last">Substantial progress has been made against this challenging enzyme target since the initial cloning of the BACE1 enzyme and disclosure of the first BACE1 enzyme crystal structure over 20 years ago.<a onclick="showRef(event, 'ref34 ref35 ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36 ref37 ref38">(34−38)</a> However, owing to multiple clinical trial failures, interest in the BACE inhibitor field for the treatment of AD has waned considerably. Recent data from antiamyloid monoclonal antibodies have shown that targeting amyloid remains a potentially viable therapeutic approach.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> It has been hypothesized that BACE inhibitors may prove more effective if evaluated years prior to Alzheimer’s disease onset, at a time when Aβ levels are gradually accruing.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> Relatedly, all recent clinical trials with BACE inhibitors have targeted soluble Aβ reductions of >50%, with most clinical doses approaching >80%.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> As BACE1 interacts with multiple proteins important for synaptic plasticity and neuronal function, high levels of BACE1 inhibition may affect other proteins beyond APP.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> All advanced clinical BACE inhibitors do not exhibit significant selectivity of BACE1 over BACE2. While BACE2 inhibition has been most associated with potential hypopigmentation effects via interactions with pigment-cell-specific melanocyte protein (PMEL), numerous other BACE2 protein substrates have been identified.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Development of selective BACE1 inhibitors without BACE2 activity could reduce off-target pharmacology. Finally, it is known that individuals with the A673T mutation in the APP gene results in less efficient BACE1 cleavage of APP, resulting in approximately a 28% plasma Aβ and a 40% reduction in Aβ deposition in elderly individuals.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a> These findings have led some researchers to propose that future clinical trials targeting lower levels of BACE inhibition may uncover therapeutic benefit; however, it remains unclear if interest in BACE1 inhibitors will be revived.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42238" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42238" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> General</h3><div class="NLM_p last">All reagents and anhydrous solvents were used as obtained from commercial sources without further purification. Air-sensitive reactions were performed under a nitrogen atmosphere. Reactions were monitored by thin layer chromatography using silica gel 60 F254 plates from EMD and staining with ninhydrin or by LCMS using an Agilent 1100 series HPLC on a Gemini-NX C18 110A, 50 mm × 2.00 mm column. Normal phase purifications were performed using RediSep prepacked columns from Teledyne Isco. Reversed-phase purifications were performed using RediSep Rf Gold prepacked columns from Teledyne Isco. Analytical HPLC and LCMS data were obtained using an Agilent 1100 series HPLC on a Gemini-NX C18 110A, 50 mm × 2.00 mm column. The purity of the samples was assessed using a UV detector at 254 nm. Unless otherwise noted,all compounds were >95% pure as judged by HPLC. <sup>1</sup>H NMR spectra were obtained on a Varian Unity INOVA 400 at 400 MHz.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Synthesis Methods</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Synthesis of Compound <b>6</b></h4><div id="sec4_2_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i17" class="anchor-spacer"></div><h5 class="article-section__title" id="_i17"> 1-(4-Bromo-2-thienyl)-2-(diallylamino)ethanone (<b>8</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0015.gif" alt="" id="fx4" /></img><div class="NLM_p last">1-(4-Bromothiophen-2-yl)ethanone (10.00 g, 48.76 mmol) was dissolved in a mixture of methanol (97 mL) and dichloromethane (162 mL). Tetra-<i>n</i>-butylammonium tribromide (28.79 g, 58.51 mmol) was added. The reaction mixture was then concentrated in the rotavap at 50 °C, diluted with minimal dichloromethane, loaded to a 330 g silica gel cartridge, and eluted with dichloromethane. The fractions containing the bromide intermediate were combined and concentrated in vacuo. The residue was dissolved in acetonitrile (200 mL), then potassium carbonate was added (20.22 g, 146.29 mmol), followed by diallylamine (12.03 mL, 97.52 mmol). Stirring occurred at rt for 2 h. Water was added to the reaction mixture and then extracted with ethyl acetate. The combined organics were dried over sodium sulfate and filtered and concentrated in vacuo. Crude product was obtained (14.64 g, 100% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.80 (d, <i>J</i> = 1.50 Hz, 1H), 7.46 (d, <i>J</i> = 1.76 Hz, 1H), 5.93–5.81 (m, 2H), 5.24–5.12 (m, 4H), 3.64 (s, 2H), 3.20 (d, <i>J</i> = 5.95 Hz, 4H). ESI<sup>+</sup><i>m</i>/<i>z</i>: 300, 302 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i18" class="anchor-spacer"></div><h5 class="article-section__title" id="_i18"> 1-(4-Bromo-2-thienyl)-2-(diallylamino)ethanone oxime (<b>8a</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0016.gif" alt="" id="fx5" /></img><div class="NLM_p last">A mixture of 1-(4-bromo-2-thienyl)-2-(diallylamino)ethanone (14.63 g, 48.748 mmol), sodium ethanoate (5.99 g), 73.122 mmol), hydroxylamine hydrochloride (5.081g, 73.122 mmol), and ethanol (195 mL) in a flask was heated to 70 °C and stirred overnight. Reaction mixture was concentrated in vacuo and then diluted with dichloromethane. Saturated sodium bicarbonate was added. The two phases were separated, and the aqueous phase was extracted with dichloromethane. The combined organics were dried over sodium sulfate and filtered, and concentrated in vacuo. Crude product was obtained (15.00 g, 100% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.70 (d, <i>J</i> = 1.21 Hz, 0.6 H), 7.40 (d, <i>J</i> = 1.43 Hz, 0.4 H), 7.14 (d, <i>J</i> = 1.32 Hz, 0.6 H), 7.12 (d, <i>J</i> = 1.43 Hz, 0.4 H), 5.95–5.83 (m, 2H), 5.28 (s, 1H), 5.27–5.18 (m, 4H), 3.74 (s, 1.20 H), 3.59 (s, 0.80 H), 3.24–318 (m, 4H).</div></div><div id="sec4_2_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i19" class="anchor-spacer"></div><h5 class="article-section__title" id="_i19"> (±)-5-Allyl-6a-(4-bromo-2-thienyl)-3,3a,4,6-tetrahydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]isoxazole (<b>9</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0017.gif" alt="" id="fx6" /></img><div class="NLM_p last">A mixture of 1-(4-bromo-2-thienyl)-2-(diallylamino)ethanone oxime (15.37 g, 48.748 mmol) and <i>p</i>-xylene (244 mL) was heated to 150 °C for 4 h. Reaction mixture was cooled and the solvent removed under reduced pressure. The crude mixture was purified over 120 g of silica gel, with a 20 min gradient of 0 to 50% EtOAc/hexanes to afford the product (5.40 g, 35% yield) (over 4 steps). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.07 (d, <i>J</i> = 1.4 Hz, 1H), 6.89 (d, <i>J</i> = 1.4 Hz, 1H), 5.88–5.80 (m, 1H), 5.53–5.43 (m, 1H), 5.18 (dq, <i>J</i> = 17.1, 1.6 Hz, 1H), 5.13–5.10 (m, 1H), 4.59–4.38 (m, 1H), 3.65–3.48 (m, 1H), 3.20–3.03 (m, 4H), 3.02–2.76 (m, 1H), 2.65–2.25 (m, 2H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 315, 317 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i20" class="anchor-spacer"></div><h5 class="article-section__title" id="_i20"> (±)-[1-Allyl-4-amino-4-(4-bromo-2-thienyl)pyrrolidin-3-yl]methanol (<b>9a</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0018.gif" alt="" id="fx7" /></img><div class="NLM_p last">(±)-5-Allyl-6a-(4-bromo-2-thienyl)-3,3a,4,6-tetrahydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]isoxazole (4.25 g, 13.482 mmol) was dissolved in acetic acid (67 mL). Zinc powder (8.82 g, 134.820 mmol) was added, and the reaction mixture was heated to 40 °C, with vigorous stirring. After 4 h, the reaction was cooled to ambient temperature, diluted with ethanol, filtered through Celite, and then washed with ethanol. The filtrate was dried in vacuo and then dissolved in water. The solution was made basic with 1 N NaOH, filtered through Celite, and then extracted with 3:1 chloroform/isopropyl alcohol. The organic phase was dried over magnesium sulfate and filtered. The solvent was removed in vacuo to give the crude product (4.00 g, 94% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.09 (d, <i>J</i> = 1.4 Hz, 1H), 6.95 (d, <i>J</i> = 1.3 Hz, 1H), 5.92–5.87 (m, 1H), 5.24–5.18 (m, 1H), 5.14–5.10 (m, 1H), 3.85–3.81 (m, 1H), 3.73–3.68 (m, 1H), 3.19–3.15 (m, 2H), 2.88–2.85 (m, 1H), 2.79–2.76 (m, 2H), 2.71 (t, <i>J</i> = 9.3 Hz, 1H), 2.53–2.45 (m, 1H), 1.20 (d, <i>J</i> = 6.2 Hz, 1H). ESI<sup>+</sup>: <i>m</i>/<i>z</i> 317, 319 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i21" class="anchor-spacer"></div><h5 class="article-section__title" id="_i21"> (±)-<i>N</i>-[[1-Allyl-3-(4-bromo-2-thienyl)-4-(hydroxymethyl)pyrrolidin-3-yl]carbamothioyl]benzamide (<b>10</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0019.gif" alt="" id="fx8" /></img><div class="NLM_p last">To a solution of (±)-[1-allyl-4-amino-4-(4-bromo-2-thienyl)pyrrolidin-3-yl]methanol (4.00 g, 12.608 mmol) in tetrahydrofuran (180 mL) was added bis(trimethylsilyl)trifluoroacetamide (3.25g, 12.608 mmol). The reaction was stirred for 1 h at ambient temperature. Benzoyl isothiocyanate (2.04 mL, 15.130 mmol) was added in one portion, and the reaction mixture was stirred for another hour, quenched with 1 N HCl (20 mL), and stirred for one additional hour. The reaction was made basic with 50 mL of saturated sodium bicarbonate. It was then diluted with water (100 mL) and extracted with dichloromethane. The organic phase was dried over sodium sulfate and filtered. The solvent was removed in vacuo. The crude product was triturated with 25 mL of 4:1 hexanes/ethyl acetate. The precipitate was collected by filtration and dried under reduced pressure. The product was obtained (5.90g, 98% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 11.73 (s, 1H), 8.92–8.88 (m, 1H), 7.84 (d, <i>J</i> = 7.28 Hz, 2H), 7.64–7.60 (m, 1H), 7.51 (t, <i>J</i> = 7.8 Hz, 2H), 7.09 (dd, <i>J</i> = 0.44, 1.43 Hz, 1H), 7.00 (dd, <i>J</i> = 0.44, 1.43 Hz, 1H), 5.98–5.85 (m, 1H), 5.26 (d, <i>J</i> = 16.98 Hz, 1H), 5.16 (d, <i>J</i> = 10.25 Hz, 1H), 3.97–3.94 (m, 2H), 3.65–3.57 (m, 1H), 3.53–3.41 (m, 1H), 3.28–3.14 (m, 2H), 3.10–2.99 (m, 1H), 2.91–2.80 (m, 1H), 2.73–2.61 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 480, 482 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i22" class="anchor-spacer"></div><h5 class="article-section__title" id="_i22"> <i>N</i>-[(4aR,7aR)-6-Allyl-7a-(4-bromo-2-thienyl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (<b>11</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0020.gif" alt="" id="fx9" /></img><div class="NLM_p last">(±)-<i>N</i>-[[1-Allyl-3-(4-bromo-2-thienyl)-4-(hydroxymethyl)pyrrolidin-3-yl]carbamothioyl]benzamide (5.90g, 12.280 mmol) was dissolved in dichloromethane (307 mL) and cooled to 0 °C. Chloro-<i>N</i>,<i>N</i>,2-trimethylpropenylamine (3.25 mL, 24.560 mmol) was added slowly. The mixture was stirred for 2 h and then warmed to ambient temperature and stirred overnight. The reaction mixture was washed with saturated sodium bicarbonate. The organic phase was dried over magnesium sulfate and filtered. The solvent was removed in vacuo. The crude product was purified over 120 g of silica gel, with a 20 min gradient of 0 to 100% EtOAc/hexanes to afford the product (2.24g, 40% yield). This mixture of <i>cis</i>-fused enantiomers was chirally purified using a 4.6 × 150 mm Chiralpak AD-H column and eluting with 0.2% DMEA in EtOH at a flow rate of 0.60 mL/min. This gave the chirally pure desired product (1.05 g, 99% ee). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.19–8.06 (m, 2H), 7.52–7.47 (m, 1H), 7.42 (t, <i>J</i> = 7.72 Hz, 2H), 7.14–7.11 (m, 1H), 6.98–6.94 (m, 1H), 5.93–5.77 (m, 1H), 5.21 (d, <i>J</i> = 17.31 Hz, 1H), 5.11 (d, <i>J</i> = 10.14 Hz, 1H), 3.29–3.11 (m, 4H), 3.10–3.01 (m, 1H), 3.01–2.90 (m, 3H), 2.77 (dd, <i>J</i> = 13.89, <i>J</i> = 4.08 Hz, 1H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 462, 464 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_1_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23"> <i>N</i>-[(4aR,7aR)-7a-(4-Bromo-2-thienyl)-4a,5,6,7-tetrahydro-4<i>H</i>-pyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (<b>11a</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0021.gif" alt="" id="fx10" /></img><div class="NLM_p">A solution of <i>N</i>-[(4aR,7aR)-6-allyl-7a-(4-bromo-2-thienyl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (1.05 g, 2.271 mol) in chloroform (23 mL) was degassed with a stream of nitrogen for 10 min and then were added <i>N</i>,<i>N</i>-dimethylbarbituric acid (2.10 g, 13.44 mmol) and tetrakis(triphenylphosphine)palladium (1.05 g; 0.909 mmol). After 30 min, the reaction was complete. It was diluted with dichloromethane and extracted with 1 N HCl.</div><div class="NLM_p last">The acidic aqueous was made basic with 5N NaOH, and extracted with dichloromethane. The organic phase was dried over magnesium sulfate and filtered. The solvent was removed in vacuo. The crude product was obtained as a solid (960 mg, 100% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.31–7.92 (m, 2H), 7.55–7.46 (m, 1H), 7.42 (t, <i>J</i> = 7.61 Hz, 2H), 6.95–6.91 (m, 1H), 3.44–3.23 (m, 5H), 2.94–2.84 (m, 1H), 2.84–2.75 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 422, 424 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_1_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> <i>N</i>-[(4aR,7aR)-7a-(4-Bromo-2-thienyl)-6-pyrimidin-2-yl-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (<b>12</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0022.gif" alt="" id="fx11" /></img><div class="NLM_p last">A solution of <i>N</i>-[(4aR,7aR)-7a-(4-bromo-2-thienyl)-4a,5,6,7-tetrahydro-4<i>H</i>-pyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (950 mg, 2.246 mmol) in 1,4-dioxane (25 mL) was treated with 2-chloro-pyrimidine and (515 mg, 4.498 mmol) and diisopropylethylamine (1.96 mL, 11.246 mmol). The reaction was heated to 110 °C for 4 h. The solvent was removed in vacuo. The crude product was purified over 40 g of silica gel, with a 20 min gradient of 0 to 50% EtOAc/hexanes to afford the product (780 mg, 69% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.32 (d, <i>J</i> = 4.9 Hz, 2H), 8.07–7.93 (m, 1H), 7.53–7.46 (m, 1H), 7.41 (t, <i>J</i> = 7.61 Hz, 2H), 7.21–7.19 (m, 1H), 7.01–6.99 (m, 1H), 6.54 (t, <i>J</i> = 4.85 Hz, 1H), 4.23–4.16 (m, 1H), 4.07–4.02 (m, 1H), 4.01–3.95 (m, 2H), 3.36–3.26 (m, 1H), 3.06–2.98 (m, 1H), 2.98–2.91 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 500, 502 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_1_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> <i>N</i>-[(4aR,7aR)-6-Pyrimidin-2-yl-7a-(2-thienyl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (<b>12a</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0023.gif" alt="" id="fx12" /></img><div class="NLM_p">A slurry of <i>N</i>-[(4aR,7aR)-7a-(4-bromo-2-thienyl)-6-pyrimidin-2-yl-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (775 mg, 1.549 mmol), palladium (1.648g, 1.549 mmol), formic acid, ammonium salt, and ethanol (31 mL) was stirred in a sealed vessel at 40 °C for 1 h. To the reaction mixture were added Celite and saturated sodium bicarbonate (1 mL).</div><div class="NLM_p last">The reaction was diluted with ethyl acetate and filtered through Celite. The filtrate was dried over sodium sulfate, filtered and then the solvent was removed in vacuo. The crude product was obtained as a solid (570 mg, 87% yield).). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.32 (d, <i>J</i> = 4.7 Hz, 2H), 8.18–7.98 (m, 1H), 7.50–7.44 (m, 1H), 7.42–7.38 (m, 2H), 7.32–7.27 (m, 1H), 7.10–7.08 (m, 1H), 7.02–7.00 (m, 1H)), 6.54 (t, <i>J</i> = 4.85 Hz, 1H), 4.30–4.21 (m, 1H), 4.17–4.10 (m, 1H), 4.04–3.97 (m, 2H), 3.40–3.34 (m, 1H), 3.11–3.02 (m, 1H), 2.95 (dd, <i>J</i> = 13.34, 4.08 Hz, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 422 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_1_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> (4aR,7aR)-6-Pyrimidin-2-yl-7a-(2-thienyl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-amine dihydrochloride (<b>6</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0024.gif" alt="" id="fx13" /></img><div class="NLM_p last">A solution of <i>N</i>-[(4aR,7aR)-6-pyrimidin-2-yl-7a-(2-thienyl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (123 mg, 0.292 mmol) in ethanol (2 mL) was treated with pyridine (236 μL, 2.918 mmol) and <i>o</i>- methylhydroxylamine hydrochloride (244 mg, 2.918 mmol). The reaction was heated to 50 °C for 4 h in a sealed vessel. The reaction was cooled to room temperature, and then the solvent was removed in vacuo. The crude product was purified over 12 g of silica gel, with a 12 min gradient of 0 to 5% 7 N NH<sub>3</sub>MeOH in CH<sub>2</sub>Cl<sub>2</sub> to afford the free base as a white solid (40 mg, 43% yield). The 2 M HCl salt was prepared by dissolving the free base in dichloromethane, then adding HCl (1.184 mmol, 1.18 mL, 1 M in ether). The mixture was stirred at room temperature for 15 min. The solvent was concentrated in vacuo and then the residue was dried in the vacuum pump overnight. The 2 M HCl salt product was a white solid (47 mg, 41% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.61–8.57 (m, 2H), 7.54 (dd, <i>J</i> = 1.2, 5.2 Hz, 1H), 7.22–7.20 (m, 1H), 7.12 (dd, <i>J</i> = 3.7, 5.1 Hz, 1H), 7.01–6.98 (m, 1H), 4.44 (d, <i>J</i> = 12.3 Hz, 1H), 4.30 (d, <i>J</i> = 12.4 Hz, 1H), 4.13–4.08 (m, 1H), 3.94–3.89 (m, 1H), 3.49–3.44 (m, 1H), 3.44–3.38 (m, 1H). HRMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> calcd forC<sub>14</sub>H<sub>15</sub>N<sub>5</sub>S<sub>2</sub> (M + H) 317.0769, found 317.0777.</div></div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Synthesis of Compound <b>15</b></h4><div id="sec4_2_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> Benzyl 3,3a,4,6-Tetrahydropyrrolo[3,4-<i>c</i>]isoxazole-5-carboxylate (<b>14</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0025.gif" alt="" id="fx14" /></img><div class="NLM_p last">To a 50 mL RBF were added benzyl <i>N</i>-allyl-<i>N</i>-[2-hydroxyiminoethyl]carbamate (24 g, 96.66 mmol) and dichloromethane (338 mL). Then, a solution of 5% w/w aqueous sodium hypochlorite (143 mL) was added dropwise over 10 min. The reaction mixture was then stirred at room temperature for 18 h. The reaction was then quenched by adding a 40% aqueous solution of sodium bisulfite (7.04g, 67.66 mmol). The mixture was transferred to a separatory funnel. The organic layer was separated, dried over magnesium sulfate, and filtered. The filtrate was evaporated to afford the crude product as an oil. The sample was purified via silica gel plug filtration using as eluent CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95/5). Fractions containing pure product were combined and solvent evaporated to afford the desired product (18 g, 73.09 mmol, 76% yield). <sup>1</sup>H NMR (300.16 MHz, CDCl<sub>3</sub>): δ 7.36 (s, 5H), 5.16 (s, 2H), 4.66–4.57 (m, 1H), 4.27–4.20 (m, 2H), 4.14–3.96 (m, 3H), 3.27–3.17 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 247 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> (±)-Benzyl (3aR,6aR)-6a-(2-Thienyl)-3,3a,4,6-tetrahydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]isoxazole-5-carboxylate (<b>15a</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0026.gif" alt="" id="fx15" /></img><div class="NLM_p last">Two side-by-side reactions were run simultaneously. The reagent amounts below represent the scale run for each of the two separately. The amount of final product and yield is for the combined total. A solution of benzyl 3,3a,4,6-tetrahydropyrrolo[3,4-<i>c</i>]isoxazole-5-carboxylate (6.16g, 25.01 mmol) in dichloromethane (250 mL, 3.90 mol) was cooled to −50 °C in a bath of dry ice and acetonitrile. The reaction was treated with boron trifluoride etherate (6.33 mL, 50.03 mmol) dropwise over a period of 3 min, with a slight internal temperature exotherm to −48 °C noted. The resulting clear light amber solution was stirred at −52 °C for 10 min. Next, thiophen-2-ylmagnesium bromide (1 M in THF, 100 mL, 100 mmol) was added slowly via cannula over a period of 25 min, while maintaining the internal temperature below −45 °C. The solution was stirred at −50 °C for 10 min, and then the cooling bath was removed, and the reaction was warmed to 0 °C over about 25 min at which point it was placed in a 0 °C ice bath and continued stirring at 0 °C for 1 h. The reaction was then quenched by the addition of saturated aqueous NH<sub>4</sub>Cl (400 mL) and stirred for 10 min. The ice bath was removed, and the mixture was stirred for 17 h. The mixtures were transferred to a separatory funnel (combining the two side-by-side reactions at this time) while being diluted with DCM (200 mL). The phases were separated, and the aqueous phase was further extracted with DCM (2 × 300 mL). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product as an amber oil. The sample was purified via silica gel chromatography eluting with a 25–50% gradient of EtOAc in hexanes to give the desired product (14.33g, 43.37 mmol, 87% yield). <sup>1</sup>H NMR (400.15 MHz, CDCl<sub>3</sub>): δ 7.38–7.31 (m, 6H), 7.05–7.04 (m, 1H), 6.99 (dd, <i>J</i> = 3.6, 5.1 Hz, 1H), 5.13 (s, 2H), 4.27–4.20 (m, 1H), 3.96–3.94 (m, 4H), 3.71–3.69 (m, 1H), 3.38–3.32 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 331[M + H]<sup>+</sup>.</div></div><div id="sec4_2_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> (±)-Benzyl (3<i>R</i>,4<i>R</i>)-3-amino-4-(hydroxymethyl)-3-(2-thienyl)pyrrolidine-1-carboxylate (<b>15b</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0027.gif" alt="" id="fx16" /></img><div class="NLM_p last">A rapidly stirring solution of (±)-benzyl (3aR,6aR)-6a-(2-thienyl)-3,3a,4,6-tetrahydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]isoxazole-5-carboxylate (14.29g, 43.25 mmol) in acetic acid (144 mL) was treated with zinc powder (28.28g, 432.50 mmol). The resulting mixture was stirred for 4.5 h, while the reaction progress was monitored by LC/MS. Additional zinc (14.14g, 216.25 mmol) was added, and stirring was continued for another 22 h. The mixture was vacuum filtered through a plug of Celite, while being rinsed with EtOAc (∼600 mL). The filtrate was concentrated and placed under high vacuum to afford a pale-yellow oil. This material was transferred to a separatory funnel while being diluted with EtOAc (500 mL). Next, 1 M NaOH (aqueous, 300 mL) was added to adjust the aqueous pH to ∼10. The phases were separated, and the aqueous phase was further extracted with EtOAc (200 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and filtered through a plug of Celite, while being rinsed with EtOAc. The filtrate was concentrated to give the desired product (13.47 g, 40.53 mmol, 94% yield). <sup>1</sup>H NMR (400.15 MHz, CDCl<sub>3</sub>): δ 7.40–7.33 (m, 6H), 7.12–7.10 (m, 2H), 5.20–5.12 (m, 3H), 3.92–3.89 (m, 6H), 2.65–2.64 (m, 2H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 333 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> (±)-Benzyl (3<i>R</i>,4<i>R</i>)-3-(Benzoylcarbamothioylamino)-4-(hydroxymethyl)-3-(2-thienyl)pyrrolidine-1-carboxylate (<b>15c</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0028.gif" alt="" id="fx17" /></img><div class="NLM_p last">A stirred light amber solution of (±)-benzyl (3<i>R</i>,4<i>R</i>)-3-amino-4-(hydroxymethyl)-3-(2-thienyl)pyrrolidine-1-carboxylate (13.47 g, 40.52 mmol) in tetrahydrofuran (135 mL) was chilled in a 0 °C ice bath under nitrogen. Benzoyl isothiocyanate (5.74 mL, 42.55 mmol) was added, and then the cooling bath was removed. The reaction was stirred for 1.5 h while being monitored by LC/MS. The reaction was then concentrated to give the crude product, which was carried on without purification (21.59g, 43.56 mmol, 110% crude yield). <sup>1</sup>H NMR (400.15 MHz, CDCl<sub>3</sub>): δ 11.83–11.80 (m, 1H), 8.97–8.94 (m, 1H), 7.84–7.80 (m, 2H), 7.69–7.64 (m, 1H), 7.50 (t, <i>J</i> = 7.6 Hz, 2H), 7.40–7.34 (m, 5H), 7.26–7.23 (m, 1H), 7.03–7.00 (m, 2H), 5.22–5.16 (m, 2H), 4.91–4.87 (m, 1H), 4.29–4.25 (m, 1H), 4.01–3.97 (m, 2H), 3.84–3.81 (m, 3H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 554 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> (±)-Benzyl (4aR,7aR)-2-Benzamido-7a-(2-thienyl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazine-6-carboxylate (<b>15d</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0029.gif" alt="" id="fx18" /></img><div class="NLM_p last">A solution of (±)-benzyl (3<i>R</i>,4<i>R</i>)-3-(benzoylcarbamothioylamino)-4-(hydroxymethyl)-3-(2-thienyl)pyrrolidine-1-carboxylate (20.08 g, 40.52 mmol) in dichloromethane (202 mL) was chilled in a 0 °C ice bath under an atmosphere of nitrogen. Then, 1-chloro-<i>N</i>,<i>N</i>,2-trimethylpropenylamine (6.43 mL, 48.625 mmol) was added dropwise over a period of 5 min. The resulting solution was stirred at 0 °C for 10 min, and then the cooling bath was removed, and the solution allowed to warm to rt with stirring for 1.5 h. The reaction was quenched by the addition of 100 mL of saturated aqueous NaHCO<sub>3</sub> and the mixture stirred for 10 min. The mixture was transferred to a separatory funnel, and the layers were separated. The organic phase was further washed with brine (1 × 100 mL), and then the organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude material was then purified via silica gel chromatography using a 2–7% EtOAc/DCM gradient to give the desired product (9.99g, 20.92 mmol, 51% yield). <sup>1</sup>H NMR (400.15 MHz, CDCl<sub>3</sub>): δ 8.11–8.10 (m, 2H), 7.54–7.51 (m, 1H), 7.46–7.42 (m, 2H), 7.39–7.32 (m, 6H), 7.02–6.99 (m, 2H), 5.21–5.16 (m, 1H), 5.12–5.08 (m, 1H), 4.02–3.96 (m, 2H), 3.87–3.82 (m, 2H), 3.30–3.27 (m, 1H), 2.97–2.94 (m, 2H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 478 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> Benzyl (4aR,7aR)-2-Benzamido-7a-(2-thienyl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazine-6-carboxylate (Chiral Purification) (<b>15e</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0068.gif" alt="" id="GRAPHIC-d7e2796-autogenerated" /></img><div class="NLM_p last">Benzyl rel-(4aR,7aR)-2-benzamido-7a-(2-thienyl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazine-6-carboxylate (13.11g, 27.44 mmol) as a mixture of the <i>cis</i>-fused diastereomers was chirally separated over multiple injections via SFC using a Chiralpak AS-H 50 × 150 mm column. The conditions used were 30% MeOH/70% CO<sub>2</sub>, flow rate = 300 g/min, 100 bar, 40 °C, 7 mL injection size (∼525 mg). This resulted in the desired product (5.73g, 12.0 mmol). <sup>1</sup>H NMR (400.15 MHz, CDCl<sub>3</sub>): δ 8.10.</div></div><div id="sec4_2_2_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> <i>N</i>-[(4aR,7aR)-7a-(2-Thienyl)-4a,5,6,7-tetrahydro-4<i>H</i>-pyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (<b>15f</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0030.gif" alt="" id="fx19" /></img><div class="NLM_p last">To a stirred solution of  benzyl (4aR,7aR)-2-benzamido-7a-(2-thienyl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazine-6-carboxylate (47.1 g, 98.6 mmol) in acetonitrile (707 mL) was added iodotrimethylsilane (26.1 mL, 177.5 mmol). The resulting yellow solution was stirred at room temperature overnight. The reaction was the concentrated to remove the acetonitrile, and aqueous 2 M HCl (1 L) was added followed by EtOAc (500 mL). The organic layer was separated and washed with aqueous 2 M HCl (150 mL). The combined aqueous layers were washed with isohexane (200 mL) and then basified to pH 10 with 50% NaOH. The basified aqueous phase was extracted with EtOAc (3 × 400 mL); the combined organic layers were dried over sodium sulfate, and the solvent was removed in vacuo to afford 33.3 g (89%) of product that was utilized as is in the next step. <sup>1</sup>H NMR (400.13 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.01 (d, <i>J</i> = 7.3 Hz, 2H), 7.60–7.55 (m, 2H), 7.49 (t, <i>J</i> = 7.6 Hz, 2H), 7.19 (d, <i>J</i> = 3.1 Hz, 1H), 7.12–7.09 (m, 1H), 3.62–3.54 (m, 3H), 3.39–3.38 (m, 1H), 3.12–3.06 (m, 1H), 3.02 (d, <i>J</i> = 3.1 Hz, 2H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 344 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_2_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> <i>N</i>-[(4aR,7aR)-6-(5-Fluoropyrimidin-2-yl)-7a-(2-thienyl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (<b>15g</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0031.gif" alt="" id="fx20" /></img><div class="NLM_p last">To a stirred solution of  <i>N</i>-[(4aR,7aR)-7a-(2-thienyl)-4a,5,6,7-tetrahydro-4<i>H</i>-pyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (35.9 g, 95.1 mmol) in <i>N</i>-methyl pyrrolidone (359 mL) at rt was added diisopropylethylamine (28.2 mL, 161.7 mmol) followed by 5-fluoro-2-chloropyrimidine (16.38 g, 11.81 mL, 123.6 mmol). The reaction was heated to 85 °C for 6 h and monitored by LC/MS until complete. The reaction was cooled and was poured into water (1.8 L) and solids precipitated. The mixture was diluted with EtOAc (500 mL); the organic layer was removed, and the aqueous layer was extracted with EtOAc (500 mL then 300 mL).  The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford 64.7 g of crude product. The material was purified by silica gel chromatography eluting with 5% EtOAc in CH<sub>2</sub>Cl<sub>2</sub> to give the desired product. <sup>1</sup>H NMR (300.11 MHz, CDCl<sub>3</sub>): δ 8.23 (d, <i>J</i> = 0.6 Hz, 2H), 8.08 (d, <i>J</i> = 6.8 Hz, 2H), 7.52–7.41 (m, 3H), 7.32 (dd, <i>J</i> = 1.1, 5.1 Hz, 1H), 7.09 (d, <i>J</i> = 2.8 Hz, 1H), 7.03 (dd, <i>J</i> = 3.6, 5.1 Hz, 1H), 4.24–4.08 (m, 2H), 3.98 (d, <i>J</i> = 9.0 Hz, 2H), 3.39–3.34 (m, 1H), 3.13–3.04 (m, 1H), 2.96 (dd, <i>J</i> = 4.1, 13.5 Hz, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 440 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_2_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> (4aR,7aR)-6-(5-Fluoropyrimidin-2-yl)-7a-(2-thienyl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-amine (<b>15h</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0032.gif" alt="" id="fx21" /></img><div class="NLM_p last">A solution of <i>N</i>-[(4aR,7aR)-6-(5-fluoropyrimidin-2-yl)-7a-(2-thienyl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (24.1 g, 51.0 mmol) in methanol (482 mL) was treated with lithium hydroxide (1.346 g, 56.2 mmol) and was heated to 76 °C for 2 h. The reaction was cooled and then concentrated. Aqueous 1 N HCl (51 mL) was added, and the mixture was extracted with EtOAc (50 mL). The organic layer was washed with 1 N HCl (51 mL). The combined aqueous layers were basified to pH 10 with 50% aqueous NaOH, and the mixture was extracted with EtOAc (3 × 100 mL). The combined EtOAc extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford 17.2 g (99%) of product. <sup>1</sup>H NMR (300.11 MHz, CDCl<sub>3</sub>): δ 8.23 (d, <i>J</i> = 0.8 Hz, 2H), 7.28–7.23 (m, 1H), 7.02–6.94 (m, 2H), 4.70–4.65 (m, 2H), 4.11–4.01 (m, 2H), 3.90–3.78 (m, 2H), 3.28 (dd, <i>J</i> = 3.9, 12.9 Hz, 1H), 2.95 (dd, <i>J</i> = 4.3, 13.0 Hz, 1H), 2.89–2.80 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 336 [M + H]<sup>+</sup>. OR [α]<sub>589</sub><sup>20</sup> = −121.4 (1.0, CH<sub>2</sub>Cl<sub>2</sub>).</div></div><div id="sec4_2_2_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> (4aR,7aR)-6-(5-Fluoropyrimidin-2-yl)-7a-(2-thienyl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-amine hydrochloride (<b>15</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0033.gif" alt="" id="fx22" /></img><div class="NLM_p last">A mixture of (4aR,7aR)-6-(5-fluoropyrimidin-2-yl)-7a-(2-thienyl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-amine (603 mg, 1.18 mmol) in MTBE (7 mL) and EtOAc (4.5 mL) was heated to 65 °C for 5 min to dissolve the solids. The resultant solution was then treated with aqueous 1 N HCl (2.15 mL, 2.15 mmol), and a white solid precipitated. The mixture was cooled to room temperature and stirred and was then filtered, and the solids were washed with 1.6:1 MTBE/EtOAc. The solids were dried in a vacuum oven at 40 °C overnight to afford 0.67 g (98%) of product. <sup>1</sup>H NMR (400.13 MHz, DMSO): δ 11.46 (s, 1H), 8.52 (s, 2H), 7.63 (dd, <i>J</i> = 1.0, 5.1 Hz, 1H), 7.23 (dd, <i>J</i> = 1.0, 3.7 Hz, 1H), 7.14 (dd, <i>J</i> = 3.7, 5.1 Hz, 1H), 4.25 (d, <i>J</i> = 11.7 Hz, 1H), 4.05–4.02 (m, 1H), 3.91 (dd, <i>J</i> = 8.4, 11.1 Hz, 1H), 3.64–3.57 (m, 1H), 3.42 (dd, <i>J</i> = 4.0, 13.6 Hz, 1H), 3.36–3.30 (m, 1H), 3.21 (dd, <i>J</i> = 3.7, 13.4 Hz, 1H). HRMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>14</sub>FN<sub>5</sub>S<sub>2</sub> (M + H) 335.0675, found 335.0684.</div></div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Synthesis of Compound <b>16</b></h4><div id="sec4_2_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> <i>tert</i>-Butyl <i>N</i>-Allyl-<i>N</i>-[2-[methoxy(methyl)amino]-2-oxoethyl]carbamate (<b>13</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0034.gif" alt="" id="fx23" /></img><div class="NLM_p last">A solution of Boc-<i>N</i>-(allyl)-glycine (85.5 g, 397.3 mmol) in tetrahydrofuran (1.30 L) was chilled in a 0 °C ice bath under an atmosphere of nitrogen. Triethylamine (83.1 mL, 596.0 mmol) was added followed by the dropwise addition of pivaloyl chloride (53.5 mL, 437.0 mmol) over a period of 15 min, while maintaining the internal temperature below 10 °C. The cooling bath was removed, and the white mixture was stirred for 1 h while being warmed to rt. The reaction was then returned to 0 °C and treated with additional triethylamine (83.1 mL, 596.0 mmol) and <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride (46.5 g, 476.8 mmol), after which the reaction was moved to rt and stirred for 15 h. The mixture was concentrated, and the resulting solid was transferred to a separatory funnel containing EtOAc (700 mL), hexanes (100 mL), and 0.5 M aqueous HCl (400 mL). The phases were partitioned, and the organic phase further washed with dilute aqueous NaHCO<sub>3</sub> (1 × 300 mL), water (1 × 200 mL), and saturated aqueous brine (1 × 200 mL). The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product as a pale-yellow liquid. The sample was purified via silica gel chromatography eluting with hexanes/EtOAc (2-step gradient from 70:30 to 60:40) to afford the desired product (80.26 g, 310.7 mmol, 78% yield). <sup>1</sup>H NMR (400.15 MHz, CDCl<sub>3</sub>): δ 5.83–5.77 (m, 1H), 5.16–5.08 (m, 2H), 4.12–4.09 (m, 1H), 4.01 (s, 1H), 3.96–3.92 (m, 1H), 3.92–3.89 (m, 1H), 3.68 (d, <i>J</i> = 10.7 Hz, 3H), 3.16 (d, <i>J</i> = 2.6 Hz, 3H), 1.43 (d, <i>J</i> = 12.1 Hz, 9H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 159 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> <i>tert</i>-Butyl <i>N</i>-Allyl-<i>N</i>-(2-oxo-2-pyrazin-2-ylethyl)carbamate (<b>16a</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0035.gif" alt="" id="fx24" /></img><div class="NLM_p last">A solution of 2,2,6,6-tetramethylpiperidine (25.4 mL, 150 mmol) in tetrahydrofuran (250 mL) was cooled to −70 °C. Butyl lithium (89.7 mL, 144 mmol) was added over 15 min. The solution was stirred at −70 °C for 10 min, and then a solution of pyrazine (10 g, 124.9 mmol) in tetrahydrofuran (25 mL) was added over 30 min while the temperature was kept below −65 °C. This resulted in a color change in the solution from yellow to a dark red. After 5 min of stirring, a solution of <i>tert</i>-butyl <i>N</i>-allyl-<i>N</i>-[2-[methoxy(methyl)amino]-2-oxoethyl]carbamate (19.4 g, 74.9 mmol) in tetrahydrofuran (25 mL) was added dropwise, again keeping the temperature of the reaction at −65 °C. The reaction was then stirred for an additional 30 min at −70 °C. Then reaction mixture was warmed to −30 °C, checked by HPLC, and then diluted with MTBE (250 mL) and water (100 mL). Some NaCl solution was added to improve the phase separation and then transferred to a separatory funnel. The organic layer was isolated and washed twice with aqueous MTBE (2 × 125 mL). The combined organic layers were dried over sodium sulfate and filtered. Filtrates were evaporated to afford the crude product as a reddish-brown oil (38 g). The crude material was filtered through silica gel using an eluent of 4:1 DCM/EtOAc. Fractions containing desired product were combined and evaporated to give the desired product (12.5 g, 45.1 mmol, 36% yield). <sup>1</sup>H NMR (300.11 MHz, CDCl<sub>3</sub>): δ 9.42–9.22 (m, 1H), 8.82–8.73 (m, 1H), 8.66–8.63 (m, 1H), 5.92–5.81 (m, 1H), 5.19–5.13 (m, 2H), 4.87 (s, 1H), 4.77 (s, 1H), 4.04–3.95 (m, 2H), 1.37 (s, 9H).). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 222 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> (±)-<i>tert</i>-Butyl (3aR,6aR)-1-[(4-Methoxyphenyl)methyl]-6a-pyrazin-2-yl-3,3a,4,6-tetrahydropyrrolo[3,4-<i>c</i>]isoxazole-5-carboxylate (<b>16b</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0036.gif" alt="" id="fx25" /></img><div class="NLM_p last">To a stirred solution of <i>tert</i>-butyl <i>N</i>-allyl-<i>N</i>-(2-oxo-2-pyrazin-2-ylethyl)carbamate (0.14 g, 0.50 mmol), in anhydrous toluene (5 mL) were added <i>N</i>-[(4-methoxyphenyl)methyl]hydroxylamine hydrochloride (123 mg, 0.65 mmol) and triethylamine (104 μL, 0.75 mmol). The resulting solution was then treated with Ti(OEt)<sub>4</sub> (416 uμL, 1.99 mmol) via syringe, and the mixture was heated at 75 °C with stirring for 5 h. The mixture was cooled to rt followed by the addition of water (5 mL) and EtOAc (50 mL). The mixture was stirred for 10 min then filtered via Celite. The organic phase was dried over MgSO<sub>4</sub> and then concentrated. The sample was purified on a column of SiO<sub>2</sub> (24 g) using a gradient of 0–40% acetone in hexanes to give the desired product as a mixture of <i>cis</i>-fused diastereomers (126 mg; 0.290 mmol, 58% yield). <sup>1</sup>H NMR (300.11 MHz, CDCl<sub>3</sub>): δ 8.91 (s, 1H), 8.57–8.52 (m, 2H), 7.26–7.21 (m, 2H), 6.84 (d, <i>J</i> = 8.5 Hz, 2H), 4.33 (t, <i>J</i> = 8.2 Hz, 1H), 4.18–4.03 (m, 2H), 3.79 (s, 5H), 3.73–3.55 (m, 2H), 3.47–3.42 (m, 2H), 1.52 (s, 9H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 413 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> (±)-(3aR,6aR)-1-[(4-Methoxyphenyl)methyl]-6a-pyrazin-2-yl-3a,4,5,6-tetrahydro-3<i>H</i>-pyrrolo[3,4-<i>c</i>]isoxazole (<b>16c</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0037.gif" alt="" id="fx26" /></img><div class="NLM_p last">Trifluoroacetic acid (21.45 mL, 283.64 mmol) was added to a stirred solution of (±)-<i>tert</i>-butyl (3aR,6aR)-1-[(4-methoxyphenyl)methyl]-6a-pyrazin-2-yl-3,3a,4,6-tetrahydropyrrolo[3,4-<i>c</i>]isoxazole-5-carboxylate (3.90 g, 9.45 mmol) in dichloromethane (100 mL) at rt. The mixture was stirred at rt for 1.5 h and then concentrated. The residue was dissolved in MeOH (15 mL). This solution was loaded onto an ion-exchange resin (SCX) column (50 g). The column was first washed with MeOH (80 mL) and then ammoniated MeOH (100 mL). The basic fraction contained product by LC/MS and was concentrated to afford the semipure product. This material was further purified on a column of SiO<sub>2</sub> (120g) using a gradient 0–10% ammoniated MeOH in DCM to give the desired product (1.98 g, 6.34 mmol, 67% yield). <sup>1</sup>H NMR (300.11 MHz, CDCl<sub>3</sub>): δ 8.86 (s, 1H), 8.55 (dd, <i>J</i> = 1.5, 2.4 Hz, 1H), 8.51 (d, <i>J</i> = 2.4 Hz, 1H), 7.20 (d, <i>J</i> = 8.7 Hz, 2H), 6.85–6.82 (m, 2H), 4.32–4.02 (m, 1H), 3.78 (s, 3H), 3.65 (dd, <i>J</i> = 4.4, 8.6 Hz, 1H), 3.43 (s, 2H), 3.39–3.21 (m, 3H), 2.99 (dd, <i>J</i> = 2.6, 11.9 Hz, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 313 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_3_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> (±)-(3aR,6aR)-5-(5-Fluoropyrimidin-2-yl)-1-[(4-methoxyphenyl)methyl]-6a-pyrazin-2-yl-3,3a,4,6-tetrahydropyrrolo[3,4-<i>c</i>]isoxazole (<b>16d</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0038.gif" alt="" id="fx27" /></img><div class="NLM_p last">A solution of (±)-(3aR,6aR)-1-[(4-methoxyphenyl)methyl]-6a-pyrazin-2-yl-3a,4,5,6-tetrahydro-3<i>H</i>-pyrrolo[3,4-<i>c</i>]isoxazole (1.98 g, 6.34 mmol) in 1,4-dioxane (44 mL) was treated with 2-chloro-5-fluoropyrimidine (3.78 g, 28.52 mmol) and diisopropylethylamine (5.53 mL, 31.69 mmol). The reaction was heated at 110 °C for 3 h. The solvent was evaporated to afford the crude product. The crude product was purified on a column of SiO<sub>2</sub> (120g) using a gradient 0–5% MeOH(NH<sub>3</sub>) in DCM to give the desired product (2.08 g; 4.58 mmol, 72% yield). <sup>1</sup>H NMR (300.11 MHz, CDCl<sub>3</sub>): δ 9.01 (d, <i>J</i> = 1.3 Hz, 1H), 8.56–8.54 (m, 1H), 8.52 (d, <i>J</i> = 2.4 Hz, 1H), 8.28 (d, <i>J</i> = 0.8 Hz, 2H), 7.25–7.21 (m, 2H), 6.86–6.82 (m, 2H), 4.41–4.31 (m, 3H), 3.93–3.84 (m, 3H), 3.80–3.79 (m, 3H), 3.72 (s, 1H), 3.61–3.50 (m, 2H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 409 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_3_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> (±)-(3aR,6aR)-5-(5-Fluoropyrimidin-2-yl)-6a-pyrazin-2-yl-3,3a,4,6-tetrahydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]isoxazole (<b>16e</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0039.gif" alt="" id="fx28" /></img><div class="NLM_p last">Compound (±)-(3aR,6aR)-5-(5-fluoropyrimidin-2-yl)-1-[(4-methoxyphenyl)methyl]-6a-pyrazin-2-yl-3,3a,4,6-tetrahydropyrrolo[3,4-<i>c</i>]isoxazole (2.08 g, 5.09 mmol) was mixed with trifluoroacetic acid (20.4 mL, 269.9 mmol) and stirred at 60 °C for 1 h. The solvent was evaporated, and the residue was dissolved in a mixture of MeOH and DMSO. The mixture was loaded onto a 25 g ion-exchange (SCX) column. The column was washed with MeOH (70 mL) and then with ammoniated methanol (70 mL). The basic fraction was concentrated to give the semipure product, which was then further purified via silica gel chromatography using a 40 g SiO<sub>2</sub> column and eluting with a gradient of 0–10% MeOH(NH<sub>3</sub>) in DCM. This resulted in the desired product (1.1 g, 3.24 mmol, 64% yield). <sup>1</sup>H NMR (300.11 MHz, CDCl<sub>3</sub>): δ 9.07 (d, <i>J</i> = 0.6 Hz, 1H), 8.56–8.52 (m, 2H), 8.25 (s, 2H), 4.55–4.42 (m, 1H), 4.27–4.07 (m, 1H), 4.04–3.86 (m, 2H), 3.84–3.77 (m, 3H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 289 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_3_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> [(±)-(3<i>R</i>,4<i>R</i>)-4-Amino-1-(5-fluoropyrimidin-2-yl)-4-pyrazin-2-yl-pyrrolidin-3-yl]methanol (<b>16f</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0040.gif" alt="" id="fx29" /></img><div class="NLM_p last">A solution of (±)-(3aR,6aR)-5-(5-fluoropyrimidin-2-yl)-6a-pyrazin-2-yl-3,3a,4,6-tetrahydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]isoxazole (1.10g, 3.82 mmol) in ethanol (30 mL) was hydrogenated at 50 psi in the presence of Raney nickel (slurry in water) (1.4 g, 23.61 mmol). The reaction was stirred for 4 h at rt. The mixture was diluted with MeOH and the catalyst removed by decantation. Organic phase was additionally filtered through Celite. The solvent was evaporated to afford the desired product (0.96 g, 3.14 mmol, 82% yield). <sup>1</sup>H NMR (300.11 MHz, CDCl<sub>3</sub>): δ 8.89–8.88 (m, 1H), 8.57–8.56 (m, 2H), 8.24 (d, <i>J</i> = 0.6 Hz, 2H), 4.08–3.89 (m, 5H), 3.64 (dd, <i>J</i> = 9.4, 11.1 Hz, 1H), 3.08–3.00 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 291 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_3_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> (±)-<i>N</i>-[[(3<i>R</i>,4<i>R</i>)-1-(5-Fluoropyrimidin-2-yl)-4-(hydroxymethyl)-3-pyrazin-2-yl-pyrrolidin-3-yl]carbamothioyl]benzamide (<b>16g</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0041.gif" alt="" id="fx30" /></img><div class="NLM_p last">To a stirred suspension of [(±)-(3<i>R</i>,4<i>R</i>)-4-amino-1-(5-fluoropyrimidin-2-yl)-4-pyrazin-2-yl-pyrrolidin-3-yl]methanol (960 mg, 3.31 mmol) in tetrahydrofuran (35 mL) under N<sub>2</sub> was added benzoyl isothiocyanate (546 μL, 3.97 mmol). The reaction was continued at rt for 40 min. The solvent was evaporated to give the crude product. The crude sample was purified on a column of SiO<sub>2</sub> (40g) using a gradient 0–10% MeOH(NH<sub>3</sub>) in DCM to give the desired product (1.57g, 3.46 mmol, 99%). <sup>1</sup>H NMR (300.11 MHz, CDCl<sub>3</sub>): δ 11.97 (s, 1H), 9.02–8.96 (m, 1H), 8.84–8.81 (m, 1H), 8.57–8.55 (m, 1H), 8.50–8.47 (m, 1H), 8.26 (d, <i>J</i> = 0.8 Hz, 2H), 7.94–7.82 (m, 2H), 7.67–7.62 (m, 1H), 7.55–7.49 (m, 2H), 4.97 (d, <i>J</i> = 12.1 Hz, 1H), 4.76 (d, <i>J</i> = 12.2 Hz, 1H), 4.17–4.07 (m, 1H), 4.06–3.98 (m, 2H), 3.86–3.76 (m, 2H), 3.51 (s, 1H), 3.11–3.06 (m, 1H), 2.97–2.86 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 454 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_3_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> (±)-<i>N</i>-[(4aR,7aR)-6-(5-Fluoropyrimidin-2-yl)-7a-pyrazin-2-yl-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (<b>16h</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0042.gif" alt="" id="fx31" /></img><div class="NLM_p last">A solution of (±)-<i>N</i>-[[(3<i>R</i>,4<i>R</i>)-1-(5-fluoropyrimidin-2-yl)-4-(hydroxymethyl)-3-pyrazin-2-yl-pyrrolidin-3-yl]carbamothioyl]benzamide (1.57g, 3.46 mmol) in dichloromethane (35 mL) was cooled to 0 °C. 1-Chloro-<i>N</i>,<i>N</i>,2-trimethylpropenylamine (480 μL, 3.64 mmol) was added. The solution was warmed to rt and stirred for 2 h. An additional aliquot of 1-chloro-<i>N</i>,<i>N</i>,2-trimethylpropenylamine (192 μL, 1.45 mmol) was added, and the reaction was continued for 45 min, at which time the reaction was observed by LC/MS to be complete. Saturated Na<sub>2</sub>CO<sub>3</sub> (aqueous, 30 mL) was added and the mixture diluted with DCM (150 mL). Aqueous phase was separated and extracted additionally with DCM (150 mL). Combined organic phases were dried, and solvent was evaporated to afford the crude product. The crude product was dissolved in MeOH (10 mL) and loaded on a SCX ion-exchange column (25 g). The column was first washed with MeOH (50 mL) and then MeOH(NH<sub>3</sub>) (50 mL). The basic fraction was concentrated to give the crude product, which was purified via silica gel chromatography using a 120 g column and eluted with a gradient of 0–5% ammoniated methanol in DCM to give the desired product as a mixture of the <i>cis</i>-fused diastereomers (900 mg, 2.07 mmol, 60% yield). <sup>1</sup>H NMR (300.11 MHz, CDCl<sub>3</sub>): δ 13.14–13.11 (m, 0H), 8.86–8.80 (m, 1H), 8.62–8.60 (m, 2H), 8.24 (s, 2H), 8.15–8.11 (m, 2H), 7.57–7.46 (m, 3H), 7.28 (s, 3H), 5.32 (s, 1H), 4.25–4.13 (m, 2H), 4.02 (d, <i>J</i> = 9.0 Hz, 2H), 3.68–3.57 (m, 1H), 3.24–3.19 (m, 1H), 3.00–2.94 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 436 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_3_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> (4aR,7aR)-6-(5-Fluoropyrimidin-2-yl)-7a-pyrazin-2-yl-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-amine (<b>16</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0043.gif" alt="" id="fx32" /></img><div class="NLM_p last">A mixture of (±)-<i>N</i>-[(4aR,7aR)-6-(5-fluoropyrimidin-2-yl)-7a-pyrazin-2-yl-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (900 mg, 2.07 mmol), pyridine (2.01 mL, 24.80 mmol) and <i>o</i>-methylhydroxylamine hydrochloride (1.59 g, 18.60 mmol) in ethanol (65 mL) was heated to 80 °C with stirring for 3 h. The solvent was evaporated, and the crude product was supported on SiO<sub>2</sub> and purified on a column of SiO<sub>2</sub> (40 g) using a gradient 0–10% MeOH(NH<sub>3</sub>) in DCM over 25 column volume, which resulted in a semipure product. The product was dissolved in MeOH (20 mL) and loaded on a SCX ion-exchange column (25g). The column was first washed with MeOH (100 mL) then MeOH(NH<sub>3</sub>) (100 mL). The basic fraction was concentrated to give the desired product as a mix of <i>cis</i>-fused diastereomers. The sample was chirally purified via SFC using a 150 × 21.2 mm i.d., 60A, 5u ODH column (Princeton Chromatography) run at 100 bar, 35 °C, and eluted with a 0–50% (0.2% diethylamine in MeOH)/CO<sub>2</sub> gradient to give the desired chirally pure material (233 mg, 0.70 mmol, 34% yield). <sup>1</sup>H NMR (300.11 MHz, CDCl<sub>3</sub>): δ 8.81 (d, <i>J</i> = 1.3 Hz, 1H), 8.53–8.48 (m, 2H), 8.21 (s, 2H), 4.16 (d, <i>J</i> = 10.9 Hz, 1H), 4.00 (d, <i>J</i> = 10.9 Hz, 1H), 3.88 (d, <i>J</i> = 8.9 Hz, 2H), 3.47 (s, 2H), 3.39–3.31 (m, 1H), 3.14 (dd, <i>J</i> = 4.0, 13.2 Hz, 1H), 2.95 (dd, <i>J</i> = 4.4, 13.1 Hz, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 332 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Synthesis of Compound <b>17</b></h4><div id="sec4_2_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> Benzyl (4aR,7aR)-2-Benzamido-7a-(5-bromo-2-thienyl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazine-6-carboxylate (<b>17a</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0044.gif" alt="" id="fx33" /></img><div class="NLM_p last">To a stirred clear and colorless solution of benzyl (4aR,7aR)-2-benzamido-7a-(2-thienyl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazine-6-carboxylate (3.71 g, 7.77 mmol) in dimethylformamide (78 mL) at rt and under an atmosphere of nitrogen was added <i>N</i>-bromosuccinimide (1.66g, 9.32 mmol). The resulting solution was stirred for 65 min. The solution was diluted with EtOAc (250 mL) and hexanes (50 mL) and then transferred to a separatory funnel, washed with water (2 × 50 mL) and with brine (1 × 50 mL). The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified via silica gel chromatography eluting with hexanes/EtOAc, gradient from 80:20 to 0:100 to afford the desired product as a white foam (3.88 g, 6.97 mmol, 90% yield). <sup>1</sup>H NMR (400.15 MHz, CDCl<sub>3</sub>): δ 8.11–8.08 (m, 2H), 7.57–7.56 (m, 1H), 7.49–7.44 (m, 2H), 7.38–7.33 (m, 5H), 6.97–6.95 (m, 1H), 6.79–6.77 (m, 1H), 5.21–5.19 (m, 2H), 3.98–3.96 (m, 4H), 3.30–3.29 (m, 1H), 2.92–2.90 (m, 2H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 556/558 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> Benzyl (4aR,7aR)-2-Benzamido-7a-(5-cyano-2-thienyl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazine-6-carboxylate (<b>17b</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0045.gif" alt="" id="fx34" /></img><div class="NLM_p">A mixture of benzyl (4aR,7aR)-2-benzamido-7a-(5-bromo-2-thienyl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazine-6-carboxylate (3.88 g, 6.97 mmol), potassium hexacyanoferrate(II) (2.57g, 6.97 mmol), copper(I) iodide (398 mg, 2.09 mmol), and 1-butylimidazole (2.75 mL, 20.92 mmol) in toluene (23 mL) was stirred together in a pressure tube at rt. A stream of nitrogen was passed over the mixture for a few minutes, and then the tube was sealed with a pressure gauge.</div><div class="NLM_p last">The stirred mixture was placed in a 140 °C oil bath for 18 h. The reaction was then cooled to rt. The mixture was diluted with EtOAc (100 mL) and water. The mixture was filtered through a pad of Celite while being rinsed with additional EtOAc (100 mL) and water (15 mL). The filtrate was transferred to a separatory funnel, and the layers were partitioned. The organic phase was further washed with water (2 × 30 mL) and brine (1 × 30 mL). The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The sample was purified via silica gel chromatography eluting with a 20–100% EtOAc/hexanes gradient to give the desired product (2.59 g, 5.15 mmol, 74% yield). <sup>1</sup>H NMR (399.83 MHz, CDCl<sub>3</sub>): δ 7.98–7.97 (m, 2H), 7.60–7.47 (m, 4H), 7.36–7.29 (m, 5H), 6.99–6.97 (m, 1H), 5.19–5.09 (m, 2H), 3.97–3.91 (m, 3H), 3.17–3.15 (m, 1H), 2.94–2.91 (m, 2H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 503 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> <i>N</i>-[(4aR,7aR)-7a-(5-Cyano-2-thienyl)-4a,5,6,7-tetrahydro-4<i>H</i>-pyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (<b>17c</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0046.gif" alt="" id="fx35" /></img><div class="NLM_p last">To a stirred clear and colorless solution of benzyl (4aR,7aR)-2-benzamido-7a-(5-cyano-2-thienyl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazine-6-carboxylate (641 mg, 1.28 mmol) in acetonitrile (26 mL) was added iodotrimethylsilane (0.55 mL, 3.83 mmol). The resulting yellow solution was stirred at room temperature for 70 min. Methanol (0.62 mL, 15.30 mmol) was added, and the reaction was stirred for 5 min. The reaction was then concentrated to give an amber solid. This material was purified via silica gel chromatography eluting with a 0–10% MeOH/DCM gradient to give the desired product as a white solid (590 mg, 1.60 mmol, 125% yield). Note, some residual DCM was present, which accounts for the extra mass, but the sample was taken on and used as is in the next step. <sup>1</sup>H NMR (400.15 MHz, CDCl<sub>3</sub>): δ 7.85–7.83 (m, 2H), 7.59–7.54 (m, 1H), 7.50 (d, <i>J</i> = 4.0 Hz, 1H), 7.46–7.41 (m, 2H), 7.10 (d, <i>J</i> = 4.0 Hz, 1H), 4.10–4.08 (m, 1H), 3.89–3.88 (m, 1H), 3.67–3.62 (m, 2H), 3.27–3.26 (m, 2H), 3.15–3.13 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 369 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_4_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> <i>N</i>-[(4aR,7aR)-7a-(5-Cyano-2-thienyl)-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (<b>17d</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0047.gif" alt="" id="fx36" /></img><div class="NLM_p last">To a stirred clear and colorless solution of <i>N</i>-[(4aR,7aR)-7a-(5-cyano-2-thienyl)-4a,5,6,7-tetrahydro-4<i>H</i>-pyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (470 mg, 1.28 mmol) in 1,4-dioxane (25 mL) at rt was added diisopropylethylamine (0.667 mL, 3.825 mmol) followed by 5-fluoro-2-chloropyrimidine (1.22 mL, 12.75 mmol). The reaction was heated to reflux (heating block temp = 110 °C) for 5 h with monitoring by LC/MS. The clear pale-yellow solution was cooled for ∼15 min. The solution was diluted with EtOAc (130 mL) and hexanes (30 mL) and then washed with dilute aqueous NaHCO<sub>3</sub> (1 × 50 mL), water (2 × 40 mL), and brine (1 × 40 mL). The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by silica gel chromatography eluting with a gradient of 50–100% hexanes/Et<sub>2</sub>O to give the desired product (453 mg, 0.98 mmol, 76% yield). <sup>1</sup>H NMR (400.15 MHz, CDCl<sub>3</sub>): δ 8.22 (d, <i>J</i> = 0.7 Hz, 2H), 8.00–7.99 (m, 2H), 7.56–7.53 (m, 2H), 7.47–7.44 (m, 2H), 7.04–7.03 (m, 1H), 4.18–4.17 (m, 1H), 4.03–4.01 (m, 3H), 3.29–3.23 (m, 1H), 3.07–3.06 (m, 2H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 465 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_4_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> 5-[(4aR,7aR)-2-Amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-7a-yl]thiophene-2-carbonitrile hydrochloride (<b>17</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0048.gif" alt="" id="fx37" /></img><div class="NLM_p last">A solution of <i>N</i>-[(4aR,7aR)-7a-(5-cyano-2-thienyl)-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (442 mg, 0.951 mmol) in ethanol (19.0 mL) was treated with pyridine (752 mg, 9.5 mmol) and <i>o</i>-methylhydroxylamine hydrochloride (795 mg, 9.5 mmol). The stirred solution was heated to 55 °C under an atmosphere of nitrogen for 12 h. The clear and colorless solution was concentrated, diluted with DCM (30 mL), and then reconcentrated. The residue was transferred to a separatory funnel, while being diluted with EtOAc (50 mL), water (25 mL), and saturated aqueous NaHCO<sub>3</sub> (10 mL). The phases were separated, and the aqueous phase extracted with EtOAc (1 × 30 mL). The combined EtOAc extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified via silica gel chromatography using a 30–100% EtOAc/hexanes gradient giving semipure product. The residue was further purified by silica gel chromatography using a 30–100% EtOAc/DCM gradient to afford the free base of the desired product. The free base was dissolved in Et<sub>2</sub>O (20 mL) and treated with 1 M HCl in Et<sub>2</sub>O (0.86 mL, 0.86 mmol). A white solid precipitated, and the mixture was stirred for a few minutes, then the white precipitate was collected by vacuum filtration through filter paper, rinsing with Et<sub>2</sub>O to afford the desired product, 5-[(4aR,7aR)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-7a-yl]thiophene-2-carbonitrile hydrochloride (255 mg, 0.643 mmol, 68% yield). <sup>1</sup>H NMR (400.15 MHz, dmso): δ 11.58–11.57 (m, 1H), 8.51 (d, <i>J</i> = 0.8 Hz, 2H), 8.00 (d, <i>J</i> = 4.1 Hz, 1H), 7.42 (d, <i>J</i> = 4.1 Hz, 1H), 4.30–4.26 (m, 1H), 4.11–4.10 (m, 4H), 3.63–3.61 (m, 1H), 3.44–3.41 (m, 2H), 3.24–3.21 (m, 1H). HRMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>13</sub>FN<sub>6</sub>S<sub>2</sub> (M + H) 360.0627, found 360.0632. OR [α]<sub>D</sub><sup>20</sup> +19.986 (<i>c</i> = 0.1, MeOH).</div></div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Synthesis of Compound <b>18</b></h4><div id="sec4_2_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> <i>tert</i>-Butyl <i>N</i>-Allyl-<i>N</i>-[2-[methoxy(methyl)amino]-2-oxoethyl]carbamate (<b>13</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0049.gif" alt="" id="fx38" /></img><div class="NLM_p last">To a three-neck round flask equipped with an overhead mechanical stir paddle, were added ethyl 2-[allyl(<i>tert</i>-butoxycarbonyl)amino]acetate (85.52 g, 397.311 mmol) and tetrahydrofuran (1.32 L) and then cooled to 0 °C in an ice bath and under an atmosphere of nitrogen. Triethylamine (83.07 mL, 595.966 mmol) was added, followed by pivaloyl chloride (53.53 mL, 437.04 mmol), which was added dropwise over a period of 15 min. The internal reaction temperature was maintained below 10 °C. Mixture was allowed to gradually reach ambient temperature for 1 h. The white suspension was cooled again to 0 °C, and then triethylamine (83.067 mL, 595.966 mmol) and <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride (46.51, 476.773 mmol) were added. Reaction mixture was stirred at ambient temperature for 16 h. The solvent was removed in vacuo, and the white residue was diluted with ethyl acetate (700 mL), hexanes (100 mL), and aqueous HCl (0.5 M, 400 mL). The phases were separated, and the organic phase was further washed with saturated NaHCO<sub>3</sub> (300 mL), water (200 mL), and brine (200 mL). The organic phase was dried over sodium sulfate and filtered. The solvent was removed under reduced pressure. The crude mixture was purified by silica gel chromatography, with a 35 min gradient of 30 to 95% EtOAc/hexanes to afford the product as a yellow oil (80.26 g, 78% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 5.84–5.68 (m, 1H), 5.22–5.09 (m, 2H), 4.04–3.84 (m, 4H), 1.95 (d, <i>J</i> = 8.79 Hz, 9 H). ESI<sup>+</sup>: <i>m</i>/<i>z</i> 214 [M – H]<sup>−</sup>.</div></div><div id="sec4_2_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> <i>tert</i>-Butyl <i>N</i>-Allyl-<i>N</i>-(2-isothiazol-5-yl-2-oxoethyl)carbamate (<b>18a</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0050.gif" alt="" id="fx39" /></img><div class="NLM_p last">A solution of diisopropylamine (36.24 mL, 257.47 mmol) in tetrahydrofuran (300 mL) was cooled to −78 °C. <i>n</i>-Butyl lithium (124 mL, 123.78 mmol, 1.6 M in hexanes) was added dropwise over 20 min. The resulting clear solution was stirred at −78 °C for an additional 45 min. A solution of isothiazole (16.86 g, 198.05 mmol) in tetrahydrofuran (50 mL) was added dropwise over 15 min. The white suspension was stirred at −78 °C for 45 min. This suspension was treated dropwise with a solution of <i>tert</i>-butyl <i>N</i>-allyl-<i>N</i>-[2-(methoxy(methyl)amino)-2-oxoethyl]carbamate (25.58 g, 99.02 mmol) in tetrahydrofuran (150 mL). Reaction mixture was allowed to gradually reach room temperature and then stirred overnight. Reaction was quenched with saturated ammonium chloride (500 mL) and extracted with ethyl acetate. The two phases were separated, and the aqueous phase was extracted with ethyl acetate (3 × 100 mL). The combined organics were dried over magnesium sulfate and filtered. The solvent was removed under reduced pressure. The crude mixture was purified over 330 g of silica gel, with a 35 min gradient of 0 to 100% EtOAc/hexanes to afford the product as a yellow solid (21.62 g, 77% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.59–8.54 (m, 1H), 7.77–7.70 (m, 1H), 5.87–5.72 (m, 1H), 5.20–5.09 (m, 2H), 4.47 (s, 1H), 4.38–4.32 (m, 1H), 4.04–3.98 (m, 1H), 3.96–3.89 (m, 1H), 1.47 (s, 4.5H), 1.34 (s, 4.5H). ESI<sup>+</sup>: <i>m</i>/<i>z</i> 281 [M – H]<sup>−</sup>.</div></div><div id="sec4_2_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> (±)-<i>tert</i>-Butyl-6a-isothiazol-5-yl-1-[(4-methoxyphenyl)methyl]-3,3a,4,6-tetrahydropyrrolo[3,4-<i>c</i>]isoxazole-5-carboxylate (<b>18b</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0051.gif" alt="" id="fx40" /></img><div class="NLM_p last">To a stirred suspension of the <i>tert</i>-butyl <i>N</i>-allyl-<i>N</i>-(2-isothiazol-5-yl-2-oxoethyl)carbamate (21.22 g, 75.15 mmol) in toluene (500 mL) were added <i>N</i>-[(4-methoxyphenyl)methyl]hydroxylamine (18.53 g, 97.70 mmol), diisopropylethylamine (17.03 mL, 97.70 mmol), and titanium tetraethoxide (31.43 mL, 150.30 mmol) under an atmosphere of nitrogen. The reaction mixture became a clear solution and was heated to 70 °C and stirred overnight, cooled to room temperature, diluted with ethyl acetate and water, and then filtered through Celite. The solid was washed with ethyl acetate; then the filtrate was placed in a separatory funnel, and the phases were separated. The organic phase was dried over magnesium sulfate and filtered. The solvent was removed under reduced pressure. The crude mixture was purified over 330 g of silica gel, with a 30 min gradient of 0 to 50% EtOAc/hexanes to afford the product as a yellow solid (31.00 g, 99% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.42 (d, <i>J</i> = 1.65 Hz, 1H), 7.26 (d, <i>J</i> = 9.02 Hz, 2H), 7.16–7.12 (m, 1H), 6.84 (d, <i>J</i> = 8.36 Hz, 2H), 4.13 (t, <i>J</i> = 8.25 Hz, 1H), 3.75 (s, 3H), 3.75–3.64 (m, 4H), 3.57–3.38 (m, 1H), 3.15–3.06 (m, 1H), 1.48 (s, 9H). ESI<sup>+</sup>: <i>m</i>/<i>z</i> 418 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_5_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> (±)-<i>tert</i>-Butyl-6a-isothiazol-5-yl-3,3a,4,6-tetrahydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]isoxazole-5-carboxylate (<b>18c</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0052.gif" alt="" id="fx41" /></img><div class="NLM_p last">To a solution of (±)-<i>tert</i>-butyl 6a-isothiazol-5-yl-1-[(4-methoxyphenyl)methyl]-3,3a,4,6-tetrahydropyrrolo[3,4-<i>c</i>]isoxazole-5-carboxylate (27.10 g, 64.91 mmol) in trifluoroacetic acid (250 mL) was added triethylsilane (20.80 mL, 129.81 mmol). Reaction was heated to 80 °C for 3 h, concentrated in vacuo to a minimum amount of TFA, and then MeOH was added until a white precipitate formed. The solid was collected by filtration and then was washed several times with ethyl acetate. After being dissolved in tetrahydrofuran/water (1:1, 150 mL), NaOH (5 N, 13 mL) was added. Reaction mixture was stirred vigorously, and di-<i>tert</i>-butyl-dicarbonate (9.03 g, 41.3 mmol) was added as a solution in tetrahydrofuran (10 mL) and stirred at room temperature for 10 min. Ethyl acetate (200 mL) and brine (150 mL) were added. The phases were separated, and the aqueous phase was extracted with ethyl acetate. The combined organics were dried over magnesium sulfate and filtered. The solvent was removed under reduced pressure to afford the product as an amber color foam (12.4 g, 64.24% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.38 (d, <i>J</i> = 1.60 Hz, 1H), 7.12 (d, <i>J</i> = 1.60 Hz, 1H), 4.40 (t, <i>J</i> = 7.37 Hz 1H), 3.98–3.88 (m, 1H), 3.75–3.64 (m, 2H), 3.63–3.56 (m, 1H), 3.53 (d, <i>J</i> = 13.19 Hz, 1H), 3.26–3.19 (m, 1H), 1.43 (s, 9H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 298 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_5_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> (±)-<i>tert</i>-Butyl-1-(benzoylcarbamothioyl)-6a-isothiazol-5-yl-3,3a,4,6-tetrahydropyrrolo[3,4-<i>c</i>]isoxazole-5-carboxylate (<b>18d</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0053.gif" alt="" id="fx42" /></img><div class="NLM_p last">(±)-<i>tert</i>-Butyl-6a-isothiazol-5-yl-3,3a,4,6-tetrahydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]isoxazole-5-carboxylate (13.75 g, 46.24 mmol) was dissolved in tetrahydrofuran (200 mL). Benzoyl isothiocyanate (9.98 mL, 73.98 mmol) was added under a nitrogen atmosphere and stirred at ambient temperature for 18 h. The solvent was removed in vacuo. The crude product was purified over 330 g of silica gel, with a 30 min gradient of 0 to 50% ethyl acetate/dichloromethane to afford the product (21.65 g, 100% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.82–8.65 (m, 1H), 8.37 (t, <i>J</i> = 1.4 Hz, 1H), 7.83–7.81 (m, 2H), 7.59–7.55 (m, 1H), 7.47 (t, <i>J</i> = 7.15 Hz, 2H), 7.23–7.23 (m, 1H), 4.86 (m, 1H), 4.51–4.48 (m, 1H), 4.31–4.17 (m, 1H), 4.11–4.04 (m, 1H), 3.89–3.81 (m, 1H), 3.64–3.48 (m, 1H), 3.39–3.31 (m, 1H), 1.47 (d, <i>J</i> = 1.0 Hz, 9H). ESI<sup>+</sup>: <i>m</i>/<i>z</i> 461 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_5_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> (±)-<i>tert</i>-Butyl-3-(benzoylcarbamothioylamino)-4-(hydroxymethyl)-3-isothiazol-5-yl-pyrrolidine-1-carboxylate (<b>18e</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0054.gif" alt="" id="fx43" /></img><div class="NLM_p last">To a solution of (±)-<i>tert</i>-butyl-1-(benzoylcarbamothioyl)-6a-isothiazol-5-yl-3,3a,4,6-tetrahydropyrrolo[3,4-<i>c</i>]isoxazole-5-carboxylate (21.65 g, 47.01 mmol) in acetic acid (235 mL) was added zinc (dust, 30.70 g, 470.06 mmol), stirred vigorously at ambient temperature for 45 min, and filtered through Celite; then the solvent was removed in vacuo. The residue was dissolved in ethyl acetate and washed with water and saturated sodium bicarbonate. The aqueous phase was extracted with ethyl acetate. The combined organics were dried over sodium sulfate and filtered. The solvent was removed under reduced pressure to afford the product as a white foam (21.60 g, 99% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 11.83 (m, 1H), (m, 1H), 9.00–8.93 (s, 1H), 7.85–7.81 (m, 2H), 7.65–7.61 (m, 1H), 7.54–7.50 (m, 2H), 7.17 (d, <i>J</i> = 1.8 Hz, 1H), 4.73 (d, <i>J</i> = 12.1 Hz, 1H), 4.25–4.09 (m, 1H), 4.01–3.95 (m, 2H), 3.80–3.68 (m, 1H), 3.67–3.57 (m, 1H), 2.74–2.61 (m, 1H), 1.48 (m, 9H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 463 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_5_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> (±)-<i>tert</i>-Butyl-2-benzamido-7a-isothiazol-5-yl-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazine-6-carboxylate (<b>18f</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0055.gif" alt="" id="fx44" /></img><div class="NLM_p last">(±)-<i>tert</i>-Butyl-3-(benzoylcarbamothioylamino)-4-(hydroxymethyl)-3-isothiazol-5-yl-pyrrolidine-1-carboxylate (21.60 g, 46.70 mmol) was dissolved in dichloromethane (500 mL) and cooled to 0 °C. Chloro-<i>N</i>,<i>N</i>,2-trimethylpropenylamine (12.35 mL, 93.385 mmol) was added slowly. The mixture was stirred for 2 h and then warmed to ambient temperature and stirred for 3 h. The reaction mixture was washed with water and then saturated sodium bicarbonate. The aqueous phase was extracted with ethyl acetate (3×). The combined organic phase was dried over magnesium sulfate and filtered. The solvent was removed in vacuo. The crude residue was purified over 330 g of silica gel, with a 20 min gradient of 0 to 50% EtOAc/dichloromethane, to afford the product (19.54 g, 94% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.41 (s, 1H), 7.99–7.87 (m, 2H), 7.57–7.49 (m, 1H), 7.49–7.41 (m, 2H), 7.13–7.05 (m, 1H), 3.84–3.65 (m, 4H), 3.21–3.04 (m, 1H), 2.87–2.72 (m, 2H), 1.45–1.41 (m, 9H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 445 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_5_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> <i>tert</i>-Butyl (4aR,7aR)-2-Benzamido-7a-isothiazol-5-yl-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazine-6-carboxylate (<b>18g</b>, Chiral Purification)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0056.gif" alt="" id="fx45" /></img><div class="NLM_p last">(±)-<i>tert</i>-Butyl-2-benzamido-7a-isothiazol-5-yl-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazine-6-carboxylate (19.57 g, 44.019 mmol) as a mixture of the <i>cis</i>-fused diastereomers was chirally separated over multiple injections via SFC using a Chiralpak IC, 50 × 150 mm column. The conditions used were 40% MeOH/60% CO<sub>2</sub>, flow rate = 300 g/min, 100 bar, 40 °C, 8 mL injection size (800 mg). This resulted in the desired product (4.65 g, 10.473 mmol, DE = 98%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.41 (d, <i>J</i> = 1.2 Hz, 1H), 8.04–7.87 (m, 2H), 7.53 (t, <i>J</i> = 7.04 Hz, 1H), 7.53 (t, <i>J</i> = 7.04 Hz, 2H), 7.13–7.05 (m, 1H), 3.92–3.66 (m, 4H), 3.17–3.07 (m, 1H), 2.93–2.78 (m, 2H), 1.43 (d, <i>J</i> = 4.95 Hz, 9H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 445 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_5_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> <i>N</i>-[(4aR,7aR)-7a-Isothiazol-5-yl-4a,5,6,7-tetrahydro-4<i>H</i>-pyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (<b>18h</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0057.gif" alt="" id="fx46" /></img><div class="NLM_p last"><i>tert</i>-Butyl (4aR,7aR)-2-benzamido-7a-isothiazol-5-yl-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazine-6-carboxylate (4.65 g, 10.46 mmol) was dissolved in dichloromethane (100 mL). Trifluoroacetic acid (15.82 mL) was added dropwise and stirred at room temperature overnight. Reaction mixture was concentrated to a minimal amount of solvent in vacuo. To the residue were added ethyl acetate and then saturated sodium bicarbonate. Product was extracted with ethyl acetate (3 × 50 mL), dried over magnesium sulfate, and filtered, and the solvent was removed under reduced pressure to afford the product as a white foam (3.06 g, 85% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.47 (s, 1H), 7.89 (d, <i>J</i> = 8.36 Hz, 2H), 7.57 (t, <i>J</i> = 6.49 Hz, 1H), 7.48 (m, 2H), 7.35 (s, 1H), 3.62–3.45 (m, 4H), 3.23–3.07 (m, 2H), 3.00–2.93 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 345 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_5_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> <i>N</i>-[(4aR,7aR)-6-(5-Fluoropyrimidin-2-yl)-7a-isothiazol-5-yl-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (<b>18i</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0058.gif" alt="" id="fx47" /></img><div class="NLM_p last">A slurry of <i>N</i>-[(4aR,7aR)-7a-isothiazol-5-yl-4a,5,6,7-tetrahydro-4<i>H</i>-pyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (1.21 g, 3.513 mmol) and 5-fluoro-2-chloropyrimidine (2.33 g, 17.564 mmol) in 1,4-dioxane (80 mL) was treated with diisopropylethylamine (1.84 mL, 10.138 mmol). The resulting suspension was heated to reflux under an atmosphere of nitrogen for 3 h to afford a yellow solution, cooled to ambient temperature, and diluted with water and ethyl acetate. The aqueous phase with extracted with ethyl acetate. Combined organics were dried over magnesium sulfate and filtered, and then the solvent was removed in vacuo. The crude product was purified over 120 g of silica gel, with a 20 min gradient of 0 to 50% EtOAc in dichloromethane to afford the product (713 mg, 46% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.43 (m, 1H), 8.20 (s, 2H), 8.03–7.84 (m, 2H), 7.51 (t, <i>J</i> = 6.71 Hz, 1H), 7.42 (t, <i>J</i> = 7.59 Hz, 2H), 7.20–7.10 (m, 1H), 4.22–4.12 (m, 1H), 4.03–3.88 (m, 3H), 3.25–3.17 (m, 1H), 3.06–2.90 (m, 2H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 441 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_5_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> (4aR,7aR)-6-(5-Fluoropyrimidin-2-yl)-7a-isothiazol-5-yl-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-amine hydrochloride (<b>18</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0059.gif" alt="" id="fx48" /></img><div class="NLM_p last">To a solution of <i>N</i>-[(4aR,7aR)-6-(5-fluoropyrimidin-2-yl)-7a-isothiazol-5-yl-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-yl]benzamide (713 mg, 1.619 mmol) in methanol (30 mL) was added lithium hydroxide (340 mg, 8.094 mmol). The reaction was heated to reflux for 5 h. The solvent was removed in vacuo, and the residue was diluted with water and extracted 3× with ethyl acetate. The combined organic layers were dried over sodium sulfate and filtered, and then the solvent was removed in vacuo. The crude product was purified over 40 g of silica gel with a 15 min gradient of 0 to 3% 7 N NH<sub>3</sub>MeOH in CH<sub>2</sub>Cl<sub>2</sub> gradient. The free base was obtained as a white solid (471 mg, 86% yield). The HCl salt was prepared by dissolving the free base in dichloromethane (10 mL), then 1 N HCl in Et<sub>2</sub>O (1.5 mL) was added. Mixture was stirred for 5 min, and then the solvent was removed under vacuum. The product was a white solid (565 mg, 94% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.52 (s, 1H), 8.34 (s, 2H), 7.43 (s, 1H), 5.45 (s, 1H), 4.36 (d, <i>J</i> = 11.88 Hz, 1H), 4.16 (d, <i>J</i> = 12.42 Hz, 1H), 4.04–3.96 (m, 1H), 3.83–3.76 (m, 1H), 3.43–3.30 (m, 2H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 337 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Synthesis of Compound <b>20</b></h4><div id="sec4_2_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> <i>N</i>-[3-[(4aR,7aS)-2-Amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide (<b>20a</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0060.gif" alt="" id="fx49" /></img><div class="NLM_p last">A solution of acetonitrile (3.7 mL) and dimethylformamide (60.5 μL, 782 μmol) was treated with oxalyl chloride (68 μL, 782 μmol) which caused bubbling. After 1–2 min, 5-difluoropyridine-2-carboxylic acid (110 mg, 782 μmol) was added in a single portion to prepare the acid chloride. A separate solution of (4aR,7aS)-7a-(5-amino-2-fluorophenyl)-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-amine (150 mg, 372 μmol) in ethanol (1.9 mL) and water (1.9 mL) was heated to 50 °C.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> To this solution while at 50 °C was added dropwise the acid chloride solution. The reaction was stirred at 50 °C for 1 h and then cooled to room temperature. The reaction was diluted with EtOAc and saturated aqueous NaHCO<sub>3</sub> and transferred to a separatory funnel. The layers were separated, and the aqueous layer was further extracted three times with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product that was purified via silica gel chromatography using a 0.5 to 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> gradient to give 119 mg (66%) of the desired product. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.78–9.75 (m, 1H), 8.41 (d, <i>J</i> = 2.7 Hz, 1H), 8.28 (dd, <i>J</i> = 4.6, 8.7 Hz, 1H), 8.19 (s, 2H), 7.95–7.91 (m, 1H), 7.58–7.53 (m, 1H), 7.46–7.44 (m, 1H), 7.07 (dd, <i>J</i> = 8.9, 11.9 Hz, 1H), 4.29 (d, <i>J</i> = 11.1 Hz, 1H), 3.89–3.85 (m, 1H), 3.82–3.79 (m, 2H), 3.34–3.32 (m, 1H), 3.10–3.06 (m, 1H), 2.94–2.90 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 486 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> 5-Fluoro-<i>N</i>-[4-fluoro-3-[rel-(4aR,7aS)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-7a-yl]phenyl]pyridine-2-carboxamide hydrochloride (<b>20</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0061.gif" alt="" id="fx50" /></img><div class="NLM_p last"><i>N</i>-[3-[(4aR,7aS)-2-Amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-7a-yl]-4-fluorophenyl]-3,5-difluoropyridine-2-carboxamide (175 mg, 0.36 mmol) was dissolved in dichloromethane (1 mL) and MeOH (0.2 mL). The solution was treated with HCl (1 M in ether, 0.36 mL, 0.36 mmol), which immediately formed a white precipitate. The mixture was stirred for 5 min and then concentrated to give the desired product (183 mg, 97% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.55 (dd, <i>J</i> = 0.4, 2.9 Hz, 1H), 8.33–8.33 (m, 2H), 8.21–8.18 (m, 1H), 8.01–7.98 (m, 1H), 7.81–7.78 (m, 2H), 7.26 (dd, <i>J</i> = 8.9, 12.1 Hz, 1H), 4.43–4.40 (m, 1H), 4.15–4.10 (m, 1H), 3.88–3.85 (m, 1H), 3.77–3.74 (m, 1H), 3.54–3.52 (m, 1H), 3.44–3.40 (m, 2H). HRMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>18</sub>F<sub>3</sub>N<sub>7</sub>OS (M + H) 485.1246, found 485.1251. OR [α]<sub>D</sub><sup>20</sup> −9.898 (<i>c</i> = 0.1, MeOH).</div></div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> Synthesis of Compound <b>21</b></h4><div id="sec4_2_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> <i>N</i>-[3-[(4aR,7aS)-2-Amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-7a-yl]-4-fluorophenyl]-3,5-difluoropyridine-2-carboxamide(<b>21a</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0062.gif" alt="" id="fx51" /></img><div class="NLM_p last">A solution of acetonitrile (5 mL) and DMF (80.7 μL) was treated with oxalyl chloride (90 μL, 1.04 mmol), which caused bubbling. After 1–2 min, 3,5-difluoropyridine-2-carboxylic acid (165 mg, 1.04 mmol) was added in a single portion to prepare the acid chloride. A separate solution of (4aR,7aS)-7a-(5-amino-2-fluorophenyl)-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-amine (200 mg, 497 μmol) in ethanol (2.5 mL) was heated to 50 °C. To this solution while at 50 °C was added dropwise the acid chloride solution. The reaction was stirred at 50 °C for 1 h and then cooled to room temperature. The reaction was diluted with EtOAc and saturated aqueous NaHCO<sub>3</sub> and transferred to a separatory funnel. The layers were separated, and the aqueous layer was further extracted three times with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product that was purified via silica gel chromatography using a 0.5 to 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> gradient to give the desired product. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.59–9.56 (m, 1H), 8.32 (d, <i>J</i> = 2.2 Hz, 1H), 8.19 (d, <i>J</i> = 0.8 Hz, 2H), 7.99–7.96 (m, 1H), 7.40–7.35 (m, 2H), 7.09–7.04 (m, 1H), 4.28 (d, <i>J</i> = 11.1 Hz, 1H), 3.89–3.86 (m, 3H), 3.36–3.34 (m, 1H), 3.11–3.07 (m, 1H), 2.95–2.92 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 504 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> <i>N</i>-[3-[(4aR,7aS)-2-Amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-7a-yl]-4-fluorophenyl]-3,5-difluoropyridine-2-carboxamide hydrochloride (<b>21</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0063.gif" alt="" id="fx52" /></img><div class="NLM_p last"><i>N</i>-[3-[(4aR,7aS)-2-Amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-7a-yl]-4-fluorophenyl]-3,5-difluoropyridine-2-carboxamide (100 mg, 0.20 mmol) was dissolved in dichloromethane (5 mL). The solution was treated with HCl (1 M in Et<sub>2</sub>O, 0.20 mL, 0.20 mmol), which immediately formed a white precipitate. The mixture was stirred for 5 min and then concentrated to give the desired product (101 mg, 0.19 mmol, 95% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.84 (d, <i>J</i> = 4.5 Hz, 2H), 8.64 (d, <i>J</i> = 2.3 Hz, 1H), 8.51 (s, 2H), 8.18–8.13 (m, 1H), 7.94 (ddd, <i>J</i> = 8.9, 4.1, 2.7 Hz, 1H), 7.86–7.82 (m, 1H), 7.37–7.32 (m, 1H), 4.28–4.25 (m, 1H), 4.12–4.09 (m, 1H), 3.80–3.75 (m, 1H), 3.63–3.57 (m, 1H), 3.48–3.47 (m, 5H). HRMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>17</sub>F<sub>4</sub>N<sub>7</sub>OS (M + H) 503.1151, found 503.1158.</div></div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> Synthesis of LY3202626 (Compound <b>22</b>)</h4><div id="sec4_2_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> <i>N</i>-[3-[(4aR,7aS)-2-Amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide hydrochloride (<b>22</b>)</h5><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0064.gif" alt="" id="fx53" /></img><div class="NLM_p last">To a slurry of 5-methoxypyrazine-2-carboxylic acid (102 mg, 0.66 mmol) in acetonitrile (7 mL) was added dimethylformamide (51 μL, 0.66 mmol). The reaction was treated with oxalyl chloride (57 μL, 0.66 mmol), which resulted in gas evolution and the slurry becoming a solution. The reaction was stirred at room temperature for 15 min to form the acid chloride. In a separate flask, (4aR,7aS)-7a-(5-amino-2-fluorophenyl)-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-<i>d</i>][1,3]thiazin-2-amine (150 mg, 0.41 mmol) was dissolved in ethanol (4 mL) and water (4 mL). This solution was warmed to 50 °C and then treated with the acid chloride solution while remaining at 50 °C. The reaction was stirred at 50 °C for 1.5 h and then cooled to room temperature. The reaction was poured into saturated aqueous NaHCO<sub>3</sub> (200 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 100 mL). The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The sample was purified via silica gel chromatography using a 24 g silica gel column and eluting with a 0–10% (7 N NH<sub>3</sub> in MeOH)/CH<sub>2</sub>Cl<sub>2</sub> gradient to give the free base of the desired product (110 mg, 53% yield). The free base was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (8 mL) and treated with HCl (4 M in dioxanes, 0.75 mL, 3.000 mmol), which caused a white precipitate to form. The solvent was removed to give the desired product (105 mg, 0.196 mmol, 47% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.77 (s, 1H), 8.84 (d, <i>J</i> = 1.3 Hz, 1H), 8.51 (d, <i>J</i> = 1.0 Hz, 2H), 8.38 (d, <i>J</i> = 1.3 Hz, 1H), 8.02–7.99 (m, 1H), 7.96–7.93 (m, 1H), 7.33 (dd, <i>J</i> = 9.0, 12.0 Hz, 1H), 5.38–5.37 (m, 2H), 4.23 (d, <i>J</i> = 12.1 Hz, 1H), 4.13–4.09 (m, 1H), 3.99 (s, 3H), 3.80–3.75 (m, 1H), 3.62–3.57 (m, 1H), 3.42–3.34 (m, 3H), 3.25–3.22 (m, 1H). HRMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>20</sub>F<sub>2</sub>N<sub>8</sub>O<sub>2</sub>S (M + H) 498.1398, found 498.1413. OR [α]<sub>D</sub><sup>20</sup> −12.248 (<i>c</i> = 0.1, CH<sub>2</sub>Cl<sub>2</sub>).</div></div></div><div id="sec4_2_8_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Recombinant BACE1 and BACE2 Assays</h4><div class="NLM_p">Human BACE1 and BACE2 enzyme assays were conducted as described previously,<a onclick="showRef(event, 'ref8 ref49'); return false;" href="javascript:void(0);" class="ref ref8 ref49">(8,49)</a> using purified recombinant human BACE1 or BACE2 as an enzyme source and a synthetic FRET peptide (sequence: methylcourmarine (MCA)-S-E-V-N-L-D-A-E-F-R-K(dinitrophenol)-R-R-R-R-NH<sub>2</sub>) as a substrate.</div><div id="sec4_2_8_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> Cathepsin D Selectivity Enzyme Assay</h5><div class="NLM_p last">The Cathepsin D assay was conducted with commercially available reagents using the protocol described by May and colleagues.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> Human liver cathepsin D was purchased from Calbiochem (catalog #219041). Porcine gastric mucosa pepsin was purchased from Sigma (catalog #P-6887). For all enzyme assays, a 10-point inhibition curve was plotted and fitted with a four-parameter logistic equation to obtain the IC<sub>50</sub> values.</div></div><div id="sec4_2_8_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> Lysotracker Assay</h5><div class="NLM_p last">The LysoTracker Green DND-26 assay was conducted with a commercially available reagent purchased from ThermoFisher Scientific (catalog #L7526). HepG2 cells were purchased from ATCC and cultured according to recommended procedures (catalog #HB-8065). HepG2 cells were treated with test article over a 10-point concentration response curve for 24 h, and fluorescent response max (<i>R</i><sub>max</sub>) was measured using an Opera, high content imaging platform (PerkinElmer).</div></div><div id="sec4_2_8_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> Mouse Primary Neuronal Cultures</h5><div class="NLM_p last">Primary cortical neurons were prepared from PDAPP embryos (gestational day 16) and cultured in 96-well plates (15 × 10<sup>4</sup> cells/well in DMEM/F12 (1:1) containing B27 supplement. Neurons were incubated at 37 °C for 24 h in the presence/absence of inhibitors at the desired concentration. Assays were run in triplicate. At the end of the incubation period, conditioned media were analyzed for Aβ peptides using a sandwich ELISA assay using monoclonal 2G3 as a capture antibody for Aβ<sub>1–40</sub> and monoclonal 21F12 as a capture antibody for Aβ<sub>1–42</sub>. Both ELISAs used biotinylated 3D6 as the reporting antibody. Treated PDAPP neuronal cultures from the conditioned medium was diluted 1:5 for Aβ<sub>1–42</sub> and 1:10 for Aβ<sub>1–40</sub> in buffer (PBS, 0.25% casein, 0.05% Tween20, pH 7.4) and 100 μL aliquots assayed in triplicate.</div></div></div><div id="sec4_2_8_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> Beagle Dog In Vivo Pharmacology</h4><div class="NLM_p">Young beagle dogs were used to determine PK/PD effects of BACE inhibitors. In this model established at MPI research (Mattawan, MI), beagle dogs were implanted with a cannula in the lumbar spine region and threaded up toward the cervical spine allowing for multiple CSF collections throughout a single 48 h study period. Following an oral dose of compound in 1% HEC, plasma samples from 5 to 6 male dogs were taken at 0.25, 0.5, 1, 2, 3, 6, 9, 12, 24, and 48 h later. To assess central pharmacology, CSF was also collected 0.5 h prior to dosing to establish a baseline and then again at 3, 6, 9, 24, and 48 h postdosing. Aβ<sub>1–<i>x</i></sub> levels were measured in CSF and plasma using a standard sandwich ELISA protocol (m266.2 and biotinylated 3D6 as the capture and reporter antibodies, respectively), averaged across all dogs, and then plotted as a function of time relative to baseline. Duplicate plasma and CSF samples were used for bioanalytical determination of compound concentrations. The use of animals in these pharmacology studies conformed to the Institutional Animal Care and Use guidelines for Eli Lilly and Company.</div><div id="sec4_2_8_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> Nonclinical Bioanalytical Methods for Compound Detection</h5><div class="NLM_p last">Brain samples were weighed, and a 3-fold volume of water/methanol (4:1, v/v) was added prior to homogenization with an ultrasonic tissue disrupter. Appropriate unlabeled internal standard was added to each brain, CSF, or plasma sample, and supernatants were subjected to LC-MS/MS analysis using an Applied Biosystems/MDS Sciex API 4000 (Foster City, CA) equipped with a TurboIonSpray interface and operated in positive ion mode.</div></div><div id="sec4_2_8_1_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> Plasma and Brain Protein Binding</h5><div class="NLM_p last">Plasma (mouse, dog, human) and brain (mouse) protein binding was determined in vitro using equilibrium dialysis, as described previously elsewhere.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Unbound brain and plasma concentrations were derived by multiplying the total measured concentrations by the fraction unbound (free) determined in vitro.</div></div><div id="sec4_2_8_1_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> In Vitro Inhibition of CYP2D6, CYP3A4, and CYP2C9</h5><div class="NLM_p last">Test compounds were solubilized in DMSO at 10 mM and then diluted with acetonitrile to 1 mM, 10% DMSO. A 2 μL aliquot of the compound was added to 148 μL human liver microsomes (Xenotech Xtreme Pool 200;100 mM NaPO<sub>4</sub>, pH 7.4) and preincubated for 10 min at 37 °C. The reaction was then initiated with addition of 50 μL of a solution containing NADPH, bufuralol, midazolam, and diclofenac (100 mM NaPO4, pH 7.4). Final concentrations in the incubation were 10 μM test compound, 10 μM bufuralol, 5 μM midazolam, 10 μM diclofenac, 1 mM NADPH, and 0.05 mg/mL human liver microsomes. Substrate concentrations were approximately <i>K</i><sub>m</sub> concentration for the specific enzyme reaction. Following a 3 min incubation, a 50 μL aliquot was quenched with 50 μL stop solution containing internal standards (acetonitrile with 0.12 μM 1-hydroxybufuralol maleate-<i>d</i><sub>9</sub>, 0.17 μM α-hydroxymidazolam-<i>d</i><sub>4</sub>, and 0.19 μM [<sup>13</sup>C6]-4′-hydroxydiclofenac). The quenched reaction mixture was centrifuged at approximately 4000 rpm for 15 min at room temperature. Following centrifugation, the samples are submitted for LC/MS/MS analysis. The concentrations of 1-hydroxybufuralol, α-hydroxymidazolam, and 4′-hydroxydiclofenac were then compared to those from a vehicle-only (no test compound) control to assess inhibition of CYP2D6, CYP3A4, and CYP2C9, respectively.</div></div><div id="sec4_2_8_1_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> In Vitro Liver Microsome Stability</h5><div class="NLM_p last">Test compounds were solubilized in DMSO to 10 μM, diluted into 50/50 water/acetonitrile solution to 200 μM, then diluted 1:10 into 100 mM NaPO<sub>4</sub>, pH 7.4, to a final concentration of 20 μM. A 100 μL aliquot of liver microsome solution (human, rat, dog, or mouse) was added to a PCR plate at 37 °C The reaction was initiated by adding prewarmed test compound and NADPH (100 mM NaPO<sub>4</sub>, pH 7.4). Final concentrations in the incubation were 2 μM test compound, 0.5 μM NADPH, and 0.5 mg/mL liver microsomes. Immediately, a 20 μL aliquot was removed and the reaction was quenched by adding (1) 90 μL of water/acetonitrile/methanol (50/25/25) with 0.5% (v/v) acetic acid containing 100 nM labetalol, 20 nM imipramine, and 500 nM diclofenac as internal standards and (2) 40 μL of 100 mM NaPO<sub>4</sub>, pH 7.4 buffer. This sample was used as time 0. Following a 30 min incubation, another 20 μL was removed and quenched in the same way as the time 0 sample. The quenched reaction mixtures were centrifuged at approximately 4000 rpm for 15 min at ambient temperature. Following centrifugation, the concentrations of test compound at time 0 and 30 min were determined by LC-MS/MS analysis. The percent metabolism was calculated as the percent decrease in test compound from time 0 to 30 min.</div></div><div id="sec4_2_8_1_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> Bidirectional Transport across MDCK Cells</h5><div class="NLM_p last">MDCKII cells stably expressing human wild-type ABCB1 (P-gp) were obtained from The Netherlands Cancer Institute (Amsterdam, The Netherlands). MDCK cells were maintained, and the assay was conducted as described previously.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a> Transport was measured in both directions across uninhibited and inhibited cell monolayers using a substrate concentration of 5 μM diluted from a 10 mM DMSO stock solution (final DMSO concentration of 0.05%) and a single 60 min time interval. A 2.5 μM concentration of LSN335984 was used to selectively inhibit Pgp. The apparent permeability coefficients (<i>P</i><sub>app</sub>) were estimated as the slope of the mass transported per 60 min relative to the total recovered mass.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> The basal-to-apical (B–A)/apical-to-basal (A–B) <i>P</i><sub>app</sub> ratios were calculated in the absence or presence of inhibitor for net efflux ratio (NER). If NER is greater than 3.0, then the compound is designated as a Pgp substrate.</div></div><div id="sec4_2_8_1_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> In Vivo Pharmacokinetic Studies</h5><div class="NLM_p last">To determine clearance and volume of distribution, compounds were administered intravenously in Captisol 20% w/v NaPO<sub>4</sub> buffer 25 mM, pH 2, at 1 mg/kg (1 mL/kg) in dogs and 2 mg/kg (2 mL/kg) in rats. Serial blood samples were collected following administration. The samples were treated with K3-EDTA, and plasma was obtained by centrifugation at 1600<i>g</i> for 10 min and stored at −70 °C until analysis by LC-MS/MS.</div></div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> Crystallographic Methods</h3><div class="NLM_p">Crystal structures of BACE bound to compounds were solved using minor modifications of previously described methods and diffraction data collected at Sector 31 of the Advanced Photon Source.<a onclick="showRef(event, 'ref8 ref34'); return false;" href="javascript:void(0);" class="ref ref8 ref34">(8,34)</a><named-content content-type="anchor" rid="tbl6" type="simple"></named-content></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Table of Crystallographic Statistics</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">BACE + compound <b>6</b> PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7MYI">7MYI</a></th><th class="colsep0 rowsep0" align="center">BACE + compound <b>18</b> PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7MYR">7MYR</a></th><th class="colsep0 rowsep0" align="center">BACE + compound <b>22</b> PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7MYU">7MYU</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>data collection</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">space group</td><td class="colsep0 rowsep0" align="left">P2(1)2(1)2(1)</td><td class="colsep0 rowsep0" align="left">P2(1)2(1)2(1)</td><td class="colsep0 rowsep0" align="left">P2(1)2(1)2(1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cell dimensions</td><td class="colsep0 rowsep0" rowspan="2" align="left">86.55, 89.49, 131.47</td><td class="colsep0 rowsep0" rowspan="2" align="left">86.48, 89.74, 131.70</td><td class="colsep0 rowsep0" rowspan="2" align="left">86.52, 90.54, 131.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>a</i>, <i>b</i>, <i>c</i> (Å)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cell dimensions</td><td class="colsep0 rowsep0" rowspan="2" align="left">90, 90, 90</td><td class="colsep0 rowsep0" rowspan="2" align="left">90, 90, 90</td><td class="colsep0 rowsep0" rowspan="2" align="left">90, 90, 90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">α, β, γ (deg)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">resolution (Å)</td><td class="colsep0 rowsep0" align="left">20–1.25 (1.32–1.25)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">31–1.72 (1.81–1.72)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">36–1.94 (2.04–1.94)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i>-merge</td><td class="colsep0 rowsep0" align="left">0.101 (0.726)</td><td class="colsep0 rowsep0" align="left">0.133 (0.697)</td><td class="colsep0 rowsep0" align="left">0.155 (0.708)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>I</i>/sigma(<i>I</i>)</td><td class="colsep0 rowsep0" align="left">8.9 (2.5)</td><td class="colsep0 rowsep0" align="left">9.3 (2.8)</td><td class="colsep0 rowsep0" align="left">7.8 (2.5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completeness (%)</td><td class="colsep0 rowsep0" align="left">98.6 (94.0)</td><td class="colsep0 rowsep0" align="left">99.9 (99.9)</td><td class="colsep0 rowsep0" align="left">99.7 (99.5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">redundancy</td><td class="colsep0 rowsep0" align="left">7.2 (5.9)</td><td class="colsep0 rowsep0" align="left">7.4 (7.3)</td><td class="colsep0 rowsep0" align="left">7.2 (7.1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>refinement</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">resolution (Å)</td><td class="colsep0 rowsep0" align="left">20–1.25</td><td class="colsep0 rowsep0" align="left">31–1.72</td><td class="colsep0 rowsep0" align="left">34–1.94</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. of reflections</td><td class="colsep0 rowsep0" align="left">275060</td><td class="colsep0 rowsep0" align="left">109159</td><td class="colsep0 rowsep0" align="left">76594</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i>-work (%)/<i>R</i>-free (%)</td><td class="colsep0 rowsep0" align="left">14.9/17.2</td><td class="colsep0 rowsep0" align="left">17.0/19.6</td><td class="colsep0 rowsep0" align="left">18.7/22.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. of non-hydrogen atoms</td><td class="colsep0 rowsep0" rowspan="2" align="left">6360/64/1188</td><td class="colsep0 rowsep0" rowspan="2" align="left">6277/71/907</td><td class="colsep0 rowsep0" rowspan="2" align="left">6187/75/730</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein/ligand/water</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">B-factors</td><td class="colsep0 rowsep0" rowspan="2" align="left">13.9/13.2/29.5</td><td class="colsep0 rowsep0" rowspan="2" align="left">15.6/19.1/30.0</td><td class="colsep0 rowsep0" rowspan="2" align="left">23.3/22.5/33.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein/ligand/water</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">root-mean-squared deviations bond length (Å)/bond angle (deg)</td><td class="colsep0 rowsep0" align="left">0.007/1.47</td><td class="colsep0 rowsep0" align="left">0.006/1.25</td><td class="colsep0 rowsep0" align="left">0.005/1.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ramachandran distribution φ–ψ favored (%)/φ–ψ allowed (%)</td><td class="colsep0 rowsep0" align="left">99.0/100</td><td class="colsep0 rowsep0" align="left">98.8/100</td><td class="colsep0 rowsep0" align="left">98.6/100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Values in parentheses denote highest resolution shell. Please note that protein coordinates and structure factors will be deposited with the Protein Data Bank.</p></div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-6"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i88"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00489" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75814" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75814" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00489?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00489</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">LCMS data for compounds <b>6</b>, <b>15</b>–<b>18</b>, and <b>20</b>–<b>22</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00489/suppl_file/jm1c00489_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">LY3202626 molecular string formulas (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00489/suppl_file/jm1c00489_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00489/suppl_file/jm1c00489_si_001.pdf">jm1c00489_si_001.pdf (729.92 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00489/suppl_file/jm1c00489_si_002.csv">jm1c00489_si_002.csv (1.28 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00489" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66354" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66354" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dustin J. Mergott</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-1802-0758" title="Orcid link">https://orcid.org/0000-0003-1802-0758</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0b666e796c647f7f6f7e4b676267677225686466"><span class="__cf_email__" data-cfemail="cda0a8bfaaa2b9b9a9b88da1a4a1a1b4e3aea2a0">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David L. McKinzie</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span>; 
    <span>Present Address:
                        Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leonard L. Winneroski</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven J. Green</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erik J. Hembre</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jon A. Erickson</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian A. Willis</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott A. Monk</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher D. Aluise</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas K. Baker</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jose E. Lopez</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jörg Hendle</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Biotechnology
Center, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James P. Beck</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Biotechnology
Center, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard A. Brier</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><sup>∥</sup><span class="hlFld-ContribAuthor strong">Leonard N. Boggs</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Biochemistry, University of Utah, Salt Lake City, Utah 84112, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Biotechnology
Center, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthony R. Borders</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><sup>∥</sup><span class="hlFld-ContribAuthor strong">Patrick J. Cocke</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Biochemistry, University of Utah, Salt Lake City, Utah 84112, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Biotechnology
Center, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pablo Garcia-Losada</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen L. Lowe</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian M. Mathes</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><sup>∥</sup><span class="hlFld-ContribAuthor strong">Patrick C. May</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Biochemistry, University of Utah, Salt Lake City, Utah 84112, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Biotechnology
Center, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><sup>∥</sup><span class="hlFld-ContribAuthor strong">Warren J. Porter</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Biochemistry, University of Utah, Salt Lake City, Utah 84112, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Biotechnology
Center, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephanie L. Stout</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David E. Timm</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span>; 
    <span>Present Address:
                        Department of Biochemistry, University of 1644 Utah, Salt Lake City, Utah 84112, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian M. Watson</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhixiang Yang</span> - <span class="hlFld-Affiliation affiliation">Lilly
Research Laboratories, A Division of Eli
Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><sup>∥</sup>Retired.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e5441-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i93">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50387" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50387" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This research was funded by Eli Lilly and Company. The crystallographic research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357. <a href="https://www.aps.anl.gov/Science/Publications/Acknowledgment-Statement-for-Publications" class="extLink">https://www.aps.anl.gov/Science/Publications/Acknowledgment-Statement-for-Publications</a> Use of the Lilly Research Laboratories Collaborative Access Team (LRL-CAT) beamline at Sector 31 of the Advanced Photon Source was provided by Eli Lilly and Company, which operates the facility. <a href="http://lrlcat.lilly.com/" class="extLink">http://lrlcat.lilly.com/</a></p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">Aβ</td><td class="NLM_def"><p class="first last">amyloid-β</p></td></tr><tr><td class="NLM_term">BACE1</td><td class="NLM_def"><p class="first last">beta-site APP cleaving enzyme 1</p></td></tr><tr><td class="NLM_term">ACN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s Disease</p></td></tr><tr><td class="NLM_term">APP</td><td class="NLM_def"><p class="first last">amyloid precursor protein</p></td></tr><tr><td class="NLM_term">CatD</td><td class="NLM_def"><p class="first last">cathepsin D</p></td></tr><tr><td class="NLM_term">Cl</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">CSF</td><td class="NLM_def"><p class="first last">cerebral spinal fluid</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450 enzymes</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">Ghosez’s reagent</td><td class="NLM_def"><p class="first last">1-chloro-<i>N</i>,<i>N</i>,2-trimethyl-1-propenylamine</p></td></tr><tr><td class="NLM_term">HCl</td><td class="NLM_def"><p class="first last">hydrochloric acid</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go related gene</p></td></tr><tr><td class="NLM_term">Hep</td><td class="NLM_def"><p class="first last">hepatic</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">NA</td><td class="NLM_def"><p class="first last">not available, meaning data were not collected for that compound in that assay</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-2-pyrrolidone</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">PDAPP mice</td><td class="NLM_def"><p class="first last">transgenic mice overexpressing mutant human amyloid precursor protein V717F</p></td></tr><tr><td class="NLM_term">Pgp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">Piv-Cl</td><td class="NLM_def"><p class="first last">pivaloyl chloride</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PSA</td><td class="NLM_def"><p class="first last">polar surface area</p></td></tr><tr><td class="NLM_term">QD dose</td><td class="NLM_def"><p class="first last">one a day dosing</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i95">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32225" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32225" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 53 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, C.</span></span> <i>World Alzheimer Report 2018</i>, <a href="https://www.alzint.org/resource/world-alzheimer-report-2018/" class="extLink">https://www.alzint.org/resource/world-alzheimer-report-2018/</a> (accessed 02-07-2021).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Patterson%2C+C.+World+Alzheimer+Report+2018%2C+https%3A%2F%2Fwww.alzint.org%2Fresource%2Fworld-alzheimer-report-2018%2F+%28accessed+02-07-2021%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DPatterson%26aufirst%3DC.%26jtitle%3DWorld%2520Alzheimer%2520Report%25202018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haass, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajendran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenthaler, S. F.</span></span> <span> </span><span class="NLM_article-title">Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>130</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1111/jnc.12715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1111%2Fjnc.12715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=24646365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVSqtL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2014&pages=4-28&issue=1&author=R.+Vassarauthor=P.+H.+Kuhnauthor=C.+Haassauthor=M.+E.+Kennedyauthor=L.+Rajendranauthor=P.+C.+Wongauthor=S.+F.+Lichtenthaler&title=Function%2C+therapeutic+potential+and+cell+biology+of+BACE+proteases%3A+current+status+and+future+prospects&doi=10.1111%2Fjnc.12715"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects</span></div><div class="casAuthors">Vassar, Robert; Kuhn, Peer-Hendrik; Haass, Christian; Kennedy, Matthew E.; Rajendran, Lawrence; Wong, Philip C.; Lichtenthaler, Stefan F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-28</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The β-site APP cleaving enzymes 1 and 2 (BACE1 and BACE2) were initially identified as transmembrane aspartyl proteases cleaving the amyloid precursor protein (APP).  BACE1 is a major drug target for Alzheimer's disease because BACE1-mediated cleavage of APP is the first step in the generation of the pathogenic amyloid-β peptides.  BACE1, which is highly expressed in the nervous system, is also required for myelination by cleaving neuregulin 1.  Several recent proteomic and in vivo studies using BACE1- and BACE2-deficient mice demonstrate a much wider range of physiol. substrates and functions for both proteases within and outside of the nervous system.  For BACE1 this includes axon guidance, neurogenesis, muscle spindle formation, and neuronal network functions, whereas BACE2 was shown to be involved in pigmentation and pancreatic β-cell function.  This review highlights the recent progress in understanding cell biol., substrates, and functions of BACE proteases and discusses the therapeutic options and potential mechanism-based liabilities, in particular for BACE inhibitors in Alzheimer's disease.  The protease BACE1 is a major drug target in Alzheimer disease.  Together with its homolog BACE2, both proteases have an increasing no. of functions within and outside of the nervous system.  This review highlights recent progress in understanding cell biol., substrates, and functions of BACE proteases and discusses the therapeutic options and potential mechanism-based liabilities, in particular for BACE inhibitors in Alzheimer disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxkCRjc9dYMLVg90H21EOLACvtfcHk0lhN7p82WJVfGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVSqtL7M&md5=79e394bb720ad6639f8efc86138fcd60</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fjnc.12715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.12715%26sid%3Dliteratum%253Aachs%26aulast%3DVassar%26aufirst%3DR.%26aulast%3DKuhn%26aufirst%3DP.%2BH.%26aulast%3DHaass%26aufirst%3DC.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DRajendran%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DLichtenthaler%26aufirst%3DS.%2BF.%26atitle%3DFunction%252C%2520therapeutic%2520potential%2520and%2520cell%2520biology%2520of%2520BACE%2520proteases%253A%2520current%2520status%2520and%2520future%2520prospects%26jtitle%3DJ.%2520Neurochem.%26date%3D2014%26volume%3D130%26issue%3D1%26spage%3D4%26epage%3D28%26doi%3D10.1111%2Fjnc.12715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masters, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selkoe, D. J.</span></span> <span> </span><span class="NLM_article-title">Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">a006262</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a006262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1101%2Fcshperspect.a006262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=22675658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlemtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=a006262&issue=6&author=C.+L.+Mastersauthor=D.+J.+Selkoe&title=Biochemistry+of+amyloid+beta-protein+and+amyloid+deposits+in+Alzheimer+disease&doi=10.1101%2Fcshperspect.a006262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease</span></div><div class="casAuthors">Masters, Colin L.; Selkoe, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">a006262/1-a006262/24</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  Progressive cerebral deposition of the amyloid β-protein (Aβ) in brain regions serving memory and cognition is an invariant and defining feature of Alzheimer disease.  A highly similar but less robust process accompanies brain aging in many nondemented humans, lower primates, and some other mammals.  The discovery of Aβ as the subunit of the amyloid fibrils in meningocerebral blood vessels and parenchymal plaques has led to innumerable studies of its biochem. and potential cytotoxic properties.  Here we will review the discovery of Aβ, numerous aspects of its complex biochem., and current attempts to understand how a range of Aβ assemblies, including sol. oligomers and insol. fibrils, may ppt. and promote neuronal and glial alterations that underlie the development of dementia.  Although the role of Aβ as a key mol. factor in the etiol. of Alzheimer disease remains controversial, clin. trials of amyloid-lowering agents, reviewed elsewhere in this book, are poised to resolve the question of its pathogenic primacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-U4pTuictTrVg90H21EOLACvtfcHk0lhN7p82WJVfGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlemtbc%253D&md5=133fd25f26d01f1c46456744d486bde2</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a006262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a006262%26sid%3Dliteratum%253Aachs%26aulast%3DMasters%26aufirst%3DC.%2BL.%26aulast%3DSelkoe%26aufirst%3DD.%2BJ.%26atitle%3DBiochemistry%2520of%2520amyloid%2520beta-protein%2520and%2520amyloid%2520deposits%2520in%2520Alzheimer%2520disease%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2012%26volume%3D2%26issue%3D6%26spage%3Da006262%26doi%3D10.1101%2Fcshperspect.a006262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Strooper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golde, T.</span></span> <span> </span><span class="NLM_article-title">The secretases: enzymes with therapeutic potential in Alzheimer disease</span>. <i>Nat. Rev. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1038/nrneurol.2009.218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1038%2Fnrneurol.2009.218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=20139999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Ogt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=99-107&issue=2&author=B.+De%0AStrooperauthor=R.+Vassarauthor=T.+Golde&title=The+secretases%3A+enzymes+with+therapeutic+potential+in+Alzheimer+disease&doi=10.1038%2Fnrneurol.2009.218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The secretases: enzymes with therapeutic potential in Alzheimer disease</span></div><div class="casAuthors">De Strooper, Bart; Vassar, Robert; Golde, Todd</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neurology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">99-107</span>CODEN:
                <span class="NLM_cas:coden">NRNACP</span>;
        ISSN:<span class="NLM_cas:issn">1759-4758</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The three secretases that process amyloid precursor protein are central to the generation of amyloid-β, and the accumulation of this peptide in extracellular plaques is one of the hallmarks of Alzheimer disease.  In this Review, De Strooper et al. discuss the evidence that suggests that these enzymes are potential therapeutic targets for Alzheimer disease drug treatments.  The amyloid hypothesis has yielded a series of well-validated candidate drug targets with potential for the treatment of Alzheimer disease (AD).  Three proteases that are involved in the processing of amyloid precursor protein-α-secretase, β-secretase and γ-secretase-are of particular interest as they are central to the generation and modulation of amyloid-β peptide and can be targeted by small compds. in vitro and in vivo.  Given that these proteases also fulfill other important biol. roles, inhibiting their activity will clearly be inherently assocd. with mechanism-based toxicity.  Carefully detg. a suitable therapeutic window and optimizing the selectivity of the drug treatments towards amyloid precursor protein processing might be ways of overcoming this potential complication.  Secretase inhibitors are likely to be the first small-mol. therapies aimed at AD modification that will be fully tested in the clinic.  Success or failure of these first-generation AD therapies will have enormous consequences for further drug development efforts for AD and possibly other neurodegenerative conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQBldqS_TKy7Vg90H21EOLACvtfcHk0lhN7p82WJVfGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Ogt70%253D&md5=40135a0a59da6b70e4856a81ddfa6088</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrneurol.2009.218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrneurol.2009.218%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26aulast%3DVassar%26aufirst%3DR.%26aulast%3DGolde%26aufirst%3DT.%26atitle%3DThe%2520secretases%253A%2520enzymes%2520with%2520therapeutic%2520potential%2520in%2520Alzheimer%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2010%26volume%3D6%26issue%3D2%26spage%3D99%26epage%3D107%26doi%3D10.1038%2Fnrneurol.2009.218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rombouts, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H. J. M.</span></span> <span> </span><span class="NLM_article-title">New evolutions in the BACE1 inhibitor field from 2014 to 2018</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">777</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.12.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1016%2Fj.bmcl.2018.12.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=30709653" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlCmu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=761-777&issue=6&author=C.+C.+Hsiaoauthor=F.+Romboutsauthor=H.+J.+M.+Gijsen&title=New+evolutions+in+the+BACE1+inhibitor+field+from+2014+to+2018&doi=10.1016%2Fj.bmcl.2018.12.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">New evolutions in the BACE1 inhibitor field from 2014 to 2018</span></div><div class="casAuthors">Hsiao, Chien-Chi; Rombouts, Frederik; Gijsen, Harrie J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">761-777</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors offer the potential of disease-modifying treatment for Alzheimer's disease (AD).  Since 2014, major breakthroughs have appeared in the field of BACE1 inhibitors.  This review provides an overview of amidine-based BACE1 inhibitors between 2014 and 2018.  Herein are summarized (i) the structure-activity relationship, (ii) the physiol. results and (iii) the potential risks from a lack of selectivity.  This review also summarizes clin. scope, results and outlook of the compds. that have been or are currently under development in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3OfI_B-BJ-LVg90H21EOLACvtfcHk0lhN7p82WJVfGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlCmu7s%253D&md5=049eda6ce97b31a04b5b579afd3e11e5</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.12.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.12.049%26sid%3Dliteratum%253Aachs%26aulast%3DHsiao%26aufirst%3DC.%2BC.%26aulast%3DRombouts%26aufirst%3DF.%26aulast%3DGijsen%26aufirst%3DH.%2BJ.%2BM.%26atitle%3DNew%2520evolutions%2520in%2520the%2520BACE1%2520inhibitor%2520field%2520from%25202014%2520to%25202018%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26issue%3D6%26spage%3D761%26epage%3D777%26doi%3D10.1016%2Fj.bmcl.2018.12.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rafii, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P. S.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s Disease Clinical Trials: Moving Toward Successful Prevention</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.1007/s40263-018-0598-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1007%2Fs40263-018-0598-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=30560544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCitb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=99-106&issue=2&author=M.+S.+Rafiiauthor=P.+S.+Aisen&title=Alzheimer%E2%80%99s+Disease+Clinical+Trials%3A+Moving+Toward+Successful+Prevention&doi=10.1007%2Fs40263-018-0598-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention</span></div><div class="casAuthors">Rafii, Michael S.; Aisen, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">99-106</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Despite major academic and industry efforts, Alzheimer's disease (AD) remains the only leading cause of death for which no disease-modifying treatment is available.  Disappointing clin. trials over the last several years have led to a growing consensus on the need to intervene earlier in the disease process, before the onset of any clin. symptoms.  However, drug development at this stage is challenging given the difficulty of assessing a therapeutic benefit in subjects who are, by definition, clin. healthy.  The US FDA recently issued new draft guidance for trials in early AD, which revised the taxonomy of AD by recognizing four stages of the disease, including an expanded view of the predementia stage.  These guidelines further advance regulatory support for clin. trials in earlier stages of AD.  We discuss the basis for this change and the impact it may have on early-intervention AD trials as well as on stimulating the need for improved biomarkers and outcome measures that will be required for a disease-modifying drug to win approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsgfxzwW4vNbVg90H21EOLACvtfcHk0lh5ykjKrqMEoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCitb7P&md5=d365e2a4b77e65b7c823141bae0074f7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs40263-018-0598-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-018-0598-1%26sid%3Dliteratum%253Aachs%26aulast%3DRafii%26aufirst%3DM.%2BS.%26aulast%3DAisen%26aufirst%3DP.%2BS.%26atitle%3DAlzheimer%25E2%2580%2599s%2520Disease%2520Clinical%2520Trials%253A%2520Moving%2520Toward%2520Successful%2520Prevention%26jtitle%3DCNS%2520Drugs%26date%3D2019%26volume%3D33%26issue%3D2%26spage%3D99%26epage%3D106%26doi%3D10.1007%2Fs40263-018-0598-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imbimbo, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watling, M.</span></span> <span> </span><span class="NLM_article-title">Investigational BACE inhibitors for the treatment of Alzheimer’s disease</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">967</span>– <span class="NLM_lpage">975</span>, <span class="refDoi"> DOI: 10.1080/13543784.2019.1683160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1080%2F13543784.2019.1683160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=31661331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKrurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2019&pages=967-975&issue=11&author=B.+P.+Imbimboauthor=M.+Watling&title=Investigational+BACE+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1080%2F13543784.2019.1683160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational BACE inhibitors for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Imbimbo, Bruno P.; Watling, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">967-975</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : The amyloid hypothesis of Alzheimer's disease (AD) states that brain accumulation of amyloid-β (Aβ) oligomers and sol. aggregates represents the major causal event of the disease.  Several small org. mols. have been synthesized and developed to inhibit the enzyme (β-site amyloid precursor protein cleaving enzyme-1 or BACE1) whose action represents the rate-limiting step in Aβ prodn.: We reviewed the pharmacol. and clin. trials of major BACE1 inhibitors.: In transgenic mouse models of AD, BACE1 inhibitors dose-dependently lower Aβ levels in brain and cerebrospinal fluid (CSF) but the evidence for attenuation or reversal cognitive or behavioral deficits is very scanty.  In AD patients, BACE1 inhibitors robustly lower plasma and CSF Aβ levels and reduce brain plaques but without cognitive, clin., or functional benefit.  To date, seventeen BACE1 inhibitors have failed in double-blind, placebo-controlled clin. trials in patients with mild-to-moderate or prodromal AD, or in cognitively normal subjects at risk of developing AD.  Several of these studies were prematurely interrupted due to toxicity or cognitive and behavioral worsening compared to placebo-treated patients.  Elenbecestat, the last BACE1 inhibitor remaining in late clin. testing for AD, was recently discontinued due to safety concerns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd-eWcjthL-rVg90H21EOLACvtfcHk0lh5ykjKrqMEoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKrurvI&md5=2431cce6d4b92d018835eb2ef4a4c0ac</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1080%2F13543784.2019.1683160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2019.1683160%26sid%3Dliteratum%253Aachs%26aulast%3DImbimbo%26aufirst%3DB.%2BP.%26aulast%3DWatling%26aufirst%3DM.%26atitle%3DInvestigational%2520BACE%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2019%26volume%3D28%26issue%3D11%26spage%3D967%26epage%3D975%26doi%3D10.1080%2F13543784.2019.1683160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">May, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martenyi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monk, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathes, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mergott, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith
Labell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhee, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ereshefsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calligaro, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocke, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greg Hall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Citron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span> <span> </span><span class="NLM_article-title">Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">46</span>),  <span class="NLM_fpage">16507</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.3647-11.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1523%2FJNEUROSCI.3647-11.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=22090477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFaksL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=16507-16&issue=46&author=P.+C.+Mayauthor=R.+A.+Deanauthor=S.+L.+Loweauthor=F.+Martenyiauthor=S.+M.+Sheehanauthor=L.+N.+Boggsauthor=S.+A.+Monkauthor=B.+M.+Mathesauthor=D.+J.+Mergottauthor=B.+M.+Watsonauthor=S.+L.+Stoutauthor=D.+E.+Timmauthor=E.+Smith%0ALabellauthor=C.+R.+Gonzalesauthor=M.+Nakanoauthor=S.+S.+Jheeauthor=M.+Yenauthor=L.+Ereshefskyauthor=T.+D.+Lindstromauthor=D.+O.+Calligaroauthor=P.+J.+Cockeauthor=D.+Greg+Hallauthor=S.+Friedrichauthor=M.+Citronauthor=J.+E.+Audia&title=Robust+central+reduction+of+amyloid-beta+in+humans+with+an+orally+available%2C+non-peptidic+beta-secretase+inhibitor&doi=10.1523%2FJNEUROSCI.3647-11.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor</span></div><div class="casAuthors">May, Patrick C.; Dean, Robert A.; Lowe, Stephen L.; Martenyi, Ferenc; Sheehan, Scott M.; Boggs, Leonard N.; Monk, Scott A.; Mathes, Brian M.; Mergott, Dustin J.; Watson, Brian M.; Stout, Stephanie L.; Timm, David E.; LaBell, Elizabeth Smith; Gonzales, Celedon R.; Nakano, Masako; Jhee, Stanford S.; Yen, Mark; Ereshefsky, Larry; Lindstrom, Terry D.; Calligaro, David O.; Cocke, Patrick J.; Hall, D. Greg; Friedrich, Stuart; Citron, Martin; Audia, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">16507-16516</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">According to the amyloid cascade hypothesis, cerebral deposition of amyloid-β peptide (Aβ) is crit. for Alzheimer's disease (AD) pathogenesis.  Aβ generation is initiated when β-secretase (BACE1) cleaves the amyloid precursor protein.  For more than a decade, BACE1 has been a prime target for designing drugs to prevent or treat AD.  However, development of such agents has turned out to be extremely challenging, with major hurdles in cell penetration, oral bioavailability/metabolic clearance, and brain access.  Using a fragment-based chem. strategy, we have generated LY2811376 [(S)-4-(2,4-difluoro-5-pyrimidin-5-yl-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]thiazin-2-ylamine], the first orally available non-peptidic BACE1 inhibitor that produces profound Aβ-lowering effects in animals.  The biomarker changes obtained in preclin. animal models translate into man at doses of LY2811376 that were safe and well tolerated in healthy volunteers.  Prominent and long-lasting Aβ redns. in lumbar CSF were measured after oral dosing of 30 or 90 mg of LY2811376.  This represents the first translation of BACE1-driven biomarker changes in CNS from preclin. animal models to man.  Because of toxicol. findings identified in longer-term preclin. studies, this compd. is no longer progressing in clin. development.  However, BACE1 remains a viable target because the adverse effects reported here were recapitulated in LY2811376-treated BACE1 KO mice and thus are unrelated to BACE1 inhibition.  The magnitude and duration of central Aβ redn. obtainable with BACE1 inhibition positions this protease as a tractable small-mol. target through which to test the amyloid hypothesis in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqns_TvT2bZrVg90H21EOLACvtfcHk0lh5ykjKrqMEoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFaksL7F&md5=8f21f91ebd77e5fcf8b58b51c73a1a6b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.3647-11.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.3647-11.2011%26sid%3Dliteratum%253Aachs%26aulast%3DMay%26aufirst%3DP.%2BC.%26aulast%3DDean%26aufirst%3DR.%2BA.%26aulast%3DLowe%26aufirst%3DS.%2BL.%26aulast%3DMartenyi%26aufirst%3DF.%26aulast%3DSheehan%26aufirst%3DS.%2BM.%26aulast%3DBoggs%26aufirst%3DL.%2BN.%26aulast%3DMonk%26aufirst%3DS.%2BA.%26aulast%3DMathes%26aufirst%3DB.%2BM.%26aulast%3DMergott%26aufirst%3DD.%2BJ.%26aulast%3DWatson%26aufirst%3DB.%2BM.%26aulast%3DStout%26aufirst%3DS.%2BL.%26aulast%3DTimm%26aufirst%3DD.%2BE.%26aulast%3DSmith%2BLabell%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DC.%2BR.%26aulast%3DNakano%26aufirst%3DM.%26aulast%3DJhee%26aufirst%3DS.%2BS.%26aulast%3DYen%26aufirst%3DM.%26aulast%3DEreshefsky%26aufirst%3DL.%26aulast%3DLindstrom%26aufirst%3DT.%2BD.%26aulast%3DCalligaro%26aufirst%3DD.%2BO.%26aulast%3DCocke%26aufirst%3DP.%2BJ.%26aulast%3DGreg%2BHall%26aufirst%3DD.%26aulast%3DFriedrich%26aufirst%3DS.%26aulast%3DCitron%26aufirst%3DM.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26atitle%3DRobust%2520central%2520reduction%2520of%2520amyloid-beta%2520in%2520humans%2520with%2520an%2520orally%2520available%252C%2520non-peptidic%2520beta-secretase%2520inhibitor%26jtitle%3DJ.%2520Neurosci.%26date%3D2011%26volume%3D31%26issue%3D46%26spage%3D16507%26epage%3D16%26doi%3D10.1523%2FJNEUROSCI.3647-11.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">May, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monk, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocke, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borders, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brier, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calligaro, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ereshefsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gevorkyan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhee, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komjathy, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathes, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martenyi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaught, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winneroski, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mergott, D. J.</span></span> <span> </span><span class="NLM_article-title">The potent BACE1 inhibitor LY2886721 elicits robust central Abeta pharmacodynamic responses in mice, dogs, and humans</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.4129-14.2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1523%2FJNEUROSCI.4129-14.2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=25609634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Oit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=1199-210&issue=3&author=P.+C.+Mayauthor=B.+A.+Willisauthor=S.+L.+Loweauthor=R.+A.+Deanauthor=S.+A.+Monkauthor=P.+J.+Cockeauthor=J.+E.+Audiaauthor=L.+N.+Boggsauthor=A.+R.+Bordersauthor=R.+A.+Brierauthor=D.+O.+Calligaroauthor=T.+A.+Dayauthor=L.+Ereshefskyauthor=J.+A.+Ericksonauthor=H.+Gevorkyanauthor=C.+R.+Gonzalesauthor=D.+E.+Jamesauthor=S.+S.+Jheeauthor=S.+F.+Komjathyauthor=L.+Liauthor=T.+D.+Lindstromauthor=B.+M.+Mathesauthor=F.+Martenyiauthor=S.+M.+Sheehanauthor=S.+L.+Stoutauthor=D.+E.+Timmauthor=G.+M.+Vaughtauthor=B.+M.+Watsonauthor=L.+L.+Winneroskiauthor=Z.+Yangauthor=D.+J.+Mergott&title=The+potent+BACE1+inhibitor+LY2886721+elicits+robust+central+Abeta+pharmacodynamic+responses+in+mice%2C+dogs%2C+and+humans&doi=10.1523%2FJNEUROSCI.4129-14.2015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans</span></div><div class="casAuthors">May, Patrick C.; Willis, Brian A.; Lowe, Stephen L.; Dean, Robert A.; Monk, Scott A.; Cocke, Patrick J.; Audia, James E.; Boggs, Leonard N.; Borders, Anthony R.; Brier, Richard A.; Calligaro, David O.; Day, Theresa A.; Ereshefsky, Larry; Erickso, Jon A.; Gevorkyan, Hykop; Gonzales, Celedon R.; James, Douglas E.; Jhee, Stanford S.; Komjathy, Steven F.; Li, Linglin; Lindstrom, Terry D.; Mathe, Brian M.; Martenyi, Ferenc; Sheehan, Scott M.; Stout, Stephanie L.; Timm, David E.; Vaught, Grant M.; Watson, Brian M.; Winneroski, Leonard L.; Yang, Zhixiang; Mergott, Dustin J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1199-1210, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">BACE1 is a key protease controlling the formation of amyloid β, a peptide hypothesized to play a significant role in the pathogenesis of Alzheimer's disease (AD).  Therefore, the development of potent and selective inhibitors of BACE1 has been a focus of many drug discovery efforts in academia and industry.  Herein, we report the nonclin. and early clin. development of LY2886721, a BACE1 active site inhibitor that reached phase 2 clin. trials in AD.  LY2886721 has high selectivity against key off-target proteases, which efficiently translates in vitro activity into robust in vivo amyloid β lowering in nonclin. animal models.  Similar potent and persistent amyloid β lowering was obsd. in plasma and lumbar CSF when single and multiple doses of LY2886721 were administered to healthy human subjects.  Collectively, these data add support for BACE1 inhibition as an effective means of amyloid lowering and as an attractive target for potential disease modification therapy in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDDFLhcsiUDLVg90H21EOLACvtfcHk0ljsJ0m5awEBbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Oit78%253D&md5=7e16cc00767a8af4da7dd17b6e40e8f5</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4129-14.2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4129-14.2015%26sid%3Dliteratum%253Aachs%26aulast%3DMay%26aufirst%3DP.%2BC.%26aulast%3DWillis%26aufirst%3DB.%2BA.%26aulast%3DLowe%26aufirst%3DS.%2BL.%26aulast%3DDean%26aufirst%3DR.%2BA.%26aulast%3DMonk%26aufirst%3DS.%2BA.%26aulast%3DCocke%26aufirst%3DP.%2BJ.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DBoggs%26aufirst%3DL.%2BN.%26aulast%3DBorders%26aufirst%3DA.%2BR.%26aulast%3DBrier%26aufirst%3DR.%2BA.%26aulast%3DCalligaro%26aufirst%3DD.%2BO.%26aulast%3DDay%26aufirst%3DT.%2BA.%26aulast%3DEreshefsky%26aufirst%3DL.%26aulast%3DErickson%26aufirst%3DJ.%2BA.%26aulast%3DGevorkyan%26aufirst%3DH.%26aulast%3DGonzales%26aufirst%3DC.%2BR.%26aulast%3DJames%26aufirst%3DD.%2BE.%26aulast%3DJhee%26aufirst%3DS.%2BS.%26aulast%3DKomjathy%26aufirst%3DS.%2BF.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLindstrom%26aufirst%3DT.%2BD.%26aulast%3DMathes%26aufirst%3DB.%2BM.%26aulast%3DMartenyi%26aufirst%3DF.%26aulast%3DSheehan%26aufirst%3DS.%2BM.%26aulast%3DStout%26aufirst%3DS.%2BL.%26aulast%3DTimm%26aufirst%3DD.%2BE.%26aulast%3DVaught%26aufirst%3DG.%2BM.%26aulast%3DWatson%26aufirst%3DB.%2BM.%26aulast%3DWinneroski%26aufirst%3DL.%2BL.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMergott%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520potent%2520BACE1%2520inhibitor%2520LY2886721%2520elicits%2520robust%2520central%2520Abeta%2520pharmacodynamic%2520responses%2520in%2520mice%252C%2520dogs%252C%2520and%2520humans%26jtitle%3DJ.%2520Neurosci.%26date%3D2015%26volume%3D35%26issue%3D3%26spage%3D1199%26epage%3D210%26doi%3D10.1523%2FJNEUROSCI.4129-14.2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lammert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einarsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niklasson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span> <span> </span><span class="NLM_article-title">Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2003</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1002/hep.22272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1002%2Fhep.22272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=18454504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVagt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=2003-9&issue=6&author=C.+Lammertauthor=S.+Einarssonauthor=C.+Sahaauthor=A.+Niklassonauthor=E.+Bjornssonauthor=N.+Chalasani&title=Relationship+between+daily+dose+of+oral+medications+and+idiosyncratic+drug-induced+liver+injury%3A+search+for+signals&doi=10.1002%2Fhep.22272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals</span></div><div class="casAuthors">Lammert, Craig; Einarsson, Stefan; Saha, Chandan; Niklasson, Anna; Bjornsson, Einar; Chalasani, Naga</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2003-2009</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Idiosyncratic drug-induced liver injury (DILI) is traditionally thought not to be dose-related.  However, it has been pointed out that most medicines that were withdrawn from marketing or received a black-box warning because of hepatotoxicity were prescribed at daily doses greater than 50 mg/day.  To examine the relationship between daily dose of medications and idiosyncratic DILI, we conducted a study with two aims.  First, using two pharmaceutical databases, we examd. the relationship between daily dose of commonly prescribed medicines in the United States and reported frequency of their selected hepatic adverse events.  Second, we examd. serious DILI cases reported to the Swedish Adverse Drug Reactions Advisory Committee (1970-2004) for any signals supporting the relationship between daily dose and idiosyncratic DILI.  Medications were categorized into ≤10 mg/day, 11-49 mg/day, and ≥50 mg/day groups.  Among US prescription medicines, a statistically significant relationship was obsd. between daily dose of oral medicines and reports of liver failure (P = 0.009), liver transplantation (P < 0.001), and death caused by DILI (P = 0.004) but not alanine aminotransferase (ALT) > 3 × upper limit of normal (P = 0.10) or jaundice (P = 0.16).  Of 598 eligible Swedish DILI cases, 9% belonged to the ≤10 mg/day group, 14.2% to the 11-49 mg/day group, and 77% of cases were caused by medications given at dose ≥50 mg/day.  A statistically significant relationship was noted between daily dose and poor outcome (death or liver transplantation) of Swedish DILI cases (2%, 9.4%, and 13.2% in ≤10, 11-49, and ≥50 mg/day groups, resp., P = 0.03).  Conclusion: These data suggest a relationship between daily doses of oral prescription medications and idiosyncratic DILI.  More studies are needed to validate these observations and to explore their implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-pByO6X3Hk7Vg90H21EOLACvtfcHk0ljsJ0m5awEBbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVagt7w%253D&md5=f497d61a5253cc653c2d955232471d65</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fhep.22272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.22272%26sid%3Dliteratum%253Aachs%26aulast%3DLammert%26aufirst%3DC.%26aulast%3DEinarsson%26aufirst%3DS.%26aulast%3DSaha%26aufirst%3DC.%26aulast%3DNiklasson%26aufirst%3DA.%26aulast%3DBjornsson%26aufirst%3DE.%26aulast%3DChalasani%26aufirst%3DN.%26atitle%3DRelationship%2520between%2520daily%2520dose%2520of%2520oral%2520medications%2520and%2520idiosyncratic%2520drug-induced%2520liver%2520injury%253A%2520search%2520for%2520signals%26jtitle%3DHepatology%26date%3D2008%26volume%3D47%26issue%3D6%26spage%3D2003%26epage%3D9%26doi%3D10.1002%2Fhep.22272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winneroski, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barberis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borders, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brier, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hembre, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Losada, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minguez, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathes, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monk, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mergott, D. J.</span></span> <span> </span><span class="NLM_article-title">Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">115194</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.115194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1016%2Fj.bmc.2019.115194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=31786008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit12jur7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115194&issue=1&author=L.+L.+Winneroskiauthor=J.+A.+Ericksonauthor=S.+J.+Greenauthor=J.+E.+Lopezauthor=S.+L.+Stoutauthor=W.+J.+Porterauthor=D.+E.+Timmauthor=J.+E.+Audiaauthor=M.+Barberisauthor=J.+P.+Beckauthor=L.+N.+Boggsauthor=A.+R.+Bordersauthor=R.+D.+Boyerauthor=R.+A.+Brierauthor=E.+J.+Hembreauthor=J.+Hendleauthor=P.+Garcia-Losadaauthor=J.+M.+Minguezauthor=B.+M.+Mathesauthor=P.+C.+Mayauthor=S.+A.+Monkauthor=Z.+Rankovicauthor=Y.+Shiauthor=B.+M.+Watsonauthor=Z.+Yangauthor=D.+J.+Mergott&title=Preparation+and+biological+evaluation+of+BACE1+inhibitors%3A+Leveraging+trans-cyclopropyl+moieties+as+ligand+efficient+conformational+constraints&doi=10.1016%2Fj.bmc.2019.115194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints</span></div><div class="casAuthors">Winneroski, Leonard L.; Erickson, Jon A.; Green, Steven J.; Lopez, Jose E.; Stout, Stephanie L.; Porter, Warren J.; Timm, David E.; Audia, James E.; Barberis, Mario; Beck, James P.; Boggs, Leonard N.; Borders, Anthony R.; Boyer, Robert D.; Brier, Richard A.; Hembre, Erik J.; Hendle, Jorg; Garcia-Losada, Pablo; Minguez, Jose Miguel; Mathes, Brian M.; May, Patrick C.; Monk, Scott A.; Rankovic, Zoran; Shi, Yuan; Watson, Brian M.; Yang, Zhixiang; Mergott, Dustin J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115194</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inhibition of BACE1 has become an important strategy in the quest for disease modifying agents to slow the progression of Alzheimer's disease.  We previously reported the fragment-based discovery of LY2811376, the first BACE1 inhibitor reported to demonstrate robust redn. of human CSF Aβ in a Phase I clin. trial.  We also reported on the discovery of LY2886721, a potent BACE1 inhibitor that reached phase 2 clin. trials.  Herein we describe the prepn. and structure activity relationships (SAR) of a series of BACE1 inhibitors utilizing trans-cyclopropyl moieties as conformational constraints.  The design, details of the stereochem. complex org. synthesis, and biol. activity of these BACE1 inhibitors is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFZW_6anOjqLVg90H21EOLACvtfcHk0lhBhSAxYg5wug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit12jur7L&md5=733e23af182c6b5d262e4563fa18117a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.115194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.115194%26sid%3Dliteratum%253Aachs%26aulast%3DWinneroski%26aufirst%3DL.%2BL.%26aulast%3DErickson%26aufirst%3DJ.%2BA.%26aulast%3DGreen%26aufirst%3DS.%2BJ.%26aulast%3DLopez%26aufirst%3DJ.%2BE.%26aulast%3DStout%26aufirst%3DS.%2BL.%26aulast%3DPorter%26aufirst%3DW.%2BJ.%26aulast%3DTimm%26aufirst%3DD.%2BE.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DBarberis%26aufirst%3DM.%26aulast%3DBeck%26aufirst%3DJ.%2BP.%26aulast%3DBoggs%26aufirst%3DL.%2BN.%26aulast%3DBorders%26aufirst%3DA.%2BR.%26aulast%3DBoyer%26aufirst%3DR.%2BD.%26aulast%3DBrier%26aufirst%3DR.%2BA.%26aulast%3DHembre%26aufirst%3DE.%2BJ.%26aulast%3DHendle%26aufirst%3DJ.%26aulast%3DGarcia-Losada%26aufirst%3DP.%26aulast%3DMinguez%26aufirst%3DJ.%2BM.%26aulast%3DMathes%26aufirst%3DB.%2BM.%26aulast%3DMay%26aufirst%3DP.%2BC.%26aulast%3DMonk%26aufirst%3DS.%2BA.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DWatson%26aufirst%3DB.%2BM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMergott%26aufirst%3DD.%2BJ.%26atitle%3DPreparation%2520and%2520biological%2520evaluation%2520of%2520BACE1%2520inhibitors%253A%2520Leveraging%2520trans-cyclopropyl%2520moieties%2520as%2520ligand%2520efficient%2520conformational%2520constraints%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26issue%3D1%26spage%3D115194%26doi%3D10.1016%2Fj.bmc.2019.115194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="note"><p class="first last">For an example of different SAR using a bicyclic iminopyrimidinone which appeared after this work was completed, see:</p></div><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mandal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzola, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzelak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuvelkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favreau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buevich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazakevich, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKittrick, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamford, A. W.</span></span> <span> </span><span class="NLM_article-title">Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9331</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1021/jm301039c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301039c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGktb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9331-45&issue=21&author=M.+Mandalauthor=Z.+Zhuauthor=J.+N.+Cummingauthor=X.+Liuauthor=C.+Stricklandauthor=R.+D.+Mazzolaauthor=J.+P.+Caldwellauthor=P.+Leachauthor=M.+Grzelakauthor=L.+Hydeauthor=Q.+Zhangauthor=G.+Terracinaauthor=L.+Zhangauthor=X.+Chenauthor=R.+Kuvelkarauthor=M.+E.+Kennedyauthor=L.+Favreauauthor=K.+Coxauthor=P.+Orthauthor=A.+Buevichauthor=J.+Voigtauthor=H.+Wangauthor=I.+Kazakevichauthor=B.+A.+McKittrickauthor=W.+Greenleeauthor=E.+M.+Parkerauthor=A.+W.+Stamford&title=Design+and+validation+of+bicyclic+iminopyrimidinones+as+beta+amyloid+cleaving+enzyme-1+%28BACE1%29+inhibitors%3A+conformational+constraint+to+favor+a+bioactive+conformation&doi=10.1021%2Fjm301039c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Validation of Bicyclic Iminopyrimidinones As Beta Amyloid Cleaving Enzyme-1 (BACE1) Inhibitors: Conformational Constraint to Favor a Bioactive Conformation</span></div><div class="casAuthors">Mandal, Mihirbaran; Zhu, Zhaoning; Cumming, Jared N.; Liu, Xiaoxiang; Strickland, Corey; Mazzola, Robert D.; Caldwell, John P.; Leach, Prescott; Grzelak, Michael; Hyde, Lynn; Zhang, Qi; Terracina, Giuseppe; Zhang, Lili; Chen, Xia; Kuvelkar, Reshma; Kennedy, Matthew E.; Favreau, Leonard; Cox, Kathleen; Orth, Peter; Buevich, Alexei; Voigt, Johannes; Wang, Hongwu; Kazakevich, Irina; McKittrick, Brian A.; Greenlee, William; Parker, Eric M.; Stamford, Andrew W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9331-9345</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of our observation that the biaryl substituent of iminopyrimidinone 7 must be in a pseudoaxial conformation to occupy the contiguous S1-S3 subsites of BACE1, we have designed a novel fused bicyclic iminopyrimidinone scaffold intended to favor this bioactive conformation.  Strategic incorporation of a nitrogen atom in the new constrained ring allowed us to develop SAR around the S2' binding pocket and ultimately resulted in analogs with low nanomolar potency for BACE1.  In particular, optimization of the prime side substituent led to major improvements in potency by displacement of two conserved water mols. from a region near S2'.  Further optimization of the pharmacokinetic properties of this fused pyrrolidine series, in conjunction with facile access to a rat pharmacodynamic model, led to identification of compd. 43, which is an orally active, brain penetrant inhibitor that reduces Aβ40 in the plasma, CSF, and cortex of rats in a dose-dependent manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprlJsgY-3wuLVg90H21EOLACvtfcHk0lhBhSAxYg5wug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGktb%252FP&md5=6fd0bc5ac847ded7e235939594d4b20d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm301039c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301039c%26sid%3Dliteratum%253Aachs%26aulast%3DMandal%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DCumming%26aufirst%3DJ.%2BN.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DStrickland%26aufirst%3DC.%26aulast%3DMazzola%26aufirst%3DR.%2BD.%26aulast%3DCaldwell%26aufirst%3DJ.%2BP.%26aulast%3DLeach%26aufirst%3DP.%26aulast%3DGrzelak%26aufirst%3DM.%26aulast%3DHyde%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DTerracina%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DKuvelkar%26aufirst%3DR.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DFavreau%26aufirst%3DL.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DOrth%26aufirst%3DP.%26aulast%3DBuevich%26aufirst%3DA.%26aulast%3DVoigt%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DKazakevich%26aufirst%3DI.%26aulast%3DMcKittrick%26aufirst%3DB.%2BA.%26aulast%3DGreenlee%26aufirst%3DW.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26atitle%3DDesign%2520and%2520validation%2520of%2520bicyclic%2520iminopyrimidinones%2520as%2520beta%2520amyloid%2520cleaving%2520enzyme-1%2520%2528BACE1%2529%2520inhibitors%253A%2520conformational%2520constraint%2520to%2520favor%2520a%2520bioactive%2520conformation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D21%26spage%3D9331%26epage%3D45%26doi%3D10.1021%2Fjm301039c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="note"><p class="first last">For an example of different SAR using a bicyclic iminopyrimidinone which appeared after this work was completed, see:</p></div><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mandal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misiaszek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buevich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzola, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzelak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuvelkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michener, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favreau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazakevich, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKittrick, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamford, A. W.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of an Iminoheterocyclic beta-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Abeta in Nonhuman Primates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3231</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01995</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01995" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsFaqur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3231-48&issue=7&author=M.+Mandalauthor=Y.+Wuauthor=J.+Misiaszekauthor=G.+Liauthor=A.+Buevichauthor=J.+P.+Caldwellauthor=X.+Liuauthor=R.+D.+Mazzolaauthor=P.+Orthauthor=C.+Stricklandauthor=J.+Voigtauthor=H.+Wangauthor=Z.+Zhuauthor=X.+Chenauthor=M.+Grzelakauthor=L.+A.+Hydeauthor=R.+Kuvelkarauthor=P.+T.+Leachauthor=G.+Terracinaauthor=L.+Zhangauthor=Q.+Zhangauthor=M.+S.+Michenerauthor=B.+Smithauthor=K.+Coxauthor=D.+Grotzauthor=L.+Favreauauthor=K.+Mitraauthor=I.+Kazakevichauthor=B.+A.+McKittrickauthor=W.+Greenleeauthor=M.+E.+Kennedyauthor=E.+M.+Parkerauthor=J.+N.+Cummingauthor=A.+W.+Stamford&title=Structure-Based+Design+of+an+Iminoheterocyclic+beta-Site+Amyloid+Precursor+Protein+Cleaving+Enzyme+%28BACE%29+Inhibitor+that+Lowers+Central+Abeta+in+Nonhuman+Primates&doi=10.1021%2Facs.jmedchem.5b01995"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates</span></div><div class="casAuthors">Mandal, Mihirbaran; Wu, Yusheng; Misiaszek, Jeffrey; Li, Guoqing; Buevich, Alexei; Caldwell, John P.; Liu, Xiaoxiang; Mazzola, Robert D.; Orth, Peter; Strickland, Corey; Voigt, Johannes; Wang, Hongwu; Zhu, Zhaoning; Chen, Xia; Grzelak, Michael; Hyde, Lynn A.; Kuvelkar, Reshma; Leach, Prescott T.; Terracina, Giuseppe; Zhang, Lili; Zhang, Qi; Michener, Maria S.; Smith, Brad; Cox, Kathleen; Grotz, Diane; Favreau, Leonard; Mitra, Kaushik; Kazakevich, Irina; McKittrick, Brian A.; Greenlee, William; Kennedy, Matthew E.; Parker, Eric M.; Cumming, Jared N.; Stamford, Andrew W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3231-3248</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe successful efforts to optimize the in vivo profile and address off-target liabilities of a series of BACE1 inhibitors represented by 6 that embodies the recently validated fused pyrrolidine iminopyrimidinone scaffold.  Employing structure-based design, truncation of the cyanophenyl group of I that binds in the S3 pocket of BACE1 followed by modification of the thienyl group in S1 was pursued.  Optimization of the pyrimidine substituent that binds in the S2'-S2'' pocket of BACE1 remediated time-dependent CYP3A4 inhibition of earlier analogs in this series and imparted high BACE1 affinity.  These efforts resulted in the discovery of difluorophenyl analog II (MBi-4), which robustly lowered CSF and cortex Aβ40 in both rats and cynomolgus monkeys following a single oral dose.  II represents a unique mol. shape among BACE inhibitors reported to potently lower central Aβ in nonrodent preclin. species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoscm_jumartLVg90H21EOLACvtfcHk0lgMbHVj3uizoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsFaqur4%253D&md5=7715946acdd54d5b11d856a37e1ef0a2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01995%26sid%3Dliteratum%253Aachs%26aulast%3DMandal%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DMisiaszek%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DBuevich%26aufirst%3DA.%26aulast%3DCaldwell%26aufirst%3DJ.%2BP.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DMazzola%26aufirst%3DR.%2BD.%26aulast%3DOrth%26aufirst%3DP.%26aulast%3DStrickland%26aufirst%3DC.%26aulast%3DVoigt%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGrzelak%26aufirst%3DM.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DKuvelkar%26aufirst%3DR.%26aulast%3DLeach%26aufirst%3DP.%2BT.%26aulast%3DTerracina%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DMichener%26aufirst%3DM.%2BS.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DGrotz%26aufirst%3DD.%26aulast%3DFavreau%26aufirst%3DL.%26aulast%3DMitra%26aufirst%3DK.%26aulast%3DKazakevich%26aufirst%3DI.%26aulast%3DMcKittrick%26aufirst%3DB.%2BA.%26aulast%3DGreenlee%26aufirst%3DW.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DCumming%26aufirst%3DJ.%2BN.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26atitle%3DStructure-Based%2520Design%2520of%2520an%2520Iminoheterocyclic%2520beta-Site%2520Amyloid%2520Precursor%2520Protein%2520Cleaving%2520Enzyme%2520%2528BACE%2529%2520Inhibitor%2520that%2520Lowers%2520Central%2520Abeta%2520in%2520Nonhuman%2520Primates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D7%26spage%3D3231%26epage%3D48%26doi%3D10.1021%2Facs.jmedchem.5b01995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="note"><p class="first last">LEAN (ligand efficiency by atom number) = −log(IC<sub>50</sub>)/<i>N</i>, where <i>N</i> is the number of heavy (non-hydrogen) atoms and IC<sub>50</sub> is in M.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fielden, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamison, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coppi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, R. T.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trueblood, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afshari, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightfoot-Dunn, R.</span></span> <span> </span><span class="NLM_article-title">Retinal Toxicity Induced by a Novel beta-secretase Inhibitor in the Sprague-Dawley Rat</span>. <i>Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1177/0192623314553804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1177%2F0192623314553804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=25361751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVCqu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=581-92&issue=4&author=M.+R.+Fieldenauthor=J.+Wernerauthor=J.+A.+Jamisonauthor=A.+Coppiauthor=D.+Hickmanauthor=R.+T.+Dunnauthor=E.+Truebloodauthor=L.+Zhouauthor=C.+A.+Afshariauthor=R.+Lightfoot-Dunn&title=Retinal+Toxicity+Induced+by+a+Novel+beta-secretase+Inhibitor+in+the+Sprague-Dawley+Rat&doi=10.1177%2F0192623314553804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Retinal toxicity induced by a novel β-secretase inhibitor in the sprague-dawley rat</span></div><div class="casAuthors">Fielden, Mark R.; Werner, Jonathan; Jamison, Jeff A.; Coppi, Aldo; Hickman, Dean; Dunn, Robert T., II; Trueblood, Esther; Zhou, Lei; Afshari, Cynthia A.; Lightfoot-Dunn, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">581-592</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">β-Secretase 1 (BACE1) represents an attractive target for the treatment of Alzheimer's disease.  In the course of development of a novel small mol. BACE1 inhibitor (AMG-8718), retinal thinning was obsd. in a 1-mo toxicity study in the rat.  To further understand the lesion, an investigational study was conducted whereby rats were treated daily with AMG-8718 for 1 mo followed by a 2-mo treatment-free phase.  The earliest detectable change in the retina was an increase in autofluorescent granules in the retinal pigment epithelium (RPE) on day 5; however, there were no treatment-related light microscopic changes obsd. in the neuroretina and no changes obsd. by fundus autofluorescence or routine ophthalmoscopic examn. after 28 days of dosing.  Following 2 mo of recovery, there was significant retinal thinning attributed to loss of photoreceptor nuclei from the outer nuclear layer.  Electroretinog. changes were obsd. as early as day 14, before any microscopic evidence of photoreceptor loss.  BACE1 knockout rats were generated and found to have normal retinal morphol. indicating that the retinal toxicity induced by AMG-8718 was likely off-target.  These results suggest that AMG-8718 impairs phagolysosomal function in the rat RPE, which leads to photoreceptor dysfunction and ultimately loss of photoreceptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfyBfTezUdUrVg90H21EOLACvtfcHk0lgMbHVj3uizoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVCqu7fP&md5=d6f4af801e795995739478385f5e36fd</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1177%2F0192623314553804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623314553804%26sid%3Dliteratum%253Aachs%26aulast%3DFielden%26aufirst%3DM.%2BR.%26aulast%3DWerner%26aufirst%3DJ.%26aulast%3DJamison%26aufirst%3DJ.%2BA.%26aulast%3DCoppi%26aufirst%3DA.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DDunn%26aufirst%3DR.%2BT.%26aulast%3DTrueblood%26aufirst%3DE.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DAfshari%26aufirst%3DC.%2BA.%26aulast%3DLightfoot-Dunn%26aufirst%3DR.%26atitle%3DRetinal%2520Toxicity%2520Induced%2520by%2520a%2520Novel%2520beta-secretase%2520Inhibitor%2520in%2520the%2520Sprague-Dawley%2520Rat%26jtitle%3DToxicol.%2520Pathol.%26date%3D2015%26volume%3D43%26issue%3D4%26spage%3D581%26epage%3D92%26doi%3D10.1177%2F0192623314553804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuhl, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atchison, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanian, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambroise, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brulet, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Am Ende, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoghegan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judkins, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span> <span> </span><span class="NLM_article-title">Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of beta-secretase inhibitors</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13042</span>, <span class="refDoi"> DOI: 10.1038/ncomms13042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1038%2Fncomms13042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=27727204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1GqtbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13042&author=A.+M.+Zuhlauthor=C.+E.+Nolanauthor=M.+A.+Brodneyauthor=S.+Niessenauthor=K.+Atchisonauthor=C.+Houleauthor=D.+A.+Karanianauthor=C.+Ambroiseauthor=J.+W.+Bruletauthor=E.+M.+Beckauthor=S.+D.+Doranauthor=B.+T.+O%E2%80%99Neillauthor=C.+W.+Am+Endeauthor=C.+Changauthor=K.+F.+Geogheganauthor=G.+M.+Westauthor=J.+C.+Judkinsauthor=X.+Houauthor=D.+R.+Riddellauthor=D.+S.+Johnson&title=Chemoproteomic+profiling+reveals+that+cathepsin+D+off-target+activity+drives+ocular+toxicity+of+beta-secretase+inhibitors&doi=10.1038%2Fncomms13042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors</span></div><div class="casAuthors">Zuhl, Andrea M.; Nolan, Charles E.; Brodney, Michael A.; Niessen, Sherry; Atchison, Kevin; Houle, Christopher; Karanian, David A.; Ambroise, Claude; Brulet, Jeffrey W.; Beck, Elizabeth M.; Doran, Shawn D.; O'Neill, Brian T.; am Ende, Christopher W.; Chang, Cheng; Geoghegan, Kieran F.; West, Graham M.; Judkins, Joshua C.; Hou, Xinjun; Riddell, David R.; Johnson, Douglas S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13042</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibition of β-secretase BACE1 is considered one of the most promising approaches for treating Alzheimer's disease.  Several structurally distinct BACE1 inhibitors have been withdrawn from development after inducing ocular toxicity in animal models, but the target mediating this toxicity has not been identified.  Here we use a clickable photoaffinity probe to identify cathepsin D (CatD) as a principal off-target of BACE1 inhibitors in human cells.  We find that several BACE1 inhibitors blocked CatD activity in cells with much greater potency than that displayed in cell-free assays with purified protein.  Through a series of exploratory toxicol. studies, we show that quantifying CatD target engagement in cells with the probe is predictive of ocular toxicity in vivo.  Taken together, our findings designate off-target inhibition of CatD as a principal driver of ocular toxicity for BACE1 inhibitors and more generally underscore the power of chem. proteomics for discerning mechanisms of drug action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-LulGVRdJLVg90H21EOLACvtfcHk0lgbPf8_MvWkmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1GqtbbL&md5=5e2c31195f4f03babec561a5824ccb0d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fncomms13042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13042%26sid%3Dliteratum%253Aachs%26aulast%3DZuhl%26aufirst%3DA.%2BM.%26aulast%3DNolan%26aufirst%3DC.%2BE.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DAtchison%26aufirst%3DK.%26aulast%3DHoule%26aufirst%3DC.%26aulast%3DKaranian%26aufirst%3DD.%2BA.%26aulast%3DAmbroise%26aufirst%3DC.%26aulast%3DBrulet%26aufirst%3DJ.%2BW.%26aulast%3DBeck%26aufirst%3DE.%2BM.%26aulast%3DDoran%26aufirst%3DS.%2BD.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DB.%2BT.%26aulast%3DAm%2BEnde%26aufirst%3DC.%2BW.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DGeoghegan%26aufirst%3DK.%2BF.%26aulast%3DWest%26aufirst%3DG.%2BM.%26aulast%3DJudkins%26aufirst%3DJ.%2BC.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DRiddell%26aufirst%3DD.%2BR.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26atitle%3DChemoproteomic%2520profiling%2520reveals%2520that%2520cathepsin%2520D%2520off-target%2520activity%2520drives%2520ocular%2520toxicity%2520of%2520beta-secretase%2520inhibitors%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D13042%26doi%3D10.1038%2Fncomms13042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koike, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakanishi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saftig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohsawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz-Schaeffer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waguri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kametaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kominami, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Figura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">6898</span>– <span class="NLM_lpage">906</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.20-18-06898.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1523%2FJNEUROSCI.20-18-06898.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10995834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmvVGhsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=6898-906&issue=18&author=M.+Koikeauthor=H.+Nakanishiauthor=P.+Saftigauthor=J.+Ezakiauthor=K.+Isaharaauthor=Y.+Ohsawaauthor=W.+Schulz-Schaefferauthor=T.+Watanabeauthor=S.+Waguriauthor=S.+Kametakaauthor=M.+Shibataauthor=K.+Yamamotoauthor=E.+Kominamiauthor=C.+Petersauthor=K.+von+Figuraauthor=Y.+Uchiyama&title=Cathepsin+D+deficiency+induces+lysosomal+storage+with+ceroid+lipofuscin+in+mouse+CNS+neurons&doi=10.1523%2FJNEUROSCI.20-18-06898.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons</span></div><div class="casAuthors">Koike, Masato; Nakanishi, Hiroshi; Saftig, Paul; Ezaki, Junji; Isahara, Kyoko; Ohsawa, Yoshiyuki; Schulz-Schaeffer, Walter; Watanabe, Tsuyoshi; Waguri, Satoshi; Kametaka, Satoshi; Shibata, Masahiro; Yamamoto, Kenji; Kominami, Eiki; Peters, Christoph; Von Figura, Kurt; Uchiyama, Yasuo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6898-6906</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Cathepsin D-deficient (CD-/-) mice have been shown to manifest seizures and become blind near the terminal stage [approx. postnatal day (P) 26].  We therefore examd. the morphol., immunocytochem., and biochem. features of CNS tissues of these mice.  By electron microscopy, autophagosome/autolysosome-like bodies contg. part of the cytoplasm, granular osmiophilic deposits, and fingerprint profiles were demonstrated in the neuronal perikarya of CD-/- mouse brains after P20.  Autophagosomes and granular osmiophilic deposits were detected in neurons at P0 but were few in no., whereas they increased in the neuronal perikarya within days after birth.  Some large-sized neurons having autophagosome/autolysosome-like bodies in the perikarya appeared in the CNS tissues, esp. in the thalamic region and the cerebral cortex, at P17.  These lysosomal bodies occupied the perikarya of almost all neurons in CD-/- mouse brains obtained from P23 until the terminal stage.  Because these neurons exhibited autofluorescence, it was considered that ceroid lipofuscin may accumulate in lysosomal structures of CD-/- neurons.  Subunit c of mitochondrial ATP synthase was found to accumulate in the lysosomes of neurons, although the activity of tripeptidyl peptidase-I significantly increased in the brain.  Moreover, neurons near the terminal stage were often shrunken and possessed irregular nuclei through which small dense chromatin masses were scattered.  These results suggest that the CNS neurons in CD-/- mice show a new form of lysosomal accumulation disease with a phenotype resembling neuronal ceroid lipofuscinosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsG5BWz7IR-LVg90H21EOLACvtfcHk0lgbPf8_MvWkmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmvVGhsrc%253D&md5=6515642d9cfc62e6c7fe3ed44d6b5a11</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.20-18-06898.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.20-18-06898.2000%26sid%3Dliteratum%253Aachs%26aulast%3DKoike%26aufirst%3DM.%26aulast%3DNakanishi%26aufirst%3DH.%26aulast%3DSaftig%26aufirst%3DP.%26aulast%3DEzaki%26aufirst%3DJ.%26aulast%3DIsahara%26aufirst%3DK.%26aulast%3DOhsawa%26aufirst%3DY.%26aulast%3DSchulz-Schaeffer%26aufirst%3DW.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DWaguri%26aufirst%3DS.%26aulast%3DKametaka%26aufirst%3DS.%26aulast%3DShibata%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DKominami%26aufirst%3DE.%26aulast%3DPeters%26aufirst%3DC.%26aulast%3Dvon%2BFigura%26aufirst%3DK.%26aulast%3DUchiyama%26aufirst%3DY.%26atitle%3DCathepsin%2520D%2520deficiency%2520induces%2520lysosomal%2520storage%2520with%2520ceroid%2520lipofuscin%2520in%2520mouse%2520CNS%2520neurons%26jtitle%3DJ.%2520Neurosci.%26date%3D2000%26volume%3D20%26issue%3D18%26spage%3D6898%26epage%3D906%26doi%3D10.1523%2FJNEUROSCI.20-18-06898.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinfeld, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhardt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillebrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraetzner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruck, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saftig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gartner, J.</span></span> <span> </span><span class="NLM_article-title">Cathepsin D deficiency is associated with a human neurodegenerative disorder</span>. <i>Am. J. Hum. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">988</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1086/504159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1086%2F504159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=16685649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD28XltVyks78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2006&pages=988-98&issue=6&author=R.+Steinfeldauthor=K.+Reinhardtauthor=K.+Schreiberauthor=M.+Hillebrandauthor=R.+Kraetznerauthor=W.+Bruckauthor=P.+Saftigauthor=J.+Gartner&title=Cathepsin+D+deficiency+is+associated+with+a+human+neurodegenerative+disorder&doi=10.1086%2F504159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin D deficiency is associated with a human neurodegenerative disorder</span></div><div class="casAuthors">Steinfeld, Robert; Reinhardt, Konstanze; Schreiber, Kathrin; Hillebrand, Merle; Kraetzner, Ralph; Brueck, Wolfgang; Saftig, Paul; Gaertner, Jutta</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">988-998</span>CODEN:
                <span class="NLM_cas:coden">AJHGAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9297</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Cathepsin D is a ubiquitously expressed lysosomal protease that is involved in proteolytic degrdn., cell invasion, and apoptosis.  In mice and sheep, cathepsin D deficiency is known to cause a fatal neurodegenerative disease.  Here, we report a novel disorder in a child with early blindness and progressive psychomotor disability.  Two missense mutations in the CTSD gene, F229I and W383C, were identified and were found to cause markedly reduced proteolytic activity and a diminished amt. of cathepsin D in patient fibroblasts.  Expression of cathepsin D mutants in cathepsin D-/- mouse fibroblasts revealed disturbed posttranslational processing and intracellular targeting for W383C and diminished maximal enzyme velocity for F229I.  The structural effects of cathepsin D mutants were estd. by computer modeling, which suggested larger structural alterations for W383C than for F229I.  Our studies broaden the group of human neurodegenerative disorders and add new insight into the cellular functions of human cathepsin D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohf0ApK0eyVLVg90H21EOLACvtfcHk0lgbPf8_MvWkmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltVyks78%253D&md5=96a9bf74f1823244552ed50391eb5278</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1086%2F504159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F504159%26sid%3Dliteratum%253Aachs%26aulast%3DSteinfeld%26aufirst%3DR.%26aulast%3DReinhardt%26aufirst%3DK.%26aulast%3DSchreiber%26aufirst%3DK.%26aulast%3DHillebrand%26aufirst%3DM.%26aulast%3DKraetzner%26aufirst%3DR.%26aulast%3DBruck%26aufirst%3DW.%26aulast%3DSaftig%26aufirst%3DP.%26aulast%3DGartner%26aufirst%3DJ.%26atitle%3DCathepsin%2520D%2520deficiency%2520is%2520associated%2520with%2520a%2520human%2520neurodegenerative%2520disorder%26jtitle%3DAm.%2520J.%2520Hum.%2520Genet.%26date%3D2006%26volume%3D78%26issue%3D6%26spage%3D988%26epage%3D98%26doi%3D10.1086%2F504159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tyynela, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleat, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gin, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haltia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobel, P.</span></span> <span> </span><span class="NLM_article-title">A mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2786</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1093/emboj/19.12.2786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1093%2Femboj%2F19.12.2786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10856224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtFCru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=2786-92&issue=12&author=J.+Tyynelaauthor=I.+Soharauthor=D.+E.+Sleatauthor=R.+M.+Ginauthor=R.+J.+Donnellyauthor=M.+Baumannauthor=M.+Haltiaauthor=P.+Lobel&title=A+mutation+in+the+ovine+cathepsin+D+gene+causes+a+congenital+lysosomal+storage+disease+with+profound+neurodegeneration&doi=10.1093%2Femboj%2F19.12.2786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration</span></div><div class="casAuthors">Tyynela, Jaana; Sohar, Istvan; Sleat, David E.; Gin, Rosalie M.; Donnelly, Robert J.; Baumann, Marc; Haltia, Matti; Lobel, Peter</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2786-2792</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The neuronal ceroid lipofuscinoses (NCLs) constitute a group of neurodegenerative storage diseases characterized by progressive psychomotor retardation, blindness and premature death.  Pathol., there is accumulation of autofluorescent material in lysosome-derived organelles in a variety of cell types, but neurons in the central nervous system appear to be selectively affected and undergo progressive death.  In this report the authors show that a novel form of NCL, congenital ovine NCL, is caused by a deficiency in the lysosomal aspartyl proteinase cathepsin D.  A single nucleotide mutation in the cathepsin D gene results in conversion of an active site aspartate to asparagine, leading to prodn. of an enzymically inactive but stable protein.  This results in severe cerebrocortical atrophy and early death, providing strong evidence for an important role of cathepsin D in neuronal development and/or homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-SI1vEX1-ALVg90H21EOLACvtfcHk0li8A7SYivRMxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtFCru7s%253D&md5=f6eecb4cdd579513f194312cbca20730</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F19.12.2786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F19.12.2786%26sid%3Dliteratum%253Aachs%26aulast%3DTyynela%26aufirst%3DJ.%26aulast%3DSohar%26aufirst%3DI.%26aulast%3DSleat%26aufirst%3DD.%2BE.%26aulast%3DGin%26aufirst%3DR.%2BM.%26aulast%3DDonnelly%26aufirst%3DR.%2BJ.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DHaltia%26aufirst%3DM.%26aulast%3DLobel%26aufirst%3DP.%26atitle%3DA%2520mutation%2520in%2520the%2520ovine%2520cathepsin%2520D%2520gene%2520causes%2520a%2520congenital%2520lysosomal%2520storage%2520disease%2520with%2520profound%2520neurodegeneration%26jtitle%3DEMBO%2520J.%26date%3D2000%26volume%3D19%26issue%3D12%26spage%3D2786%26epage%3D92%26doi%3D10.1093%2Femboj%2F19.12.2786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span> <span> </span><span class="NLM_article-title">Conformational dynamics of cathepsin D and binding to a small-molecule BACE1 inhibitor</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">1260</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.1002/jcc.24719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1002%2Fjcc.24719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=28370344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsV2jsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=1260-1269&issue=15&author=C.+R.+Ellisauthor=C.+C.+Tsaiauthor=F.+Y.+Linauthor=J.+Shen&title=Conformational+dynamics+of+cathepsin+D+and+binding+to+a+small-molecule+BACE1+inhibitor&doi=10.1002%2Fjcc.24719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational dynamics of cathepsin D and binding to a small-molecule BACE1 inhibitor</span></div><div class="casAuthors">Ellis, Christopher R.; Tsai, Cheng-Chieh; Lin, Fang-Yu; Shen, Jana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1260-1269</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">BACE1 is a major therapeutic target for prevention and treatment of Alzheimer's disease.  Developing inhibitors that can selectively target BACE1 in favor of other proteases, esp. cathepsin D (CatD), has presented significant challenges.  Here, the authors investigate the conformational dynamics and protonation states of BACE1 and CatD using continuous const. pH mol. dynamics with pH replica-exchange sampling protocol.  Despite similar structure, BACE1 and CatD exhibit markedly different active site dynamics.  BACE1 displays pH-dependent flap dynamics that controls substrate accessibility, while the CatD flap is relatively rigid and remains open in the pH range 2.5-6.  Interestingly, although each protease hydrolyzes peptide bonds, the protonation states of the catalytic dyads are different within the active pH range.  The acidic and basic components of the BACE1 catalytic dyad are clear, while either aspartic acid of the CatD catalytic dyad could play the role of acid or base.  Finally, the authors investigate binding of the inhibitor LY2811376 developed by Eli Lilly to BACE1 and CatD.  Surprisingly, in the enzyme active pH range, LY2811376 forms a stronger salt bridge with the catalytic dyad in CatD than in BACE1, which might explain the retinal toxicity of the inhibitor related to off-target inhibition of CatD.  This work highlights the complexity and challenge in structure-based drug design where receptor-ligand binding induces protonation state change in both the protein and the inhibitor. © 2017 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqzUs1RP_fBLVg90H21EOLACvtfcHk0li8A7SYivRMxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsV2jsLo%253D&md5=bf7903e2c8828a3bfa2b2a14b9a1ec6b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fjcc.24719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.24719%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DC.%2BR.%26aulast%3DTsai%26aufirst%3DC.%2BC.%26aulast%3DLin%26aufirst%3DF.%2BY.%26aulast%3DShen%26aufirst%3DJ.%26atitle%3DConformational%2520dynamics%2520of%2520cathepsin%2520D%2520and%2520binding%2520to%2520a%2520small-molecule%2520BACE1%2520inhibitor%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2017%26volume%3D38%26issue%3D15%26spage%3D1260%26epage%3D1269%26doi%3D10.1002%2Fjcc.24719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Polo, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boya, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauleau, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalil, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larochette, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souquere, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eskelinen, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saftig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">3091</span>– <span class="NLM_lpage">102</span>, <span class="refDoi"> DOI: 10.1242/jcs.02447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1242%2Fjcs.02447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=15985464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD2MXosVemtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2005&pages=3091-102&author=R.+A.+Gonzalez-Poloauthor=P.+Boyaauthor=A.+L.+Pauleauauthor=A.+Jalilauthor=N.+Larochetteauthor=S.+Souquereauthor=E.+L.+Eskelinenauthor=G.+Pierronauthor=P.+Saftigauthor=G.+Kroemer&title=The+apoptosis%2Fautophagy+paradox%3A+autophagic+vacuolization+before+apoptotic+death&doi=10.1242%2Fjcs.02447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The apoptosis/autophagy paradox: Autophagic vacuolization before apoptotic death</span></div><div class="casAuthors">Gonzalez-Polo, Rosa-Ana; Boya, Patricia; Pauleau, Anne-Laure; Jalil, Abdelali; Larochette, Nathanael; Souquere, Sylvie; Eskelinen, Eeva-Liisa; Pierron, Gerard; Saftig, Paul; Kroemer, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3091-3102</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Autophagic cell death is morphol. characterized by an accumulation of autophagic vacuoles.  Here, we show that inactivation of LAMP2 by RNA interference or by homologous recombination leads to autophagic vacuolization in nutrient-depleted cells.  Cells that lack LAMP2 expression showed an enhanced accumulation of vacuoles carrying the marker LC3, yet a decreased colocalization of LC3 and lysosomes, suggesting that the fusion between autophagic vacuoles and lysosomes was inhibited.  While a fraction of mitochondria from starved LAMP2-expressing cells colocalized with lysosomal markers, within autophagolysosomes, no such colocalization was found on removal of LAMP2 from the exptl. system.  Of note, LAMP1 depletion had no such effects and did not aggravate the phenotype induced by LAMP2-specific small interfering RNA.  Serum and amino acid-starved LAMP2-neg. cells exhibited an accumulation of autophagic vacuoles and then succumbed to cell death with hallmarks of apoptosis such as loss of the mitochondrial transmembrane potential, caspase activation and chromatin condensation.  While caspase inhibition retarded cell death, it had no protective effect on mitochondria.  Stabilization of mitochondria by overexpression of Bcl-2 or the mitochondrion-targeted cytomegalovirus protein vMIA, however, blocked all signs of apoptosis.  Neither caspase inhibition nor mitochondrial stabilization antagonized autophagic vacuolization in LAMP2-deficient cells.  Altogether, these data indicate that accumulation of autophagic vacuoles can precede apoptotic cell death.  These findings argue against the clear-cut distinction between type 1 (apoptotic) and type 2 (autophagic) cell death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFwZpnW6oPorVg90H21EOLACvtfcHk0li8A7SYivRMxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXosVemtbY%253D&md5=6d85b66e3fd8a75dc1d52d1347086e72</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1242%2Fjcs.02447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.02447%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Polo%26aufirst%3DR.%2BA.%26aulast%3DBoya%26aufirst%3DP.%26aulast%3DPauleau%26aufirst%3DA.%2BL.%26aulast%3DJalil%26aufirst%3DA.%26aulast%3DLarochette%26aufirst%3DN.%26aulast%3DSouquere%26aufirst%3DS.%26aulast%3DEskelinen%26aufirst%3DE.%2BL.%26aulast%3DPierron%26aufirst%3DG.%26aulast%3DSaftig%26aufirst%3DP.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DThe%2520apoptosis%252Fautophagy%2520paradox%253A%2520autophagic%2520vacuolization%2520before%2520apoptotic%2520death%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2005%26volume%3D118%26spage%3D3091%26epage%3D102%26doi%3D10.1242%2Fjcs.02447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzon, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutra, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barreiro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Alsina, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogilvie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaChapelle, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanyon, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steppan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robshaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hales, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambroise, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bales, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4476</span>– <span class="NLM_lpage">4504</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00246</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00246" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4476-4504&issue=10&author=B.+T.+O%E2%80%99Neillauthor=E.+M.+Beckauthor=C.+R.+Butlerauthor=C.+E.+Nolanauthor=C.+Gonzalesauthor=L.+Zhangauthor=S.+D.+Doranauthor=K.+Laphamauthor=L.+M.+Buzonauthor=J.+K.+Dutraauthor=G.+Barreiroauthor=X.+Houauthor=L.+A.+Martinez-Alsinaauthor=B.+N.+Rogersauthor=A.+Villalobosauthor=J.+C.+Murrayauthor=K.+Ogilvieauthor=E.+A.+LaChapelleauthor=C.+Changauthor=L.+F.+Lanyonauthor=C.+M.+Steppanauthor=A.+Robshawauthor=K.+Halesauthor=G.+G.+Boucherauthor=K.+Pandherauthor=C.+Houleauthor=C.+W.+Ambroiseauthor=D.+Karanianauthor=D.+Riddellauthor=K.+R.+Balesauthor=M.+A.+Brodney&title=Design+and+Synthesis+of+Clinical+Candidate+PF-06751979%3A+A+Potent%2C+Brain+Penetrant%2C+beta-Site+Amyloid+Precursor+Protein+Cleaving+Enzyme+1+%28BACE1%29+Inhibitor+Lacking+Hypopigmentation&doi=10.1021%2Facs.jmedchem.8b00246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation</span></div><div class="casAuthors">O'Neill, Brian T.; Beck, Elizabeth M.; Butler, Christopher R.; Nolan, Charles E.; Gonzales, Cathleen; Zhang, Lei; Doran, Shawn D.; Lapham, Kimberly; Buzon, Leanne M.; Dutra, Jason K.; Barreiro, Gabriela; Hou, Xinjun; Martinez-Alsina, Luis A.; Rogers, Bruce N.; Villalobos, Anabella; Murray, John C.; Ogilvie, Kevin; La Chapelle, Erik A.; Chang, Cheng; Lanyon, Lorraine F.; Steppan, Claire M.; Robshaw, Ashley; Hales, Katherine; Boucher, Germaine G.; Pandher, Karamjeet; Houle, Christopher; Ambroise, Claude W.; Karanian, David; Riddell, David; Bales, Kelly R.; Brodney, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4476-4504</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A major challenge in the development of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease is the alignment of potency, drug-like properties, and selectivity over related aspartyl proteases such as Cathepsin D (CatD) and BACE2.  The potential liabilities of inhibiting BACE2 chronically have only recently begun to emerge as BACE2 impacts the processing of the premelanosome protein (PMEL17) and disrupts melanosome morphol. resulting in a depigmentation phenotype.  Herein, the authors describe the identification of clin. candidate PF-06751979 (I), which displays excellent brain penetration, potent in vivo efficacy, and broad selectivity over related aspartyl proteases including BACE2.  Chronic dosing of I for up to 9 mo in dog did not reveal any observation of hair coat color (pigmentation) changes and suggests a key differentiator over current BACE1 inhibitors that are nonselective against BACE2 in later stage clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs1F61vo0jBbVg90H21EOLACvtfcHk0lgRCjbSRxogAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCmtrs%253D&md5=3d8cae0bb20298e66f6da1c26cf8d5bc</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00246%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DB.%2BT.%26aulast%3DBeck%26aufirst%3DE.%2BM.%26aulast%3DButler%26aufirst%3DC.%2BR.%26aulast%3DNolan%26aufirst%3DC.%2BE.%26aulast%3DGonzales%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DDoran%26aufirst%3DS.%2BD.%26aulast%3DLapham%26aufirst%3DK.%26aulast%3DBuzon%26aufirst%3DL.%2BM.%26aulast%3DDutra%26aufirst%3DJ.%2BK.%26aulast%3DBarreiro%26aufirst%3DG.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DMartinez-Alsina%26aufirst%3DL.%2BA.%26aulast%3DRogers%26aufirst%3DB.%2BN.%26aulast%3DVillalobos%26aufirst%3DA.%26aulast%3DMurray%26aufirst%3DJ.%2BC.%26aulast%3DOgilvie%26aufirst%3DK.%26aulast%3DLaChapelle%26aufirst%3DE.%2BA.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DLanyon%26aufirst%3DL.%2BF.%26aulast%3DSteppan%26aufirst%3DC.%2BM.%26aulast%3DRobshaw%26aufirst%3DA.%26aulast%3DHales%26aufirst%3DK.%26aulast%3DBoucher%26aufirst%3DG.%2BG.%26aulast%3DPandher%26aufirst%3DK.%26aulast%3DHoule%26aufirst%3DC.%26aulast%3DAmbroise%26aufirst%3DC.%2BW.%26aulast%3DKaranian%26aufirst%3DD.%26aulast%3DRiddell%26aufirst%3DD.%26aulast%3DBales%26aufirst%3DK.%2BR.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Clinical%2520Candidate%2520PF-06751979%253A%2520A%2520Potent%252C%2520Brain%2520Penetrant%252C%2520beta-Site%2520Amyloid%2520Precursor%2520Protein%2520Cleaving%2520Enzyme%25201%2520%2528BACE1%2529%2520Inhibitor%2520Lacking%2520Hypopigmentation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D10%26spage%3D4476%26epage%3D4504%26doi%3D10.1021%2Facs.jmedchem.8b00246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hilpert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guba, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woltering, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wostl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayweg, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers-Evans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humm, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krummenacher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnider, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozmen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergadano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochstrasser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David-Pierson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narquizian, R.</span></span> <span> </span><span class="NLM_article-title">beta-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">3980</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1021/jm400225m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400225m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVymuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3980-95&issue=10&author=H.+Hilpertauthor=W.+Gubaauthor=T.+J.+Wolteringauthor=W.+Wostlauthor=E.+Pinardauthor=H.+Mauserauthor=A.+V.+Maywegauthor=M.+Rogers-Evansauthor=R.+Hummauthor=D.+Krummenacherauthor=T.+Muserauthor=C.+Schniderauthor=H.+Jacobsenauthor=L.+Ozmenauthor=A.+Bergadanoauthor=D.+W.+Bannerauthor=R.+Hochstrasserauthor=A.+Kuglstatterauthor=P.+David-Piersonauthor=H.+Fischerauthor=A.+Polaraauthor=R.+Narquizian&title=beta-Secretase+%28BACE1%29+inhibitors+with+high+in+vivo+efficacy+suitable+for+clinical+evaluation+in+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm400225m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer's Disease</span></div><div class="casAuthors">Hilpert, Hans; Guba, Wolfgang; Woltering, Thomas J.; Wostl, Wolfgang; Pinard, Emmanuel; Mauser, Harald; Mayweg, Alexander V.; Rogers-Evans, Mark; Humm, Roland; Krummenacher, Daniela; Muser, Thorsten; Schnider, Christian; Jacobsen, Helmut; Ozmen, Laurence; Bergadano, Alessandra; Banner, David W.; Hochstrasser, Remo; Kuglstatter, Andreas; David-Pierson, Pascale; Fischer, Holger; Polara, Alessandra; Narquizian, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3980-3995</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An extensive fluorine scan of 1,3-oxazines revealed the power of fluorine(s) to lower the pKa and thereby dramatically change the pharmacol. profile of this class of BACE1 inhibitors.  The CF3 substituted oxazine 89, a potent and highly brain penetrant BACE1 inhibitor, was able to reduce significantly CSF Aβ40 and 42 in rats at oral doses as low as 1 mg/kg.  The effect was long lasting, showing a significant redn. of Aβ40 and 42 even after 24 h.  In contrast to 89, compd. 1b lacking the CF3 group was virtually inactive in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmoKRrAxxHErVg90H21EOLACvtfcHk0lgRCjbSRxogAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVymuro%253D&md5=e5d311d1c8fecfaed043d3a0bf16c168</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm400225m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400225m%26sid%3Dliteratum%253Aachs%26aulast%3DHilpert%26aufirst%3DH.%26aulast%3DGuba%26aufirst%3DW.%26aulast%3DWoltering%26aufirst%3DT.%2BJ.%26aulast%3DWostl%26aufirst%3DW.%26aulast%3DPinard%26aufirst%3DE.%26aulast%3DMauser%26aufirst%3DH.%26aulast%3DMayweg%26aufirst%3DA.%2BV.%26aulast%3DRogers-Evans%26aufirst%3DM.%26aulast%3DHumm%26aufirst%3DR.%26aulast%3DKrummenacher%26aufirst%3DD.%26aulast%3DMuser%26aufirst%3DT.%26aulast%3DSchnider%26aufirst%3DC.%26aulast%3DJacobsen%26aufirst%3DH.%26aulast%3DOzmen%26aufirst%3DL.%26aulast%3DBergadano%26aufirst%3DA.%26aulast%3DBanner%26aufirst%3DD.%2BW.%26aulast%3DHochstrasser%26aufirst%3DR.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DDavid-Pierson%26aufirst%3DP.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DPolara%26aufirst%3DA.%26aulast%3DNarquizian%26aufirst%3DR.%26atitle%3Dbeta-Secretase%2520%2528BACE1%2529%2520inhibitors%2520with%2520high%2520in%2520vivo%2520efficacy%2520suitable%2520for%2520clinical%2520evaluation%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D10%26spage%3D3980%26epage%3D95%26doi%3D10.1021%2Fjm400225m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rombouts, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tresadern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Lamenca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Gool, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Molina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso de Diego, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehlrich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prokopcova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghys, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Brandt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surkyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Cleyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moechars, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trabanco, A. A.</span></span> <span> </span><span class="NLM_article-title">1,4-Oxazine beta-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8216</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01101</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01101" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFWktL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8216-35&issue=20&author=F.+J.+Romboutsauthor=G.+Tresadernauthor=O.+Delgadoauthor=C.+Martinez-Lamencaauthor=M.+Van+Goolauthor=A.+Garcia-Molinaauthor=S.+A.+Alonso+de+Diegoauthor=D.+Oehlrichauthor=H.+Prokopcovaauthor=J.+M.+Alonsoauthor=N.+Austinauthor=H.+Borghysauthor=S.+Van+Brandtauthor=M.+Surkynauthor=M.+De+Cleynauthor=A.+Vosauthor=R.+Alexanderauthor=G.+Macdonaldauthor=D.+Moecharsauthor=H.+Gijsenauthor=A.+A.+Trabanco&title=1%2C4-Oxazine+beta-Secretase+1+%28BACE1%29+Inhibitors%3A+From+Hit+Generation+to+Orally+Bioavailable+Brain+Penetrant+Leads&doi=10.1021%2Facs.jmedchem.5b01101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads</span></div><div class="casAuthors">Rombouts, Frederik J. R.; Tresadern, Gary; Delgado, Oscar; Martinez-Lamenca, Carolina; Van Gool, Michiel; Garcia-Molina, Aranzazu; Alonso de Diego, Sergio A.; Oehlrich, Daniel; Prokopcova, Hana; Alonso, Jose Manuel; Austin, Nigel; Borghys, Herman; Van Brandt, Sven; Surkyn, Michel; De Cleyn, Michel; Vos, Ann; Alexander, Richard; Macdonald, Gregor; Moechars, Dieder; Gijsen, Harrie; Trabanco, Andres A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8216-8235</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1,4-Oxazines are presented, which show good in vitro inhibition in enzymic and cellular BACE1 assays.  We describe lead optimization focused on reducing the amidine pKa while optimizing interactions in the BACE1 active site.  Our strategy permitted modulation of properties such as permeation and esp. P-glycoprotein efflux.  This led to compds. which were orally bioavailable, centrally active, and which demonstrated robust lowering of brain and CSF Aβ levels, resp., in mouse and dog models.  The amyloid lowering potential of these mols. makes them valuable leads in the search for new BACE1 inhibitors for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHVm9JF2kNa7Vg90H21EOLACvtfcHk0lgRCjbSRxogAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFWktL3L&md5=d3563a26a17a1c86c45a4f99b18be251</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01101%26sid%3Dliteratum%253Aachs%26aulast%3DRombouts%26aufirst%3DF.%2BJ.%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DDelgado%26aufirst%3DO.%26aulast%3DMartinez-Lamenca%26aufirst%3DC.%26aulast%3DVan%2BGool%26aufirst%3DM.%26aulast%3DGarcia-Molina%26aufirst%3DA.%26aulast%3DAlonso%2Bde%2BDiego%26aufirst%3DS.%2BA.%26aulast%3DOehlrich%26aufirst%3DD.%26aulast%3DProkopcova%26aufirst%3DH.%26aulast%3DAlonso%26aufirst%3DJ.%2BM.%26aulast%3DAustin%26aufirst%3DN.%26aulast%3DBorghys%26aufirst%3DH.%26aulast%3DVan%2BBrandt%26aufirst%3DS.%26aulast%3DSurkyn%26aufirst%3DM.%26aulast%3DDe%2BCleyn%26aufirst%3DM.%26aulast%3DVos%26aufirst%3DA.%26aulast%3DAlexander%26aufirst%3DR.%26aulast%3DMacdonald%26aufirst%3DG.%26aulast%3DMoechars%26aufirst%3DD.%26aulast%3DGijsen%26aufirst%3DH.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26atitle%3D1%252C4-Oxazine%2520beta-Secretase%25201%2520%2528BACE1%2529%2520Inhibitors%253A%2520From%2520Hit%2520Generation%2520to%2520Orally%2520Bioavailable%2520Brain%2520Penetrant%2520Leads%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D20%26spage%3D8216%26epage%3D35%26doi%3D10.1021%2Facs.jmedchem.5b01101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ploemen, J.-P. H.T.M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Sandt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Burgsteden, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salemink, P. J.M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van
Esch, E.</span></span> <span> </span><span class="NLM_article-title">Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines</span>. <i>Exp. Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">355</span>, <span class="refDoi"> DOI: 10.1078/0940-2993-00338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1078%2F0940-2993-00338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=15088636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksFGltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2004&pages=347-355&issue=5&author=J.-P.+H.T.M.+Ploemenauthor=J.+Kelderauthor=T.+Hafmansauthor=H.+van+de+Sandtauthor=J.+A.+van+Burgstedenauthor=P.+J.M.+Saleminkauthor=E.+van%0AEsch&title=Use+of+physicochemical+calculation+of+pKa+and+CLogP+to+predict+phospholipidosis-inducing+potential%3A+a+case+study+with+structurally+related+piperazines&doi=10.1078%2F0940-2993-00338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines</span></div><div class="casAuthors">Ploemen, Jan-Peter H. T. M.; Kelder, Jan; Hafmans, Theo; van de Sandt, Han; van Burgsteden, Johan A.; Salemink, Paul J. M.; van Esch, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">347-355</span>CODEN:
                <span class="NLM_cas:coden">ETPAEK</span>;
        ISSN:<span class="NLM_cas:issn">0940-2993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Several cationic amphiphilic compds. are known to induce phospholipidosis, a condition primarily characterized by excessive accumulation of phospholipids in different cell types, giving the affected cells a finely foamy appearance.  Excessive storage of lamellar membranous intralysosomal inclusion bodies is the hallmark for phospholipidosis on the electron microscopic level.  In case of alveolar phospholipidosis, foamy macrophages accumulate within the alveolar spaces of the lung.  Based on such findings in a one-year toxicity study with gepirone in rats, we studied the mol. properties of this compd. and compds. suspected of being phospholipidosis inducers by means of physicochem. calcns.  Physicochem. mol. calcns. of mol. wt., ClogP (partition coeff. octanol/water), logD at pH 7.4, and pKa were performed, for the cationic amphiphilic compds. chlorpromazine, amiodarone, imipramine, propranolol and fluoxetine, and for the structurally related compds. 1-phenylpiperazine (1-PHP), gepirone (and its major metabolites, 3-OH-gepirone and 1-pyrimidinylpiperazine [1-PP]), and buspirone.  ClogP and calcd. pKa cluster differently for the amphiphilic drugs compared to the chem. series of piperazines.  In line with this anal., lamellar inclusion bodies were found in an in vitro validation expt. in the human monoblastoid cell line U-937, incubated for 96 h at 10 μg/mL with cationic amphiphilic drugs (amiodarone, imipramine, or propranolol).  No such lamellar inclusion bodies were seen for any of the compds. from the chem. series of piperazines including gepirone and its metabolites.  The data presented support the use of simple physicochem. calcns. of ClogP and pKa to discriminate rapidly between compds. suspected of being phospholipidosis inducers.  Finally, the discriminative power of these physicochem. ClogP and pKa calcns. to predict phospholipidosis-inducing potential was further validated by extension of the set of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-qnA3_zghvbVg90H21EOLACvtfcHk0lg7ACtNSW_zlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksFGltL0%253D&md5=caf5e68d3d5356dfef1cc29dbaf5ca87</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1078%2F0940-2993-00338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1078%252F0940-2993-00338%26sid%3Dliteratum%253Aachs%26aulast%3DPloemen%26aufirst%3DJ.-P.%2BH.T.M.%26aulast%3DKelder%26aufirst%3DJ.%26aulast%3DHafmans%26aufirst%3DT.%26aulast%3Dvan%2Bde%2BSandt%26aufirst%3DH.%26aulast%3Dvan%2BBurgsteden%26aufirst%3DJ.%2BA.%26aulast%3DSalemink%26aufirst%3DP.%2BJ.M.%26aulast%3Dvan%2BEsch%26aufirst%3DE.%26atitle%3DUse%2520of%2520physicochemical%2520calculation%2520of%2520pKa%2520and%2520CLogP%2520to%2520predict%2520phospholipidosis-inducing%2520potential%253A%2520a%2520case%2520study%2520with%2520structurally%2520related%2520piperazines%26jtitle%3DExp.%2520Toxicol.%2520Pathol.%26date%3D2004%26volume%3D55%26issue%3D5%26spage%3D347%26epage%3D355%26doi%3D10.1078%2F0940-2993-00338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopeit, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villaverde, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gossas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otero, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nystrom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraznenok, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danielson, U. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, F.</span></span> <span> </span><span class="NLM_article-title">Effect of the protonation state of the titratable residues on the inhibitor affinity to BACE-1</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">34</span>),  <span class="NLM_fpage">7255</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1021/bi100637n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi100637n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpslKjsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=7255-63&issue=34&author=J.+L.+Dominguezauthor=T.+Christopeitauthor=M.+C.+Villaverdeauthor=T.+Gossasauthor=J.+M.+Oteroauthor=S.+Nystromauthor=V.+Baraznenokauthor=E.+Lindstromauthor=U.+H.+Danielsonauthor=F.+Sussman&title=Effect+of+the+protonation+state+of+the+titratable+residues+on+the+inhibitor+affinity+to+BACE-1&doi=10.1021%2Fbi100637n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the Protonation State of the Titratable Residues on the Inhibitor Affinity to BACE-1</span></div><div class="casAuthors">Dominguez, Jose L.; Christopeit, Tony; Villaverde, M. Carmen; Gossas, Thomas; Otero, Jose M.; Nystrom, Susanne; Baraznenok, Vera; Lindstrom, Erik; Danielson, U. Helena; Sussman, Fredy</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">7255-7263</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">BACE-1 is one of the aspartic proteases involved in the cleavage of β amyloid peptide, an initial step in the formation of amyloid plaques whose toxicity induces neuron death in Alzheimer's disease patients.  One of the central issues in the search of novel BACE-1 inhibitors is the optimum pH for the binding of inhibitors to the enzyme.  It is known that the enzyme has optimal catalytic activity at acidic pH, while cell active inhibitors may bind optimally at higher pH.  In this work we det. the effect of the pH on the affinities of a set of inhibitors, with a variety of chem. motifs, for the ectodomain region of BACE-1 by a surface plasmon resonance (SPR) biosensor based assay.  In order to understand the mol. interactions that underlie the diverse optimum pH for the binding of the various inhibitors as obsd. exptl., we have calcd. the titrn. curves for a set of BACE-1 ligand complexes.  The results indicate that the pKa values of the titratable residues of the protein depend on the nature of the ligand involved, in disagreement with previous work.  The enzyme-inhibitor structures with the resulting protonation states at pH values 4.5 and 7.4 served as the starting point for the prediction of the pH-dependent binding ranking.  Our calcns. reproduced the entire affinity ranking obsd. upon pH increase and most of the binding trends among inhibitors, esp. at low pH.  Finally, our cell-based assays indicate a possible correlation between high inhibitor affinity at both acidic and neutral pH values, with optimal cell response, a result that may open new venues for the search of potent BACE-1 inhibitors that are active at the cellular level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprMAi9258abLVg90H21EOLACvtfcHk0lg7ACtNSW_zlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpslKjsro%253D&md5=17d462cc2666acaa43f6e48f3d757847</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fbi100637n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi100637n%26sid%3Dliteratum%253Aachs%26aulast%3DDominguez%26aufirst%3DJ.%2BL.%26aulast%3DChristopeit%26aufirst%3DT.%26aulast%3DVillaverde%26aufirst%3DM.%2BC.%26aulast%3DGossas%26aufirst%3DT.%26aulast%3DOtero%26aufirst%3DJ.%2BM.%26aulast%3DNystrom%26aufirst%3DS.%26aulast%3DBaraznenok%26aufirst%3DV.%26aulast%3DLindstrom%26aufirst%3DE.%26aulast%3DDanielson%26aufirst%3DU.%2BH.%26aulast%3DSussman%26aufirst%3DF.%26atitle%3DEffect%2520of%2520the%2520protonation%2520state%2520of%2520the%2520titratable%2520residues%2520on%2520the%2520inhibitor%2520affinity%2520to%2520BACE-1%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26issue%3D34%26spage%3D7255%26epage%3D63%26doi%3D10.1021%2Fbi100637n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rombouts, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusakabe, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H. J. M.</span></span> <span> </span><span class="NLM_article-title">Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1080/13543776.2021.1832463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1080%2F13543776.2021.1832463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=33006491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis1WkurnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2021&pages=25-52&issue=1&author=F.+Romboutsauthor=K.+I.+Kusakabeauthor=C.+C.+Hsiaoauthor=H.+J.+M.+Gijsen&title=Small-molecule+BACE1+inhibitors%3A+a+patent+literature+review+%282011+to+2020%29&doi=10.1080%2F13543776.2021.1832463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020)</span></div><div class="casAuthors">Rombouts, Frederik; Kusakabe, Ken-ichi; Hsiao, Chien-Chi; Gijsen, Harrie J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-52</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Inhibition of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) has been extensively pursued as potential disease-modifying treatment for Alzheimer's disease (AD).  Clin. failures with BACE inhibitors have progressively raised the bar forever cleaner candidates with reduced cardiovascular liability, toxicity risk, and increased selectivity over cathepsin D (CatD) and BACE2.  This review provides an overview of patented BACE1 inhibitors between 2011 and 2020 per pharmaceutical company or research group and highlights the progress that was made in dialing out toxicity liabilities.  Despite an increasingly crowded IP situation, significant progress was made using highly complex chem. in avoiding toxicity liabilities, with BACE1/BACE2 selectivity being the most remarkable achievement.  However, clin. trial data suggest on-target toxicity is likely a contributing factor, which implies the only potential future of BACE1 inhibitors lies in careful titrn. of highly selective compds. in early populations where the amyloid burden is still minimal as prophylactic therapy, or as an affordable oral maintenance therapy following amyloid-clearing therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGjbsg5JsFnbVg90H21EOLACvtfcHk0lg7ACtNSW_zlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis1WkurnP&md5=1efb3b0aee8954550732b3f12b679087</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1080%2F13543776.2021.1832463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2021.1832463%26sid%3Dliteratum%253Aachs%26aulast%3DRombouts%26aufirst%3DF.%26aulast%3DKusakabe%26aufirst%3DK.%2BI.%26aulast%3DHsiao%26aufirst%3DC.%2BC.%26aulast%3DGijsen%26aufirst%3DH.%2BJ.%2BM.%26atitle%3DSmall-molecule%2520BACE1%2520inhibitors%253A%2520a%2520patent%2520literature%2520review%2520%25282011%2520to%25202020%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2021%26volume%3D31%26issue%3D1%26spage%3D25%26epage%3D52%26doi%3D10.1080%2F13543776.2021.1832463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Losada, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBaillie, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eugenio de Diego, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaramillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaoudi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsay-Scott, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mergott, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rincon, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothhaar, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seibert, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winneroski, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, M. O.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Optimization, and Large-Scale Preparation of the Low-Dose Central Nervous System-Penetrant BACE1 Inhibitor LY3202626 via a [3 + 2] Nitrone Cycloaddition</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.9b00471</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.9b00471" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvV2qurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2020&pages=306-314&issue=2&author=P.+Garcia-Losadaauthor=A.+C.+DeBaillieauthor=J.+Eugenio+de+Diegoauthor=S.+J.+Greenauthor=M.+M.+Hansenauthor=C.+Jaramilloauthor=M.+Johnsonauthor=T.+Kaoudiauthor=J.+Liauthor=P.+J.+Lindsay-Scottauthor=C.+Mateosauthor=D.+J.+Mergottauthor=J.+A.+Rinconauthor=R.+R.+Rothhaarauthor=K.+D.+Seibertauthor=B.+M.+Watsonauthor=L.+L.+Winneroskiauthor=S.+Gangulaauthor=D.+Jingauthor=H.+Sunauthor=L.+Zhangauthor=M.+O.+Frederick&title=Synthesis%2C+Optimization%2C+and+Large-Scale+Preparation+of+the+Low-Dose+Central+Nervous+System-Penetrant+BACE1+Inhibitor+LY3202626+via+a+%5B3+%2B+2%5D+Nitrone+Cycloaddition&doi=10.1021%2Facs.oprd.9b00471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Optimization, and Large-Scale Preparation of the Low-Dose Central Nervous System-Penetrant BACE1 Inhibitor LY3202626 via a [3 + 2] Nitrone Cycloaddition</span></div><div class="casAuthors">Garcia-Losada, Pablo; De Baillie, Amy C.; Eugenio de Diego, Jose; Green, Steven J.; Hansen, Marvin M.; Jaramillo, Carlos; Johnson, Matt; Kaoudi, Talbi; Li, Jiuyuan; Lindsay-Scott, Peter J.; Mateos, Carlos; Mergott, Dustin J.; Rincon, Juan Antonio; Rothhaar, Roger R.; Seibert, Kevin D.; Watson, Brian M.; Winneroski, Leonard L.; Gangula, Srinivas; Jing, Dajiang; Sun, Hao; Zhang, Lei; Frederick, Michael O.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">306-314</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein a summary of the synthetic development of LY3202626 from the initial discovery route to a final route that was scaled to make 150 kg is reported.  Key developments include the use of a [3 + 2] cyclization to set the cis ring junction of the formed isoxazoline, a one-pot thiazine formation, and three different ways to install the aniline: (1) Cu-catalyzed azide coupling and redn., (2) nitration and redn., and (3) Buchwald coupling with acetamide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoggDUjmE_88rVg90H21EOLACvtfcHk0lhBBsYOSAfH-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvV2qurc%253D&md5=ded0222bbf1578a1f9b8b3864858094c</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.9b00471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.9b00471%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Losada%26aufirst%3DP.%26aulast%3DDeBaillie%26aufirst%3DA.%2BC.%26aulast%3DEugenio%2Bde%2BDiego%26aufirst%3DJ.%26aulast%3DGreen%26aufirst%3DS.%2BJ.%26aulast%3DHansen%26aufirst%3DM.%2BM.%26aulast%3DJaramillo%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DKaoudi%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLindsay-Scott%26aufirst%3DP.%2BJ.%26aulast%3DMateos%26aufirst%3DC.%26aulast%3DMergott%26aufirst%3DD.%2BJ.%26aulast%3DRincon%26aufirst%3DJ.%2BA.%26aulast%3DRothhaar%26aufirst%3DR.%2BR.%26aulast%3DSeibert%26aufirst%3DK.%2BD.%26aulast%3DWatson%26aufirst%3DB.%2BM.%26aulast%3DWinneroski%26aufirst%3DL.%2BL.%26aulast%3DGangula%26aufirst%3DS.%26aulast%3DJing%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DFrederick%26aufirst%3DM.%2BO.%26atitle%3DSynthesis%252C%2520Optimization%252C%2520and%2520Large-Scale%2520Preparation%2520of%2520the%2520Low-Dose%2520Central%2520Nervous%2520System-Penetrant%2520BACE1%2520Inhibitor%2520LY3202626%2520via%2520a%2520%255B3%2520%252B%25202%255D%2520Nitrone%2520Cycloaddition%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2020%26volume%3D24%26issue%3D2%26spage%3D306%26epage%3D314%26doi%3D10.1021%2Facs.oprd.9b00471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasser, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohrbacher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermans, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrannes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grantham, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Rossem, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaplan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallacher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathes, C.</span></span> <span> </span><span class="NLM_article-title">Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">168</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1177/1087057104272295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1177%2F1087057104272295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=15799960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFWnsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=168-81&issue=2&author=A.+E.+Dubinauthor=N.+Nasserauthor=J.+Rohrbacherauthor=A.+N.+Hermansauthor=R.+Marrannesauthor=C.+Granthamauthor=K.+Van+Rossemauthor=M.+Cikauthor=S.+R.+Chaplanauthor=D.+Gallacherauthor=J.+Xuauthor=A.+Guiaauthor=N.+G.+Byrneauthor=C.+Mathes&title=Identifying+modulators+of+hERG+channel+activity+using+the+PatchXpress+planar+patch+clamp&doi=10.1177%2F1087057104272295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp</span></div><div class="casAuthors">Dubin, Adrienne E.; Nasser, Nadia; Rohrbacher, Jutta; Hermans, An N.; Marrannes, Roger; Grantham, Christopher; Van Rossem, Koen; Cik, Miroslav; Chaplan, Sandra R.; Gallacher, David; Xu, Jia; Guia, Antonio; Byrne, Nicholas G.; Mathes, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">168-181</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The authors used the PatchXpress 7000A system to measure compd. activity at the hERG channel using procedures that mimicked the "gold-std." conventional whole-cell patch clamp.  A set of 70 compds., including hERG antagonists with potencies spanning 3 orders of magnitude, were tested on hERG302-HEK cells using protocols aimed at either identifying compd. activity at a single concn. or obtaining compd. potency from a cumulative concn. dependence paradigm.  After exposure to compds. and subsequent washout of the wells to det. reversibility of the block, blockade by a ref. compd. served as a quality control.  Elec. parameters and voltage dependence were similar to those obtained using a conventional whole-cell patch clamp.  Rank order of compd. potency was also comparable to that detd. by conventional methods.  One exception was flunarizine, a particularly lipophilic compd.  The PatchXpress accurately identified the activity of 29 moderately potent antagonists, which only weakly displace radiolabeled astemizole and are false negatives in the binding assay.  Finally, no false hits were obsd. from a collection of relatively inactive compds.  High-quality data acquisition by PatchXpress should help accelerate secondary screening for ion channel modulators and the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI60gDgyGLsrVg90H21EOLACvtfcHk0lhBBsYOSAfH-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFWnsbY%253D&md5=387d30ff8033356d9045121a371be559</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1177%2F1087057104272295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057104272295%26sid%3Dliteratum%253Aachs%26aulast%3DDubin%26aufirst%3DA.%2BE.%26aulast%3DNasser%26aufirst%3DN.%26aulast%3DRohrbacher%26aufirst%3DJ.%26aulast%3DHermans%26aufirst%3DA.%2BN.%26aulast%3DMarrannes%26aufirst%3DR.%26aulast%3DGrantham%26aufirst%3DC.%26aulast%3DVan%2BRossem%26aufirst%3DK.%26aulast%3DCik%26aufirst%3DM.%26aulast%3DChaplan%26aufirst%3DS.%2BR.%26aulast%3DGallacher%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DGuia%26aufirst%3DA.%26aulast%3DByrne%26aufirst%3DN.%2BG.%26aulast%3DMathes%26aufirst%3DC.%26atitle%3DIdentifying%2520modulators%2520of%2520hERG%2520channel%2520activity%2520using%2520the%2520PatchXpress%2520planar%2520patch%2520clamp%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2005%26volume%3D10%26issue%3D2%26spage%3D168%26epage%3D81%26doi%3D10.1177%2F1087057104272295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ly, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shyy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span> <span> </span><span class="NLM_article-title">Assessing hERG Channel Inhibition Using PatchXpress</span>. <i>JALA</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1016/j.jala.2005.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1016%2Fj.jala.2005.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVersLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=225-230&issue=4&author=J.+Q.+Lyauthor=G.+Shyyauthor=D.+L.+Misner&title=Assessing+hERG+Channel+Inhibition+Using+PatchXpress&doi=10.1016%2Fj.jala.2005.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing hERG channel inhibition using PatchXpress</span></div><div class="casAuthors">Ly, Justin Q.; Shyy, Gordon; Misner, Dinah L.</div><div class="citationInfo"><span class="NLM_cas:title">JALA</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">225-230</span>CODEN:
                <span class="NLM_cas:coden">JALLFO</span>;
        ISSN:<span class="NLM_cas:issn">1535-5535</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">PatchXpress, an automated 16-channel parallel patch clamp system, was used to det. inhibition of human ether-a-go-go related gene (hERG) potassium channels by known blockers.  A monoclonal cell line stably expressing hERG potassium channels was generated in CHO-KI cells.  Results were compared to conventional patch clamp expts. using similar voltage protocols and solns.  Success rates were evaluated for cell recordings under a variety of conditions, including Accumax vs. trypsin treatment to harvest cells, single vs. double compd. addns., and polystyrene vs. glass-coated compd. plates.  We found that the av. success rates rose from 27% with trypsin treatment to 38% with Accumax treatment, which improved to 55-65% following long-term culturing using only Accumax to harvest cells.  Two drug addns. (spaced 1 min apart with suction off) were also found to produce data that more closely matched conventional expts.  Finally, polystyrene vs. glass-coated compd. plates were evaluated, and we found that for some compds. (but not all), prepn. of compd. samples in glass-coated plates resulted in inhibition that more closely matched data obtained by conventional expts.  Therefore, we have established an assay to evaluate the ability of compds. to inhibit hERG potassium channels, which closely matches data produced using conventional methods but with much greater throughput.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpayPs_n_5gs7Vg90H21EOLACvtfcHk0lhBBsYOSAfH-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVersLjE&md5=f87ac889c6582adcd56a3bee6a5b4a73</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.jala.2005.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jala.2005.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DLy%26aufirst%3DJ.%2BQ.%26aulast%3DShyy%26aufirst%3DG.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26atitle%3DAssessing%2520hERG%2520Channel%2520Inhibition%2520Using%2520PatchXpress%26jtitle%3DJALA%26date%3D2005%26volume%3D10%26issue%3D4%26spage%3D225%26epage%3D230%26doi%3D10.1016%2Fj.jala.2005.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. C.</span></span> <span> </span><span class="NLM_article-title">Methods to optimize CNS exposure of drug candidates</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">127503</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1016%2Fj.bmcl.2020.127503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=32853684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlWgu73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127503&issue=23&author=N.+C.+Patel&title=Methods+to+optimize+CNS+exposure+of+drug+candidates&doi=10.1016%2Fj.bmcl.2020.127503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Methods to optimize CNS exposure of drug candidates</span></div><div class="casAuthors">Patel, Nandini C.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">127503</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Among the most devastating disorders of our time, neurol. and psychiatric diseases combine to cause more disability than any other disease area.  One of the key objectives within the medicinal chem. discipline is to design mols. that penetrate into the target tissue.  The objective of tissue specificity can be to gain or restrict drug access to the compartment of interest.  This article briefly reviews the progress of CNS drug discovery over the past few decades.  Included are the most recent efforts to harness structural and physicochem. properties assessment coupled with the impact of efflux transporters in detg. brain penetration and the translation from rodent to human brain tissue targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov5f7cocOoS7Vg90H21EOLACvtfcHk0lj7VBg4ejMEQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlWgu73F&md5=628b1587796ccfabaa50b3612d654bbf</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127503%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DN.%2BC.%26atitle%3DMethods%2520to%2520optimize%2520CNS%2520exposure%2520of%2520drug%2520candidates%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26issue%3D23%26spage%3D127503%26doi%3D10.1016%2Fj.bmcl.2020.127503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willis, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daugherty, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">English, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ereshefsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gevorkyan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhee, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mergott, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monk, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irizarry, M. C.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics, pharmacodynamics, safety, and tolerability of LY3202626, a novel Bace1 inhibitor, in healthy subjects and patients with Alzheimer’s disease</span>. <i>Alzheimer's Dementia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">P418</span>, <span class="refDoi"> DOI: 10.1016/j.jalz.2016.06.791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1016%2Fj.jalz.2016.06.791" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=P418&author=B.+A.+Willisauthor=S.+L.+Loweauthor=L.+L.+Daughertyauthor=R.+A.+Deanauthor=B.+Englishauthor=L.+Ereshefskyauthor=H.+Gevorkyanauthor=D.+E.+Jamesauthor=S.+S.+Jheeauthor=Q.+Linauthor=A.+C.+Loauthor=D.+J.+Mergottauthor=S.+A.+Monkauthor=M.+Nakanoauthor=J.+A.+Zimmerauthor=M.+C.+Irizarry&title=Pharmacokinetics%2C+pharmacodynamics%2C+safety%2C+and+tolerability+of+LY3202626%2C+a+novel+Bace1+inhibitor%2C+in+healthy+subjects+and+patients+with+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.jalz.2016.06.791"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2016.06.791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2016.06.791%26sid%3Dliteratum%253Aachs%26aulast%3DWillis%26aufirst%3DB.%2BA.%26aulast%3DLowe%26aufirst%3DS.%2BL.%26aulast%3DDaugherty%26aufirst%3DL.%2BL.%26aulast%3DDean%26aufirst%3DR.%2BA.%26aulast%3DEnglish%26aufirst%3DB.%26aulast%3DEreshefsky%26aufirst%3DL.%26aulast%3DGevorkyan%26aufirst%3DH.%26aulast%3DJames%26aufirst%3DD.%2BE.%26aulast%3DJhee%26aufirst%3DS.%2BS.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DLo%26aufirst%3DA.%2BC.%26aulast%3DMergott%26aufirst%3DD.%2BJ.%26aulast%3DMonk%26aufirst%3DS.%2BA.%26aulast%3DNakano%26aufirst%3DM.%26aulast%3DZimmer%26aufirst%3DJ.%2BA.%26aulast%3DIrizarry%26aufirst%3DM.%2BC.%26atitle%3DPharmacokinetics%252C%2520pharmacodynamics%252C%2520safety%252C%2520and%2520tolerability%2520of%2520LY3202626%252C%2520a%2520novel%2520Bace1%2520inhibitor%252C%2520in%2520healthy%2520subjects%2520and%2520patients%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAlzheimer%2527s%2520Dementia%26date%3D2016%26volume%3D12%26spage%3DP418%26doi%3D10.1016%2Fj.jalz.2016.06.791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lo, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shcherbinin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natanegara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, B. A.</span></span> <span> </span><span class="NLM_article-title">Phase 2 (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer’s Disease Dementia</span>. <i>J. Alzheimers Dis Rep</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">321</span>, <span class="refDoi"> DOI: 10.3233/ADR-210296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.3233%2FADR-210296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=34113788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A280%3ADC%252BB2c7mvVegsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2021&pages=321&author=A.+C.+Loauthor=C.+D.+Evansauthor=M.+Manciniauthor=H.+Wangauthor=S.+Shcherbininauthor=M.+Luauthor=F.+Natanegaraauthor=B.+A.+Willis&title=Phase+2+%28NAVIGATE-AD+study%29+Results+of+LY3202626+Effects+on+Patients+with+Mild+Alzheimer%E2%80%99s+Disease+Dementia&doi=10.3233%2FADR-210296"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer's Disease Dementia</span></div><div class="casAuthors">Lo Albert C; Evans Cynthia Duggan; Mancini Michele; Wang Hong; Shcherbinin Sergey; Natanegara Fanni; Willis Brian A; Lu Ming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's disease reports</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">321-336</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  LY3202626 is a small molecule inhibitor of β-site amyloid precursor protein cleaving enzyme (BACE)1 shown to reduce amyloid-β (Aβ)1-40 and Aβ1-42 concentrations in plasma and cerebrospinal fluid developed for the treatment of Alzheimer's disease (AD).  Objective:  To assess the change from baseline in flortaucipir positron emission tomography (PET) after treatment with LY3202626 compared with placebo in patients with mild AD dementia.  Methods:  Patients received daily 3 mg or 12 mg doses of LY3202626 or placebo for 52 weeks.  The primary outcome was assessment of cerebral neurofibrillary tangle load by flortaucipir PET.  The study was terminated early following an interim analysis due to a low probability of identifying a statistically significant slowing of cognitive and/or functional decline.  Results:  A total of 316 patients were randomized and 47 completed the study.  There was no statistically significant difference between placebo and either dose of LY3202626 from baseline to 52 weeks, or in annualized change for flortaucipir PET.  There was no clinically meaningful difference between placebo and LY3202626 doses on efficacy measures of cognition and function.  No deaths or serious adverse events considered related to LY3202626 were reported.  A statistically significant increase in treatment-emergent adverse events in the psychiatric disorders system organ class was reported for both LY3202626 doses compared to placebo.  Conclusion:  LY3202626 tested at doses generating 70-90% BACE inhibition was generally well tolerated in this study.  LY3202626 treatment did not result in a clinically significant change in cerebral tau burden as measured by flortaucipir nor in change of functional or cognitive decline compared to placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRq3wjPN4ZWpS-bLEOO4dYpfW6udTcc2eYyNEnmpDv4jbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB2c7mvVegsg%253D%253D&md5=2e2ee67f856fd5626bdeac4309036d54</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.3233%2FADR-210296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FADR-210296%26sid%3Dliteratum%253Aachs%26aulast%3DLo%26aufirst%3DA.%2BC.%26aulast%3DEvans%26aufirst%3DC.%2BD.%26aulast%3DMancini%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DShcherbinin%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DNatanegara%26aufirst%3DF.%26aulast%3DWillis%26aufirst%3DB.%2BA.%26atitle%3DPhase%25202%2520%2528NAVIGATE-AD%2520study%2529%2520Results%2520of%2520LY3202626%2520Effects%2520on%2520Patients%2520with%2520Mild%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Dementia%26jtitle%3DJ.%2520Alzheimers%2520Dis%2520Rep%26date%3D2021%26volume%3D5%26spage%3D321%26doi%3D10.3233%2FADR-210296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koelsch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terzyan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span> <span> </span><span class="NLM_article-title">Structure of the Protease Domain of Memapsin 2 (β-Secretase) Complexed with Inhibitor</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>290</i></span> (<span class="NLM_issue">5489</span>),  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1126/science.290.5489.150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1126%2Fscience.290.5489.150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=11021803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1Chtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2000&pages=150-153&issue=5489&author=L.+Hongauthor=G.+Koelschauthor=X.+Linauthor=S.+Wuauthor=S.+Terzyanauthor=A.+K.+Ghoshauthor=X.+C.+Zhangauthor=J.+Tang&title=Structure+of+the+Protease+Domain+of+Memapsin+2+%28%CE%B2-Secretase%29+Complexed+with+Inhibitor&doi=10.1126%2Fscience.290.5489.150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor</span></div><div class="casAuthors">Hong, Lin; Koelsch, Gerald; Lin, Xinli; Wu, Shili; Terzyan, Simon; Ghosh, Arun K.; Zhang, Xuenjun C.; Tang, Jordan</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">5489</span>),
    <span class="NLM_cas:pages">150-153</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Memapsin 2 (β-secretase) is a membrane-assocd. aspartic protease involved in the prodn. of β-amyloid peptide in Alzheimer's disease and is a major target for drug design.  We detd. the crystal structure of the protease domain of human memapsin 2 complexed to an eight-residue inhibitor at 1.9 angstrom resoln.  The active site of memapsin 2 is more open and less hydrophobic than that of other human aspartic proteases.  The subsite locations from S4 to S2' are well defined.  A kink of the inhibitor chain at P2' and the change of chain direction of P3' and P4' may be mimicked to provide inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtz4LHUXVGBrVg90H21EOLACvtfcHk0lgaf1YQgPhE8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1Chtrs%253D&md5=c5d15af5ae58e6c3f46da1b22f7d4df9</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1126%2Fscience.290.5489.150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.290.5489.150%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DL.%26aulast%3DKoelsch%26aufirst%3DG.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DTerzyan%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DZhang%26aufirst%3DX.%2BC.%26aulast%3DTang%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520the%2520Protease%2520Domain%2520of%2520Memapsin%25202%2520%2528%25CE%25B2-Secretase%2529%2520Complexed%2520with%2520Inhibitor%26jtitle%3DScience%26date%3D2000%26volume%3D290%26issue%3D5489%26spage%3D150%26epage%3D153%26doi%3D10.1126%2Fscience.290.5489.150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howlett, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tew, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloger, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southan, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingwall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, G.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel aspartic protease (Asp 2) as beta-secretase</span>. <i>Mol. Cell. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1006/mcne.1999.0811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1006%2Fmcne.1999.0811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10656250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADyaK1MXnt1Chsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1999&pages=419-27&issue=6&author=I.+Hussainauthor=D.+Powellauthor=D.+R.+Howlettauthor=D.+G.+Tewauthor=T.+D.+Meekauthor=C.+Chapmanauthor=I.+S.+Glogerauthor=K.+E.+Murphyauthor=C.+D.+Southanauthor=D.+M.+Ryanauthor=T.+S.+Smithauthor=D.+L.+Simmonsauthor=F.+S.+Walshauthor=C.+Dingwallauthor=G.+Christie&title=Identification+of+a+novel+aspartic+protease+%28Asp+2%29+as+beta-secretase&doi=10.1006%2Fmcne.1999.0811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase</span></div><div class="casAuthors">Hussain, Ishrut; Powell, David; Howlett, David R.; Tew, David G.; Meek, Thomas D.; Chapman, Conrad; Gloger, Israel S.; Murphy, Kay E.; Southan, Christopher D.; Ryan, Dominic M.; Smith, Trudi S.; Simmons, David L.; Walsh, Frank S.; Dingwall, Colin; Christie, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Neuroscience</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">419-427</span>CODEN:
                <span class="NLM_cas:coden">MOCNED</span>;
        ISSN:<span class="NLM_cas:issn">1044-7431</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The Alzheimer's disease β-amyloid peptide (Aβ) is produced by excision from the type 1 integral membrane glycoprotein amyloid precursor protein (APP) by the sequential actions of β- and then γ-secretases.  Here we report that Asp 2, a novel transmembrane aspartic protease, has the key activities expected of β-secretase.  Transient expression of Asp 2 in cells expressing APP causes an increase in the secretion of the N-terminal fragment of APP and an increase in the cell-assocd. C-terminal β-secretase APP fragment.  Mutation of either of the putative catalytic aspartyl residues in Asp 2 abrogates the prodn. of the fragments characteristic of cleavage at the β-secretase site.  The enzyme is present in normal and Alzheimer's disease (AD) brain and is also found in cell lines known to produce Aβ.  Asp 2 localizes to the Golgi/endoplasmic reticulum in transfected cells and shows clear colocalization with APP in cells stably expressing the 751-amino-acid isoform of APP.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDUBbUoO6SgLVg90H21EOLACvtfcHk0lgaf1YQgPhE8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXnt1Chsrs%253D&md5=aba834d907c5dae03f060d94729576e9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1006%2Fmcne.1999.0811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fmcne.1999.0811%26sid%3Dliteratum%253Aachs%26aulast%3DHussain%26aufirst%3DI.%26aulast%3DPowell%26aufirst%3DD.%26aulast%3DHowlett%26aufirst%3DD.%2BR.%26aulast%3DTew%26aufirst%3DD.%2BG.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26aulast%3DChapman%26aufirst%3DC.%26aulast%3DGloger%26aufirst%3DI.%2BS.%26aulast%3DMurphy%26aufirst%3DK.%2BE.%26aulast%3DSouthan%26aufirst%3DC.%2BD.%26aulast%3DRyan%26aufirst%3DD.%2BM.%26aulast%3DSmith%26aufirst%3DT.%2BS.%26aulast%3DSimmons%26aufirst%3DD.%2BL.%26aulast%3DWalsh%26aufirst%3DF.%2BS.%26aulast%3DDingwall%26aufirst%3DC.%26aulast%3DChristie%26aufirst%3DG.%26atitle%3DIdentification%2520of%2520a%2520novel%2520aspartic%2520protease%2520%2528Asp%25202%2529%2520as%2520beta-secretase%26jtitle%3DMol.%2520Cell.%2520Neurosci.%26date%3D1999%26volume%3D14%26issue%3D6%26spage%3D419%26epage%3D27%26doi%3D10.1006%2Fmcne.1999.0811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbour, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basi, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccavello, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dovey, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frigon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson-Croak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewett, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knops, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberburg, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Power, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsuno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seubert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suomensaari, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConlogue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, V.</span></span> <span> </span><span class="NLM_article-title">Purification and cloning of amyloid precursor protein beta-secretase from human brain</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>402</i></span> (<span class="NLM_issue">6761</span>),  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1038/990114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1038%2F990114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10591214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADyaK1MXotFKlsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=402&publication_year=1999&pages=537-40&issue=6761&author=S.+Sinhaauthor=J.+P.+Andersonauthor=R.+Barbourauthor=G.+S.+Basiauthor=R.+Caccavelloauthor=D.+Davisauthor=M.+Doanauthor=H.+F.+Doveyauthor=N.+Frigonauthor=J.+Hongauthor=K.+Jacobson-Croakauthor=N.+Jewettauthor=P.+Keimauthor=J.+Knopsauthor=I.+Lieberburgauthor=M.+Powerauthor=H.+Tanauthor=G.+Tatsunoauthor=J.+Tungauthor=D.+Schenkauthor=P.+Seubertauthor=S.+M.+Suomensaariauthor=S.+Wangauthor=D.+Walkerauthor=J.+Zhaoauthor=L.+McConlogueauthor=V.+John&title=Purification+and+cloning+of+amyloid+precursor+protein+beta-secretase+from+human+brain&doi=10.1038%2F990114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Purification and cloning of amyloid precursor protein β-secretase from human brain</span></div><div class="casAuthors">Sinha, Sukanto; Anderson, John P.; Barbour, Robin; Basi, Guriqbal S.; Caccavello, Russell; Davis, David; Doan, Minhtam; Dovey, Harry F.; Frigon, Normand; Hong, Jin; Jacobson-Croak, Kirsten; Jewett, Nancy; Keim, Pamela; Knops, Jeroen; Lieberburg, Ivan; Power, Michael; Tan, Hua; Tatsuno, Gwen; Tung, Jay; Schenk, Dale; Seubert, Peter; Suomensaari, Susanna M.; Wang, Shuwen; Walker, Donald; Zhao, Jun; McConlogue, Lisa; John, Varghese</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">402</span>
        (<span class="NLM_cas:issue">6761</span>),
    <span class="NLM_cas:pages">537-540</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Proteolytic processing of the amyloid precursor protein (APP) generates amyloid β (AP) peptide, which is thought to be causal for the pathol. and subsequent cognitive decline in Alzheimer's disease.  Cleavage by β-secretase at the amino terminus of the Aβ peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of β-cleaved sol. APP, and a corresponding cell-assocd. carboxy-terminal fragment.  Cleavage of the C-terminal fragment by γ-secretase(s) leads to the formation of Aβ.  The pathogenic mutation K670M671 → N670L671 at the β-secretase cleavage site in APP, which was discovered in a Swedish family with familial Alzheimer's disease, leads to increased β-secretase cleavage of the mutant substrate.  Here the authors describe a membrane-bound enzyme activity that cleaves full-length APP at the β-secretase cleavage site, and find it to be the predominant β-cleavage activity in human brain.  The authors have purified this enzyme activity to homogeneity from human brain using a new substrate analog inhibitor of the enzyme activity, and show that the purified enzyme has all the properties predicted for β-secretase.  Cloning and expression of the enzyme reveals that human brain β-secretase is a new membrane-bound aspartic proteinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDI4TZ3cM4orVg90H21EOLACvtfcHk0lgaf1YQgPhE8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXotFKlsrc%253D&md5=819ccc5a27ec4c56128d6b6944878c42</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2F990114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F990114%26sid%3Dliteratum%253Aachs%26aulast%3DSinha%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DJ.%2BP.%26aulast%3DBarbour%26aufirst%3DR.%26aulast%3DBasi%26aufirst%3DG.%2BS.%26aulast%3DCaccavello%26aufirst%3DR.%26aulast%3DDavis%26aufirst%3DD.%26aulast%3DDoan%26aufirst%3DM.%26aulast%3DDovey%26aufirst%3DH.%2BF.%26aulast%3DFrigon%26aufirst%3DN.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DJacobson-Croak%26aufirst%3DK.%26aulast%3DJewett%26aufirst%3DN.%26aulast%3DKeim%26aufirst%3DP.%26aulast%3DKnops%26aufirst%3DJ.%26aulast%3DLieberburg%26aufirst%3DI.%26aulast%3DPower%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DTatsuno%26aufirst%3DG.%26aulast%3DTung%26aufirst%3DJ.%26aulast%3DSchenk%26aufirst%3DD.%26aulast%3DSeubert%26aufirst%3DP.%26aulast%3DSuomensaari%26aufirst%3DS.%2BM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DMcConlogue%26aufirst%3DL.%26aulast%3DJohn%26aufirst%3DV.%26atitle%3DPurification%2520and%2520cloning%2520of%2520amyloid%2520precursor%2520protein%2520beta-secretase%2520from%2520human%2520brain%26jtitle%3DNature%26date%3D1999%26volume%3D402%26issue%3D6761%26spage%3D537%26epage%3D40%26doi%3D10.1038%2F990114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu-Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendiaz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teplow, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amarante, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeloff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edenson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lile, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarosinski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biere, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treanor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Citron, M.</span></span> <span> </span><span class="NLM_article-title">Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>286</i></span> (<span class="NLM_issue">5440</span>),  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1126/science.286.5440.735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1126%2Fscience.286.5440.735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10531052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADyaK1MXntFWit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=1999&pages=735-41&issue=5440&author=R.+Vassarauthor=B.+D.+Bennettauthor=S.+Babu-Khanauthor=S.+Kahnauthor=E.+A.+Mendiazauthor=P.+Denisauthor=D.+B.+Teplowauthor=S.+Rossauthor=P.+Amaranteauthor=R.+Loeloffauthor=Y.+Luoauthor=S.+Fisherauthor=J.+Fullerauthor=S.+Edensonauthor=J.+Lileauthor=M.+A.+Jarosinskiauthor=A.+L.+Biereauthor=E.+Curranauthor=T.+Burgessauthor=J.+C.+Louisauthor=F.+Collinsauthor=J.+Treanorauthor=G.+Rogersauthor=M.+Citron&title=Beta-secretase+cleavage+of+Alzheimer%E2%80%99s+amyloid+precursor+protein+by+the+transmembrane+aspartic+protease+BACE&doi=10.1126%2Fscience.286.5440.735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE</span></div><div class="casAuthors">Vassar, Robert; Bennett, Brian D.; Babu-Khan, Safura; Kahn, Steve; Mendiaz, Elizabeth A.; Denis, Paul; Teplow, David B.; Ross, Sandra; Amarante, Patricia; Loeloff, Richard; Luo, Yi; Fisher, Seth; Fuller, Janis; Edenson, Steven; Lile, Jackson; Jarosinski, Mark A.; Biere, Anja Leona; Curran, Eileen; Burgess, Teresa; Louis, Jean-Claude; Collins, Frank; Treanor, James; Rogers, Gary; Citron, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">5440</span>),
    <span class="NLM_cas:pages">735-741</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Cerebral deposition of amyloid β peptide (Aβ) is an early and crit. feature of Alzheimer's disease.  Aβ generation depends on proteolytic cleavage of the amyloid precursor protein (APP) by two unknown proteases: β-secretase and γ-secretase.  These proteases are prime therapeutic targets.  A transmembrane aspartic protease with all the known characteristics of β-secretase was cloned and characterized.  Overexpression of this protease, termed BACE (for beta-site APP-cleaving enzyme) increased the amt. of β-secretase cleavage products, and these were cleaved exactly and only at known β-secretase positions.  Antisense inhibition of endogenous BACE mRNA decreased the amt. of β-secretase cleavage products, and purified BACE protein cleaved APP-derived substrates with the same sequence specificity as β-secretase.  Finally, the expression pattern and subcellular localization of BACE were consistent with that expected for β-secretase.  Future development of BACE inhibitors may prove beneficial for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSx3s1NFyByrVg90H21EOLACvtfcHk0ljkml1e3LbC6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFWit74%253D&md5=3f36e8e5b5e9441c7670ccaeb0d2dd4f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1126%2Fscience.286.5440.735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.286.5440.735%26sid%3Dliteratum%253Aachs%26aulast%3DVassar%26aufirst%3DR.%26aulast%3DBennett%26aufirst%3DB.%2BD.%26aulast%3DBabu-Khan%26aufirst%3DS.%26aulast%3DKahn%26aufirst%3DS.%26aulast%3DMendiaz%26aufirst%3DE.%2BA.%26aulast%3DDenis%26aufirst%3DP.%26aulast%3DTeplow%26aufirst%3DD.%2BB.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DAmarante%26aufirst%3DP.%26aulast%3DLoeloff%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DFisher%26aufirst%3DS.%26aulast%3DFuller%26aufirst%3DJ.%26aulast%3DEdenson%26aufirst%3DS.%26aulast%3DLile%26aufirst%3DJ.%26aulast%3DJarosinski%26aufirst%3DM.%2BA.%26aulast%3DBiere%26aufirst%3DA.%2BL.%26aulast%3DCurran%26aufirst%3DE.%26aulast%3DBurgess%26aufirst%3DT.%26aulast%3DLouis%26aufirst%3DJ.%2BC.%26aulast%3DCollins%26aufirst%3DF.%26aulast%3DTreanor%26aufirst%3DJ.%26aulast%3DRogers%26aufirst%3DG.%26aulast%3DCitron%26aufirst%3DM.%26atitle%3DBeta-secretase%2520cleavage%2520of%2520Alzheimer%25E2%2580%2599s%2520amyloid%2520precursor%2520protein%2520by%2520the%2520transmembrane%2520aspartic%2520protease%2520BACE%26jtitle%3DScience%26date%3D1999%26volume%3D286%26issue%3D5440%26spage%3D735%26epage%3D41%26doi%3D10.1126%2Fscience.286.5440.735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bienkowski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuck, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tory, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauley, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brashler, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratman, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhl, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasselli, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parodi, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrikson, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span> <span> </span><span class="NLM_article-title">Membrane-anchored aspartyl protease with Alzheimer’s disease beta-secretase activity</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>402</i></span> (<span class="NLM_issue">6761</span>),  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">537</span>, <span class="refDoi"> DOI: 10.1038/990107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1038%2F990107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10591213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADyaK1MXotFKmu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=402&publication_year=1999&pages=533-537&issue=6761&author=R.+Yanauthor=M.+J.+Bienkowskiauthor=M.+E.+Shuckauthor=H.+Miaoauthor=M.+C.+Toryauthor=A.+M.+Pauleyauthor=J.+R.+Brashlerauthor=N.+C.+Stratmanauthor=W.+R.+Mathewsauthor=A.+E.+Buhlauthor=D.+B.+Carterauthor=A.+G.+Tomasselliauthor=L.+A.+Parodiauthor=R.+L.+Heinriksonauthor=M.+E.+Gurney&title=Membrane-anchored+aspartyl+protease+with+Alzheimer%E2%80%99s+disease+beta-secretase+activity&doi=10.1038%2F990107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity</span></div><div class="casAuthors">Yan, Riqiang; Bienkowski, Michael J.; Shuck, Mary E.; Miao, Huiyi; Tory, Monica C.; Pauley, Adele M.; Brashler, John R.; Stratman, Nancy C.; Mathews, W. Rodney; Buhl, Allen E.; Carter, Donald B.; Tomasselli, Alfredo G.; Parodi, Luis A.; Heinrikson, Robert L.; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">402</span>
        (<span class="NLM_cas:issue">6761</span>),
    <span class="NLM_cas:pages">533-537</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Mutations in the gene encoding the amyloid protein precursor (APP) cause autosomal dominant Alzheimer's disease.  Cleavage of APP by unidentified proteases, referred to as β- and γ-secretases, generates the amyloid β-peptide, the main component of the amyloid plaques found in Alzheimer's disease patients.  The disease-causing mutations flank the protease cleavage sites in APP and facilitate its cleavage.  Here the authors identify a new membrane-bound aspartyl protease (Asp2) with β-secretase activity.  The Asp2 gene is expressed widely in brain and other tissues.  Decreasing the expression of Asp2 in cells reduces amyloid β-peptide prodn. and blocks the accumulation of the carboxy-terminal APP fragment that is created by β-secretase cleavage.  Solubilized Asp2 protein cleaves a synthetic APP peptide substrate at the β-secretase site, and the rate of cleavage is increased tenfold by a mutation assocd. with early-onset Alzheimer's disease in Sweden.  Thus, Asp2 is a new protein target for drugs that are designed to block the prodn. of amyloid β-peptide peptide and the consequent formation of amyloid plaque in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd6iE74jtk5LVg90H21EOLACvtfcHk0ljkml1e3LbC6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXotFKmu7k%253D&md5=96af7cd9b7c3315de029937497f04616</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2F990107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F990107%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DR.%26aulast%3DBienkowski%26aufirst%3DM.%2BJ.%26aulast%3DShuck%26aufirst%3DM.%2BE.%26aulast%3DMiao%26aufirst%3DH.%26aulast%3DTory%26aufirst%3DM.%2BC.%26aulast%3DPauley%26aufirst%3DA.%2BM.%26aulast%3DBrashler%26aufirst%3DJ.%2BR.%26aulast%3DStratman%26aufirst%3DN.%2BC.%26aulast%3DMathews%26aufirst%3DW.%2BR.%26aulast%3DBuhl%26aufirst%3DA.%2BE.%26aulast%3DCarter%26aufirst%3DD.%2BB.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DParodi%26aufirst%3DL.%2BA.%26aulast%3DHeinrikson%26aufirst%3DR.%2BL.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DMembrane-anchored%2520aspartyl%2520protease%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%2520beta-secretase%2520activity%26jtitle%3DNature%26date%3D1999%26volume%3D402%26issue%3D6761%26spage%3D533%26epage%3D537%26doi%3D10.1038%2F990107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, L.</span></span> <span> </span><span class="NLM_article-title">A resurrection of aducanumab for Alzheimer’s disease</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(19)30480-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1016%2FS1474-4422%2819%2930480-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=31978357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FktFKrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=111-112&issue=2&author=L.+Schneider&title=A+resurrection+of+aducanumab+for+Alzheimer%E2%80%99s+disease&doi=10.1016%2FS1474-4422%2819%2930480-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A resurrection of aducanumab for Alzheimer's disease</span></div><div class="casAuthors">Schneider Lon</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-112</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtdxhWBoi5aDQLBVDQn4bCfW6udTcc2eZq2OUjF0Yph7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FktFKrtg%253D%253D&md5=5ce903ac47c76caa5954b1d7feafdb97</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2819%2930480-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252819%252930480-6%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DL.%26atitle%3DA%2520resurrection%2520of%2520aducanumab%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DLancet%2520Neurol.%26date%3D2020%26volume%3D19%26issue%3D2%26spage%3D111%26epage%3D112%26doi%3D10.1016%2FS1474-4422%2819%2930480-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hampel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanmechelen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nisticò, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbimbo, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streffer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voytyuk, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahami Monfared, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irizarry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albala, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarenis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lista, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergallo, A.</span></span> <span> </span><span class="NLM_article-title">The β-Secretase BACE1 in Alzheimer’s Disease</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2020.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1016%2Fj.biopsych.2020.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=32223911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlvFGksLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2021&pages=745-756&author=H.+Hampelauthor=R.+Vassarauthor=B.+De+Strooperauthor=J.+Hardyauthor=M.+Willemauthor=N.+Singhauthor=J.+Zhouauthor=R.+Yanauthor=E.+Vanmechelenauthor=A.+De+Vosauthor=R.+Nistic%C3%B2author=M.+Corboauthor=B.+P.+Imbimboauthor=J.+Strefferauthor=I.+Voytyukauthor=M.+Timmersauthor=A.+A.+Tahami+Monfaredauthor=M.+Irizarryauthor=B.+Albalaauthor=A.+Koyamaauthor=N.+Watanabeauthor=T.+Kimuraauthor=L.+Yarenisauthor=S.+Listaauthor=L.+Kramerauthor=A.+Vergallo&title=The+%CE%B2-Secretase+BACE1+in+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.biopsych.2020.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The β-Secretase BACE1 in Alzheimer's Disease</span></div><div class="casAuthors">Hampel, Harald; Vassar, Robert; De Strooper, Bart; Hardy, John; Willem, Michael; Singh, Neeraj; Zhou, John; Yan, Riqiang; Vanmechelen, Eugeen; De Vos, Ann; Nistico, Robert; Corbo, Massimo; Imbimbo, Bruno Pietro; Streffer, Johannes; Voytyuk, Iryna; Timmers, Maarten; Tahami Monfared, Amir Abbas; Irizarry, Michael; Albala, Bruce; Koyama, Akihiko; Watanabe, Naoto; Kimura, Teiji; Yarenis, Lisa; Lista, Simone; Kramer, Lynn; Vergallo, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">745-756</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) was initially cloned and characterized in 1999.  It is required for the generation of all monomeric forms of amyloid-β (Aβ), including Aβ42, which aggregates into bioactive conformational species and likely initiates toxicity in Alzheimer's disease (AD).  BACE1 concns. and rates of activity are increased in AD brains and body fluids, thereby supporting the hypothesis that BACE1 plays a crit. role in AD pathophysiol.  Therefore, BACE1 is a prime drug target for slowing down Aβ prodn. in early AD.  Besides the amyloidogenic pathway, BACE1 has other substrates that may be important for synaptic plasticity and synaptic homeostasis.  Indeed, germline and adult conditional BACE1 knockout mice display complex neurol. phenotypes.  Despite BACE1 inhibitor clin. trials conducted so far being discontinued for futility or safety reasons, BACE1 remains a well-validated therapeutic target for AD.  A safe and efficacious compd. with high substrate selectivity as well as a more accurate dose regimen, patient population, and disease stage may yet be found.  Further research should focus on the role of Aβ and BACE1 in physiol. processes and key pathophysiol. mechanisms of AD.  The functions of BACE1 and the homolog BACE2, as well as the biol. of Aβ in neurons and glia, deserve further investigation.  Cellular and mol. studies of BACE1 and BACE2 knockout mice coupled with biomarker-based human research will help elucidate the biol. functions of these important enzymes and identify their substrates and downstream effects.  Such studies will have crit. implications for BACE1 inhibition as a therapeutic approach for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj9wLxG_m2P7Vg90H21EOLACvtfcHk0lij1k-N4Hw6Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlvFGksLo%253D&md5=11c76a8ef4ca3b228b6973c7edc3a8f6</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2020.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2020.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DHampel%26aufirst%3DH.%26aulast%3DVassar%26aufirst%3DR.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26aulast%3DHardy%26aufirst%3DJ.%26aulast%3DWillem%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DR.%26aulast%3DVanmechelen%26aufirst%3DE.%26aulast%3DDe%2BVos%26aufirst%3DA.%26aulast%3DNistic%25C3%25B2%26aufirst%3DR.%26aulast%3DCorbo%26aufirst%3DM.%26aulast%3DImbimbo%26aufirst%3DB.%2BP.%26aulast%3DStreffer%26aufirst%3DJ.%26aulast%3DVoytyuk%26aufirst%3DI.%26aulast%3DTimmers%26aufirst%3DM.%26aulast%3DTahami%2BMonfared%26aufirst%3DA.%2BA.%26aulast%3DIrizarry%26aufirst%3DM.%26aulast%3DAlbala%26aufirst%3DB.%26aulast%3DKoyama%26aufirst%3DA.%26aulast%3DWatanabe%26aufirst%3DN.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DYarenis%26aufirst%3DL.%26aulast%3DLista%26aufirst%3DS.%26aulast%3DKramer%26aufirst%3DL.%26aulast%3DVergallo%26aufirst%3DA.%26atitle%3DThe%2520%25CE%25B2-Secretase%2520BACE1%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DBiol.%2520Psychiatry%26date%3D2021%26volume%3D89%26spage%3D745%26epage%3D756%26doi%3D10.1016%2Fj.biopsych.2020.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lopez
Lopez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariot, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caputo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langbaum, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riviere, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouzade-Dominguez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalesak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viglietta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiman, E. M.</span></span> <span> </span><span class="NLM_article-title">The Alzheimer’s Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer’s disease</span>. <i>Alzheimers Dement (N Y)</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">216</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1016/j.trci.2019.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1016%2Fj.trci.2019.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=31211217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A280%3ADC%252BB3M3nvFGhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=216-227&author=C.+Lopez%0ALopezauthor=P.+N.+Tariotauthor=A.+Caputoauthor=J.+B.+Langbaumauthor=F.+Liuauthor=M.+E.+Riviereauthor=C.+Langloisauthor=M.+L.+Rouzade-Dominguezauthor=M.+Zalesakauthor=S.+Hendrixauthor=R.+G.+Thomasauthor=V.+Vigliettaauthor=R.+Lenzauthor=J.+M.+Ryanauthor=A.+Grafauthor=E.+M.+Reiman&title=The+Alzheimer%E2%80%99s+Prevention+Initiative+Generation+Program%3A+Study+design+of+two+randomized+controlled+trials+for+individuals+at+risk+for+clinical+onset+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.trci.2019.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease</span></div><div class="casAuthors">Lopez Lopez Cristina; Caputo Angelika; Riviere Marie-Emmanuelle; Rouzade-Dominguez Marie-Laure; Zalesak Martin; Graf Ana; Tariot Pierre N; Langbaum Jessica B; Langlois Carolyn; Reiman Eric M; Liu Fonda; Hendrix Suzanne; Thomas Ronald G; Viglietta Vissia; Lenz Rob; Ryan J Michael</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's & dementia (New York, N. Y.)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">216-227</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Introduction:  Alzheimer's disease (AD) pathology, including the accumulation of amyloid beta (Aβ) species and tau pathology, begins decades before the onset of cognitive impairment.  This long preclinical period provides an opportunity for clinical trials designed to prevent or delay the onset of cognitive impairment due to AD.  Under the umbrella of the Alzheimer's Prevention Initiative Generation Program, therapies targeting Aβ, including CNP520 (umibecestat), a β-site-amyloid precursor protein cleaving enzyme-1 (BACE-1) inhibitor, and CAD106, an active Aβ immunotherapy, are in clinical development in preclinical AD.  Methods:  The Alzheimer's Prevention Initiative Generation Program comprises two pivotal (phase 2/3) studies that assess the efficacy and safety of umibecestat and CAD106 in cognitively unimpaired individuals with high risk for developing symptoms of AD based on their age (60-75 years), APOE4 genotype, and, for heterozygotes (APOE ε2/ε4 or ε3/ε4), elevated brain amyloid.  Approximately, 3500 individuals will be enrolled in either Generation Study 1 (randomized to cohort 1 [CAD106 injection or placebo, 5:3] or cohort 2 [oral umibecestat 50 mg or placebo, 3:2]) or Generation Study 2 (randomized to oral umibecestat 50 mg and 15 mg, or placebo [2:1:2]).  Participants receive treatment for at least 60 months and up to a maximum of 96 months.  Primary outcomes include time to event, with event defined as diagnosis of mild cognitive impairment due to AD and/or dementia due to AD, and the Alzheimer's Prevention Initiative preclinical composite cognitive test battery.  Secondary endpoints include the Clinical Dementia Rating Sum of Boxes, Repeatable Battery for the Assessment of Neuropsychological Status total score, Everyday Cognition Scale, biomarkers, and brain imaging.  Discussion:  The Generation Program is designed to assess the efficacy, safety, and biomarker effects of the two treatments in individuals at high risk for AD.  It may also provide a plausible test of the amyloid hypothesis and further accelerate the evaluation of AD prevention therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzTVdi99KAcAqdek-gHSrIfW6udTcc2ebS-B3R55R8-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3nvFGhug%253D%253D&md5=733d6670d4abb4b673fa5dc91213910c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.trci.2019.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trci.2019.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DLopez%2BLopez%26aufirst%3DC.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26aulast%3DCaputo%26aufirst%3DA.%26aulast%3DLangbaum%26aufirst%3DJ.%2BB.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DRiviere%26aufirst%3DM.%2BE.%26aulast%3DLanglois%26aufirst%3DC.%26aulast%3DRouzade-Dominguez%26aufirst%3DM.%2BL.%26aulast%3DZalesak%26aufirst%3DM.%26aulast%3DHendrix%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DR.%2BG.%26aulast%3DViglietta%26aufirst%3DV.%26aulast%3DLenz%26aufirst%3DR.%26aulast%3DRyan%26aufirst%3DJ.%2BM.%26aulast%3DGraf%26aufirst%3DA.%26aulast%3DReiman%26aufirst%3DE.%2BM.%26atitle%3DThe%2520Alzheimer%25E2%2580%2599s%2520Prevention%2520Initiative%2520Generation%2520Program%253A%2520Study%2520design%2520of%2520two%2520randomized%2520controlled%2520trials%2520for%2520individuals%2520at%2520risk%2520for%2520clinical%2520onset%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAlzheimers%2520Dement%2520%2528N%2520Y%2529%26date%3D2019%26volume%3D5%26spage%3D216%26epage%3D227%26doi%3D10.1016%2Fj.trci.2019.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egan, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kost, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariot, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Dyck, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furtek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper Mozley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sur, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelson, D.</span></span> <span> </span><span class="NLM_article-title">Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">1408</span>– <span class="NLM_lpage">1420</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1812840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1056%2FNEJMoa1812840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=30970186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotFehtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=1408-1420&issue=15&author=M.+F.+Eganauthor=J.+Kostauthor=T.+Vossauthor=Y.+Mukaiauthor=P.+S.+Aisenauthor=J.+L.+Cummingsauthor=P.+N.+Tariotauthor=B.+Vellasauthor=C.+H.+van+Dyckauthor=M.+Boadaauthor=Y.+Zhangauthor=W.+Liauthor=C.+Furtekauthor=E.+Mahoneyauthor=L.+Harper+Mozleyauthor=Y.+Moauthor=C.+Surauthor=D.+Michelson&title=Randomized+Trial+of+Verubecestat+for+Prodromal+Alzheimer%E2%80%99s+Disease&doi=10.1056%2FNEJMoa1812840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of verubecestat for prodromal Alzheimer's disease</span></div><div class="casAuthors">Egan, Michael F.; Kost, James; Voss, Tiffini; Mukai, Yuki; Aisen, Paul S.; Cummings, Jeffrey L.; Tariot, Pierre N.; Vellas, Bruno; van Dyck, Christopher H.; Boada, Merce; Zhang, Ying; Li, Wen; Furtek, Christine; Mahoney, Erin; Mozley, Lyn Harper; Mo, Yi; Sur, Cyrille; Michelson, David</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1408-1420</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Prodromal Alzheimer's disease offers an opportunity to test the effect of drugs that modify the deposition of amyloid in the brain before the onset of dementia.  Verubecestat is an orally administered β-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) inhibitor that blocks prodn. of amyloid-beta (Aβ).  The drug did not prevent clin. progression in a trial involving patients with mild-to-moderate dementia due to Alzheimer's disease.  We conducted a randomized, double-blind, placebo-controlled, 104-wk trial to evaluate verubecestat at doses of 12 mg and 40 mg per day, as compared with placebo, in patients who had memory impairment and elevated brain amyloid levels but whose condition did not meet the case definition of dementia.  The primary outcome was the change from baseline to week 104 in the score on the Clin. Dementia Rating Scale-Sum of Boxes (CDR-SB; scores range from 0 to 18, with higher scores indicating worse cognition and daily function).  Secondary outcomes included other assessments of cognition and daily function.  The trial was terminated for futility after 1454 patients had been enrolled; 485 had been assigned to receive verubecestat at a dose of 12 mg per day (the 12-mg group), 484 to receive verubecestat at a dose of 40 mg per day (the 40-mg group), and 485 to receive placebo.  A total of 234 patients, 231 patients, and 239 patients per group, resp., completed 104 wk of the trial regimen.  The estd. mean change from baseline to week 104 in the CDR-SB score was 1.65 in the 12-mg group, 2.02 in the 40-mg group, and 1.58 in the placebo group (P = 0.67 for the comparison between the 12-mg group and the placebo group and P = 0.01 for the comparison between the 40-mg group and the placebo group), suggesting a worse outcome in the higher-dose group than in the placebo group.  The estd. rate of progression to dementia due to Alzheimer's disease was 24.5, 25.5, and 19.3 events per 100 patient-years in the 12-mg group, the 40-mg group, and the placebo group, resp. (hazard ratio for 40 mg vs. placebo, 1.38; 97.51% confidence interval, 1.07 to 1.79, not adjusted for multiple comparisons), favoring placebo.  Adverse events were more common in the verubecestat groups than in the placebo group. conclusions Verubecestat did not improve clin. ratings of dementia among patients with prodromal Alzheimer's disease, and some measures suggested that cognition and daily function were worse among patients who received verubecestat than among those who received placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2_0d9EBVvSrVg90H21EOLACvtfcHk0lij1k-N4Hw6Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotFehtrY%253D&md5=4f46fb485bfbd366eca939d40a7ee873</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1812840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1812840%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DM.%2BF.%26aulast%3DKost%26aufirst%3DJ.%26aulast%3DVoss%26aufirst%3DT.%26aulast%3DMukai%26aufirst%3DY.%26aulast%3DAisen%26aufirst%3DP.%2BS.%26aulast%3DCummings%26aufirst%3DJ.%2BL.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26aulast%3DVellas%26aufirst%3DB.%26aulast%3Dvan%2BDyck%26aufirst%3DC.%2BH.%26aulast%3DBoada%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DFurtek%26aufirst%3DC.%26aulast%3DMahoney%26aufirst%3DE.%26aulast%3DHarper%2BMozley%26aufirst%3DL.%26aulast%3DMo%26aufirst%3DY.%26aulast%3DSur%26aufirst%3DC.%26aulast%3DMichelson%26aufirst%3DD.%26atitle%3DRandomized%2520Trial%2520of%2520Verubecestat%2520for%2520Prodromal%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26issue%3D15%26spage%3D1408%26epage%3D1420%26doi%3D10.1056%2FNEJMoa1812840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moechars, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenthaler, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span> <span> </span><span class="NLM_article-title">BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer’s Disease</span>. <i>Trends Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1016/j.tins.2016.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1016%2Fj.tins.2016.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=26833257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2016&pages=158-169&issue=3&author=S.+Baraoauthor=D.+Moecharsauthor=S.+F.+Lichtenthalerauthor=B.+De+Strooper&title=BACE1+Physiological+Functions+May+Limit+Its+Use+as+Therapeutic+Target+for+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.tins.2016.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease</span></div><div class="casAuthors">Barao, Soraia; Moechars, Diederik; Lichtenthaler, Stefan F.; De Strooper, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Neurosciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">158-169</span>CODEN:
                <span class="NLM_cas:coden">TNSCDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-2236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The protease β-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) is required for the prodn. of the amyloid-β (Aβ) peptide, which is central to the pathogenesis of Alzheimer's disease (AD).  Chronic inhibition of this protease may temper amyloid prodn. and cure or prevent AD.  However, while BACE1 inhibitors are being pushed forward as drug candidates, a remarkable gap in knowledge on the physiol. functions of BACE1 and its close homolog BACE2 becomes apparent.  Here we discuss the major discoveries of the past 3 years concerning BACE1 biol. and to what extent these could limit the use of BACE1 inhibitors in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtIpCCZlND1LVg90H21EOLACvtfcHk0liPqUgi0eDvhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaksb4%253D&md5=2f85406ce8d4a917de49e26f0ae1ea87</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.tins.2016.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tins.2016.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DBarao%26aufirst%3DS.%26aulast%3DMoechars%26aufirst%3DD.%26aulast%3DLichtenthaler%26aufirst%3DS.%2BF.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26atitle%3DBACE1%2520Physiological%2520Functions%2520May%2520Limit%2520Its%2520Use%2520as%2520Therapeutic%2520Target%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DTrends%2520Neurosci.%26date%3D2016%26volume%3D39%26issue%3D3%26spage%3D158%26epage%3D169%26doi%3D10.1016%2Fj.tins.2016.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wessels, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariot, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selzler, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bragg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krull, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downing, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shcherbinin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shering, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacSweeney, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, J. R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials</span>. <i>JAMA Neurol</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.1001/jamaneurol.2019.3988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1001%2Fjamaneurol.2019.3988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=31764959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A280%3ADC%252BB3MfivFehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2020&pages=199-209&issue=2&author=A.+M.+Wesselsauthor=P.+N.+Tariotauthor=J.+A.+Zimmerauthor=K.+J.+Selzlerauthor=S.+M.+Braggauthor=S.+W.+Andersenauthor=J.+Landryauthor=J.+H.+Krullauthor=A.+M.+Downingauthor=B.+A.+Willisauthor=S.+Shcherbininauthor=J.+Mullenauthor=P.+Barkerauthor=J.+Schumiauthor=C.+Sheringauthor=B.+R.+Matthewsauthor=R.+A.+Sternauthor=B.+Vellasauthor=S.+Cohenauthor=E.+MacSweeneyauthor=M.+Boadaauthor=J.+R.+Sims&title=Efficacy+and+Safety+of+Lanabecestat+for+Treatment+of+Early+and+Mild+Alzheimer+Disease%3A+The+AMARANTH+and+DAYBREAK-ALZ+Randomized+Clinical+Trials&doi=10.1001%2Fjamaneurol.2019.3988"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials</span></div><div class="casAuthors">Wessels Alette M; Zimmer Jennifer A; Selzler Katherine J; Bragg Sonja M; Andersen Scott W; Landry John; Krull James H; Downing AnnCatherine M; Willis Brian A; Shcherbinin Sergey; Matthews Brandy R; Sims John R; Tariot Pierre N; Mullen Jamie; Barker Peter; Schumi Jennifer; Shering Craig; Mullen Jamie; Stern Robert A; Vellas Bruno; Cohen Sharon; MacSweeney Emer; Boada Merce; Boada Merce</div><div class="citationInfo"><span class="NLM_cas:title">JAMA neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-209</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Alzheimer disease (AD) is a neurodegenerative disorder characterized by cognitive deterioration and impaired activities of daily living.  Current treatments provide only minor symptomatic improvements with limited benefit duration.  Lanabecestat, a brain-permeable inhibitor of human beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1/β-secretase), was developed to modify the clinical course of AD by slowing disease progression.  Objective:  To assess whether lanabecestat slows the progression of AD compared with placebo in patients with early AD (mild cognitive impairment) and mild AD dementia.  Design, Setting, and Participants:  AMARANTH (first patient visit on September 30, 2014; last patient visit on October 4, 2018) and DAYBREAK-ALZ (first patient visit on July 1, 2016; last patient visit on September 28, 2018) were randomized, placebo-controlled, phase 2/3 and phase 3 clinical trials lasting 104 weeks and 78 weeks, respectively.  AMARANTH and DAYBREAK-ALZ were multicenter, global, double-blind studies conducted at 257 and 251 centers, respectively, located in 15 and 18 countries or territories, respectively.  A population-based sample of men and women aged 55 to 85 years who met National Institute on Aging-Alzheimer's Association criteria for early AD or mild AD dementia was screened using cognitive assessments, and the presence of amyloid was confirmed.  Patients were excluded for unstable medical conditions or medication use, significant cerebrovascular pathologic findings, or a history of vitiligo and/or current evidence of postinflammatory hypopigmentation.  AMARANTH screened 6871 patients; 2218 (32.3%) were randomized, and 539 patients completed the study.  DAYBREAK-ALZ screened 5706 patients; 1722 (30.2%) were randomized, and 76 patients completed the study.  Interventions:  Patients were randomized (1:1:1) to once-daily oral doses of lanabecestat (20 mg), lanabecestat (50 mg), or placebo.  Main Outcomes and Measures:  The primary outcome measure was change from baseline on the 13-item Alzheimer Disease Assessment Scale-cognitive subscale.  Secondary outcomes included Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Inventory, Clinical Dementia Rating, Functional Activities Questionnaire, Mini-Mental State Examination, and Neuropsychiatric Inventory.  Efficacy analyses were conducted on the intent-to-treat population.  Results:  Among 2218 AMARANTH patients, the mean (SD) age was 71.3 (7.1) years, and 1177 of 2218 (53.1%) were women.  Among 1722 DAYBREAK-ALZ patients, the mean (SD) age was 72.3 (7.0) years, and 1023 of 1722 (59.4%) were women.  Both studies were terminated early after futility analysis.  There were no consistent, reproducible dose-related findings on primary or secondary efficacy measures.  Psychiatric adverse events, weight loss, and hair color changes were reported in a higher percentage of patients receiving lanabecestat than placebo.  Conclusions and Relevance:  Treatment with lanabecestat was well tolerated and did not slow cognitive or functional decline.  Trial Registration:  ClinicalTrials.gov identifiers: NCT02245737 and NCT02783573.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWiVGh1IBjdC86Js-BCLiifW6udTcc2eYDYsVH0fNmzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MfivFehug%253D%253D&md5=af37918a3575efef243bd58895bcdb78</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1001%2Fjamaneurol.2019.3988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaneurol.2019.3988%26sid%3Dliteratum%253Aachs%26aulast%3DWessels%26aufirst%3DA.%2BM.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26aulast%3DZimmer%26aufirst%3DJ.%2BA.%26aulast%3DSelzler%26aufirst%3DK.%2BJ.%26aulast%3DBragg%26aufirst%3DS.%2BM.%26aulast%3DAndersen%26aufirst%3DS.%2BW.%26aulast%3DLandry%26aufirst%3DJ.%26aulast%3DKrull%26aufirst%3DJ.%2BH.%26aulast%3DDowning%26aufirst%3DA.%2BM.%26aulast%3DWillis%26aufirst%3DB.%2BA.%26aulast%3DShcherbinin%26aufirst%3DS.%26aulast%3DMullen%26aufirst%3DJ.%26aulast%3DBarker%26aufirst%3DP.%26aulast%3DSchumi%26aufirst%3DJ.%26aulast%3DShering%26aufirst%3DC.%26aulast%3DMatthews%26aufirst%3DB.%2BR.%26aulast%3DStern%26aufirst%3DR.%2BA.%26aulast%3DVellas%26aufirst%3DB.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DMacSweeney%26aufirst%3DE.%26aulast%3DBoada%26aufirst%3DM.%26aulast%3DSims%26aufirst%3DJ.%2BR.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Lanabecestat%2520for%2520Treatment%2520of%2520Early%2520and%2520Mild%2520Alzheimer%2520Disease%253A%2520The%2520AMARANTH%2520and%2520DAYBREAK-ALZ%2520Randomized%2520Clinical%2520Trials%26jtitle%3DJAMA%2520Neurol%26date%3D2020%26volume%3D77%26issue%3D2%26spage%3D199%26epage%3D209%26doi%3D10.1001%2Fjamaneurol.2019.3988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span> <span> </span><span class="NLM_article-title">Physiological Functions of the beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">97</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2017.00097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.3389%2Ffnmol.2017.00097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=28469554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A280%3ADC%252BC1crjvVWksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=97&author=R.+Yan&title=Physiological+Functions+of+the+beta-Site+Amyloid+Precursor+Protein+Cleaving+Enzyme+1+and+2&doi=10.3389%2Ffnmol.2017.00097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Physiological Functions of the β-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2</span></div><div class="casAuthors">Yan Riqiang</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in molecular neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">97</span>
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    </div><div class="casAbstract">BACE1 was discovered as the β-secretase for initiating the cleavage of amyloid precursor protein (APP) at the β-secretase site, while its close homology BACE2 cleaves APP within the β-amyloid (Aβ) domain region and shows distinct cleavage preferences in vivo.  Inhibition of BACE1 proteolytic activity has been confirmed to decrease Aβ generation and amyloid deposition, and thus specific inhibition of BACE1 by small molecules is a current focus for Alzheimer's disease therapy.  While BACE1 inhibitors are being tested in advanced clinical trials, knowledge regarding the properties and physiological functions of BACE is highly important and this review summarizes advancements in BACE1 research over the past several years.  We and others have shown that BACE1 is not only a critical enzyme for testing the "Amyloid Hypothesis" associated with Alzheimer's pathogenesis, but also important for various functions such as axon growth and pathfinding, astrogenesis, neurogenesis, hyperexcitation, and synaptic plasticity.  BACE2 appears to play different roles such as glucose homeostasis and pigmentation.  This knowledge regarding BACE1 functions is critical for monitoring the safe use of BACE1 inhibitors in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbYoN5Bm7IDcScOqQTSkOffW6udTcc2eYDYsVH0fNmzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crjvVWksQ%253D%253D&md5=b8e9ffa2007cebb2ae68c0074b7dea06</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2017.00097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2017.00097%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DR.%26atitle%3DPhysiological%2520Functions%2520of%2520the%2520beta-Site%2520Amyloid%2520Precursor%2520Protein%2520Cleaving%2520Enzyme%25201%2520and%25202%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2017%26volume%3D10%26spage%3D97%26doi%3D10.3389%2Ffnmol.2017.00097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atwal, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snaedal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulem, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudbjartsson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyte, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhangale, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huttenlocher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsdottir, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreassen, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palotie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrens, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsteinsdottir, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, K.</span></span> <span> </span><span class="NLM_article-title">A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>488</i></span> (<span class="NLM_issue">7409</span>),  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1038/nature11283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1038%2Fnature11283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=22801501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWmt73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=488&publication_year=2012&pages=96-9&issue=7409&author=T.+Jonssonauthor=J.+K.+Atwalauthor=S.+Steinbergauthor=J.+Snaedalauthor=P.+V.+Jonssonauthor=S.+Bjornssonauthor=H.+Stefanssonauthor=P.+Sulemauthor=D.+Gudbjartssonauthor=J.+Maloneyauthor=K.+Hoyteauthor=A.+Gustafsonauthor=Y.+Liuauthor=Y.+Luauthor=T.+Bhangaleauthor=R.+R.+Grahamauthor=J.+Huttenlocherauthor=G.+Bjornsdottirauthor=O.+A.+Andreassenauthor=E.+G.+Jonssonauthor=A.+Palotieauthor=T.+W.+Behrensauthor=O.+T.+Magnussonauthor=A.+Kongauthor=U.+Thorsteinsdottirauthor=R.+J.+Wattsauthor=K.+Stefansson&title=A+mutation+in+APP+protects+against+Alzheimer%E2%80%99s+disease+and+age-related+cognitive+decline&doi=10.1038%2Fnature11283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A mutation in APP protects against Alzheimer's disease and age-related cognitive decline</span></div><div class="casAuthors">Jonsson, Thorlakur; Atwal, Jasvinder K.; Steinberg, Stacy; Snaedal, Jon; Jonsson, Palmi V.; Bjornsson, Sigurbjorn; Stefansson, Hreinn; Sulem, Patrick; Gudbjartsson, Daniel; Maloney, Janice; Hoyte, Kwame; Gustafson, Amy; Liu, Yichin; Lu, Yanmei; Bhangale, Tushar; Graham, Robert R.; Huttenlocher, Johanna; Bjornsdottir, Gyda; Andreassen, Ole A.; Joensson, Erik G.; Palotie, Aarno; Behrens, Timothy W.; Magnusson, Olafur T.; Kong, Augustine; Thorsteinsdottir, Unnur; Watts, Ryan J.; Stefansson, Kari</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">488</span>
        (<span class="NLM_cas:issue">7409</span>),
    <span class="NLM_cas:pages">96-99</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The prevalence of dementia in the Western world in people over the age of 60 has been estd. to be greater than 5%, about two-thirds of which are due to Alzheimer's disease.  The age-specific prevalence of Alzheimer's disease nearly doubles every 5 years after age 65, leading to a prevalence of greater than 25% in those over the age of 90 (ref. 3).  Here, to search for low-frequency variants in the amyloid-β precursor protein (APP) gene with a significant effect on the risk of Alzheimer's disease, we studied coding variants in APP in a set of whole-genome sequence data from 1795 Icelanders.  We found a coding mutation (A673T) in the APP gene that protects against Alzheimer's disease and cognitive decline in the elderly without Alzheimer's disease.  This substitution is adjacent to the aspartyl protease β-site in APP, and results in an approx. 40% redn. in the formation of amyloidogenic peptides in vitro.  The strong protective effect of the A673T substitution against Alzheimer's disease provides proof of principle for the hypothesis that reducing the β-cleavage of APP may protect against the disease.  Furthermore, as the A673T allele also protects against cognitive decline in the elderly without Alzheimer's disease, the two may be mediated through the same or similar mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4AFwQCLRQOLVg90H21EOLACvtfcHk0ljCbm9c5GnkXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWmt73M&md5=4db9cb2e3842d5a9d4af4ce102249b70</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnature11283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11283%26sid%3Dliteratum%253Aachs%26aulast%3DJonsson%26aufirst%3DT.%26aulast%3DAtwal%26aufirst%3DJ.%2BK.%26aulast%3DSteinberg%26aufirst%3DS.%26aulast%3DSnaedal%26aufirst%3DJ.%26aulast%3DJonsson%26aufirst%3DP.%2BV.%26aulast%3DBjornsson%26aufirst%3DS.%26aulast%3DStefansson%26aufirst%3DH.%26aulast%3DSulem%26aufirst%3DP.%26aulast%3DGudbjartsson%26aufirst%3DD.%26aulast%3DMaloney%26aufirst%3DJ.%26aulast%3DHoyte%26aufirst%3DK.%26aulast%3DGustafson%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DBhangale%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DR.%2BR.%26aulast%3DHuttenlocher%26aufirst%3DJ.%26aulast%3DBjornsdottir%26aufirst%3DG.%26aulast%3DAndreassen%26aufirst%3DO.%2BA.%26aulast%3DJonsson%26aufirst%3DE.%2BG.%26aulast%3DPalotie%26aufirst%3DA.%26aulast%3DBehrens%26aufirst%3DT.%2BW.%26aulast%3DMagnusson%26aufirst%3DO.%2BT.%26aulast%3DKong%26aufirst%3DA.%26aulast%3DThorsteinsdottir%26aufirst%3DU.%26aulast%3DWatts%26aufirst%3DR.%2BJ.%26aulast%3DStefansson%26aufirst%3DK.%26atitle%3DA%2520mutation%2520in%2520APP%2520protects%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520age-related%2520cognitive%2520decline%26jtitle%3DNature%26date%3D2012%26volume%3D488%26issue%3D7409%26spage%3D96%26epage%3D9%26doi%3D10.1038%2Fnature11283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martiskainen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herukka, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stancakova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paananen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soininen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuusisto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laakso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiltunen, M.</span></span> <span> </span><span class="NLM_article-title">Decreased plasma beta-amyloid in the Alzheimer’s disease APP A673T variant carriers</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>82</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1002/ana.24969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1002%2Fana.24969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=28556232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1WrsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2017&pages=128-132&issue=1&author=H.+Martiskainenauthor=S.+K.+Herukkaauthor=A.+Stancakovaauthor=J.+Paananenauthor=H.+Soininenauthor=J.+Kuusistoauthor=M.+Laaksoauthor=M.+Hiltunen&title=Decreased+plasma+beta-amyloid+in+the+Alzheimer%E2%80%99s+disease+APP+A673T+variant+carriers&doi=10.1002%2Fana.24969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Decreased plasma β-amyloid in the Alzheimer's disease APP A673T variant carriers</span></div><div class="casAuthors">Martiskainen, Henna; Herukka, Sanna-Kaisa; Stancakova, Alena; Paananen, Jussi; Soininen, Hilkka; Kuusisto, Johanna; Laakso, Markku; Hiltunen, Mikko</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-132</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">We investigated the assocn. of Alzheimer's disease (AD)-related rare variants APP A673T and ABCA7 rs200538373-C with the levels of β-amyloid (Aβ) and parameters of metabolic and cardiovascular health in a population-based cohort of healthy middle-aged and elderly men.  Carriers of protective APP A673T variant had, on av., 28% lower levels of Aβ40 and Aβ42 in plasma as compared to the controls and the carriers of ABCA7 rs200538373-C.  This is the first report to show decreased Aβ levels in plasma in APP A673T carriers and thus provides evidence that lower Aβ levels throughout life may be protective against AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_Xdy_-kVupLVg90H21EOLACvtfcHk0ljCbm9c5GnkXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1WrsL3L&md5=54fe8da37f480b062ac27548c47893c8</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fana.24969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.24969%26sid%3Dliteratum%253Aachs%26aulast%3DMartiskainen%26aufirst%3DH.%26aulast%3DHerukka%26aufirst%3DS.%2BK.%26aulast%3DStancakova%26aufirst%3DA.%26aulast%3DPaananen%26aufirst%3DJ.%26aulast%3DSoininen%26aufirst%3DH.%26aulast%3DKuusisto%26aufirst%3DJ.%26aulast%3DLaakso%26aufirst%3DM.%26aulast%3DHiltunen%26aufirst%3DM.%26atitle%3DDecreased%2520plasma%2520beta-amyloid%2520in%2520the%2520Alzheimer%25E2%2580%2599s%2520disease%2520APP%2520A673T%2520variant%2520carriers%26jtitle%3DAnn.%2520Neurol.%26date%3D2017%26volume%3D82%26issue%3D1%26spage%3D128%26epage%3D132%26doi%3D10.1002%2Fana.24969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span> <span> </span><span class="NLM_article-title">Editorial: Implications for BACE1 Inhibitor Clinical Trials: Adult Conditional BACE1 Knockout Mice Exhibit Axonal Organization Defects in the Hippocampus</span>. <i>J. Prev Alzheimers Dis</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.14283/jpad.2019.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.14283%2Fjpad.2019.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=30756113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A280%3ADC%252BB3cfis1Kmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=78-84&issue=2&author=R.+Vassar&title=Editorial%3A+Implications+for+BACE1+Inhibitor+Clinical+Trials%3A+Adult+Conditional+BACE1+Knockout+Mice+Exhibit+Axonal+Organization+Defects+in+the+Hippocampus&doi=10.14283%2Fjpad.2019.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Editorial: Implications for BACE1 Inhibitor Clinical Trials: Adult Conditional BACE1 Knockout Mice Exhibit Axonal Organization Defects in the Hippocampus</span></div><div class="casAuthors">Vassar R</div><div class="citationInfo"><span class="NLM_cas:title">The journal of prevention of Alzheimer's disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">78-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACE1 is the rate-limiting enzyme for the production of the Aβ peptide that forms amyloid plaques in Alzheimer's disease (AD).  Small molecule inhibitors of BACE1 are being tested in clinical trials for AD, but the safety and efficacy of BACE1 inhibition has yet to be fully explored.  Knockout of the Bace1 gene in the germline of mice causes multiple neurological phenotypes, suggesting that BACE1 inhibition could be toxic.  However, these phenotypes could be the result of BACE1 deficiency during development rather than due to the lack of BACE1 function in the adult.  To address this problem, we generated tamoxifen-inducible conditional BACE1 knockout mice in which the Bace1 gene may be deleted in the whole body of the adult at will.  Importantly, the adult conditional BACE1 knockout mice largely lack phenotypes, indicating that many BACE1 functions are not required in the adult organism.  However, a germline phenotype was observed after BACE1 knockout in the adult: reduced length and disorganization of the hippocampal mossy fiber infrapyramidal bundle comprised of axons of dentate gyrus granule cells.  The infrapyramidal bundle abnormality correlated with reduced proteolytic processing of the neural cell adhesion protein CHL1 that is involved in axonal guidance.  We conclude that BACE1 inhibition in the adult mouse brain does not lead to the phenotypes associated with BACE1 deficiency during embryonic and postnatal development.  However, adult conditional BACE1 knockout mice also suggest that BACE1 inhibitor drugs may disrupt the organization of an axonal pathway in the hippocampus, an important structure for learning and memory.  Here, I review the adult conditional BACE1 knockout results and consider their implications for BACE1 inhibitor clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcjPd2J9N9MMzK395ZObgVfW6udTcc2eYu_HSoe_YaQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfis1Kmug%253D%253D&md5=35c7251ad1415ebbdd30df3ea32c1b29</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.14283%2Fjpad.2019.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14283%252Fjpad.2019.3%26sid%3Dliteratum%253Aachs%26aulast%3DVassar%26aufirst%3DR.%26atitle%3DEditorial%253A%2520Implications%2520for%2520BACE1%2520Inhibitor%2520Clinical%2520Trials%253A%2520Adult%2520Conditional%2520BACE1%2520Knockout%2520Mice%2520Exhibit%2520Axonal%2520Organization%2520Defects%2520in%2520the%2520Hippocampus%26jtitle%3DJ.%2520Prev%2520Alzheimers%2520Dis%26date%3D2019%26volume%3D6%26issue%3D2%26spage%3D78%26epage%3D84%26doi%3D10.14283%2Fjpad.2019.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosior, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-DeWhitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueno, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, P. C.</span></span> <span> </span><span class="NLM_article-title">Biochemical and kinetic characterization of BACE1: investigation into the putative species-specificity for beta- and beta’-cleavage sites by human and murine BACE1</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1249</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2004.02764.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1111%2Fj.1471-4159.2004.02764.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=15584902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmslah" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2004&pages=1249-59&issue=6&author=H.+C.+Yangauthor=X.+Chaiauthor=M.+Mosiorauthor=W.+Kohnauthor=L.+N.+Boggsauthor=J.+A.+Ericksonauthor=D.+B.+McClureauthor=W.+K.+Yehauthor=L.+Zhangauthor=P.+Gonzalez-DeWhittauthor=J.+P.+Mayerauthor=J.+A.+Martinauthor=J.+Huauthor=S.+H.+Chenauthor=A.+B.+Buenoauthor=S.+P.+Littleauthor=J.+R.+McCarthyauthor=P.+C.+May&title=Biochemical+and+kinetic+characterization+of+BACE1%3A+investigation+into+the+putative+species-specificity+for+beta-+and+beta%E2%80%99-cleavage+sites+by+human+and+murine+BACE1&doi=10.1111%2Fj.1471-4159.2004.02764.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical and kinetic characterization of BACE1: Investigation into the putative species-specificity for β- and β'-cleavage sites by human and murine BACE1</span></div><div class="casAuthors">Yang, Hsiu-Chiung; Chai, Xiyun; Mosior, Marian; Kohn, Wayne; Boggs, Leonard N.; Erickson, Jon A.; McClure, Don B.; Yeh, Wu-Kuang; Zhang, Lianshen; Gonzalez-DeWhitt, Patricia; Mayer, John P.; Martin, Jose Alfredo; Hu, Jingdan; Chen, Shu-hui; Bueno, Ana Belen; Little, Sheila P.; McCarthy, James R.; May, Patrick C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1249-1259</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">β-Amyloid peptides (Aβ) are produced by a sequential cleavage of amyloid precursor protein (APP) by β- and γ-secretases.  The lack of Aβ prodn. in beta-APP cleaving enzyme (BACE1)-/- mice suggests that BACE1 is the principal β-secretase in mammalian neurons.  Transfection of human APP and BACE1 into neurons derived from wild-type and BACE1-/- mice supports cleavage of APP at the canonical β-secretase site.  However, these studies also revealed an alternative BACE1 cleavage site in APP, designated as β', resulting in Aβ peptides starting at Glu11.  The apparent inability of human BACE1 to make this β'-cleavage in murine APP, and vice versa, led to the hypothesis that this alternative cleavage was species-specific.  In contrast, the results from human BACE1 transgenic mice demonstrated that the human BACE1 is able to cleave the endogenous murine APP at the β'-cleavage site.  To address this discrepancy, we designed fluorescent resonance energy transfer peptide substrates contg. the β- and β'-cleavage sites within human and murine APP to compare:.  (i) the enzymic efficiency; (ii) binding kinetics of a BACE1 active site inhibitor LY2039911; and (ii) the pharmacol. profiles for human and murine recombinant BACE1.  Both BACE1 orthologs were able to cleave APP at the β- and β'-sites, although with different efficiencies.  Moreover, the inhibitory potency of LY2039911 toward recombinant human and native BACE1 from mouse or guinea pig was indistinguishable.  In summary, we have demonstrated, for the first time, that recombinant BACE1 can recognize and cleave APP peptide substrates at the postulated β'-cleavage site.  It does not appear to be a significant species specificity to this cleavage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj_CAuH6Gw07Vg90H21EOLACvtfcHk0lhGEIr49fYfSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmslah&md5=77cf9dbc8e90ec9e128cdf97ac9b6d07</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2004.02764.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2004.02764.x%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%2BC.%26aulast%3DChai%26aufirst%3DX.%26aulast%3DMosior%26aufirst%3DM.%26aulast%3DKohn%26aufirst%3DW.%26aulast%3DBoggs%26aufirst%3DL.%2BN.%26aulast%3DErickson%26aufirst%3DJ.%2BA.%26aulast%3DMcClure%26aufirst%3DD.%2BB.%26aulast%3DYeh%26aufirst%3DW.%2BK.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DGonzalez-DeWhitt%26aufirst%3DP.%26aulast%3DMayer%26aufirst%3DJ.%2BP.%26aulast%3DMartin%26aufirst%3DJ.%2BA.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%2BH.%26aulast%3DBueno%26aufirst%3DA.%2BB.%26aulast%3DLittle%26aufirst%3DS.%2BP.%26aulast%3DMcCarthy%26aufirst%3DJ.%2BR.%26aulast%3DMay%26aufirst%3DP.%2BC.%26atitle%3DBiochemical%2520and%2520kinetic%2520characterization%2520of%2520BACE1%253A%2520investigation%2520into%2520the%2520putative%2520species-specificity%2520for%2520beta-%2520and%2520beta%25E2%2580%2599-cleavage%2520sites%2520by%2520human%2520and%2520murine%2520BACE1%26jtitle%3DJ.%2520Neurochem.%26date%3D2004%26volume%3D91%26issue%3D6%26spage%3D1249%26epage%3D59%26doi%3D10.1111%2Fj.1471-4159.2004.02764.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zamek-Gliszczynski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruterbories, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajamie, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickremsinhe, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pothuri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basavanakatti, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinjari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, A. K.</span></span> <span> </span><span class="NLM_article-title">Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>100</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2498</span>– <span class="NLM_lpage">507</span>, <span class="refDoi"> DOI: 10.1002/jps.22452</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1002%2Fjps.22452" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=21213309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC3MXks1Wlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=2498-507&issue=6&author=M.+J.+Zamek-Gliszczynskiauthor=K.+J.+Ruterboriesauthor=R.+T.+Ajamieauthor=E.+R.+Wickremsinheauthor=L.+Pothuriauthor=M.+V.+Raoauthor=V.+N.+Basavanakattiauthor=J.+Pinjariauthor=V.+K.+Ramanathanauthor=A.+K.+Chaudhary&title=Validation+of+96-well+equilibrium+dialysis+with+non-radiolabeled+drug+for+definitive+measurement+of+protein+binding+and+application+to+clinical+development+of+highly-bound+drugs&doi=10.1002%2Fjps.22452"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs</span></div><div class="casAuthors">Zamek-Gliszczynski, Maciej J.; Ruterbories, Kenneth J.; Ajamie, Rose T.; Wickremsinhe, Enaksha R.; Pothuri, Lavanya; Rao, Mukkavilli V. S.; Basavanakatti, Vinay N.; Pinjari, Jakir; Ramanathan, Vikram K.; Chaudhary, Ajai K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2498-2507</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Definitive plasma protein binding (PB) studies in drug development are routinely conducted with radiolabeled material, where the radiochem. purity limits quant. PB measurement.  Recent and emerging regulatory guidances increasingly expect quant. detn. of the fraction unbound (Fu) for key decision making.  In the present study, PB of 11 structurally- and therapeutically-diverse drugs spanning the full range of plasma binding was detd. by equil. dialysis of non-radiolabeled compd. and was validated against the resp. definitive values obtained by accepted radiolabeled protocols.  The extent of plasma binding was in agreement with the radiolabeled studies; however, the methodol. reported herein enables reliable quantification of fraction unbound (Fu) values for highly-bound drugs and is not limited by the radiochem. purity.  In order to meet the rigor of a development study, equil. dialysis of unlabeled drug must be supported by an appropriately validated bioanal. method along with studies to det. compd. soly. and stability in matrix and dialysis buffer, nonspecific binding to the dialysis device, and ability to achieve equil. in the absence of protein.  The presented methodol. establishes an exptl. protocol for definitive PB measurement, which enables quant. detn. of low Fu values, necessary for navigation of new regulatory guidances in clin. drug development. © 2011 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci 100:2498-2507, 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM32vmmYFDz7Vg90H21EOLACvtfcHk0lhGEIr49fYfSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXks1Wlsrk%253D&md5=f4fc7251d5220a0474f4eefb2c7692a8</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Fjps.22452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22452%26sid%3Dliteratum%253Aachs%26aulast%3DZamek-Gliszczynski%26aufirst%3DM.%2BJ.%26aulast%3DRuterbories%26aufirst%3DK.%2BJ.%26aulast%3DAjamie%26aufirst%3DR.%2BT.%26aulast%3DWickremsinhe%26aufirst%3DE.%2BR.%26aulast%3DPothuri%26aufirst%3DL.%26aulast%3DRao%26aufirst%3DM.%2BV.%26aulast%3DBasavanakatti%26aufirst%3DV.%2BN.%26aulast%3DPinjari%26aufirst%3DJ.%26aulast%3DRamanathan%26aufirst%3DV.%2BK.%26aulast%3DChaudhary%26aufirst%3DA.%2BK.%26atitle%3DValidation%2520of%252096-well%2520equilibrium%2520dialysis%2520with%2520non-radiolabeled%2520drug%2520for%2520definitive%2520measurement%2520of%2520protein%2520binding%2520and%2520application%2520to%2520clinical%2520development%2520of%2520highly-bound%2520drugs%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26issue%3D6%26spage%3D2498%26epage%3D507%26doi%3D10.1002%2Fjps.22452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawada, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raub, T. J.</span></span> <span> </span><span class="NLM_article-title">Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1249</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1021/mp300555n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp300555n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1aju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=1249-61&issue=4&author=P.+V.+Desaiauthor=G.+A.+Sawadaauthor=I.+A.+Watsonauthor=T.+J.+Raub&title=Integration+of+in+silico+and+in+vitro+tools+for+scaffold+optimization+during+drug+discovery%3A+predicting+P-glycoprotein+efflux&doi=10.1021%2Fmp300555n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Integration of in Silico and in Vitro Tools for Scaffold Optimization during Drug Discovery: Predicting P-Glycoprotein Efflux</span></div><div class="casAuthors">Desai, Prashant V.; Sawada, Geri A.; Watson, Ian A.; Raub, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1249-1261</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In silico tools are regularly utilized for designing and prioritizing compds. to address challenges related to drug metab. and pharmacokinetics (DMPK) during the process of drug discovery.  P-Glycoprotein (P-gp) is a member of the ATP-binding cassette (ABC) transporters with broad substrate specificity that plays a significant role in absorption and distribution of drugs that are P-gp substrates.  As a result, screening for P-gp transport has now become routine in the drug discovery process.  Typically, bidirectional permeability assays are employed to assess in vitro P-gp efflux.  In this article, we use P-gp as an example to illustrate a well-validated methodol. to effectively integrate in silico and in vitro tools to identify and resolve key barriers during the early stages of drug discovery.  A detailed account of development and application of in silico tools such as simple guidelines based on physicochem. properties and more complex quant. structure-activity relationship (QSAR) models is provided.  The tools were developed based on structurally diverse data for more than 2000 compds. generated using a robust P-gp substrate assay over the past several years.  Anal. of physicochem. properties revealed a significantly lower proportion (<10%) of P-gp substrates among the compds. with topol. polar surface area (TPSA) <60 Å2 and the most basic cpKa <8.  In contrast, this proportion of substrates was greater than 75% for compds. with TPSA >60 Å2 and the most basic cpKa >8.  Among the various QSAR models evaluated to predict P-gp efflux, the Bagging model provided optimum prediction performance for prospective validation based on chronol. test sets.  Four sequential versions of the model were built with increasing nos. of compds. to train the models as new data became available.  Except for the first version with the smallest training set, the QSAR models exhibited robust prediction profiles with pos. prediction values (PPV) and neg. prediction values (NPV) exceeding 80%.  The QSAR model demonstrated better concordance with the manual P-gp substrate assay than an automated P-gp substrate screen.  The in silico and the in vitro tools have been effectively integrated during early stages of drug discovery to resolve P-gp-related challenges exemplified by several case studies.  Key learning based on our experience with P-gp can be widely applicable across other DMPK-related challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Q5Y8HssxH7Vg90H21EOLACvtfcHk0lhTPOkzdVEJQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1aju7o%253D&md5=3bd5239b80270c0f4ed85dffb86704ed</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fmp300555n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp300555n%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DP.%2BV.%26aulast%3DSawada%26aufirst%3DG.%2BA.%26aulast%3DWatson%26aufirst%3DI.%2BA.%26aulast%3DRaub%26aufirst%3DT.%2BJ.%26atitle%3DIntegration%2520of%2520in%2520silico%2520and%2520in%2520vitro%2520tools%2520for%2520scaffold%2520optimization%2520during%2520drug%2520discovery%253A%2520predicting%2520P-glycoprotein%2520efflux%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2013%26volume%3D10%26issue%3D4%26spage%3D1249%26epage%3D61%26doi%3D10.1021%2Fmp300555n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raub, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawada, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasper, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacon, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, G. M.</span></span> <span> </span><span class="NLM_article-title">Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1251</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.025064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1124%2Fdmd.108.025064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=19273529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmslamu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1251-8&issue=6&author=R.+Zhaoauthor=T.+J.+Raubauthor=G.+A.+Sawadaauthor=S.+C.+Kasperauthor=J.+A.+Baconauthor=A.+S.+Bridgesauthor=G.+M.+Pollack&title=Breast+cancer+resistance+protein+interacts+with+various+compounds+in+vitro%2C+but+plays+a+minor+role+in+substrate+efflux+at+the+blood-brain+barrier&doi=10.1124%2Fdmd.108.025064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier</span></div><div class="casAuthors">Zhao, Rong; Raub, Thomas J.; Sawada, Geri A.; Kasper, Steven C.; Bacon, James A.; Bridges, Arlene S.; Pollack, Gary M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1251-1258</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Expression of breast cancer resistance protein (Bcrp) at the blood-brain barrier (BBB) has been revealed recently.  To investigate comprehensively the potential role of Bcrp at the murine BBB, a chem. diverse set of model compds. (cimetidine, alfuzosin, dipyridamole, and LY2228820) was evaluated using a multiexperimental design.  Bcrp1 stably transfected MDCKII cell monolayer transport studies demonstrated that each compd. had affinity for Bcrp and that polarized transport by Bcrp was abolished completely by the Bcrp inhibitor chrysin.  However, none of the compds. differed in brain uptake between Bcrp wild-type and knockout mice under either an in situ brain perfusion or a 24-h s.c. osmotic minipump continuous infusion exptl. paradigm.  In addn., alfuzosin and dipyridamole were shown to undergo transport by P-glycoprotein (P-gp) in an MDCKII-MDR1 cell monolayer model.  Alfuzosin brain uptake was 4-fold higher in mdr1a(-/-) mice than in mdr1a(+/+) mice in in situ and in vivo studies, demonstrating for the first time that it undergoes P-gp-mediated efflux at the BBB.  In contrast, P-gp had no effect on dipyridamole brain penetration in situ or in vivo.  In fact, in situ BBB permeability of these solutes appeared to be primarily dependent on their lipophilicity in the absence of efflux transport, and in situ brain uptake clearance correlated with the intrinsic transcellular passive permeability from in vitro transport and cellular accumulation studies.  In summary, Bcrp mediates in vitro transport of various compds., but seems to play a minimal role at the BBB in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO3WJxNsYgobVg90H21EOLACvtfcHk0lhTPOkzdVEJQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmslamu7g%253D&md5=3c274c38a03cbe512c471d826b2ce9e4</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.025064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.025064%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DRaub%26aufirst%3DT.%2BJ.%26aulast%3DSawada%26aufirst%3DG.%2BA.%26aulast%3DKasper%26aufirst%3DS.%2BC.%26aulast%3DBacon%26aufirst%3DJ.%2BA.%26aulast%3DBridges%26aufirst%3DA.%2BS.%26aulast%3DPollack%26aufirst%3DG.%2BM.%26atitle%3DBreast%2520cancer%2520resistance%2520protein%2520interacts%2520with%2520various%2520compounds%2520in%2520vitro%252C%2520but%2520plays%2520a%2520minor%2520role%2520in%2520substrate%2520efflux%2520at%2520the%2520blood-brain%2520barrier%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26issue%3D6%26spage%3D1251%26epage%3D8%26doi%3D10.1124%2Fdmd.108.025064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, N. F. H.</span>; <span class="NLM_string-name">Raub, T. J.</span>; <span class="NLM_string-name">Burton, P. S.</span>; <span class="NLM_string-name">Barsuhn, C. L.</span></span> <span> </span><span class="NLM_article-title">Quantitative Approaches to Delineate Passive Transport Mechanisms in Cell Culture Monolayers</span>. In  <i>Transport Processes in Pharmaceutical Systems</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, G. L.</span>, <span class="NLM_string-name">Lee, P. I.</span>, <span class="NLM_string-name">Topp, E. M.</span></span>, Eds.; <span class="NLM_publisher-name">Marcel Dekker</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2000</span>; pp  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">316</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=219-316&author=N.+F.+H.+Ho&author=T.+J.+Raub&author=P.+S.+Burton&author=C.+L.+Barsuhnauthor=G.+L.+Gordon&author=P.+I.+Lee&author=E.+M.+Topp&title=Transport+Processes+in+Pharmaceutical+Systems"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DN.%2BF.%2BH.%26atitle%3DQuantitative%2520Approaches%2520to%2520Delineate%2520Passive%2520Transport%2520Mechanisms%2520in%2520Cell%2520Culture%2520Monolayers%26btitle%3DTransport%2520Processes%2520in%2520Pharmaceutical%2520Systems%26aulast%3DGordon%26aufirst%3DG.%2BL.%26pub%3DMarcel%2520Dekker%26date%3D2000%26spage%3D219%26epage%3D316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':[],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0065.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0065.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Previously reported Lilly BACE inhibitors LY2811376 and LY2886721.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray crystal structure of compound <b>5</b> (green) bound to the BACE1 binding site (amino acid residues labeled in yellow, protease pocket labels in red, hydrogen bonds in dashed yellow lines).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> PDB access code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UWV">6UWV</a>, final model derived by molecular replacement and structure refinement from PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UVV">6UVV</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Bu<sub>4</sub>N–Br<sub>3</sub>, MeOH, CH<sub>2</sub>Cl<sub>2</sub>; (b) diallylamine, K<sub>2</sub>CO<sub>3</sub>, ACN, rt; (c) NH<sub>2</sub>OH–HCl, NaOAc, EtOH, 70 °C; (d) xylenes, 150 °C, 35% yield (4 steps); (e) Zn, AcOH, 40 °C; (f) PhCONSC, bis(trimethylsilyl)trifluoroacetamide, THF, rt, 97% (2 steps); (g) 1-chloro-<i>N</i>,<i>N</i>,2-trimethylpropenylamine, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C for 2 h then warmed to rt, 39%; (h) chiral HPLC to separate mix of <i>cis</i>-fused enantiomers; (i) <i>N</i>,<i>N</i>-dimethylbarbituric acid, Pd(Ph<sub>3</sub>)<sub>4</sub>, CHCl<sub>3</sub>, rt; (j) 2-chloropyrimidine, DIEA, 1,4-dioxane, 110 °C, 69% (2 steps); (k) 10% Pd/C, ammonium formate, EtOH, 40 °C, 87%; (l) methoxylamine hydrochloride, pyridine, EtOH, 55 °C, 40%; (m) 1 M HCl in ether, rt, 100%.</p></p></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystal structure of compound <b>6</b> (green) bound to the BACE1 binding site (amino acid residues labeled in yellow, protease pocket labels in red, hydrogen bonds in dashed yellow lines). PDB access code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7MYI">7MYI</a>, final model derived by molecular replacement and structure refinement from PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UVV">6UVV</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>15</b>–<b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, NaI, Et<sub>3</sub>N, DMF; (b) (Boc)<sub>2</sub>O, Et<sub>3</sub>N, EtOH; (c) NaOH, MeOH (d) Piv-Cl, HN(Me)OMe-HCl, Et<sub>3</sub>N, THF; (e) ArLi, THF, −40 °C; (f) Ti(OEt)<sub>4</sub>, DIPEA, toluene, reflux; (g) TFA; CH<sub>2</sub>Cl<sub>2</sub>, rt; (h) 2-chloro-4-fluoropyrimidine, DIEA, NMP, 100 °C; (i) TFA, 60 °C; (j) Zn, AcOH; (k) PhCONSC, THF then CDI rt to reflux; (l) LiOH, MeOH; (m) HCl, CH<sub>2</sub>Cl<sub>2</sub>/Et<sub>2</sub>O; (n) BF<sub>3</sub>-Et<sub>2</sub>O, ArMgBr, CH<sub>2</sub>Cl<sub>2</sub>/THF, −50 °C; (o) Zn, AcOH; (p) PhCONSC, THF; (q) 1-chloro-<i>N</i>,<i>N</i>,2-trimethylpropenylamine, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (r) TMS-I, ACN; (s) 2-chloro-4-fluoropyrimidine, DIEA, NMP, 100 °C; (t) LiOH, MeOH; (u) HCl, CH<sub>2</sub>Cl<sub>2</sub>/Et<sub>2</sub>O.</p></p></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystal structure of compound <b>18</b> (green) bound to the BACE1 binding site. (amino acid residues labeled in yellow, protease pocket labels in red, hydrogen bonds in dashed yellow lines). PDB access code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7MYR">7MYR</a>, final model derived by molecular replacement and structure refinement from PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UVV">6UVV</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>20</b>–<b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Ar–COCl, ACN/EtOH, 50 °C.</p></p></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray crystal structure of compound <b>22</b> (green) bound to the BACE1 binding site. (amino acid residues labeled in yellow, protease pocket labels in red, hydrogen bonds in dashed yellow lines). PDB access code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7MYU">7MYU</a>, final model derived by molecular replacement and structure refinement from PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UVV">6UVV</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Plasma and CSF Aβ 1–<i>x</i> response in beagle dog to 1.5 mg/kg oral dose of LY3202626 (<b>22</b>). Value of **<i>p</i> < 0.01 vs baseline for CSF 6, 12, and 24 h time points [ANOVA; <i>F</i>(5,28) = 9.40, <i>p</i> < 0.001; Dunnett posthoc comparisons] and #<i>p</i> < 0.01 vs baseline for all plasma time points [ANOVA; <i>F</i>(9,49) =43.93, <i>p</i> < 0.0001; Dunnett posthoc comparison]. Data are means ± SE from 5 to 6 dogs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Relationship between total daily dose and change in CSF Aβ for LY3202626 (<b>22</b>). Light blue region represents the 90% confidence interval of the relationship. Vertical bars represent point estimate for doses projected to produce 50, 70, and 90% CSF Aβ reduction. Colored horizontal bars represent the 90% confidence interval around these point estimates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/medium/jm1c00489_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Change in human CSF Aβ concentrations following daily LY3202626 (<b>22</b>) Administration. Concentrations of CSF Aβ<sub>1–40</sub> (○) and Aβ<sub>1–42</sub> (Δ) were measured at baseline and after 14 days of LY3202626 administration. If the post-treatment Aβ concentration was below detectable limits, a value of one-half the lower limit of quantification was used in the calculation, and the value was plotted in red to denote this. Nine healthy subjects were included in each cohort.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00489/20210616/images/large/jm1c00489_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00489&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i95">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52573" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52573" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 53 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, C.</span></span> <i>World Alzheimer Report 2018</i>, <a href="https://www.alzint.org/resource/world-alzheimer-report-2018/" class="extLink">https://www.alzint.org/resource/world-alzheimer-report-2018/</a> (accessed 02-07-2021).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Patterson%2C+C.+World+Alzheimer+Report+2018%2C+https%3A%2F%2Fwww.alzint.org%2Fresource%2Fworld-alzheimer-report-2018%2F+%28accessed+02-07-2021%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DPatterson%26aufirst%3DC.%26jtitle%3DWorld%2520Alzheimer%2520Report%25202018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haass, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajendran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenthaler, S. F.</span></span> <span> </span><span class="NLM_article-title">Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>130</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1111/jnc.12715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1111%2Fjnc.12715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=24646365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVSqtL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2014&pages=4-28&issue=1&author=R.+Vassarauthor=P.+H.+Kuhnauthor=C.+Haassauthor=M.+E.+Kennedyauthor=L.+Rajendranauthor=P.+C.+Wongauthor=S.+F.+Lichtenthaler&title=Function%2C+therapeutic+potential+and+cell+biology+of+BACE+proteases%3A+current+status+and+future+prospects&doi=10.1111%2Fjnc.12715"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects</span></div><div class="casAuthors">Vassar, Robert; Kuhn, Peer-Hendrik; Haass, Christian; Kennedy, Matthew E.; Rajendran, Lawrence; Wong, Philip C.; Lichtenthaler, Stefan F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-28</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The β-site APP cleaving enzymes 1 and 2 (BACE1 and BACE2) were initially identified as transmembrane aspartyl proteases cleaving the amyloid precursor protein (APP).  BACE1 is a major drug target for Alzheimer's disease because BACE1-mediated cleavage of APP is the first step in the generation of the pathogenic amyloid-β peptides.  BACE1, which is highly expressed in the nervous system, is also required for myelination by cleaving neuregulin 1.  Several recent proteomic and in vivo studies using BACE1- and BACE2-deficient mice demonstrate a much wider range of physiol. substrates and functions for both proteases within and outside of the nervous system.  For BACE1 this includes axon guidance, neurogenesis, muscle spindle formation, and neuronal network functions, whereas BACE2 was shown to be involved in pigmentation and pancreatic β-cell function.  This review highlights the recent progress in understanding cell biol., substrates, and functions of BACE proteases and discusses the therapeutic options and potential mechanism-based liabilities, in particular for BACE inhibitors in Alzheimer's disease.  The protease BACE1 is a major drug target in Alzheimer disease.  Together with its homolog BACE2, both proteases have an increasing no. of functions within and outside of the nervous system.  This review highlights recent progress in understanding cell biol., substrates, and functions of BACE proteases and discusses the therapeutic options and potential mechanism-based liabilities, in particular for BACE inhibitors in Alzheimer disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxkCRjc9dYMLVg90H21EOLACvtfcHk0liFu4sSzdjOqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVSqtL7M&md5=79e394bb720ad6639f8efc86138fcd60</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fjnc.12715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.12715%26sid%3Dliteratum%253Aachs%26aulast%3DVassar%26aufirst%3DR.%26aulast%3DKuhn%26aufirst%3DP.%2BH.%26aulast%3DHaass%26aufirst%3DC.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DRajendran%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DLichtenthaler%26aufirst%3DS.%2BF.%26atitle%3DFunction%252C%2520therapeutic%2520potential%2520and%2520cell%2520biology%2520of%2520BACE%2520proteases%253A%2520current%2520status%2520and%2520future%2520prospects%26jtitle%3DJ.%2520Neurochem.%26date%3D2014%26volume%3D130%26issue%3D1%26spage%3D4%26epage%3D28%26doi%3D10.1111%2Fjnc.12715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masters, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selkoe, D. J.</span></span> <span> </span><span class="NLM_article-title">Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">a006262</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a006262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1101%2Fcshperspect.a006262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=22675658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlemtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=a006262&issue=6&author=C.+L.+Mastersauthor=D.+J.+Selkoe&title=Biochemistry+of+amyloid+beta-protein+and+amyloid+deposits+in+Alzheimer+disease&doi=10.1101%2Fcshperspect.a006262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease</span></div><div class="casAuthors">Masters, Colin L.; Selkoe, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">a006262/1-a006262/24</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  Progressive cerebral deposition of the amyloid β-protein (Aβ) in brain regions serving memory and cognition is an invariant and defining feature of Alzheimer disease.  A highly similar but less robust process accompanies brain aging in many nondemented humans, lower primates, and some other mammals.  The discovery of Aβ as the subunit of the amyloid fibrils in meningocerebral blood vessels and parenchymal plaques has led to innumerable studies of its biochem. and potential cytotoxic properties.  Here we will review the discovery of Aβ, numerous aspects of its complex biochem., and current attempts to understand how a range of Aβ assemblies, including sol. oligomers and insol. fibrils, may ppt. and promote neuronal and glial alterations that underlie the development of dementia.  Although the role of Aβ as a key mol. factor in the etiol. of Alzheimer disease remains controversial, clin. trials of amyloid-lowering agents, reviewed elsewhere in this book, are poised to resolve the question of its pathogenic primacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-U4pTuictTrVg90H21EOLACvtfcHk0liFu4sSzdjOqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlemtbc%253D&md5=133fd25f26d01f1c46456744d486bde2</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a006262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a006262%26sid%3Dliteratum%253Aachs%26aulast%3DMasters%26aufirst%3DC.%2BL.%26aulast%3DSelkoe%26aufirst%3DD.%2BJ.%26atitle%3DBiochemistry%2520of%2520amyloid%2520beta-protein%2520and%2520amyloid%2520deposits%2520in%2520Alzheimer%2520disease%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2012%26volume%3D2%26issue%3D6%26spage%3Da006262%26doi%3D10.1101%2Fcshperspect.a006262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Strooper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golde, T.</span></span> <span> </span><span class="NLM_article-title">The secretases: enzymes with therapeutic potential in Alzheimer disease</span>. <i>Nat. Rev. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1038/nrneurol.2009.218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1038%2Fnrneurol.2009.218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=20139999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Ogt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=99-107&issue=2&author=B.+De%0AStrooperauthor=R.+Vassarauthor=T.+Golde&title=The+secretases%3A+enzymes+with+therapeutic+potential+in+Alzheimer+disease&doi=10.1038%2Fnrneurol.2009.218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The secretases: enzymes with therapeutic potential in Alzheimer disease</span></div><div class="casAuthors">De Strooper, Bart; Vassar, Robert; Golde, Todd</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neurology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">99-107</span>CODEN:
                <span class="NLM_cas:coden">NRNACP</span>;
        ISSN:<span class="NLM_cas:issn">1759-4758</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The three secretases that process amyloid precursor protein are central to the generation of amyloid-β, and the accumulation of this peptide in extracellular plaques is one of the hallmarks of Alzheimer disease.  In this Review, De Strooper et al. discuss the evidence that suggests that these enzymes are potential therapeutic targets for Alzheimer disease drug treatments.  The amyloid hypothesis has yielded a series of well-validated candidate drug targets with potential for the treatment of Alzheimer disease (AD).  Three proteases that are involved in the processing of amyloid precursor protein-α-secretase, β-secretase and γ-secretase-are of particular interest as they are central to the generation and modulation of amyloid-β peptide and can be targeted by small compds. in vitro and in vivo.  Given that these proteases also fulfill other important biol. roles, inhibiting their activity will clearly be inherently assocd. with mechanism-based toxicity.  Carefully detg. a suitable therapeutic window and optimizing the selectivity of the drug treatments towards amyloid precursor protein processing might be ways of overcoming this potential complication.  Secretase inhibitors are likely to be the first small-mol. therapies aimed at AD modification that will be fully tested in the clinic.  Success or failure of these first-generation AD therapies will have enormous consequences for further drug development efforts for AD and possibly other neurodegenerative conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQBldqS_TKy7Vg90H21EOLACvtfcHk0liFu4sSzdjOqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Ogt70%253D&md5=40135a0a59da6b70e4856a81ddfa6088</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrneurol.2009.218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrneurol.2009.218%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26aulast%3DVassar%26aufirst%3DR.%26aulast%3DGolde%26aufirst%3DT.%26atitle%3DThe%2520secretases%253A%2520enzymes%2520with%2520therapeutic%2520potential%2520in%2520Alzheimer%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2010%26volume%3D6%26issue%3D2%26spage%3D99%26epage%3D107%26doi%3D10.1038%2Fnrneurol.2009.218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rombouts, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H. J. M.</span></span> <span> </span><span class="NLM_article-title">New evolutions in the BACE1 inhibitor field from 2014 to 2018</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">777</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.12.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1016%2Fj.bmcl.2018.12.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=30709653" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlCmu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=761-777&issue=6&author=C.+C.+Hsiaoauthor=F.+Romboutsauthor=H.+J.+M.+Gijsen&title=New+evolutions+in+the+BACE1+inhibitor+field+from+2014+to+2018&doi=10.1016%2Fj.bmcl.2018.12.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">New evolutions in the BACE1 inhibitor field from 2014 to 2018</span></div><div class="casAuthors">Hsiao, Chien-Chi; Rombouts, Frederik; Gijsen, Harrie J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">761-777</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors offer the potential of disease-modifying treatment for Alzheimer's disease (AD).  Since 2014, major breakthroughs have appeared in the field of BACE1 inhibitors.  This review provides an overview of amidine-based BACE1 inhibitors between 2014 and 2018.  Herein are summarized (i) the structure-activity relationship, (ii) the physiol. results and (iii) the potential risks from a lack of selectivity.  This review also summarizes clin. scope, results and outlook of the compds. that have been or are currently under development in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3OfI_B-BJ-LVg90H21EOLACvtfcHk0lh4CueHgV1lrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlCmu7s%253D&md5=049eda6ce97b31a04b5b579afd3e11e5</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.12.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.12.049%26sid%3Dliteratum%253Aachs%26aulast%3DHsiao%26aufirst%3DC.%2BC.%26aulast%3DRombouts%26aufirst%3DF.%26aulast%3DGijsen%26aufirst%3DH.%2BJ.%2BM.%26atitle%3DNew%2520evolutions%2520in%2520the%2520BACE1%2520inhibitor%2520field%2520from%25202014%2520to%25202018%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26issue%3D6%26spage%3D761%26epage%3D777%26doi%3D10.1016%2Fj.bmcl.2018.12.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rafii, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P. S.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s Disease Clinical Trials: Moving Toward Successful Prevention</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.1007/s40263-018-0598-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1007%2Fs40263-018-0598-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=30560544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCitb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=99-106&issue=2&author=M.+S.+Rafiiauthor=P.+S.+Aisen&title=Alzheimer%E2%80%99s+Disease+Clinical+Trials%3A+Moving+Toward+Successful+Prevention&doi=10.1007%2Fs40263-018-0598-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention</span></div><div class="casAuthors">Rafii, Michael S.; Aisen, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">99-106</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Despite major academic and industry efforts, Alzheimer's disease (AD) remains the only leading cause of death for which no disease-modifying treatment is available.  Disappointing clin. trials over the last several years have led to a growing consensus on the need to intervene earlier in the disease process, before the onset of any clin. symptoms.  However, drug development at this stage is challenging given the difficulty of assessing a therapeutic benefit in subjects who are, by definition, clin. healthy.  The US FDA recently issued new draft guidance for trials in early AD, which revised the taxonomy of AD by recognizing four stages of the disease, including an expanded view of the predementia stage.  These guidelines further advance regulatory support for clin. trials in earlier stages of AD.  We discuss the basis for this change and the impact it may have on early-intervention AD trials as well as on stimulating the need for improved biomarkers and outcome measures that will be required for a disease-modifying drug to win approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsgfxzwW4vNbVg90H21EOLACvtfcHk0lh4CueHgV1lrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCitb7P&md5=d365e2a4b77e65b7c823141bae0074f7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs40263-018-0598-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-018-0598-1%26sid%3Dliteratum%253Aachs%26aulast%3DRafii%26aufirst%3DM.%2BS.%26aulast%3DAisen%26aufirst%3DP.%2BS.%26atitle%3DAlzheimer%25E2%2580%2599s%2520Disease%2520Clinical%2520Trials%253A%2520Moving%2520Toward%2520Successful%2520Prevention%26jtitle%3DCNS%2520Drugs%26date%3D2019%26volume%3D33%26issue%3D2%26spage%3D99%26epage%3D106%26doi%3D10.1007%2Fs40263-018-0598-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imbimbo, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watling, M.</span></span> <span> </span><span class="NLM_article-title">Investigational BACE inhibitors for the treatment of Alzheimer’s disease</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">967</span>– <span class="NLM_lpage">975</span>, <span class="refDoi"> DOI: 10.1080/13543784.2019.1683160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1080%2F13543784.2019.1683160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=31661331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKrurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2019&pages=967-975&issue=11&author=B.+P.+Imbimboauthor=M.+Watling&title=Investigational+BACE+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1080%2F13543784.2019.1683160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational BACE inhibitors for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Imbimbo, Bruno P.; Watling, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">967-975</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : The amyloid hypothesis of Alzheimer's disease (AD) states that brain accumulation of amyloid-β (Aβ) oligomers and sol. aggregates represents the major causal event of the disease.  Several small org. mols. have been synthesized and developed to inhibit the enzyme (β-site amyloid precursor protein cleaving enzyme-1 or BACE1) whose action represents the rate-limiting step in Aβ prodn.: We reviewed the pharmacol. and clin. trials of major BACE1 inhibitors.: In transgenic mouse models of AD, BACE1 inhibitors dose-dependently lower Aβ levels in brain and cerebrospinal fluid (CSF) but the evidence for attenuation or reversal cognitive or behavioral deficits is very scanty.  In AD patients, BACE1 inhibitors robustly lower plasma and CSF Aβ levels and reduce brain plaques but without cognitive, clin., or functional benefit.  To date, seventeen BACE1 inhibitors have failed in double-blind, placebo-controlled clin. trials in patients with mild-to-moderate or prodromal AD, or in cognitively normal subjects at risk of developing AD.  Several of these studies were prematurely interrupted due to toxicity or cognitive and behavioral worsening compared to placebo-treated patients.  Elenbecestat, the last BACE1 inhibitor remaining in late clin. testing for AD, was recently discontinued due to safety concerns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd-eWcjthL-rVg90H21EOLACvtfcHk0lh4CueHgV1lrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKrurvI&md5=2431cce6d4b92d018835eb2ef4a4c0ac</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1080%2F13543784.2019.1683160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2019.1683160%26sid%3Dliteratum%253Aachs%26aulast%3DImbimbo%26aufirst%3DB.%2BP.%26aulast%3DWatling%26aufirst%3DM.%26atitle%3DInvestigational%2520BACE%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2019%26volume%3D28%26issue%3D11%26spage%3D967%26epage%3D975%26doi%3D10.1080%2F13543784.2019.1683160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">May, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martenyi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monk, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathes, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mergott, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith
Labell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhee, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ereshefsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calligaro, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocke, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greg Hall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Citron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span> <span> </span><span class="NLM_article-title">Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">46</span>),  <span class="NLM_fpage">16507</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.3647-11.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1523%2FJNEUROSCI.3647-11.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=22090477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFaksL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=16507-16&issue=46&author=P.+C.+Mayauthor=R.+A.+Deanauthor=S.+L.+Loweauthor=F.+Martenyiauthor=S.+M.+Sheehanauthor=L.+N.+Boggsauthor=S.+A.+Monkauthor=B.+M.+Mathesauthor=D.+J.+Mergottauthor=B.+M.+Watsonauthor=S.+L.+Stoutauthor=D.+E.+Timmauthor=E.+Smith%0ALabellauthor=C.+R.+Gonzalesauthor=M.+Nakanoauthor=S.+S.+Jheeauthor=M.+Yenauthor=L.+Ereshefskyauthor=T.+D.+Lindstromauthor=D.+O.+Calligaroauthor=P.+J.+Cockeauthor=D.+Greg+Hallauthor=S.+Friedrichauthor=M.+Citronauthor=J.+E.+Audia&title=Robust+central+reduction+of+amyloid-beta+in+humans+with+an+orally+available%2C+non-peptidic+beta-secretase+inhibitor&doi=10.1523%2FJNEUROSCI.3647-11.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor</span></div><div class="casAuthors">May, Patrick C.; Dean, Robert A.; Lowe, Stephen L.; Martenyi, Ferenc; Sheehan, Scott M.; Boggs, Leonard N.; Monk, Scott A.; Mathes, Brian M.; Mergott, Dustin J.; Watson, Brian M.; Stout, Stephanie L.; Timm, David E.; LaBell, Elizabeth Smith; Gonzales, Celedon R.; Nakano, Masako; Jhee, Stanford S.; Yen, Mark; Ereshefsky, Larry; Lindstrom, Terry D.; Calligaro, David O.; Cocke, Patrick J.; Hall, D. Greg; Friedrich, Stuart; Citron, Martin; Audia, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">16507-16516</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">According to the amyloid cascade hypothesis, cerebral deposition of amyloid-β peptide (Aβ) is crit. for Alzheimer's disease (AD) pathogenesis.  Aβ generation is initiated when β-secretase (BACE1) cleaves the amyloid precursor protein.  For more than a decade, BACE1 has been a prime target for designing drugs to prevent or treat AD.  However, development of such agents has turned out to be extremely challenging, with major hurdles in cell penetration, oral bioavailability/metabolic clearance, and brain access.  Using a fragment-based chem. strategy, we have generated LY2811376 [(S)-4-(2,4-difluoro-5-pyrimidin-5-yl-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]thiazin-2-ylamine], the first orally available non-peptidic BACE1 inhibitor that produces profound Aβ-lowering effects in animals.  The biomarker changes obtained in preclin. animal models translate into man at doses of LY2811376 that were safe and well tolerated in healthy volunteers.  Prominent and long-lasting Aβ redns. in lumbar CSF were measured after oral dosing of 30 or 90 mg of LY2811376.  This represents the first translation of BACE1-driven biomarker changes in CNS from preclin. animal models to man.  Because of toxicol. findings identified in longer-term preclin. studies, this compd. is no longer progressing in clin. development.  However, BACE1 remains a viable target because the adverse effects reported here were recapitulated in LY2811376-treated BACE1 KO mice and thus are unrelated to BACE1 inhibition.  The magnitude and duration of central Aβ redn. obtainable with BACE1 inhibition positions this protease as a tractable small-mol. target through which to test the amyloid hypothesis in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqns_TvT2bZrVg90H21EOLACvtfcHk0lh4CueHgV1lrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFaksL7F&md5=8f21f91ebd77e5fcf8b58b51c73a1a6b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.3647-11.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.3647-11.2011%26sid%3Dliteratum%253Aachs%26aulast%3DMay%26aufirst%3DP.%2BC.%26aulast%3DDean%26aufirst%3DR.%2BA.%26aulast%3DLowe%26aufirst%3DS.%2BL.%26aulast%3DMartenyi%26aufirst%3DF.%26aulast%3DSheehan%26aufirst%3DS.%2BM.%26aulast%3DBoggs%26aufirst%3DL.%2BN.%26aulast%3DMonk%26aufirst%3DS.%2BA.%26aulast%3DMathes%26aufirst%3DB.%2BM.%26aulast%3DMergott%26aufirst%3DD.%2BJ.%26aulast%3DWatson%26aufirst%3DB.%2BM.%26aulast%3DStout%26aufirst%3DS.%2BL.%26aulast%3DTimm%26aufirst%3DD.%2BE.%26aulast%3DSmith%2BLabell%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DC.%2BR.%26aulast%3DNakano%26aufirst%3DM.%26aulast%3DJhee%26aufirst%3DS.%2BS.%26aulast%3DYen%26aufirst%3DM.%26aulast%3DEreshefsky%26aufirst%3DL.%26aulast%3DLindstrom%26aufirst%3DT.%2BD.%26aulast%3DCalligaro%26aufirst%3DD.%2BO.%26aulast%3DCocke%26aufirst%3DP.%2BJ.%26aulast%3DGreg%2BHall%26aufirst%3DD.%26aulast%3DFriedrich%26aufirst%3DS.%26aulast%3DCitron%26aufirst%3DM.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26atitle%3DRobust%2520central%2520reduction%2520of%2520amyloid-beta%2520in%2520humans%2520with%2520an%2520orally%2520available%252C%2520non-peptidic%2520beta-secretase%2520inhibitor%26jtitle%3DJ.%2520Neurosci.%26date%3D2011%26volume%3D31%26issue%3D46%26spage%3D16507%26epage%3D16%26doi%3D10.1523%2FJNEUROSCI.3647-11.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">May, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monk, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocke, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borders, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brier, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calligaro, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ereshefsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gevorkyan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhee, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komjathy, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathes, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martenyi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaught, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winneroski, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mergott, D. J.</span></span> <span> </span><span class="NLM_article-title">The potent BACE1 inhibitor LY2886721 elicits robust central Abeta pharmacodynamic responses in mice, dogs, and humans</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.4129-14.2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1523%2FJNEUROSCI.4129-14.2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=25609634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Oit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=1199-210&issue=3&author=P.+C.+Mayauthor=B.+A.+Willisauthor=S.+L.+Loweauthor=R.+A.+Deanauthor=S.+A.+Monkauthor=P.+J.+Cockeauthor=J.+E.+Audiaauthor=L.+N.+Boggsauthor=A.+R.+Bordersauthor=R.+A.+Brierauthor=D.+O.+Calligaroauthor=T.+A.+Dayauthor=L.+Ereshefskyauthor=J.+A.+Ericksonauthor=H.+Gevorkyanauthor=C.+R.+Gonzalesauthor=D.+E.+Jamesauthor=S.+S.+Jheeauthor=S.+F.+Komjathyauthor=L.+Liauthor=T.+D.+Lindstromauthor=B.+M.+Mathesauthor=F.+Martenyiauthor=S.+M.+Sheehanauthor=S.+L.+Stoutauthor=D.+E.+Timmauthor=G.+M.+Vaughtauthor=B.+M.+Watsonauthor=L.+L.+Winneroskiauthor=Z.+Yangauthor=D.+J.+Mergott&title=The+potent+BACE1+inhibitor+LY2886721+elicits+robust+central+Abeta+pharmacodynamic+responses+in+mice%2C+dogs%2C+and+humans&doi=10.1523%2FJNEUROSCI.4129-14.2015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans</span></div><div class="casAuthors">May, Patrick C.; Willis, Brian A.; Lowe, Stephen L.; Dean, Robert A.; Monk, Scott A.; Cocke, Patrick J.; Audia, James E.; Boggs, Leonard N.; Borders, Anthony R.; Brier, Richard A.; Calligaro, David O.; Day, Theresa A.; Ereshefsky, Larry; Erickso, Jon A.; Gevorkyan, Hykop; Gonzales, Celedon R.; James, Douglas E.; Jhee, Stanford S.; Komjathy, Steven F.; Li, Linglin; Lindstrom, Terry D.; Mathe, Brian M.; Martenyi, Ferenc; Sheehan, Scott M.; Stout, Stephanie L.; Timm, David E.; Vaught, Grant M.; Watson, Brian M.; Winneroski, Leonard L.; Yang, Zhixiang; Mergott, Dustin J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1199-1210, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">BACE1 is a key protease controlling the formation of amyloid β, a peptide hypothesized to play a significant role in the pathogenesis of Alzheimer's disease (AD).  Therefore, the development of potent and selective inhibitors of BACE1 has been a focus of many drug discovery efforts in academia and industry.  Herein, we report the nonclin. and early clin. development of LY2886721, a BACE1 active site inhibitor that reached phase 2 clin. trials in AD.  LY2886721 has high selectivity against key off-target proteases, which efficiently translates in vitro activity into robust in vivo amyloid β lowering in nonclin. animal models.  Similar potent and persistent amyloid β lowering was obsd. in plasma and lumbar CSF when single and multiple doses of LY2886721 were administered to healthy human subjects.  Collectively, these data add support for BACE1 inhibition as an effective means of amyloid lowering and as an attractive target for potential disease modification therapy in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDDFLhcsiUDLVg90H21EOLACvtfcHk0lhwzgm8Oo_DiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Oit78%253D&md5=7e16cc00767a8af4da7dd17b6e40e8f5</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4129-14.2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4129-14.2015%26sid%3Dliteratum%253Aachs%26aulast%3DMay%26aufirst%3DP.%2BC.%26aulast%3DWillis%26aufirst%3DB.%2BA.%26aulast%3DLowe%26aufirst%3DS.%2BL.%26aulast%3DDean%26aufirst%3DR.%2BA.%26aulast%3DMonk%26aufirst%3DS.%2BA.%26aulast%3DCocke%26aufirst%3DP.%2BJ.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DBoggs%26aufirst%3DL.%2BN.%26aulast%3DBorders%26aufirst%3DA.%2BR.%26aulast%3DBrier%26aufirst%3DR.%2BA.%26aulast%3DCalligaro%26aufirst%3DD.%2BO.%26aulast%3DDay%26aufirst%3DT.%2BA.%26aulast%3DEreshefsky%26aufirst%3DL.%26aulast%3DErickson%26aufirst%3DJ.%2BA.%26aulast%3DGevorkyan%26aufirst%3DH.%26aulast%3DGonzales%26aufirst%3DC.%2BR.%26aulast%3DJames%26aufirst%3DD.%2BE.%26aulast%3DJhee%26aufirst%3DS.%2BS.%26aulast%3DKomjathy%26aufirst%3DS.%2BF.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLindstrom%26aufirst%3DT.%2BD.%26aulast%3DMathes%26aufirst%3DB.%2BM.%26aulast%3DMartenyi%26aufirst%3DF.%26aulast%3DSheehan%26aufirst%3DS.%2BM.%26aulast%3DStout%26aufirst%3DS.%2BL.%26aulast%3DTimm%26aufirst%3DD.%2BE.%26aulast%3DVaught%26aufirst%3DG.%2BM.%26aulast%3DWatson%26aufirst%3DB.%2BM.%26aulast%3DWinneroski%26aufirst%3DL.%2BL.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMergott%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520potent%2520BACE1%2520inhibitor%2520LY2886721%2520elicits%2520robust%2520central%2520Abeta%2520pharmacodynamic%2520responses%2520in%2520mice%252C%2520dogs%252C%2520and%2520humans%26jtitle%3DJ.%2520Neurosci.%26date%3D2015%26volume%3D35%26issue%3D3%26spage%3D1199%26epage%3D210%26doi%3D10.1523%2FJNEUROSCI.4129-14.2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lammert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einarsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niklasson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span> <span> </span><span class="NLM_article-title">Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2003</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1002/hep.22272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1002%2Fhep.22272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=18454504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVagt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=2003-9&issue=6&author=C.+Lammertauthor=S.+Einarssonauthor=C.+Sahaauthor=A.+Niklassonauthor=E.+Bjornssonauthor=N.+Chalasani&title=Relationship+between+daily+dose+of+oral+medications+and+idiosyncratic+drug-induced+liver+injury%3A+search+for+signals&doi=10.1002%2Fhep.22272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals</span></div><div class="casAuthors">Lammert, Craig; Einarsson, Stefan; Saha, Chandan; Niklasson, Anna; Bjornsson, Einar; Chalasani, Naga</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2003-2009</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Idiosyncratic drug-induced liver injury (DILI) is traditionally thought not to be dose-related.  However, it has been pointed out that most medicines that were withdrawn from marketing or received a black-box warning because of hepatotoxicity were prescribed at daily doses greater than 50 mg/day.  To examine the relationship between daily dose of medications and idiosyncratic DILI, we conducted a study with two aims.  First, using two pharmaceutical databases, we examd. the relationship between daily dose of commonly prescribed medicines in the United States and reported frequency of their selected hepatic adverse events.  Second, we examd. serious DILI cases reported to the Swedish Adverse Drug Reactions Advisory Committee (1970-2004) for any signals supporting the relationship between daily dose and idiosyncratic DILI.  Medications were categorized into ≤10 mg/day, 11-49 mg/day, and ≥50 mg/day groups.  Among US prescription medicines, a statistically significant relationship was obsd. between daily dose of oral medicines and reports of liver failure (P = 0.009), liver transplantation (P < 0.001), and death caused by DILI (P = 0.004) but not alanine aminotransferase (ALT) > 3 × upper limit of normal (P = 0.10) or jaundice (P = 0.16).  Of 598 eligible Swedish DILI cases, 9% belonged to the ≤10 mg/day group, 14.2% to the 11-49 mg/day group, and 77% of cases were caused by medications given at dose ≥50 mg/day.  A statistically significant relationship was noted between daily dose and poor outcome (death or liver transplantation) of Swedish DILI cases (2%, 9.4%, and 13.2% in ≤10, 11-49, and ≥50 mg/day groups, resp., P = 0.03).  Conclusion: These data suggest a relationship between daily doses of oral prescription medications and idiosyncratic DILI.  More studies are needed to validate these observations and to explore their implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-pByO6X3Hk7Vg90H21EOLACvtfcHk0lhwzgm8Oo_DiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVagt7w%253D&md5=f497d61a5253cc653c2d955232471d65</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fhep.22272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.22272%26sid%3Dliteratum%253Aachs%26aulast%3DLammert%26aufirst%3DC.%26aulast%3DEinarsson%26aufirst%3DS.%26aulast%3DSaha%26aufirst%3DC.%26aulast%3DNiklasson%26aufirst%3DA.%26aulast%3DBjornsson%26aufirst%3DE.%26aulast%3DChalasani%26aufirst%3DN.%26atitle%3DRelationship%2520between%2520daily%2520dose%2520of%2520oral%2520medications%2520and%2520idiosyncratic%2520drug-induced%2520liver%2520injury%253A%2520search%2520for%2520signals%26jtitle%3DHepatology%26date%3D2008%26volume%3D47%26issue%3D6%26spage%3D2003%26epage%3D9%26doi%3D10.1002%2Fhep.22272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winneroski, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barberis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borders, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brier, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hembre, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Losada, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minguez, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathes, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monk, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mergott, D. J.</span></span> <span> </span><span class="NLM_article-title">Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">115194</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.115194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1016%2Fj.bmc.2019.115194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=31786008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit12jur7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115194&issue=1&author=L.+L.+Winneroskiauthor=J.+A.+Ericksonauthor=S.+J.+Greenauthor=J.+E.+Lopezauthor=S.+L.+Stoutauthor=W.+J.+Porterauthor=D.+E.+Timmauthor=J.+E.+Audiaauthor=M.+Barberisauthor=J.+P.+Beckauthor=L.+N.+Boggsauthor=A.+R.+Bordersauthor=R.+D.+Boyerauthor=R.+A.+Brierauthor=E.+J.+Hembreauthor=J.+Hendleauthor=P.+Garcia-Losadaauthor=J.+M.+Minguezauthor=B.+M.+Mathesauthor=P.+C.+Mayauthor=S.+A.+Monkauthor=Z.+Rankovicauthor=Y.+Shiauthor=B.+M.+Watsonauthor=Z.+Yangauthor=D.+J.+Mergott&title=Preparation+and+biological+evaluation+of+BACE1+inhibitors%3A+Leveraging+trans-cyclopropyl+moieties+as+ligand+efficient+conformational+constraints&doi=10.1016%2Fj.bmc.2019.115194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints</span></div><div class="casAuthors">Winneroski, Leonard L.; Erickson, Jon A.; Green, Steven J.; Lopez, Jose E.; Stout, Stephanie L.; Porter, Warren J.; Timm, David E.; Audia, James E.; Barberis, Mario; Beck, James P.; Boggs, Leonard N.; Borders, Anthony R.; Boyer, Robert D.; Brier, Richard A.; Hembre, Erik J.; Hendle, Jorg; Garcia-Losada, Pablo; Minguez, Jose Miguel; Mathes, Brian M.; May, Patrick C.; Monk, Scott A.; Rankovic, Zoran; Shi, Yuan; Watson, Brian M.; Yang, Zhixiang; Mergott, Dustin J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115194</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inhibition of BACE1 has become an important strategy in the quest for disease modifying agents to slow the progression of Alzheimer's disease.  We previously reported the fragment-based discovery of LY2811376, the first BACE1 inhibitor reported to demonstrate robust redn. of human CSF Aβ in a Phase I clin. trial.  We also reported on the discovery of LY2886721, a potent BACE1 inhibitor that reached phase 2 clin. trials.  Herein we describe the prepn. and structure activity relationships (SAR) of a series of BACE1 inhibitors utilizing trans-cyclopropyl moieties as conformational constraints.  The design, details of the stereochem. complex org. synthesis, and biol. activity of these BACE1 inhibitors is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFZW_6anOjqLVg90H21EOLACvtfcHk0lhUue2gTBP12g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit12jur7L&md5=733e23af182c6b5d262e4563fa18117a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.115194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.115194%26sid%3Dliteratum%253Aachs%26aulast%3DWinneroski%26aufirst%3DL.%2BL.%26aulast%3DErickson%26aufirst%3DJ.%2BA.%26aulast%3DGreen%26aufirst%3DS.%2BJ.%26aulast%3DLopez%26aufirst%3DJ.%2BE.%26aulast%3DStout%26aufirst%3DS.%2BL.%26aulast%3DPorter%26aufirst%3DW.%2BJ.%26aulast%3DTimm%26aufirst%3DD.%2BE.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DBarberis%26aufirst%3DM.%26aulast%3DBeck%26aufirst%3DJ.%2BP.%26aulast%3DBoggs%26aufirst%3DL.%2BN.%26aulast%3DBorders%26aufirst%3DA.%2BR.%26aulast%3DBoyer%26aufirst%3DR.%2BD.%26aulast%3DBrier%26aufirst%3DR.%2BA.%26aulast%3DHembre%26aufirst%3DE.%2BJ.%26aulast%3DHendle%26aufirst%3DJ.%26aulast%3DGarcia-Losada%26aufirst%3DP.%26aulast%3DMinguez%26aufirst%3DJ.%2BM.%26aulast%3DMathes%26aufirst%3DB.%2BM.%26aulast%3DMay%26aufirst%3DP.%2BC.%26aulast%3DMonk%26aufirst%3DS.%2BA.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DWatson%26aufirst%3DB.%2BM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMergott%26aufirst%3DD.%2BJ.%26atitle%3DPreparation%2520and%2520biological%2520evaluation%2520of%2520BACE1%2520inhibitors%253A%2520Leveraging%2520trans-cyclopropyl%2520moieties%2520as%2520ligand%2520efficient%2520conformational%2520constraints%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26issue%3D1%26spage%3D115194%26doi%3D10.1016%2Fj.bmc.2019.115194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="note"><p class="first last">For an example of different SAR using a bicyclic iminopyrimidinone which appeared after this work was completed, see:</p></div><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mandal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzola, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzelak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuvelkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favreau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buevich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazakevich, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKittrick, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamford, A. W.</span></span> <span> </span><span class="NLM_article-title">Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9331</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1021/jm301039c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301039c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGktb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9331-45&issue=21&author=M.+Mandalauthor=Z.+Zhuauthor=J.+N.+Cummingauthor=X.+Liuauthor=C.+Stricklandauthor=R.+D.+Mazzolaauthor=J.+P.+Caldwellauthor=P.+Leachauthor=M.+Grzelakauthor=L.+Hydeauthor=Q.+Zhangauthor=G.+Terracinaauthor=L.+Zhangauthor=X.+Chenauthor=R.+Kuvelkarauthor=M.+E.+Kennedyauthor=L.+Favreauauthor=K.+Coxauthor=P.+Orthauthor=A.+Buevichauthor=J.+Voigtauthor=H.+Wangauthor=I.+Kazakevichauthor=B.+A.+McKittrickauthor=W.+Greenleeauthor=E.+M.+Parkerauthor=A.+W.+Stamford&title=Design+and+validation+of+bicyclic+iminopyrimidinones+as+beta+amyloid+cleaving+enzyme-1+%28BACE1%29+inhibitors%3A+conformational+constraint+to+favor+a+bioactive+conformation&doi=10.1021%2Fjm301039c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Validation of Bicyclic Iminopyrimidinones As Beta Amyloid Cleaving Enzyme-1 (BACE1) Inhibitors: Conformational Constraint to Favor a Bioactive Conformation</span></div><div class="casAuthors">Mandal, Mihirbaran; Zhu, Zhaoning; Cumming, Jared N.; Liu, Xiaoxiang; Strickland, Corey; Mazzola, Robert D.; Caldwell, John P.; Leach, Prescott; Grzelak, Michael; Hyde, Lynn; Zhang, Qi; Terracina, Giuseppe; Zhang, Lili; Chen, Xia; Kuvelkar, Reshma; Kennedy, Matthew E.; Favreau, Leonard; Cox, Kathleen; Orth, Peter; Buevich, Alexei; Voigt, Johannes; Wang, Hongwu; Kazakevich, Irina; McKittrick, Brian A.; Greenlee, William; Parker, Eric M.; Stamford, Andrew W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9331-9345</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of our observation that the biaryl substituent of iminopyrimidinone 7 must be in a pseudoaxial conformation to occupy the contiguous S1-S3 subsites of BACE1, we have designed a novel fused bicyclic iminopyrimidinone scaffold intended to favor this bioactive conformation.  Strategic incorporation of a nitrogen atom in the new constrained ring allowed us to develop SAR around the S2' binding pocket and ultimately resulted in analogs with low nanomolar potency for BACE1.  In particular, optimization of the prime side substituent led to major improvements in potency by displacement of two conserved water mols. from a region near S2'.  Further optimization of the pharmacokinetic properties of this fused pyrrolidine series, in conjunction with facile access to a rat pharmacodynamic model, led to identification of compd. 43, which is an orally active, brain penetrant inhibitor that reduces Aβ40 in the plasma, CSF, and cortex of rats in a dose-dependent manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprlJsgY-3wuLVg90H21EOLACvtfcHk0lhUue2gTBP12g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGktb%252FP&md5=6fd0bc5ac847ded7e235939594d4b20d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm301039c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301039c%26sid%3Dliteratum%253Aachs%26aulast%3DMandal%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DCumming%26aufirst%3DJ.%2BN.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DStrickland%26aufirst%3DC.%26aulast%3DMazzola%26aufirst%3DR.%2BD.%26aulast%3DCaldwell%26aufirst%3DJ.%2BP.%26aulast%3DLeach%26aufirst%3DP.%26aulast%3DGrzelak%26aufirst%3DM.%26aulast%3DHyde%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DTerracina%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DKuvelkar%26aufirst%3DR.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DFavreau%26aufirst%3DL.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DOrth%26aufirst%3DP.%26aulast%3DBuevich%26aufirst%3DA.%26aulast%3DVoigt%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DKazakevich%26aufirst%3DI.%26aulast%3DMcKittrick%26aufirst%3DB.%2BA.%26aulast%3DGreenlee%26aufirst%3DW.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26atitle%3DDesign%2520and%2520validation%2520of%2520bicyclic%2520iminopyrimidinones%2520as%2520beta%2520amyloid%2520cleaving%2520enzyme-1%2520%2528BACE1%2529%2520inhibitors%253A%2520conformational%2520constraint%2520to%2520favor%2520a%2520bioactive%2520conformation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D21%26spage%3D9331%26epage%3D45%26doi%3D10.1021%2Fjm301039c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="note"><p class="first last">For an example of different SAR using a bicyclic iminopyrimidinone which appeared after this work was completed, see:</p></div><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mandal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misiaszek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buevich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzola, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzelak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuvelkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michener, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favreau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazakevich, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKittrick, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamford, A. W.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of an Iminoheterocyclic beta-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Abeta in Nonhuman Primates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3231</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01995</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01995" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsFaqur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3231-48&issue=7&author=M.+Mandalauthor=Y.+Wuauthor=J.+Misiaszekauthor=G.+Liauthor=A.+Buevichauthor=J.+P.+Caldwellauthor=X.+Liuauthor=R.+D.+Mazzolaauthor=P.+Orthauthor=C.+Stricklandauthor=J.+Voigtauthor=H.+Wangauthor=Z.+Zhuauthor=X.+Chenauthor=M.+Grzelakauthor=L.+A.+Hydeauthor=R.+Kuvelkarauthor=P.+T.+Leachauthor=G.+Terracinaauthor=L.+Zhangauthor=Q.+Zhangauthor=M.+S.+Michenerauthor=B.+Smithauthor=K.+Coxauthor=D.+Grotzauthor=L.+Favreauauthor=K.+Mitraauthor=I.+Kazakevichauthor=B.+A.+McKittrickauthor=W.+Greenleeauthor=M.+E.+Kennedyauthor=E.+M.+Parkerauthor=J.+N.+Cummingauthor=A.+W.+Stamford&title=Structure-Based+Design+of+an+Iminoheterocyclic+beta-Site+Amyloid+Precursor+Protein+Cleaving+Enzyme+%28BACE%29+Inhibitor+that+Lowers+Central+Abeta+in+Nonhuman+Primates&doi=10.1021%2Facs.jmedchem.5b01995"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates</span></div><div class="casAuthors">Mandal, Mihirbaran; Wu, Yusheng; Misiaszek, Jeffrey; Li, Guoqing; Buevich, Alexei; Caldwell, John P.; Liu, Xiaoxiang; Mazzola, Robert D.; Orth, Peter; Strickland, Corey; Voigt, Johannes; Wang, Hongwu; Zhu, Zhaoning; Chen, Xia; Grzelak, Michael; Hyde, Lynn A.; Kuvelkar, Reshma; Leach, Prescott T.; Terracina, Giuseppe; Zhang, Lili; Zhang, Qi; Michener, Maria S.; Smith, Brad; Cox, Kathleen; Grotz, Diane; Favreau, Leonard; Mitra, Kaushik; Kazakevich, Irina; McKittrick, Brian A.; Greenlee, William; Kennedy, Matthew E.; Parker, Eric M.; Cumming, Jared N.; Stamford, Andrew W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3231-3248</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe successful efforts to optimize the in vivo profile and address off-target liabilities of a series of BACE1 inhibitors represented by 6 that embodies the recently validated fused pyrrolidine iminopyrimidinone scaffold.  Employing structure-based design, truncation of the cyanophenyl group of I that binds in the S3 pocket of BACE1 followed by modification of the thienyl group in S1 was pursued.  Optimization of the pyrimidine substituent that binds in the S2'-S2'' pocket of BACE1 remediated time-dependent CYP3A4 inhibition of earlier analogs in this series and imparted high BACE1 affinity.  These efforts resulted in the discovery of difluorophenyl analog II (MBi-4), which robustly lowered CSF and cortex Aβ40 in both rats and cynomolgus monkeys following a single oral dose.  II represents a unique mol. shape among BACE inhibitors reported to potently lower central Aβ in nonrodent preclin. species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoscm_jumartLVg90H21EOLACvtfcHk0ljLogvckmfKMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsFaqur4%253D&md5=7715946acdd54d5b11d856a37e1ef0a2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01995%26sid%3Dliteratum%253Aachs%26aulast%3DMandal%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DMisiaszek%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DBuevich%26aufirst%3DA.%26aulast%3DCaldwell%26aufirst%3DJ.%2BP.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DMazzola%26aufirst%3DR.%2BD.%26aulast%3DOrth%26aufirst%3DP.%26aulast%3DStrickland%26aufirst%3DC.%26aulast%3DVoigt%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGrzelak%26aufirst%3DM.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DKuvelkar%26aufirst%3DR.%26aulast%3DLeach%26aufirst%3DP.%2BT.%26aulast%3DTerracina%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DMichener%26aufirst%3DM.%2BS.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DGrotz%26aufirst%3DD.%26aulast%3DFavreau%26aufirst%3DL.%26aulast%3DMitra%26aufirst%3DK.%26aulast%3DKazakevich%26aufirst%3DI.%26aulast%3DMcKittrick%26aufirst%3DB.%2BA.%26aulast%3DGreenlee%26aufirst%3DW.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DCumming%26aufirst%3DJ.%2BN.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26atitle%3DStructure-Based%2520Design%2520of%2520an%2520Iminoheterocyclic%2520beta-Site%2520Amyloid%2520Precursor%2520Protein%2520Cleaving%2520Enzyme%2520%2528BACE%2529%2520Inhibitor%2520that%2520Lowers%2520Central%2520Abeta%2520in%2520Nonhuman%2520Primates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D7%26spage%3D3231%26epage%3D48%26doi%3D10.1021%2Facs.jmedchem.5b01995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="note"><p class="first last">LEAN (ligand efficiency by atom number) = −log(IC<sub>50</sub>)/<i>N</i>, where <i>N</i> is the number of heavy (non-hydrogen) atoms and IC<sub>50</sub> is in M.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fielden, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamison, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coppi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, R. T.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trueblood, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afshari, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightfoot-Dunn, R.</span></span> <span> </span><span class="NLM_article-title">Retinal Toxicity Induced by a Novel beta-secretase Inhibitor in the Sprague-Dawley Rat</span>. <i>Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1177/0192623314553804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1177%2F0192623314553804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=25361751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVCqu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=581-92&issue=4&author=M.+R.+Fieldenauthor=J.+Wernerauthor=J.+A.+Jamisonauthor=A.+Coppiauthor=D.+Hickmanauthor=R.+T.+Dunnauthor=E.+Truebloodauthor=L.+Zhouauthor=C.+A.+Afshariauthor=R.+Lightfoot-Dunn&title=Retinal+Toxicity+Induced+by+a+Novel+beta-secretase+Inhibitor+in+the+Sprague-Dawley+Rat&doi=10.1177%2F0192623314553804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Retinal toxicity induced by a novel β-secretase inhibitor in the sprague-dawley rat</span></div><div class="casAuthors">Fielden, Mark R.; Werner, Jonathan; Jamison, Jeff A.; Coppi, Aldo; Hickman, Dean; Dunn, Robert T., II; Trueblood, Esther; Zhou, Lei; Afshari, Cynthia A.; Lightfoot-Dunn, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">581-592</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">β-Secretase 1 (BACE1) represents an attractive target for the treatment of Alzheimer's disease.  In the course of development of a novel small mol. BACE1 inhibitor (AMG-8718), retinal thinning was obsd. in a 1-mo toxicity study in the rat.  To further understand the lesion, an investigational study was conducted whereby rats were treated daily with AMG-8718 for 1 mo followed by a 2-mo treatment-free phase.  The earliest detectable change in the retina was an increase in autofluorescent granules in the retinal pigment epithelium (RPE) on day 5; however, there were no treatment-related light microscopic changes obsd. in the neuroretina and no changes obsd. by fundus autofluorescence or routine ophthalmoscopic examn. after 28 days of dosing.  Following 2 mo of recovery, there was significant retinal thinning attributed to loss of photoreceptor nuclei from the outer nuclear layer.  Electroretinog. changes were obsd. as early as day 14, before any microscopic evidence of photoreceptor loss.  BACE1 knockout rats were generated and found to have normal retinal morphol. indicating that the retinal toxicity induced by AMG-8718 was likely off-target.  These results suggest that AMG-8718 impairs phagolysosomal function in the rat RPE, which leads to photoreceptor dysfunction and ultimately loss of photoreceptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfyBfTezUdUrVg90H21EOLACvtfcHk0ljLogvckmfKMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVCqu7fP&md5=d6f4af801e795995739478385f5e36fd</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1177%2F0192623314553804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623314553804%26sid%3Dliteratum%253Aachs%26aulast%3DFielden%26aufirst%3DM.%2BR.%26aulast%3DWerner%26aufirst%3DJ.%26aulast%3DJamison%26aufirst%3DJ.%2BA.%26aulast%3DCoppi%26aufirst%3DA.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DDunn%26aufirst%3DR.%2BT.%26aulast%3DTrueblood%26aufirst%3DE.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DAfshari%26aufirst%3DC.%2BA.%26aulast%3DLightfoot-Dunn%26aufirst%3DR.%26atitle%3DRetinal%2520Toxicity%2520Induced%2520by%2520a%2520Novel%2520beta-secretase%2520Inhibitor%2520in%2520the%2520Sprague-Dawley%2520Rat%26jtitle%3DToxicol.%2520Pathol.%26date%3D2015%26volume%3D43%26issue%3D4%26spage%3D581%26epage%3D92%26doi%3D10.1177%2F0192623314553804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuhl, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atchison, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanian, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambroise, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brulet, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Am Ende, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoghegan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judkins, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span> <span> </span><span class="NLM_article-title">Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of beta-secretase inhibitors</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13042</span>, <span class="refDoi"> DOI: 10.1038/ncomms13042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1038%2Fncomms13042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=27727204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1GqtbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13042&author=A.+M.+Zuhlauthor=C.+E.+Nolanauthor=M.+A.+Brodneyauthor=S.+Niessenauthor=K.+Atchisonauthor=C.+Houleauthor=D.+A.+Karanianauthor=C.+Ambroiseauthor=J.+W.+Bruletauthor=E.+M.+Beckauthor=S.+D.+Doranauthor=B.+T.+O%E2%80%99Neillauthor=C.+W.+Am+Endeauthor=C.+Changauthor=K.+F.+Geogheganauthor=G.+M.+Westauthor=J.+C.+Judkinsauthor=X.+Houauthor=D.+R.+Riddellauthor=D.+S.+Johnson&title=Chemoproteomic+profiling+reveals+that+cathepsin+D+off-target+activity+drives+ocular+toxicity+of+beta-secretase+inhibitors&doi=10.1038%2Fncomms13042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors</span></div><div class="casAuthors">Zuhl, Andrea M.; Nolan, Charles E.; Brodney, Michael A.; Niessen, Sherry; Atchison, Kevin; Houle, Christopher; Karanian, David A.; Ambroise, Claude; Brulet, Jeffrey W.; Beck, Elizabeth M.; Doran, Shawn D.; O'Neill, Brian T.; am Ende, Christopher W.; Chang, Cheng; Geoghegan, Kieran F.; West, Graham M.; Judkins, Joshua C.; Hou, Xinjun; Riddell, David R.; Johnson, Douglas S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13042</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibition of β-secretase BACE1 is considered one of the most promising approaches for treating Alzheimer's disease.  Several structurally distinct BACE1 inhibitors have been withdrawn from development after inducing ocular toxicity in animal models, but the target mediating this toxicity has not been identified.  Here we use a clickable photoaffinity probe to identify cathepsin D (CatD) as a principal off-target of BACE1 inhibitors in human cells.  We find that several BACE1 inhibitors blocked CatD activity in cells with much greater potency than that displayed in cell-free assays with purified protein.  Through a series of exploratory toxicol. studies, we show that quantifying CatD target engagement in cells with the probe is predictive of ocular toxicity in vivo.  Taken together, our findings designate off-target inhibition of CatD as a principal driver of ocular toxicity for BACE1 inhibitors and more generally underscore the power of chem. proteomics for discerning mechanisms of drug action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-LulGVRdJLVg90H21EOLACvtfcHk0ljLogvckmfKMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1GqtbbL&md5=5e2c31195f4f03babec561a5824ccb0d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fncomms13042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13042%26sid%3Dliteratum%253Aachs%26aulast%3DZuhl%26aufirst%3DA.%2BM.%26aulast%3DNolan%26aufirst%3DC.%2BE.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DAtchison%26aufirst%3DK.%26aulast%3DHoule%26aufirst%3DC.%26aulast%3DKaranian%26aufirst%3DD.%2BA.%26aulast%3DAmbroise%26aufirst%3DC.%26aulast%3DBrulet%26aufirst%3DJ.%2BW.%26aulast%3DBeck%26aufirst%3DE.%2BM.%26aulast%3DDoran%26aufirst%3DS.%2BD.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DB.%2BT.%26aulast%3DAm%2BEnde%26aufirst%3DC.%2BW.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DGeoghegan%26aufirst%3DK.%2BF.%26aulast%3DWest%26aufirst%3DG.%2BM.%26aulast%3DJudkins%26aufirst%3DJ.%2BC.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DRiddell%26aufirst%3DD.%2BR.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26atitle%3DChemoproteomic%2520profiling%2520reveals%2520that%2520cathepsin%2520D%2520off-target%2520activity%2520drives%2520ocular%2520toxicity%2520of%2520beta-secretase%2520inhibitors%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D13042%26doi%3D10.1038%2Fncomms13042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koike, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakanishi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saftig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohsawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz-Schaeffer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waguri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kametaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kominami, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Figura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">6898</span>– <span class="NLM_lpage">906</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.20-18-06898.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1523%2FJNEUROSCI.20-18-06898.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10995834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmvVGhsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=6898-906&issue=18&author=M.+Koikeauthor=H.+Nakanishiauthor=P.+Saftigauthor=J.+Ezakiauthor=K.+Isaharaauthor=Y.+Ohsawaauthor=W.+Schulz-Schaefferauthor=T.+Watanabeauthor=S.+Waguriauthor=S.+Kametakaauthor=M.+Shibataauthor=K.+Yamamotoauthor=E.+Kominamiauthor=C.+Petersauthor=K.+von+Figuraauthor=Y.+Uchiyama&title=Cathepsin+D+deficiency+induces+lysosomal+storage+with+ceroid+lipofuscin+in+mouse+CNS+neurons&doi=10.1523%2FJNEUROSCI.20-18-06898.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons</span></div><div class="casAuthors">Koike, Masato; Nakanishi, Hiroshi; Saftig, Paul; Ezaki, Junji; Isahara, Kyoko; Ohsawa, Yoshiyuki; Schulz-Schaeffer, Walter; Watanabe, Tsuyoshi; Waguri, Satoshi; Kametaka, Satoshi; Shibata, Masahiro; Yamamoto, Kenji; Kominami, Eiki; Peters, Christoph; Von Figura, Kurt; Uchiyama, Yasuo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6898-6906</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Cathepsin D-deficient (CD-/-) mice have been shown to manifest seizures and become blind near the terminal stage [approx. postnatal day (P) 26].  We therefore examd. the morphol., immunocytochem., and biochem. features of CNS tissues of these mice.  By electron microscopy, autophagosome/autolysosome-like bodies contg. part of the cytoplasm, granular osmiophilic deposits, and fingerprint profiles were demonstrated in the neuronal perikarya of CD-/- mouse brains after P20.  Autophagosomes and granular osmiophilic deposits were detected in neurons at P0 but were few in no., whereas they increased in the neuronal perikarya within days after birth.  Some large-sized neurons having autophagosome/autolysosome-like bodies in the perikarya appeared in the CNS tissues, esp. in the thalamic region and the cerebral cortex, at P17.  These lysosomal bodies occupied the perikarya of almost all neurons in CD-/- mouse brains obtained from P23 until the terminal stage.  Because these neurons exhibited autofluorescence, it was considered that ceroid lipofuscin may accumulate in lysosomal structures of CD-/- neurons.  Subunit c of mitochondrial ATP synthase was found to accumulate in the lysosomes of neurons, although the activity of tripeptidyl peptidase-I significantly increased in the brain.  Moreover, neurons near the terminal stage were often shrunken and possessed irregular nuclei through which small dense chromatin masses were scattered.  These results suggest that the CNS neurons in CD-/- mice show a new form of lysosomal accumulation disease with a phenotype resembling neuronal ceroid lipofuscinosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsG5BWz7IR-LVg90H21EOLACvtfcHk0lgTgTdXGKugSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmvVGhsrc%253D&md5=6515642d9cfc62e6c7fe3ed44d6b5a11</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.20-18-06898.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.20-18-06898.2000%26sid%3Dliteratum%253Aachs%26aulast%3DKoike%26aufirst%3DM.%26aulast%3DNakanishi%26aufirst%3DH.%26aulast%3DSaftig%26aufirst%3DP.%26aulast%3DEzaki%26aufirst%3DJ.%26aulast%3DIsahara%26aufirst%3DK.%26aulast%3DOhsawa%26aufirst%3DY.%26aulast%3DSchulz-Schaeffer%26aufirst%3DW.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DWaguri%26aufirst%3DS.%26aulast%3DKametaka%26aufirst%3DS.%26aulast%3DShibata%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DKominami%26aufirst%3DE.%26aulast%3DPeters%26aufirst%3DC.%26aulast%3Dvon%2BFigura%26aufirst%3DK.%26aulast%3DUchiyama%26aufirst%3DY.%26atitle%3DCathepsin%2520D%2520deficiency%2520induces%2520lysosomal%2520storage%2520with%2520ceroid%2520lipofuscin%2520in%2520mouse%2520CNS%2520neurons%26jtitle%3DJ.%2520Neurosci.%26date%3D2000%26volume%3D20%26issue%3D18%26spage%3D6898%26epage%3D906%26doi%3D10.1523%2FJNEUROSCI.20-18-06898.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinfeld, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhardt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillebrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraetzner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruck, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saftig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gartner, J.</span></span> <span> </span><span class="NLM_article-title">Cathepsin D deficiency is associated with a human neurodegenerative disorder</span>. <i>Am. J. Hum. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">988</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1086/504159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1086%2F504159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=16685649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD28XltVyks78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2006&pages=988-98&issue=6&author=R.+Steinfeldauthor=K.+Reinhardtauthor=K.+Schreiberauthor=M.+Hillebrandauthor=R.+Kraetznerauthor=W.+Bruckauthor=P.+Saftigauthor=J.+Gartner&title=Cathepsin+D+deficiency+is+associated+with+a+human+neurodegenerative+disorder&doi=10.1086%2F504159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin D deficiency is associated with a human neurodegenerative disorder</span></div><div class="casAuthors">Steinfeld, Robert; Reinhardt, Konstanze; Schreiber, Kathrin; Hillebrand, Merle; Kraetzner, Ralph; Brueck, Wolfgang; Saftig, Paul; Gaertner, Jutta</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">988-998</span>CODEN:
                <span class="NLM_cas:coden">AJHGAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9297</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Cathepsin D is a ubiquitously expressed lysosomal protease that is involved in proteolytic degrdn., cell invasion, and apoptosis.  In mice and sheep, cathepsin D deficiency is known to cause a fatal neurodegenerative disease.  Here, we report a novel disorder in a child with early blindness and progressive psychomotor disability.  Two missense mutations in the CTSD gene, F229I and W383C, were identified and were found to cause markedly reduced proteolytic activity and a diminished amt. of cathepsin D in patient fibroblasts.  Expression of cathepsin D mutants in cathepsin D-/- mouse fibroblasts revealed disturbed posttranslational processing and intracellular targeting for W383C and diminished maximal enzyme velocity for F229I.  The structural effects of cathepsin D mutants were estd. by computer modeling, which suggested larger structural alterations for W383C than for F229I.  Our studies broaden the group of human neurodegenerative disorders and add new insight into the cellular functions of human cathepsin D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohf0ApK0eyVLVg90H21EOLACvtfcHk0lgTgTdXGKugSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltVyks78%253D&md5=96a9bf74f1823244552ed50391eb5278</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1086%2F504159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F504159%26sid%3Dliteratum%253Aachs%26aulast%3DSteinfeld%26aufirst%3DR.%26aulast%3DReinhardt%26aufirst%3DK.%26aulast%3DSchreiber%26aufirst%3DK.%26aulast%3DHillebrand%26aufirst%3DM.%26aulast%3DKraetzner%26aufirst%3DR.%26aulast%3DBruck%26aufirst%3DW.%26aulast%3DSaftig%26aufirst%3DP.%26aulast%3DGartner%26aufirst%3DJ.%26atitle%3DCathepsin%2520D%2520deficiency%2520is%2520associated%2520with%2520a%2520human%2520neurodegenerative%2520disorder%26jtitle%3DAm.%2520J.%2520Hum.%2520Genet.%26date%3D2006%26volume%3D78%26issue%3D6%26spage%3D988%26epage%3D98%26doi%3D10.1086%2F504159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tyynela, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleat, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gin, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haltia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobel, P.</span></span> <span> </span><span class="NLM_article-title">A mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2786</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1093/emboj/19.12.2786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1093%2Femboj%2F19.12.2786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10856224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtFCru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=2786-92&issue=12&author=J.+Tyynelaauthor=I.+Soharauthor=D.+E.+Sleatauthor=R.+M.+Ginauthor=R.+J.+Donnellyauthor=M.+Baumannauthor=M.+Haltiaauthor=P.+Lobel&title=A+mutation+in+the+ovine+cathepsin+D+gene+causes+a+congenital+lysosomal+storage+disease+with+profound+neurodegeneration&doi=10.1093%2Femboj%2F19.12.2786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration</span></div><div class="casAuthors">Tyynela, Jaana; Sohar, Istvan; Sleat, David E.; Gin, Rosalie M.; Donnelly, Robert J.; Baumann, Marc; Haltia, Matti; Lobel, Peter</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2786-2792</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The neuronal ceroid lipofuscinoses (NCLs) constitute a group of neurodegenerative storage diseases characterized by progressive psychomotor retardation, blindness and premature death.  Pathol., there is accumulation of autofluorescent material in lysosome-derived organelles in a variety of cell types, but neurons in the central nervous system appear to be selectively affected and undergo progressive death.  In this report the authors show that a novel form of NCL, congenital ovine NCL, is caused by a deficiency in the lysosomal aspartyl proteinase cathepsin D.  A single nucleotide mutation in the cathepsin D gene results in conversion of an active site aspartate to asparagine, leading to prodn. of an enzymically inactive but stable protein.  This results in severe cerebrocortical atrophy and early death, providing strong evidence for an important role of cathepsin D in neuronal development and/or homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-SI1vEX1-ALVg90H21EOLACvtfcHk0lgTgTdXGKugSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtFCru7s%253D&md5=f6eecb4cdd579513f194312cbca20730</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F19.12.2786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F19.12.2786%26sid%3Dliteratum%253Aachs%26aulast%3DTyynela%26aufirst%3DJ.%26aulast%3DSohar%26aufirst%3DI.%26aulast%3DSleat%26aufirst%3DD.%2BE.%26aulast%3DGin%26aufirst%3DR.%2BM.%26aulast%3DDonnelly%26aufirst%3DR.%2BJ.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DHaltia%26aufirst%3DM.%26aulast%3DLobel%26aufirst%3DP.%26atitle%3DA%2520mutation%2520in%2520the%2520ovine%2520cathepsin%2520D%2520gene%2520causes%2520a%2520congenital%2520lysosomal%2520storage%2520disease%2520with%2520profound%2520neurodegeneration%26jtitle%3DEMBO%2520J.%26date%3D2000%26volume%3D19%26issue%3D12%26spage%3D2786%26epage%3D92%26doi%3D10.1093%2Femboj%2F19.12.2786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span> <span> </span><span class="NLM_article-title">Conformational dynamics of cathepsin D and binding to a small-molecule BACE1 inhibitor</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">1260</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.1002/jcc.24719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1002%2Fjcc.24719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=28370344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsV2jsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=1260-1269&issue=15&author=C.+R.+Ellisauthor=C.+C.+Tsaiauthor=F.+Y.+Linauthor=J.+Shen&title=Conformational+dynamics+of+cathepsin+D+and+binding+to+a+small-molecule+BACE1+inhibitor&doi=10.1002%2Fjcc.24719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational dynamics of cathepsin D and binding to a small-molecule BACE1 inhibitor</span></div><div class="casAuthors">Ellis, Christopher R.; Tsai, Cheng-Chieh; Lin, Fang-Yu; Shen, Jana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1260-1269</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">BACE1 is a major therapeutic target for prevention and treatment of Alzheimer's disease.  Developing inhibitors that can selectively target BACE1 in favor of other proteases, esp. cathepsin D (CatD), has presented significant challenges.  Here, the authors investigate the conformational dynamics and protonation states of BACE1 and CatD using continuous const. pH mol. dynamics with pH replica-exchange sampling protocol.  Despite similar structure, BACE1 and CatD exhibit markedly different active site dynamics.  BACE1 displays pH-dependent flap dynamics that controls substrate accessibility, while the CatD flap is relatively rigid and remains open in the pH range 2.5-6.  Interestingly, although each protease hydrolyzes peptide bonds, the protonation states of the catalytic dyads are different within the active pH range.  The acidic and basic components of the BACE1 catalytic dyad are clear, while either aspartic acid of the CatD catalytic dyad could play the role of acid or base.  Finally, the authors investigate binding of the inhibitor LY2811376 developed by Eli Lilly to BACE1 and CatD.  Surprisingly, in the enzyme active pH range, LY2811376 forms a stronger salt bridge with the catalytic dyad in CatD than in BACE1, which might explain the retinal toxicity of the inhibitor related to off-target inhibition of CatD.  This work highlights the complexity and challenge in structure-based drug design where receptor-ligand binding induces protonation state change in both the protein and the inhibitor. © 2017 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqzUs1RP_fBLVg90H21EOLACvtfcHk0ljJsPnUfum8fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsV2jsLo%253D&md5=bf7903e2c8828a3bfa2b2a14b9a1ec6b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fjcc.24719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.24719%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DC.%2BR.%26aulast%3DTsai%26aufirst%3DC.%2BC.%26aulast%3DLin%26aufirst%3DF.%2BY.%26aulast%3DShen%26aufirst%3DJ.%26atitle%3DConformational%2520dynamics%2520of%2520cathepsin%2520D%2520and%2520binding%2520to%2520a%2520small-molecule%2520BACE1%2520inhibitor%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2017%26volume%3D38%26issue%3D15%26spage%3D1260%26epage%3D1269%26doi%3D10.1002%2Fjcc.24719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Polo, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boya, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauleau, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalil, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larochette, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souquere, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eskelinen, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saftig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">3091</span>– <span class="NLM_lpage">102</span>, <span class="refDoi"> DOI: 10.1242/jcs.02447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1242%2Fjcs.02447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=15985464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD2MXosVemtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2005&pages=3091-102&author=R.+A.+Gonzalez-Poloauthor=P.+Boyaauthor=A.+L.+Pauleauauthor=A.+Jalilauthor=N.+Larochetteauthor=S.+Souquereauthor=E.+L.+Eskelinenauthor=G.+Pierronauthor=P.+Saftigauthor=G.+Kroemer&title=The+apoptosis%2Fautophagy+paradox%3A+autophagic+vacuolization+before+apoptotic+death&doi=10.1242%2Fjcs.02447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The apoptosis/autophagy paradox: Autophagic vacuolization before apoptotic death</span></div><div class="casAuthors">Gonzalez-Polo, Rosa-Ana; Boya, Patricia; Pauleau, Anne-Laure; Jalil, Abdelali; Larochette, Nathanael; Souquere, Sylvie; Eskelinen, Eeva-Liisa; Pierron, Gerard; Saftig, Paul; Kroemer, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3091-3102</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Autophagic cell death is morphol. characterized by an accumulation of autophagic vacuoles.  Here, we show that inactivation of LAMP2 by RNA interference or by homologous recombination leads to autophagic vacuolization in nutrient-depleted cells.  Cells that lack LAMP2 expression showed an enhanced accumulation of vacuoles carrying the marker LC3, yet a decreased colocalization of LC3 and lysosomes, suggesting that the fusion between autophagic vacuoles and lysosomes was inhibited.  While a fraction of mitochondria from starved LAMP2-expressing cells colocalized with lysosomal markers, within autophagolysosomes, no such colocalization was found on removal of LAMP2 from the exptl. system.  Of note, LAMP1 depletion had no such effects and did not aggravate the phenotype induced by LAMP2-specific small interfering RNA.  Serum and amino acid-starved LAMP2-neg. cells exhibited an accumulation of autophagic vacuoles and then succumbed to cell death with hallmarks of apoptosis such as loss of the mitochondrial transmembrane potential, caspase activation and chromatin condensation.  While caspase inhibition retarded cell death, it had no protective effect on mitochondria.  Stabilization of mitochondria by overexpression of Bcl-2 or the mitochondrion-targeted cytomegalovirus protein vMIA, however, blocked all signs of apoptosis.  Neither caspase inhibition nor mitochondrial stabilization antagonized autophagic vacuolization in LAMP2-deficient cells.  Altogether, these data indicate that accumulation of autophagic vacuoles can precede apoptotic cell death.  These findings argue against the clear-cut distinction between type 1 (apoptotic) and type 2 (autophagic) cell death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFwZpnW6oPorVg90H21EOLACvtfcHk0ljJsPnUfum8fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXosVemtbY%253D&md5=6d85b66e3fd8a75dc1d52d1347086e72</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1242%2Fjcs.02447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.02447%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Polo%26aufirst%3DR.%2BA.%26aulast%3DBoya%26aufirst%3DP.%26aulast%3DPauleau%26aufirst%3DA.%2BL.%26aulast%3DJalil%26aufirst%3DA.%26aulast%3DLarochette%26aufirst%3DN.%26aulast%3DSouquere%26aufirst%3DS.%26aulast%3DEskelinen%26aufirst%3DE.%2BL.%26aulast%3DPierron%26aufirst%3DG.%26aulast%3DSaftig%26aufirst%3DP.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DThe%2520apoptosis%252Fautophagy%2520paradox%253A%2520autophagic%2520vacuolization%2520before%2520apoptotic%2520death%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2005%26volume%3D118%26spage%3D3091%26epage%3D102%26doi%3D10.1242%2Fjcs.02447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzon, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutra, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barreiro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Alsina, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogilvie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaChapelle, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanyon, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steppan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robshaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hales, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambroise, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bales, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4476</span>– <span class="NLM_lpage">4504</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00246</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00246" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4476-4504&issue=10&author=B.+T.+O%E2%80%99Neillauthor=E.+M.+Beckauthor=C.+R.+Butlerauthor=C.+E.+Nolanauthor=C.+Gonzalesauthor=L.+Zhangauthor=S.+D.+Doranauthor=K.+Laphamauthor=L.+M.+Buzonauthor=J.+K.+Dutraauthor=G.+Barreiroauthor=X.+Houauthor=L.+A.+Martinez-Alsinaauthor=B.+N.+Rogersauthor=A.+Villalobosauthor=J.+C.+Murrayauthor=K.+Ogilvieauthor=E.+A.+LaChapelleauthor=C.+Changauthor=L.+F.+Lanyonauthor=C.+M.+Steppanauthor=A.+Robshawauthor=K.+Halesauthor=G.+G.+Boucherauthor=K.+Pandherauthor=C.+Houleauthor=C.+W.+Ambroiseauthor=D.+Karanianauthor=D.+Riddellauthor=K.+R.+Balesauthor=M.+A.+Brodney&title=Design+and+Synthesis+of+Clinical+Candidate+PF-06751979%3A+A+Potent%2C+Brain+Penetrant%2C+beta-Site+Amyloid+Precursor+Protein+Cleaving+Enzyme+1+%28BACE1%29+Inhibitor+Lacking+Hypopigmentation&doi=10.1021%2Facs.jmedchem.8b00246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation</span></div><div class="casAuthors">O'Neill, Brian T.; Beck, Elizabeth M.; Butler, Christopher R.; Nolan, Charles E.; Gonzales, Cathleen; Zhang, Lei; Doran, Shawn D.; Lapham, Kimberly; Buzon, Leanne M.; Dutra, Jason K.; Barreiro, Gabriela; Hou, Xinjun; Martinez-Alsina, Luis A.; Rogers, Bruce N.; Villalobos, Anabella; Murray, John C.; Ogilvie, Kevin; La Chapelle, Erik A.; Chang, Cheng; Lanyon, Lorraine F.; Steppan, Claire M.; Robshaw, Ashley; Hales, Katherine; Boucher, Germaine G.; Pandher, Karamjeet; Houle, Christopher; Ambroise, Claude W.; Karanian, David; Riddell, David; Bales, Kelly R.; Brodney, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4476-4504</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A major challenge in the development of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease is the alignment of potency, drug-like properties, and selectivity over related aspartyl proteases such as Cathepsin D (CatD) and BACE2.  The potential liabilities of inhibiting BACE2 chronically have only recently begun to emerge as BACE2 impacts the processing of the premelanosome protein (PMEL17) and disrupts melanosome morphol. resulting in a depigmentation phenotype.  Herein, the authors describe the identification of clin. candidate PF-06751979 (I), which displays excellent brain penetration, potent in vivo efficacy, and broad selectivity over related aspartyl proteases including BACE2.  Chronic dosing of I for up to 9 mo in dog did not reveal any observation of hair coat color (pigmentation) changes and suggests a key differentiator over current BACE1 inhibitors that are nonselective against BACE2 in later stage clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs1F61vo0jBbVg90H21EOLACvtfcHk0ljJsPnUfum8fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCmtrs%253D&md5=3d8cae0bb20298e66f6da1c26cf8d5bc</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00246%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DB.%2BT.%26aulast%3DBeck%26aufirst%3DE.%2BM.%26aulast%3DButler%26aufirst%3DC.%2BR.%26aulast%3DNolan%26aufirst%3DC.%2BE.%26aulast%3DGonzales%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DDoran%26aufirst%3DS.%2BD.%26aulast%3DLapham%26aufirst%3DK.%26aulast%3DBuzon%26aufirst%3DL.%2BM.%26aulast%3DDutra%26aufirst%3DJ.%2BK.%26aulast%3DBarreiro%26aufirst%3DG.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DMartinez-Alsina%26aufirst%3DL.%2BA.%26aulast%3DRogers%26aufirst%3DB.%2BN.%26aulast%3DVillalobos%26aufirst%3DA.%26aulast%3DMurray%26aufirst%3DJ.%2BC.%26aulast%3DOgilvie%26aufirst%3DK.%26aulast%3DLaChapelle%26aufirst%3DE.%2BA.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DLanyon%26aufirst%3DL.%2BF.%26aulast%3DSteppan%26aufirst%3DC.%2BM.%26aulast%3DRobshaw%26aufirst%3DA.%26aulast%3DHales%26aufirst%3DK.%26aulast%3DBoucher%26aufirst%3DG.%2BG.%26aulast%3DPandher%26aufirst%3DK.%26aulast%3DHoule%26aufirst%3DC.%26aulast%3DAmbroise%26aufirst%3DC.%2BW.%26aulast%3DKaranian%26aufirst%3DD.%26aulast%3DRiddell%26aufirst%3DD.%26aulast%3DBales%26aufirst%3DK.%2BR.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Clinical%2520Candidate%2520PF-06751979%253A%2520A%2520Potent%252C%2520Brain%2520Penetrant%252C%2520beta-Site%2520Amyloid%2520Precursor%2520Protein%2520Cleaving%2520Enzyme%25201%2520%2528BACE1%2529%2520Inhibitor%2520Lacking%2520Hypopigmentation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D10%26spage%3D4476%26epage%3D4504%26doi%3D10.1021%2Facs.jmedchem.8b00246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hilpert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guba, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woltering, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wostl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayweg, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers-Evans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humm, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krummenacher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnider, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozmen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergadano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochstrasser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David-Pierson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narquizian, R.</span></span> <span> </span><span class="NLM_article-title">beta-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">3980</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1021/jm400225m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400225m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVymuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3980-95&issue=10&author=H.+Hilpertauthor=W.+Gubaauthor=T.+J.+Wolteringauthor=W.+Wostlauthor=E.+Pinardauthor=H.+Mauserauthor=A.+V.+Maywegauthor=M.+Rogers-Evansauthor=R.+Hummauthor=D.+Krummenacherauthor=T.+Muserauthor=C.+Schniderauthor=H.+Jacobsenauthor=L.+Ozmenauthor=A.+Bergadanoauthor=D.+W.+Bannerauthor=R.+Hochstrasserauthor=A.+Kuglstatterauthor=P.+David-Piersonauthor=H.+Fischerauthor=A.+Polaraauthor=R.+Narquizian&title=beta-Secretase+%28BACE1%29+inhibitors+with+high+in+vivo+efficacy+suitable+for+clinical+evaluation+in+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm400225m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer's Disease</span></div><div class="casAuthors">Hilpert, Hans; Guba, Wolfgang; Woltering, Thomas J.; Wostl, Wolfgang; Pinard, Emmanuel; Mauser, Harald; Mayweg, Alexander V.; Rogers-Evans, Mark; Humm, Roland; Krummenacher, Daniela; Muser, Thorsten; Schnider, Christian; Jacobsen, Helmut; Ozmen, Laurence; Bergadano, Alessandra; Banner, David W.; Hochstrasser, Remo; Kuglstatter, Andreas; David-Pierson, Pascale; Fischer, Holger; Polara, Alessandra; Narquizian, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3980-3995</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An extensive fluorine scan of 1,3-oxazines revealed the power of fluorine(s) to lower the pKa and thereby dramatically change the pharmacol. profile of this class of BACE1 inhibitors.  The CF3 substituted oxazine 89, a potent and highly brain penetrant BACE1 inhibitor, was able to reduce significantly CSF Aβ40 and 42 in rats at oral doses as low as 1 mg/kg.  The effect was long lasting, showing a significant redn. of Aβ40 and 42 even after 24 h.  In contrast to 89, compd. 1b lacking the CF3 group was virtually inactive in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmoKRrAxxHErVg90H21EOLACvtfcHk0ljB7vCyN5BGNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVymuro%253D&md5=e5d311d1c8fecfaed043d3a0bf16c168</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm400225m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400225m%26sid%3Dliteratum%253Aachs%26aulast%3DHilpert%26aufirst%3DH.%26aulast%3DGuba%26aufirst%3DW.%26aulast%3DWoltering%26aufirst%3DT.%2BJ.%26aulast%3DWostl%26aufirst%3DW.%26aulast%3DPinard%26aufirst%3DE.%26aulast%3DMauser%26aufirst%3DH.%26aulast%3DMayweg%26aufirst%3DA.%2BV.%26aulast%3DRogers-Evans%26aufirst%3DM.%26aulast%3DHumm%26aufirst%3DR.%26aulast%3DKrummenacher%26aufirst%3DD.%26aulast%3DMuser%26aufirst%3DT.%26aulast%3DSchnider%26aufirst%3DC.%26aulast%3DJacobsen%26aufirst%3DH.%26aulast%3DOzmen%26aufirst%3DL.%26aulast%3DBergadano%26aufirst%3DA.%26aulast%3DBanner%26aufirst%3DD.%2BW.%26aulast%3DHochstrasser%26aufirst%3DR.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DDavid-Pierson%26aufirst%3DP.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DPolara%26aufirst%3DA.%26aulast%3DNarquizian%26aufirst%3DR.%26atitle%3Dbeta-Secretase%2520%2528BACE1%2529%2520inhibitors%2520with%2520high%2520in%2520vivo%2520efficacy%2520suitable%2520for%2520clinical%2520evaluation%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D10%26spage%3D3980%26epage%3D95%26doi%3D10.1021%2Fjm400225m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rombouts, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tresadern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Lamenca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Gool, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Molina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso de Diego, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehlrich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prokopcova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghys, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Brandt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surkyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Cleyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moechars, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trabanco, A. A.</span></span> <span> </span><span class="NLM_article-title">1,4-Oxazine beta-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8216</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01101</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01101" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFWktL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8216-35&issue=20&author=F.+J.+Romboutsauthor=G.+Tresadernauthor=O.+Delgadoauthor=C.+Martinez-Lamencaauthor=M.+Van+Goolauthor=A.+Garcia-Molinaauthor=S.+A.+Alonso+de+Diegoauthor=D.+Oehlrichauthor=H.+Prokopcovaauthor=J.+M.+Alonsoauthor=N.+Austinauthor=H.+Borghysauthor=S.+Van+Brandtauthor=M.+Surkynauthor=M.+De+Cleynauthor=A.+Vosauthor=R.+Alexanderauthor=G.+Macdonaldauthor=D.+Moecharsauthor=H.+Gijsenauthor=A.+A.+Trabanco&title=1%2C4-Oxazine+beta-Secretase+1+%28BACE1%29+Inhibitors%3A+From+Hit+Generation+to+Orally+Bioavailable+Brain+Penetrant+Leads&doi=10.1021%2Facs.jmedchem.5b01101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads</span></div><div class="casAuthors">Rombouts, Frederik J. R.; Tresadern, Gary; Delgado, Oscar; Martinez-Lamenca, Carolina; Van Gool, Michiel; Garcia-Molina, Aranzazu; Alonso de Diego, Sergio A.; Oehlrich, Daniel; Prokopcova, Hana; Alonso, Jose Manuel; Austin, Nigel; Borghys, Herman; Van Brandt, Sven; Surkyn, Michel; De Cleyn, Michel; Vos, Ann; Alexander, Richard; Macdonald, Gregor; Moechars, Dieder; Gijsen, Harrie; Trabanco, Andres A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8216-8235</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1,4-Oxazines are presented, which show good in vitro inhibition in enzymic and cellular BACE1 assays.  We describe lead optimization focused on reducing the amidine pKa while optimizing interactions in the BACE1 active site.  Our strategy permitted modulation of properties such as permeation and esp. P-glycoprotein efflux.  This led to compds. which were orally bioavailable, centrally active, and which demonstrated robust lowering of brain and CSF Aβ levels, resp., in mouse and dog models.  The amyloid lowering potential of these mols. makes them valuable leads in the search for new BACE1 inhibitors for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHVm9JF2kNa7Vg90H21EOLACvtfcHk0ljB7vCyN5BGNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFWktL3L&md5=d3563a26a17a1c86c45a4f99b18be251</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01101%26sid%3Dliteratum%253Aachs%26aulast%3DRombouts%26aufirst%3DF.%2BJ.%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DDelgado%26aufirst%3DO.%26aulast%3DMartinez-Lamenca%26aufirst%3DC.%26aulast%3DVan%2BGool%26aufirst%3DM.%26aulast%3DGarcia-Molina%26aufirst%3DA.%26aulast%3DAlonso%2Bde%2BDiego%26aufirst%3DS.%2BA.%26aulast%3DOehlrich%26aufirst%3DD.%26aulast%3DProkopcova%26aufirst%3DH.%26aulast%3DAlonso%26aufirst%3DJ.%2BM.%26aulast%3DAustin%26aufirst%3DN.%26aulast%3DBorghys%26aufirst%3DH.%26aulast%3DVan%2BBrandt%26aufirst%3DS.%26aulast%3DSurkyn%26aufirst%3DM.%26aulast%3DDe%2BCleyn%26aufirst%3DM.%26aulast%3DVos%26aufirst%3DA.%26aulast%3DAlexander%26aufirst%3DR.%26aulast%3DMacdonald%26aufirst%3DG.%26aulast%3DMoechars%26aufirst%3DD.%26aulast%3DGijsen%26aufirst%3DH.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26atitle%3D1%252C4-Oxazine%2520beta-Secretase%25201%2520%2528BACE1%2529%2520Inhibitors%253A%2520From%2520Hit%2520Generation%2520to%2520Orally%2520Bioavailable%2520Brain%2520Penetrant%2520Leads%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D20%26spage%3D8216%26epage%3D35%26doi%3D10.1021%2Facs.jmedchem.5b01101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ploemen, J.-P. H.T.M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Sandt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Burgsteden, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salemink, P. J.M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van
Esch, E.</span></span> <span> </span><span class="NLM_article-title">Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines</span>. <i>Exp. Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">355</span>, <span class="refDoi"> DOI: 10.1078/0940-2993-00338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1078%2F0940-2993-00338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=15088636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksFGltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2004&pages=347-355&issue=5&author=J.-P.+H.T.M.+Ploemenauthor=J.+Kelderauthor=T.+Hafmansauthor=H.+van+de+Sandtauthor=J.+A.+van+Burgstedenauthor=P.+J.M.+Saleminkauthor=E.+van%0AEsch&title=Use+of+physicochemical+calculation+of+pKa+and+CLogP+to+predict+phospholipidosis-inducing+potential%3A+a+case+study+with+structurally+related+piperazines&doi=10.1078%2F0940-2993-00338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines</span></div><div class="casAuthors">Ploemen, Jan-Peter H. T. M.; Kelder, Jan; Hafmans, Theo; van de Sandt, Han; van Burgsteden, Johan A.; Salemink, Paul J. M.; van Esch, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">347-355</span>CODEN:
                <span class="NLM_cas:coden">ETPAEK</span>;
        ISSN:<span class="NLM_cas:issn">0940-2993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Several cationic amphiphilic compds. are known to induce phospholipidosis, a condition primarily characterized by excessive accumulation of phospholipids in different cell types, giving the affected cells a finely foamy appearance.  Excessive storage of lamellar membranous intralysosomal inclusion bodies is the hallmark for phospholipidosis on the electron microscopic level.  In case of alveolar phospholipidosis, foamy macrophages accumulate within the alveolar spaces of the lung.  Based on such findings in a one-year toxicity study with gepirone in rats, we studied the mol. properties of this compd. and compds. suspected of being phospholipidosis inducers by means of physicochem. calcns.  Physicochem. mol. calcns. of mol. wt., ClogP (partition coeff. octanol/water), logD at pH 7.4, and pKa were performed, for the cationic amphiphilic compds. chlorpromazine, amiodarone, imipramine, propranolol and fluoxetine, and for the structurally related compds. 1-phenylpiperazine (1-PHP), gepirone (and its major metabolites, 3-OH-gepirone and 1-pyrimidinylpiperazine [1-PP]), and buspirone.  ClogP and calcd. pKa cluster differently for the amphiphilic drugs compared to the chem. series of piperazines.  In line with this anal., lamellar inclusion bodies were found in an in vitro validation expt. in the human monoblastoid cell line U-937, incubated for 96 h at 10 μg/mL with cationic amphiphilic drugs (amiodarone, imipramine, or propranolol).  No such lamellar inclusion bodies were seen for any of the compds. from the chem. series of piperazines including gepirone and its metabolites.  The data presented support the use of simple physicochem. calcns. of ClogP and pKa to discriminate rapidly between compds. suspected of being phospholipidosis inducers.  Finally, the discriminative power of these physicochem. ClogP and pKa calcns. to predict phospholipidosis-inducing potential was further validated by extension of the set of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-qnA3_zghvbVg90H21EOLACvtfcHk0lhtHTdKYfE_WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksFGltL0%253D&md5=caf5e68d3d5356dfef1cc29dbaf5ca87</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1078%2F0940-2993-00338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1078%252F0940-2993-00338%26sid%3Dliteratum%253Aachs%26aulast%3DPloemen%26aufirst%3DJ.-P.%2BH.T.M.%26aulast%3DKelder%26aufirst%3DJ.%26aulast%3DHafmans%26aufirst%3DT.%26aulast%3Dvan%2Bde%2BSandt%26aufirst%3DH.%26aulast%3Dvan%2BBurgsteden%26aufirst%3DJ.%2BA.%26aulast%3DSalemink%26aufirst%3DP.%2BJ.M.%26aulast%3Dvan%2BEsch%26aufirst%3DE.%26atitle%3DUse%2520of%2520physicochemical%2520calculation%2520of%2520pKa%2520and%2520CLogP%2520to%2520predict%2520phospholipidosis-inducing%2520potential%253A%2520a%2520case%2520study%2520with%2520structurally%2520related%2520piperazines%26jtitle%3DExp.%2520Toxicol.%2520Pathol.%26date%3D2004%26volume%3D55%26issue%3D5%26spage%3D347%26epage%3D355%26doi%3D10.1078%2F0940-2993-00338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopeit, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villaverde, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gossas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otero, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nystrom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraznenok, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danielson, U. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, F.</span></span> <span> </span><span class="NLM_article-title">Effect of the protonation state of the titratable residues on the inhibitor affinity to BACE-1</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">34</span>),  <span class="NLM_fpage">7255</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1021/bi100637n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi100637n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpslKjsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=7255-63&issue=34&author=J.+L.+Dominguezauthor=T.+Christopeitauthor=M.+C.+Villaverdeauthor=T.+Gossasauthor=J.+M.+Oteroauthor=S.+Nystromauthor=V.+Baraznenokauthor=E.+Lindstromauthor=U.+H.+Danielsonauthor=F.+Sussman&title=Effect+of+the+protonation+state+of+the+titratable+residues+on+the+inhibitor+affinity+to+BACE-1&doi=10.1021%2Fbi100637n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the Protonation State of the Titratable Residues on the Inhibitor Affinity to BACE-1</span></div><div class="casAuthors">Dominguez, Jose L.; Christopeit, Tony; Villaverde, M. Carmen; Gossas, Thomas; Otero, Jose M.; Nystrom, Susanne; Baraznenok, Vera; Lindstrom, Erik; Danielson, U. Helena; Sussman, Fredy</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">7255-7263</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">BACE-1 is one of the aspartic proteases involved in the cleavage of β amyloid peptide, an initial step in the formation of amyloid plaques whose toxicity induces neuron death in Alzheimer's disease patients.  One of the central issues in the search of novel BACE-1 inhibitors is the optimum pH for the binding of inhibitors to the enzyme.  It is known that the enzyme has optimal catalytic activity at acidic pH, while cell active inhibitors may bind optimally at higher pH.  In this work we det. the effect of the pH on the affinities of a set of inhibitors, with a variety of chem. motifs, for the ectodomain region of BACE-1 by a surface plasmon resonance (SPR) biosensor based assay.  In order to understand the mol. interactions that underlie the diverse optimum pH for the binding of the various inhibitors as obsd. exptl., we have calcd. the titrn. curves for a set of BACE-1 ligand complexes.  The results indicate that the pKa values of the titratable residues of the protein depend on the nature of the ligand involved, in disagreement with previous work.  The enzyme-inhibitor structures with the resulting protonation states at pH values 4.5 and 7.4 served as the starting point for the prediction of the pH-dependent binding ranking.  Our calcns. reproduced the entire affinity ranking obsd. upon pH increase and most of the binding trends among inhibitors, esp. at low pH.  Finally, our cell-based assays indicate a possible correlation between high inhibitor affinity at both acidic and neutral pH values, with optimal cell response, a result that may open new venues for the search of potent BACE-1 inhibitors that are active at the cellular level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprMAi9258abLVg90H21EOLACvtfcHk0lhtHTdKYfE_WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpslKjsro%253D&md5=17d462cc2666acaa43f6e48f3d757847</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fbi100637n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi100637n%26sid%3Dliteratum%253Aachs%26aulast%3DDominguez%26aufirst%3DJ.%2BL.%26aulast%3DChristopeit%26aufirst%3DT.%26aulast%3DVillaverde%26aufirst%3DM.%2BC.%26aulast%3DGossas%26aufirst%3DT.%26aulast%3DOtero%26aufirst%3DJ.%2BM.%26aulast%3DNystrom%26aufirst%3DS.%26aulast%3DBaraznenok%26aufirst%3DV.%26aulast%3DLindstrom%26aufirst%3DE.%26aulast%3DDanielson%26aufirst%3DU.%2BH.%26aulast%3DSussman%26aufirst%3DF.%26atitle%3DEffect%2520of%2520the%2520protonation%2520state%2520of%2520the%2520titratable%2520residues%2520on%2520the%2520inhibitor%2520affinity%2520to%2520BACE-1%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26issue%3D34%26spage%3D7255%26epage%3D63%26doi%3D10.1021%2Fbi100637n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rombouts, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusakabe, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H. J. M.</span></span> <span> </span><span class="NLM_article-title">Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1080/13543776.2021.1832463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1080%2F13543776.2021.1832463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=33006491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis1WkurnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2021&pages=25-52&issue=1&author=F.+Romboutsauthor=K.+I.+Kusakabeauthor=C.+C.+Hsiaoauthor=H.+J.+M.+Gijsen&title=Small-molecule+BACE1+inhibitors%3A+a+patent+literature+review+%282011+to+2020%29&doi=10.1080%2F13543776.2021.1832463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020)</span></div><div class="casAuthors">Rombouts, Frederik; Kusakabe, Ken-ichi; Hsiao, Chien-Chi; Gijsen, Harrie J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-52</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Inhibition of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) has been extensively pursued as potential disease-modifying treatment for Alzheimer's disease (AD).  Clin. failures with BACE inhibitors have progressively raised the bar forever cleaner candidates with reduced cardiovascular liability, toxicity risk, and increased selectivity over cathepsin D (CatD) and BACE2.  This review provides an overview of patented BACE1 inhibitors between 2011 and 2020 per pharmaceutical company or research group and highlights the progress that was made in dialing out toxicity liabilities.  Despite an increasingly crowded IP situation, significant progress was made using highly complex chem. in avoiding toxicity liabilities, with BACE1/BACE2 selectivity being the most remarkable achievement.  However, clin. trial data suggest on-target toxicity is likely a contributing factor, which implies the only potential future of BACE1 inhibitors lies in careful titrn. of highly selective compds. in early populations where the amyloid burden is still minimal as prophylactic therapy, or as an affordable oral maintenance therapy following amyloid-clearing therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGjbsg5JsFnbVg90H21EOLACvtfcHk0lhtHTdKYfE_WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis1WkurnP&md5=1efb3b0aee8954550732b3f12b679087</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1080%2F13543776.2021.1832463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2021.1832463%26sid%3Dliteratum%253Aachs%26aulast%3DRombouts%26aufirst%3DF.%26aulast%3DKusakabe%26aufirst%3DK.%2BI.%26aulast%3DHsiao%26aufirst%3DC.%2BC.%26aulast%3DGijsen%26aufirst%3DH.%2BJ.%2BM.%26atitle%3DSmall-molecule%2520BACE1%2520inhibitors%253A%2520a%2520patent%2520literature%2520review%2520%25282011%2520to%25202020%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2021%26volume%3D31%26issue%3D1%26spage%3D25%26epage%3D52%26doi%3D10.1080%2F13543776.2021.1832463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Losada, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBaillie, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eugenio de Diego, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaramillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaoudi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsay-Scott, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mergott, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rincon, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothhaar, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seibert, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winneroski, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, M. O.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Optimization, and Large-Scale Preparation of the Low-Dose Central Nervous System-Penetrant BACE1 Inhibitor LY3202626 via a [3 + 2] Nitrone Cycloaddition</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.9b00471</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.9b00471" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvV2qurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2020&pages=306-314&issue=2&author=P.+Garcia-Losadaauthor=A.+C.+DeBaillieauthor=J.+Eugenio+de+Diegoauthor=S.+J.+Greenauthor=M.+M.+Hansenauthor=C.+Jaramilloauthor=M.+Johnsonauthor=T.+Kaoudiauthor=J.+Liauthor=P.+J.+Lindsay-Scottauthor=C.+Mateosauthor=D.+J.+Mergottauthor=J.+A.+Rinconauthor=R.+R.+Rothhaarauthor=K.+D.+Seibertauthor=B.+M.+Watsonauthor=L.+L.+Winneroskiauthor=S.+Gangulaauthor=D.+Jingauthor=H.+Sunauthor=L.+Zhangauthor=M.+O.+Frederick&title=Synthesis%2C+Optimization%2C+and+Large-Scale+Preparation+of+the+Low-Dose+Central+Nervous+System-Penetrant+BACE1+Inhibitor+LY3202626+via+a+%5B3+%2B+2%5D+Nitrone+Cycloaddition&doi=10.1021%2Facs.oprd.9b00471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Optimization, and Large-Scale Preparation of the Low-Dose Central Nervous System-Penetrant BACE1 Inhibitor LY3202626 via a [3 + 2] Nitrone Cycloaddition</span></div><div class="casAuthors">Garcia-Losada, Pablo; De Baillie, Amy C.; Eugenio de Diego, Jose; Green, Steven J.; Hansen, Marvin M.; Jaramillo, Carlos; Johnson, Matt; Kaoudi, Talbi; Li, Jiuyuan; Lindsay-Scott, Peter J.; Mateos, Carlos; Mergott, Dustin J.; Rincon, Juan Antonio; Rothhaar, Roger R.; Seibert, Kevin D.; Watson, Brian M.; Winneroski, Leonard L.; Gangula, Srinivas; Jing, Dajiang; Sun, Hao; Zhang, Lei; Frederick, Michael O.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">306-314</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein a summary of the synthetic development of LY3202626 from the initial discovery route to a final route that was scaled to make 150 kg is reported.  Key developments include the use of a [3 + 2] cyclization to set the cis ring junction of the formed isoxazoline, a one-pot thiazine formation, and three different ways to install the aniline: (1) Cu-catalyzed azide coupling and redn., (2) nitration and redn., and (3) Buchwald coupling with acetamide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoggDUjmE_88rVg90H21EOLACvtfcHk0ljUyXMwbOxfFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvV2qurc%253D&md5=ded0222bbf1578a1f9b8b3864858094c</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.9b00471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.9b00471%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Losada%26aufirst%3DP.%26aulast%3DDeBaillie%26aufirst%3DA.%2BC.%26aulast%3DEugenio%2Bde%2BDiego%26aufirst%3DJ.%26aulast%3DGreen%26aufirst%3DS.%2BJ.%26aulast%3DHansen%26aufirst%3DM.%2BM.%26aulast%3DJaramillo%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DKaoudi%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLindsay-Scott%26aufirst%3DP.%2BJ.%26aulast%3DMateos%26aufirst%3DC.%26aulast%3DMergott%26aufirst%3DD.%2BJ.%26aulast%3DRincon%26aufirst%3DJ.%2BA.%26aulast%3DRothhaar%26aufirst%3DR.%2BR.%26aulast%3DSeibert%26aufirst%3DK.%2BD.%26aulast%3DWatson%26aufirst%3DB.%2BM.%26aulast%3DWinneroski%26aufirst%3DL.%2BL.%26aulast%3DGangula%26aufirst%3DS.%26aulast%3DJing%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DFrederick%26aufirst%3DM.%2BO.%26atitle%3DSynthesis%252C%2520Optimization%252C%2520and%2520Large-Scale%2520Preparation%2520of%2520the%2520Low-Dose%2520Central%2520Nervous%2520System-Penetrant%2520BACE1%2520Inhibitor%2520LY3202626%2520via%2520a%2520%255B3%2520%252B%25202%255D%2520Nitrone%2520Cycloaddition%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2020%26volume%3D24%26issue%3D2%26spage%3D306%26epage%3D314%26doi%3D10.1021%2Facs.oprd.9b00471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasser, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohrbacher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermans, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrannes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grantham, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Rossem, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaplan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallacher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathes, C.</span></span> <span> </span><span class="NLM_article-title">Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">168</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1177/1087057104272295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1177%2F1087057104272295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=15799960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFWnsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=168-81&issue=2&author=A.+E.+Dubinauthor=N.+Nasserauthor=J.+Rohrbacherauthor=A.+N.+Hermansauthor=R.+Marrannesauthor=C.+Granthamauthor=K.+Van+Rossemauthor=M.+Cikauthor=S.+R.+Chaplanauthor=D.+Gallacherauthor=J.+Xuauthor=A.+Guiaauthor=N.+G.+Byrneauthor=C.+Mathes&title=Identifying+modulators+of+hERG+channel+activity+using+the+PatchXpress+planar+patch+clamp&doi=10.1177%2F1087057104272295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp</span></div><div class="casAuthors">Dubin, Adrienne E.; Nasser, Nadia; Rohrbacher, Jutta; Hermans, An N.; Marrannes, Roger; Grantham, Christopher; Van Rossem, Koen; Cik, Miroslav; Chaplan, Sandra R.; Gallacher, David; Xu, Jia; Guia, Antonio; Byrne, Nicholas G.; Mathes, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">168-181</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The authors used the PatchXpress 7000A system to measure compd. activity at the hERG channel using procedures that mimicked the "gold-std." conventional whole-cell patch clamp.  A set of 70 compds., including hERG antagonists with potencies spanning 3 orders of magnitude, were tested on hERG302-HEK cells using protocols aimed at either identifying compd. activity at a single concn. or obtaining compd. potency from a cumulative concn. dependence paradigm.  After exposure to compds. and subsequent washout of the wells to det. reversibility of the block, blockade by a ref. compd. served as a quality control.  Elec. parameters and voltage dependence were similar to those obtained using a conventional whole-cell patch clamp.  Rank order of compd. potency was also comparable to that detd. by conventional methods.  One exception was flunarizine, a particularly lipophilic compd.  The PatchXpress accurately identified the activity of 29 moderately potent antagonists, which only weakly displace radiolabeled astemizole and are false negatives in the binding assay.  Finally, no false hits were obsd. from a collection of relatively inactive compds.  High-quality data acquisition by PatchXpress should help accelerate secondary screening for ion channel modulators and the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI60gDgyGLsrVg90H21EOLACvtfcHk0ljUyXMwbOxfFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFWnsbY%253D&md5=387d30ff8033356d9045121a371be559</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1177%2F1087057104272295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057104272295%26sid%3Dliteratum%253Aachs%26aulast%3DDubin%26aufirst%3DA.%2BE.%26aulast%3DNasser%26aufirst%3DN.%26aulast%3DRohrbacher%26aufirst%3DJ.%26aulast%3DHermans%26aufirst%3DA.%2BN.%26aulast%3DMarrannes%26aufirst%3DR.%26aulast%3DGrantham%26aufirst%3DC.%26aulast%3DVan%2BRossem%26aufirst%3DK.%26aulast%3DCik%26aufirst%3DM.%26aulast%3DChaplan%26aufirst%3DS.%2BR.%26aulast%3DGallacher%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DGuia%26aufirst%3DA.%26aulast%3DByrne%26aufirst%3DN.%2BG.%26aulast%3DMathes%26aufirst%3DC.%26atitle%3DIdentifying%2520modulators%2520of%2520hERG%2520channel%2520activity%2520using%2520the%2520PatchXpress%2520planar%2520patch%2520clamp%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2005%26volume%3D10%26issue%3D2%26spage%3D168%26epage%3D81%26doi%3D10.1177%2F1087057104272295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ly, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shyy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span> <span> </span><span class="NLM_article-title">Assessing hERG Channel Inhibition Using PatchXpress</span>. <i>JALA</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1016/j.jala.2005.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1016%2Fj.jala.2005.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVersLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=225-230&issue=4&author=J.+Q.+Lyauthor=G.+Shyyauthor=D.+L.+Misner&title=Assessing+hERG+Channel+Inhibition+Using+PatchXpress&doi=10.1016%2Fj.jala.2005.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing hERG channel inhibition using PatchXpress</span></div><div class="casAuthors">Ly, Justin Q.; Shyy, Gordon; Misner, Dinah L.</div><div class="citationInfo"><span class="NLM_cas:title">JALA</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">225-230</span>CODEN:
                <span class="NLM_cas:coden">JALLFO</span>;
        ISSN:<span class="NLM_cas:issn">1535-5535</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">PatchXpress, an automated 16-channel parallel patch clamp system, was used to det. inhibition of human ether-a-go-go related gene (hERG) potassium channels by known blockers.  A monoclonal cell line stably expressing hERG potassium channels was generated in CHO-KI cells.  Results were compared to conventional patch clamp expts. using similar voltage protocols and solns.  Success rates were evaluated for cell recordings under a variety of conditions, including Accumax vs. trypsin treatment to harvest cells, single vs. double compd. addns., and polystyrene vs. glass-coated compd. plates.  We found that the av. success rates rose from 27% with trypsin treatment to 38% with Accumax treatment, which improved to 55-65% following long-term culturing using only Accumax to harvest cells.  Two drug addns. (spaced 1 min apart with suction off) were also found to produce data that more closely matched conventional expts.  Finally, polystyrene vs. glass-coated compd. plates were evaluated, and we found that for some compds. (but not all), prepn. of compd. samples in glass-coated plates resulted in inhibition that more closely matched data obtained by conventional expts.  Therefore, we have established an assay to evaluate the ability of compds. to inhibit hERG potassium channels, which closely matches data produced using conventional methods but with much greater throughput.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpayPs_n_5gs7Vg90H21EOLACvtfcHk0ljUyXMwbOxfFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVersLjE&md5=f87ac889c6582adcd56a3bee6a5b4a73</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.jala.2005.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jala.2005.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DLy%26aufirst%3DJ.%2BQ.%26aulast%3DShyy%26aufirst%3DG.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26atitle%3DAssessing%2520hERG%2520Channel%2520Inhibition%2520Using%2520PatchXpress%26jtitle%3DJALA%26date%3D2005%26volume%3D10%26issue%3D4%26spage%3D225%26epage%3D230%26doi%3D10.1016%2Fj.jala.2005.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. C.</span></span> <span> </span><span class="NLM_article-title">Methods to optimize CNS exposure of drug candidates</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">127503</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1016%2Fj.bmcl.2020.127503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=32853684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlWgu73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127503&issue=23&author=N.+C.+Patel&title=Methods+to+optimize+CNS+exposure+of+drug+candidates&doi=10.1016%2Fj.bmcl.2020.127503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Methods to optimize CNS exposure of drug candidates</span></div><div class="casAuthors">Patel, Nandini C.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">127503</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Among the most devastating disorders of our time, neurol. and psychiatric diseases combine to cause more disability than any other disease area.  One of the key objectives within the medicinal chem. discipline is to design mols. that penetrate into the target tissue.  The objective of tissue specificity can be to gain or restrict drug access to the compartment of interest.  This article briefly reviews the progress of CNS drug discovery over the past few decades.  Included are the most recent efforts to harness structural and physicochem. properties assessment coupled with the impact of efflux transporters in detg. brain penetration and the translation from rodent to human brain tissue targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov5f7cocOoS7Vg90H21EOLACvtfcHk0ljUyXMwbOxfFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlWgu73F&md5=628b1587796ccfabaa50b3612d654bbf</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127503%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DN.%2BC.%26atitle%3DMethods%2520to%2520optimize%2520CNS%2520exposure%2520of%2520drug%2520candidates%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26issue%3D23%26spage%3D127503%26doi%3D10.1016%2Fj.bmcl.2020.127503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willis, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daugherty, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">English, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ereshefsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gevorkyan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhee, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mergott, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monk, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irizarry, M. C.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics, pharmacodynamics, safety, and tolerability of LY3202626, a novel Bace1 inhibitor, in healthy subjects and patients with Alzheimer’s disease</span>. <i>Alzheimer's Dementia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">P418</span>, <span class="refDoi"> DOI: 10.1016/j.jalz.2016.06.791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1016%2Fj.jalz.2016.06.791" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=P418&author=B.+A.+Willisauthor=S.+L.+Loweauthor=L.+L.+Daughertyauthor=R.+A.+Deanauthor=B.+Englishauthor=L.+Ereshefskyauthor=H.+Gevorkyanauthor=D.+E.+Jamesauthor=S.+S.+Jheeauthor=Q.+Linauthor=A.+C.+Loauthor=D.+J.+Mergottauthor=S.+A.+Monkauthor=M.+Nakanoauthor=J.+A.+Zimmerauthor=M.+C.+Irizarry&title=Pharmacokinetics%2C+pharmacodynamics%2C+safety%2C+and+tolerability+of+LY3202626%2C+a+novel+Bace1+inhibitor%2C+in+healthy+subjects+and+patients+with+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.jalz.2016.06.791"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2016.06.791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2016.06.791%26sid%3Dliteratum%253Aachs%26aulast%3DWillis%26aufirst%3DB.%2BA.%26aulast%3DLowe%26aufirst%3DS.%2BL.%26aulast%3DDaugherty%26aufirst%3DL.%2BL.%26aulast%3DDean%26aufirst%3DR.%2BA.%26aulast%3DEnglish%26aufirst%3DB.%26aulast%3DEreshefsky%26aufirst%3DL.%26aulast%3DGevorkyan%26aufirst%3DH.%26aulast%3DJames%26aufirst%3DD.%2BE.%26aulast%3DJhee%26aufirst%3DS.%2BS.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DLo%26aufirst%3DA.%2BC.%26aulast%3DMergott%26aufirst%3DD.%2BJ.%26aulast%3DMonk%26aufirst%3DS.%2BA.%26aulast%3DNakano%26aufirst%3DM.%26aulast%3DZimmer%26aufirst%3DJ.%2BA.%26aulast%3DIrizarry%26aufirst%3DM.%2BC.%26atitle%3DPharmacokinetics%252C%2520pharmacodynamics%252C%2520safety%252C%2520and%2520tolerability%2520of%2520LY3202626%252C%2520a%2520novel%2520Bace1%2520inhibitor%252C%2520in%2520healthy%2520subjects%2520and%2520patients%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAlzheimer%2527s%2520Dementia%26date%3D2016%26volume%3D12%26spage%3DP418%26doi%3D10.1016%2Fj.jalz.2016.06.791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lo, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shcherbinin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natanegara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, B. A.</span></span> <span> </span><span class="NLM_article-title">Phase 2 (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer’s Disease Dementia</span>. <i>J. Alzheimers Dis Rep</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">321</span>, <span class="refDoi"> DOI: 10.3233/ADR-210296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.3233%2FADR-210296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=34113788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A280%3ADC%252BB2c7mvVegsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2021&pages=321&author=A.+C.+Loauthor=C.+D.+Evansauthor=M.+Manciniauthor=H.+Wangauthor=S.+Shcherbininauthor=M.+Luauthor=F.+Natanegaraauthor=B.+A.+Willis&title=Phase+2+%28NAVIGATE-AD+study%29+Results+of+LY3202626+Effects+on+Patients+with+Mild+Alzheimer%E2%80%99s+Disease+Dementia&doi=10.3233%2FADR-210296"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer's Disease Dementia</span></div><div class="casAuthors">Lo Albert C; Evans Cynthia Duggan; Mancini Michele; Wang Hong; Shcherbinin Sergey; Natanegara Fanni; Willis Brian A; Lu Ming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's disease reports</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">321-336</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  LY3202626 is a small molecule inhibitor of β-site amyloid precursor protein cleaving enzyme (BACE)1 shown to reduce amyloid-β (Aβ)1-40 and Aβ1-42 concentrations in plasma and cerebrospinal fluid developed for the treatment of Alzheimer's disease (AD).  Objective:  To assess the change from baseline in flortaucipir positron emission tomography (PET) after treatment with LY3202626 compared with placebo in patients with mild AD dementia.  Methods:  Patients received daily 3 mg or 12 mg doses of LY3202626 or placebo for 52 weeks.  The primary outcome was assessment of cerebral neurofibrillary tangle load by flortaucipir PET.  The study was terminated early following an interim analysis due to a low probability of identifying a statistically significant slowing of cognitive and/or functional decline.  Results:  A total of 316 patients were randomized and 47 completed the study.  There was no statistically significant difference between placebo and either dose of LY3202626 from baseline to 52 weeks, or in annualized change for flortaucipir PET.  There was no clinically meaningful difference between placebo and LY3202626 doses on efficacy measures of cognition and function.  No deaths or serious adverse events considered related to LY3202626 were reported.  A statistically significant increase in treatment-emergent adverse events in the psychiatric disorders system organ class was reported for both LY3202626 doses compared to placebo.  Conclusion:  LY3202626 tested at doses generating 70-90% BACE inhibition was generally well tolerated in this study.  LY3202626 treatment did not result in a clinically significant change in cerebral tau burden as measured by flortaucipir nor in change of functional or cognitive decline compared to placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRq3wjPN4ZWpS-bLEOO4dYpfW6udTcc2eZ6gvtC2DBwfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB2c7mvVegsg%253D%253D&md5=2e2ee67f856fd5626bdeac4309036d54</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.3233%2FADR-210296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FADR-210296%26sid%3Dliteratum%253Aachs%26aulast%3DLo%26aufirst%3DA.%2BC.%26aulast%3DEvans%26aufirst%3DC.%2BD.%26aulast%3DMancini%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DShcherbinin%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DNatanegara%26aufirst%3DF.%26aulast%3DWillis%26aufirst%3DB.%2BA.%26atitle%3DPhase%25202%2520%2528NAVIGATE-AD%2520study%2529%2520Results%2520of%2520LY3202626%2520Effects%2520on%2520Patients%2520with%2520Mild%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Dementia%26jtitle%3DJ.%2520Alzheimers%2520Dis%2520Rep%26date%3D2021%26volume%3D5%26spage%3D321%26doi%3D10.3233%2FADR-210296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koelsch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terzyan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span> <span> </span><span class="NLM_article-title">Structure of the Protease Domain of Memapsin 2 (β-Secretase) Complexed with Inhibitor</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>290</i></span> (<span class="NLM_issue">5489</span>),  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1126/science.290.5489.150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1126%2Fscience.290.5489.150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=11021803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1Chtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2000&pages=150-153&issue=5489&author=L.+Hongauthor=G.+Koelschauthor=X.+Linauthor=S.+Wuauthor=S.+Terzyanauthor=A.+K.+Ghoshauthor=X.+C.+Zhangauthor=J.+Tang&title=Structure+of+the+Protease+Domain+of+Memapsin+2+%28%CE%B2-Secretase%29+Complexed+with+Inhibitor&doi=10.1126%2Fscience.290.5489.150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor</span></div><div class="casAuthors">Hong, Lin; Koelsch, Gerald; Lin, Xinli; Wu, Shili; Terzyan, Simon; Ghosh, Arun K.; Zhang, Xuenjun C.; Tang, Jordan</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">5489</span>),
    <span class="NLM_cas:pages">150-153</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Memapsin 2 (β-secretase) is a membrane-assocd. aspartic protease involved in the prodn. of β-amyloid peptide in Alzheimer's disease and is a major target for drug design.  We detd. the crystal structure of the protease domain of human memapsin 2 complexed to an eight-residue inhibitor at 1.9 angstrom resoln.  The active site of memapsin 2 is more open and less hydrophobic than that of other human aspartic proteases.  The subsite locations from S4 to S2' are well defined.  A kink of the inhibitor chain at P2' and the change of chain direction of P3' and P4' may be mimicked to provide inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtz4LHUXVGBrVg90H21EOLACvtfcHk0lic-XSutijTaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1Chtrs%253D&md5=c5d15af5ae58e6c3f46da1b22f7d4df9</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1126%2Fscience.290.5489.150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.290.5489.150%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DL.%26aulast%3DKoelsch%26aufirst%3DG.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DTerzyan%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DZhang%26aufirst%3DX.%2BC.%26aulast%3DTang%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520the%2520Protease%2520Domain%2520of%2520Memapsin%25202%2520%2528%25CE%25B2-Secretase%2529%2520Complexed%2520with%2520Inhibitor%26jtitle%3DScience%26date%3D2000%26volume%3D290%26issue%3D5489%26spage%3D150%26epage%3D153%26doi%3D10.1126%2Fscience.290.5489.150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howlett, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tew, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloger, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southan, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingwall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, G.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel aspartic protease (Asp 2) as beta-secretase</span>. <i>Mol. Cell. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1006/mcne.1999.0811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1006%2Fmcne.1999.0811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10656250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADyaK1MXnt1Chsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1999&pages=419-27&issue=6&author=I.+Hussainauthor=D.+Powellauthor=D.+R.+Howlettauthor=D.+G.+Tewauthor=T.+D.+Meekauthor=C.+Chapmanauthor=I.+S.+Glogerauthor=K.+E.+Murphyauthor=C.+D.+Southanauthor=D.+M.+Ryanauthor=T.+S.+Smithauthor=D.+L.+Simmonsauthor=F.+S.+Walshauthor=C.+Dingwallauthor=G.+Christie&title=Identification+of+a+novel+aspartic+protease+%28Asp+2%29+as+beta-secretase&doi=10.1006%2Fmcne.1999.0811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase</span></div><div class="casAuthors">Hussain, Ishrut; Powell, David; Howlett, David R.; Tew, David G.; Meek, Thomas D.; Chapman, Conrad; Gloger, Israel S.; Murphy, Kay E.; Southan, Christopher D.; Ryan, Dominic M.; Smith, Trudi S.; Simmons, David L.; Walsh, Frank S.; Dingwall, Colin; Christie, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Neuroscience</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">419-427</span>CODEN:
                <span class="NLM_cas:coden">MOCNED</span>;
        ISSN:<span class="NLM_cas:issn">1044-7431</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The Alzheimer's disease β-amyloid peptide (Aβ) is produced by excision from the type 1 integral membrane glycoprotein amyloid precursor protein (APP) by the sequential actions of β- and then γ-secretases.  Here we report that Asp 2, a novel transmembrane aspartic protease, has the key activities expected of β-secretase.  Transient expression of Asp 2 in cells expressing APP causes an increase in the secretion of the N-terminal fragment of APP and an increase in the cell-assocd. C-terminal β-secretase APP fragment.  Mutation of either of the putative catalytic aspartyl residues in Asp 2 abrogates the prodn. of the fragments characteristic of cleavage at the β-secretase site.  The enzyme is present in normal and Alzheimer's disease (AD) brain and is also found in cell lines known to produce Aβ.  Asp 2 localizes to the Golgi/endoplasmic reticulum in transfected cells and shows clear colocalization with APP in cells stably expressing the 751-amino-acid isoform of APP.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDUBbUoO6SgLVg90H21EOLACvtfcHk0litp9LBRwQowQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXnt1Chsrs%253D&md5=aba834d907c5dae03f060d94729576e9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1006%2Fmcne.1999.0811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fmcne.1999.0811%26sid%3Dliteratum%253Aachs%26aulast%3DHussain%26aufirst%3DI.%26aulast%3DPowell%26aufirst%3DD.%26aulast%3DHowlett%26aufirst%3DD.%2BR.%26aulast%3DTew%26aufirst%3DD.%2BG.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26aulast%3DChapman%26aufirst%3DC.%26aulast%3DGloger%26aufirst%3DI.%2BS.%26aulast%3DMurphy%26aufirst%3DK.%2BE.%26aulast%3DSouthan%26aufirst%3DC.%2BD.%26aulast%3DRyan%26aufirst%3DD.%2BM.%26aulast%3DSmith%26aufirst%3DT.%2BS.%26aulast%3DSimmons%26aufirst%3DD.%2BL.%26aulast%3DWalsh%26aufirst%3DF.%2BS.%26aulast%3DDingwall%26aufirst%3DC.%26aulast%3DChristie%26aufirst%3DG.%26atitle%3DIdentification%2520of%2520a%2520novel%2520aspartic%2520protease%2520%2528Asp%25202%2529%2520as%2520beta-secretase%26jtitle%3DMol.%2520Cell.%2520Neurosci.%26date%3D1999%26volume%3D14%26issue%3D6%26spage%3D419%26epage%3D27%26doi%3D10.1006%2Fmcne.1999.0811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbour, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basi, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccavello, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dovey, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frigon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson-Croak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewett, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knops, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberburg, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Power, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsuno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seubert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suomensaari, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConlogue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, V.</span></span> <span> </span><span class="NLM_article-title">Purification and cloning of amyloid precursor protein beta-secretase from human brain</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>402</i></span> (<span class="NLM_issue">6761</span>),  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1038/990114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1038%2F990114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10591214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADyaK1MXotFKlsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=402&publication_year=1999&pages=537-40&issue=6761&author=S.+Sinhaauthor=J.+P.+Andersonauthor=R.+Barbourauthor=G.+S.+Basiauthor=R.+Caccavelloauthor=D.+Davisauthor=M.+Doanauthor=H.+F.+Doveyauthor=N.+Frigonauthor=J.+Hongauthor=K.+Jacobson-Croakauthor=N.+Jewettauthor=P.+Keimauthor=J.+Knopsauthor=I.+Lieberburgauthor=M.+Powerauthor=H.+Tanauthor=G.+Tatsunoauthor=J.+Tungauthor=D.+Schenkauthor=P.+Seubertauthor=S.+M.+Suomensaariauthor=S.+Wangauthor=D.+Walkerauthor=J.+Zhaoauthor=L.+McConlogueauthor=V.+John&title=Purification+and+cloning+of+amyloid+precursor+protein+beta-secretase+from+human+brain&doi=10.1038%2F990114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Purification and cloning of amyloid precursor protein β-secretase from human brain</span></div><div class="casAuthors">Sinha, Sukanto; Anderson, John P.; Barbour, Robin; Basi, Guriqbal S.; Caccavello, Russell; Davis, David; Doan, Minhtam; Dovey, Harry F.; Frigon, Normand; Hong, Jin; Jacobson-Croak, Kirsten; Jewett, Nancy; Keim, Pamela; Knops, Jeroen; Lieberburg, Ivan; Power, Michael; Tan, Hua; Tatsuno, Gwen; Tung, Jay; Schenk, Dale; Seubert, Peter; Suomensaari, Susanna M.; Wang, Shuwen; Walker, Donald; Zhao, Jun; McConlogue, Lisa; John, Varghese</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">402</span>
        (<span class="NLM_cas:issue">6761</span>),
    <span class="NLM_cas:pages">537-540</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Proteolytic processing of the amyloid precursor protein (APP) generates amyloid β (AP) peptide, which is thought to be causal for the pathol. and subsequent cognitive decline in Alzheimer's disease.  Cleavage by β-secretase at the amino terminus of the Aβ peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of β-cleaved sol. APP, and a corresponding cell-assocd. carboxy-terminal fragment.  Cleavage of the C-terminal fragment by γ-secretase(s) leads to the formation of Aβ.  The pathogenic mutation K670M671 → N670L671 at the β-secretase cleavage site in APP, which was discovered in a Swedish family with familial Alzheimer's disease, leads to increased β-secretase cleavage of the mutant substrate.  Here the authors describe a membrane-bound enzyme activity that cleaves full-length APP at the β-secretase cleavage site, and find it to be the predominant β-cleavage activity in human brain.  The authors have purified this enzyme activity to homogeneity from human brain using a new substrate analog inhibitor of the enzyme activity, and show that the purified enzyme has all the properties predicted for β-secretase.  Cloning and expression of the enzyme reveals that human brain β-secretase is a new membrane-bound aspartic proteinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDI4TZ3cM4orVg90H21EOLACvtfcHk0litp9LBRwQowQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXotFKlsrc%253D&md5=819ccc5a27ec4c56128d6b6944878c42</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2F990114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F990114%26sid%3Dliteratum%253Aachs%26aulast%3DSinha%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DJ.%2BP.%26aulast%3DBarbour%26aufirst%3DR.%26aulast%3DBasi%26aufirst%3DG.%2BS.%26aulast%3DCaccavello%26aufirst%3DR.%26aulast%3DDavis%26aufirst%3DD.%26aulast%3DDoan%26aufirst%3DM.%26aulast%3DDovey%26aufirst%3DH.%2BF.%26aulast%3DFrigon%26aufirst%3DN.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DJacobson-Croak%26aufirst%3DK.%26aulast%3DJewett%26aufirst%3DN.%26aulast%3DKeim%26aufirst%3DP.%26aulast%3DKnops%26aufirst%3DJ.%26aulast%3DLieberburg%26aufirst%3DI.%26aulast%3DPower%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DTatsuno%26aufirst%3DG.%26aulast%3DTung%26aufirst%3DJ.%26aulast%3DSchenk%26aufirst%3DD.%26aulast%3DSeubert%26aufirst%3DP.%26aulast%3DSuomensaari%26aufirst%3DS.%2BM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DMcConlogue%26aufirst%3DL.%26aulast%3DJohn%26aufirst%3DV.%26atitle%3DPurification%2520and%2520cloning%2520of%2520amyloid%2520precursor%2520protein%2520beta-secretase%2520from%2520human%2520brain%26jtitle%3DNature%26date%3D1999%26volume%3D402%26issue%3D6761%26spage%3D537%26epage%3D40%26doi%3D10.1038%2F990114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu-Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendiaz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teplow, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amarante, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeloff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edenson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lile, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarosinski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biere, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treanor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Citron, M.</span></span> <span> </span><span class="NLM_article-title">Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>286</i></span> (<span class="NLM_issue">5440</span>),  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1126/science.286.5440.735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1126%2Fscience.286.5440.735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10531052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADyaK1MXntFWit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=1999&pages=735-41&issue=5440&author=R.+Vassarauthor=B.+D.+Bennettauthor=S.+Babu-Khanauthor=S.+Kahnauthor=E.+A.+Mendiazauthor=P.+Denisauthor=D.+B.+Teplowauthor=S.+Rossauthor=P.+Amaranteauthor=R.+Loeloffauthor=Y.+Luoauthor=S.+Fisherauthor=J.+Fullerauthor=S.+Edensonauthor=J.+Lileauthor=M.+A.+Jarosinskiauthor=A.+L.+Biereauthor=E.+Curranauthor=T.+Burgessauthor=J.+C.+Louisauthor=F.+Collinsauthor=J.+Treanorauthor=G.+Rogersauthor=M.+Citron&title=Beta-secretase+cleavage+of+Alzheimer%E2%80%99s+amyloid+precursor+protein+by+the+transmembrane+aspartic+protease+BACE&doi=10.1126%2Fscience.286.5440.735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE</span></div><div class="casAuthors">Vassar, Robert; Bennett, Brian D.; Babu-Khan, Safura; Kahn, Steve; Mendiaz, Elizabeth A.; Denis, Paul; Teplow, David B.; Ross, Sandra; Amarante, Patricia; Loeloff, Richard; Luo, Yi; Fisher, Seth; Fuller, Janis; Edenson, Steven; Lile, Jackson; Jarosinski, Mark A.; Biere, Anja Leona; Curran, Eileen; Burgess, Teresa; Louis, Jean-Claude; Collins, Frank; Treanor, James; Rogers, Gary; Citron, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">5440</span>),
    <span class="NLM_cas:pages">735-741</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Cerebral deposition of amyloid β peptide (Aβ) is an early and crit. feature of Alzheimer's disease.  Aβ generation depends on proteolytic cleavage of the amyloid precursor protein (APP) by two unknown proteases: β-secretase and γ-secretase.  These proteases are prime therapeutic targets.  A transmembrane aspartic protease with all the known characteristics of β-secretase was cloned and characterized.  Overexpression of this protease, termed BACE (for beta-site APP-cleaving enzyme) increased the amt. of β-secretase cleavage products, and these were cleaved exactly and only at known β-secretase positions.  Antisense inhibition of endogenous BACE mRNA decreased the amt. of β-secretase cleavage products, and purified BACE protein cleaved APP-derived substrates with the same sequence specificity as β-secretase.  Finally, the expression pattern and subcellular localization of BACE were consistent with that expected for β-secretase.  Future development of BACE inhibitors may prove beneficial for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSx3s1NFyByrVg90H21EOLACvtfcHk0litp9LBRwQowQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFWit74%253D&md5=3f36e8e5b5e9441c7670ccaeb0d2dd4f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1126%2Fscience.286.5440.735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.286.5440.735%26sid%3Dliteratum%253Aachs%26aulast%3DVassar%26aufirst%3DR.%26aulast%3DBennett%26aufirst%3DB.%2BD.%26aulast%3DBabu-Khan%26aufirst%3DS.%26aulast%3DKahn%26aufirst%3DS.%26aulast%3DMendiaz%26aufirst%3DE.%2BA.%26aulast%3DDenis%26aufirst%3DP.%26aulast%3DTeplow%26aufirst%3DD.%2BB.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DAmarante%26aufirst%3DP.%26aulast%3DLoeloff%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DFisher%26aufirst%3DS.%26aulast%3DFuller%26aufirst%3DJ.%26aulast%3DEdenson%26aufirst%3DS.%26aulast%3DLile%26aufirst%3DJ.%26aulast%3DJarosinski%26aufirst%3DM.%2BA.%26aulast%3DBiere%26aufirst%3DA.%2BL.%26aulast%3DCurran%26aufirst%3DE.%26aulast%3DBurgess%26aufirst%3DT.%26aulast%3DLouis%26aufirst%3DJ.%2BC.%26aulast%3DCollins%26aufirst%3DF.%26aulast%3DTreanor%26aufirst%3DJ.%26aulast%3DRogers%26aufirst%3DG.%26aulast%3DCitron%26aufirst%3DM.%26atitle%3DBeta-secretase%2520cleavage%2520of%2520Alzheimer%25E2%2580%2599s%2520amyloid%2520precursor%2520protein%2520by%2520the%2520transmembrane%2520aspartic%2520protease%2520BACE%26jtitle%3DScience%26date%3D1999%26volume%3D286%26issue%3D5440%26spage%3D735%26epage%3D41%26doi%3D10.1126%2Fscience.286.5440.735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bienkowski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuck, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tory, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauley, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brashler, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratman, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhl, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasselli, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parodi, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrikson, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span> <span> </span><span class="NLM_article-title">Membrane-anchored aspartyl protease with Alzheimer’s disease beta-secretase activity</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>402</i></span> (<span class="NLM_issue">6761</span>),  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">537</span>, <span class="refDoi"> DOI: 10.1038/990107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1038%2F990107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10591213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADyaK1MXotFKmu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=402&publication_year=1999&pages=533-537&issue=6761&author=R.+Yanauthor=M.+J.+Bienkowskiauthor=M.+E.+Shuckauthor=H.+Miaoauthor=M.+C.+Toryauthor=A.+M.+Pauleyauthor=J.+R.+Brashlerauthor=N.+C.+Stratmanauthor=W.+R.+Mathewsauthor=A.+E.+Buhlauthor=D.+B.+Carterauthor=A.+G.+Tomasselliauthor=L.+A.+Parodiauthor=R.+L.+Heinriksonauthor=M.+E.+Gurney&title=Membrane-anchored+aspartyl+protease+with+Alzheimer%E2%80%99s+disease+beta-secretase+activity&doi=10.1038%2F990107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity</span></div><div class="casAuthors">Yan, Riqiang; Bienkowski, Michael J.; Shuck, Mary E.; Miao, Huiyi; Tory, Monica C.; Pauley, Adele M.; Brashler, John R.; Stratman, Nancy C.; Mathews, W. Rodney; Buhl, Allen E.; Carter, Donald B.; Tomasselli, Alfredo G.; Parodi, Luis A.; Heinrikson, Robert L.; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">402</span>
        (<span class="NLM_cas:issue">6761</span>),
    <span class="NLM_cas:pages">533-537</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Mutations in the gene encoding the amyloid protein precursor (APP) cause autosomal dominant Alzheimer's disease.  Cleavage of APP by unidentified proteases, referred to as β- and γ-secretases, generates the amyloid β-peptide, the main component of the amyloid plaques found in Alzheimer's disease patients.  The disease-causing mutations flank the protease cleavage sites in APP and facilitate its cleavage.  Here the authors identify a new membrane-bound aspartyl protease (Asp2) with β-secretase activity.  The Asp2 gene is expressed widely in brain and other tissues.  Decreasing the expression of Asp2 in cells reduces amyloid β-peptide prodn. and blocks the accumulation of the carboxy-terminal APP fragment that is created by β-secretase cleavage.  Solubilized Asp2 protein cleaves a synthetic APP peptide substrate at the β-secretase site, and the rate of cleavage is increased tenfold by a mutation assocd. with early-onset Alzheimer's disease in Sweden.  Thus, Asp2 is a new protein target for drugs that are designed to block the prodn. of amyloid β-peptide peptide and the consequent formation of amyloid plaque in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd6iE74jtk5LVg90H21EOLACvtfcHk0li5tBl8J-zNLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXotFKmu7k%253D&md5=96af7cd9b7c3315de029937497f04616</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2F990107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F990107%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DR.%26aulast%3DBienkowski%26aufirst%3DM.%2BJ.%26aulast%3DShuck%26aufirst%3DM.%2BE.%26aulast%3DMiao%26aufirst%3DH.%26aulast%3DTory%26aufirst%3DM.%2BC.%26aulast%3DPauley%26aufirst%3DA.%2BM.%26aulast%3DBrashler%26aufirst%3DJ.%2BR.%26aulast%3DStratman%26aufirst%3DN.%2BC.%26aulast%3DMathews%26aufirst%3DW.%2BR.%26aulast%3DBuhl%26aufirst%3DA.%2BE.%26aulast%3DCarter%26aufirst%3DD.%2BB.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DParodi%26aufirst%3DL.%2BA.%26aulast%3DHeinrikson%26aufirst%3DR.%2BL.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DMembrane-anchored%2520aspartyl%2520protease%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%2520beta-secretase%2520activity%26jtitle%3DNature%26date%3D1999%26volume%3D402%26issue%3D6761%26spage%3D533%26epage%3D537%26doi%3D10.1038%2F990107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, L.</span></span> <span> </span><span class="NLM_article-title">A resurrection of aducanumab for Alzheimer’s disease</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(19)30480-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1016%2FS1474-4422%2819%2930480-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=31978357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FktFKrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=111-112&issue=2&author=L.+Schneider&title=A+resurrection+of+aducanumab+for+Alzheimer%E2%80%99s+disease&doi=10.1016%2FS1474-4422%2819%2930480-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A resurrection of aducanumab for Alzheimer's disease</span></div><div class="casAuthors">Schneider Lon</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-112</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtdxhWBoi5aDQLBVDQn4bCfW6udTcc2eYzxSZnggcEcbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FktFKrtg%253D%253D&md5=5ce903ac47c76caa5954b1d7feafdb97</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2819%2930480-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252819%252930480-6%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DL.%26atitle%3DA%2520resurrection%2520of%2520aducanumab%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DLancet%2520Neurol.%26date%3D2020%26volume%3D19%26issue%3D2%26spage%3D111%26epage%3D112%26doi%3D10.1016%2FS1474-4422%2819%2930480-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hampel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanmechelen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nisticò, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbimbo, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streffer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voytyuk, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahami Monfared, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irizarry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albala, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarenis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lista, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergallo, A.</span></span> <span> </span><span class="NLM_article-title">The β-Secretase BACE1 in Alzheimer’s Disease</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2020.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1016%2Fj.biopsych.2020.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=32223911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlvFGksLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2021&pages=745-756&author=H.+Hampelauthor=R.+Vassarauthor=B.+De+Strooperauthor=J.+Hardyauthor=M.+Willemauthor=N.+Singhauthor=J.+Zhouauthor=R.+Yanauthor=E.+Vanmechelenauthor=A.+De+Vosauthor=R.+Nistic%C3%B2author=M.+Corboauthor=B.+P.+Imbimboauthor=J.+Strefferauthor=I.+Voytyukauthor=M.+Timmersauthor=A.+A.+Tahami+Monfaredauthor=M.+Irizarryauthor=B.+Albalaauthor=A.+Koyamaauthor=N.+Watanabeauthor=T.+Kimuraauthor=L.+Yarenisauthor=S.+Listaauthor=L.+Kramerauthor=A.+Vergallo&title=The+%CE%B2-Secretase+BACE1+in+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.biopsych.2020.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The β-Secretase BACE1 in Alzheimer's Disease</span></div><div class="casAuthors">Hampel, Harald; Vassar, Robert; De Strooper, Bart; Hardy, John; Willem, Michael; Singh, Neeraj; Zhou, John; Yan, Riqiang; Vanmechelen, Eugeen; De Vos, Ann; Nistico, Robert; Corbo, Massimo; Imbimbo, Bruno Pietro; Streffer, Johannes; Voytyuk, Iryna; Timmers, Maarten; Tahami Monfared, Amir Abbas; Irizarry, Michael; Albala, Bruce; Koyama, Akihiko; Watanabe, Naoto; Kimura, Teiji; Yarenis, Lisa; Lista, Simone; Kramer, Lynn; Vergallo, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">745-756</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) was initially cloned and characterized in 1999.  It is required for the generation of all monomeric forms of amyloid-β (Aβ), including Aβ42, which aggregates into bioactive conformational species and likely initiates toxicity in Alzheimer's disease (AD).  BACE1 concns. and rates of activity are increased in AD brains and body fluids, thereby supporting the hypothesis that BACE1 plays a crit. role in AD pathophysiol.  Therefore, BACE1 is a prime drug target for slowing down Aβ prodn. in early AD.  Besides the amyloidogenic pathway, BACE1 has other substrates that may be important for synaptic plasticity and synaptic homeostasis.  Indeed, germline and adult conditional BACE1 knockout mice display complex neurol. phenotypes.  Despite BACE1 inhibitor clin. trials conducted so far being discontinued for futility or safety reasons, BACE1 remains a well-validated therapeutic target for AD.  A safe and efficacious compd. with high substrate selectivity as well as a more accurate dose regimen, patient population, and disease stage may yet be found.  Further research should focus on the role of Aβ and BACE1 in physiol. processes and key pathophysiol. mechanisms of AD.  The functions of BACE1 and the homolog BACE2, as well as the biol. of Aβ in neurons and glia, deserve further investigation.  Cellular and mol. studies of BACE1 and BACE2 knockout mice coupled with biomarker-based human research will help elucidate the biol. functions of these important enzymes and identify their substrates and downstream effects.  Such studies will have crit. implications for BACE1 inhibition as a therapeutic approach for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj9wLxG_m2P7Vg90H21EOLACvtfcHk0li5tBl8J-zNLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlvFGksLo%253D&md5=11c76a8ef4ca3b228b6973c7edc3a8f6</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2020.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2020.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DHampel%26aufirst%3DH.%26aulast%3DVassar%26aufirst%3DR.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26aulast%3DHardy%26aufirst%3DJ.%26aulast%3DWillem%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DR.%26aulast%3DVanmechelen%26aufirst%3DE.%26aulast%3DDe%2BVos%26aufirst%3DA.%26aulast%3DNistic%25C3%25B2%26aufirst%3DR.%26aulast%3DCorbo%26aufirst%3DM.%26aulast%3DImbimbo%26aufirst%3DB.%2BP.%26aulast%3DStreffer%26aufirst%3DJ.%26aulast%3DVoytyuk%26aufirst%3DI.%26aulast%3DTimmers%26aufirst%3DM.%26aulast%3DTahami%2BMonfared%26aufirst%3DA.%2BA.%26aulast%3DIrizarry%26aufirst%3DM.%26aulast%3DAlbala%26aufirst%3DB.%26aulast%3DKoyama%26aufirst%3DA.%26aulast%3DWatanabe%26aufirst%3DN.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DYarenis%26aufirst%3DL.%26aulast%3DLista%26aufirst%3DS.%26aulast%3DKramer%26aufirst%3DL.%26aulast%3DVergallo%26aufirst%3DA.%26atitle%3DThe%2520%25CE%25B2-Secretase%2520BACE1%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DBiol.%2520Psychiatry%26date%3D2021%26volume%3D89%26spage%3D745%26epage%3D756%26doi%3D10.1016%2Fj.biopsych.2020.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lopez
Lopez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariot, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caputo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langbaum, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riviere, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouzade-Dominguez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalesak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viglietta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiman, E. M.</span></span> <span> </span><span class="NLM_article-title">The Alzheimer’s Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer’s disease</span>. <i>Alzheimers Dement (N Y)</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">216</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1016/j.trci.2019.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1016%2Fj.trci.2019.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=31211217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A280%3ADC%252BB3M3nvFGhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=216-227&author=C.+Lopez%0ALopezauthor=P.+N.+Tariotauthor=A.+Caputoauthor=J.+B.+Langbaumauthor=F.+Liuauthor=M.+E.+Riviereauthor=C.+Langloisauthor=M.+L.+Rouzade-Dominguezauthor=M.+Zalesakauthor=S.+Hendrixauthor=R.+G.+Thomasauthor=V.+Vigliettaauthor=R.+Lenzauthor=J.+M.+Ryanauthor=A.+Grafauthor=E.+M.+Reiman&title=The+Alzheimer%E2%80%99s+Prevention+Initiative+Generation+Program%3A+Study+design+of+two+randomized+controlled+trials+for+individuals+at+risk+for+clinical+onset+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.trci.2019.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease</span></div><div class="casAuthors">Lopez Lopez Cristina; Caputo Angelika; Riviere Marie-Emmanuelle; Rouzade-Dominguez Marie-Laure; Zalesak Martin; Graf Ana; Tariot Pierre N; Langbaum Jessica B; Langlois Carolyn; Reiman Eric M; Liu Fonda; Hendrix Suzanne; Thomas Ronald G; Viglietta Vissia; Lenz Rob; Ryan J Michael</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's & dementia (New York, N. Y.)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">216-227</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Introduction:  Alzheimer's disease (AD) pathology, including the accumulation of amyloid beta (Aβ) species and tau pathology, begins decades before the onset of cognitive impairment.  This long preclinical period provides an opportunity for clinical trials designed to prevent or delay the onset of cognitive impairment due to AD.  Under the umbrella of the Alzheimer's Prevention Initiative Generation Program, therapies targeting Aβ, including CNP520 (umibecestat), a β-site-amyloid precursor protein cleaving enzyme-1 (BACE-1) inhibitor, and CAD106, an active Aβ immunotherapy, are in clinical development in preclinical AD.  Methods:  The Alzheimer's Prevention Initiative Generation Program comprises two pivotal (phase 2/3) studies that assess the efficacy and safety of umibecestat and CAD106 in cognitively unimpaired individuals with high risk for developing symptoms of AD based on their age (60-75 years), APOE4 genotype, and, for heterozygotes (APOE ε2/ε4 or ε3/ε4), elevated brain amyloid.  Approximately, 3500 individuals will be enrolled in either Generation Study 1 (randomized to cohort 1 [CAD106 injection or placebo, 5:3] or cohort 2 [oral umibecestat 50 mg or placebo, 3:2]) or Generation Study 2 (randomized to oral umibecestat 50 mg and 15 mg, or placebo [2:1:2]).  Participants receive treatment for at least 60 months and up to a maximum of 96 months.  Primary outcomes include time to event, with event defined as diagnosis of mild cognitive impairment due to AD and/or dementia due to AD, and the Alzheimer's Prevention Initiative preclinical composite cognitive test battery.  Secondary endpoints include the Clinical Dementia Rating Sum of Boxes, Repeatable Battery for the Assessment of Neuropsychological Status total score, Everyday Cognition Scale, biomarkers, and brain imaging.  Discussion:  The Generation Program is designed to assess the efficacy, safety, and biomarker effects of the two treatments in individuals at high risk for AD.  It may also provide a plausible test of the amyloid hypothesis and further accelerate the evaluation of AD prevention therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzTVdi99KAcAqdek-gHSrIfW6udTcc2eYFUPdDj0EVz7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3nvFGhug%253D%253D&md5=733d6670d4abb4b673fa5dc91213910c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.trci.2019.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trci.2019.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DLopez%2BLopez%26aufirst%3DC.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26aulast%3DCaputo%26aufirst%3DA.%26aulast%3DLangbaum%26aufirst%3DJ.%2BB.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DRiviere%26aufirst%3DM.%2BE.%26aulast%3DLanglois%26aufirst%3DC.%26aulast%3DRouzade-Dominguez%26aufirst%3DM.%2BL.%26aulast%3DZalesak%26aufirst%3DM.%26aulast%3DHendrix%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DR.%2BG.%26aulast%3DViglietta%26aufirst%3DV.%26aulast%3DLenz%26aufirst%3DR.%26aulast%3DRyan%26aufirst%3DJ.%2BM.%26aulast%3DGraf%26aufirst%3DA.%26aulast%3DReiman%26aufirst%3DE.%2BM.%26atitle%3DThe%2520Alzheimer%25E2%2580%2599s%2520Prevention%2520Initiative%2520Generation%2520Program%253A%2520Study%2520design%2520of%2520two%2520randomized%2520controlled%2520trials%2520for%2520individuals%2520at%2520risk%2520for%2520clinical%2520onset%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAlzheimers%2520Dement%2520%2528N%2520Y%2529%26date%3D2019%26volume%3D5%26spage%3D216%26epage%3D227%26doi%3D10.1016%2Fj.trci.2019.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egan, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kost, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariot, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Dyck, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furtek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper Mozley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sur, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelson, D.</span></span> <span> </span><span class="NLM_article-title">Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">1408</span>– <span class="NLM_lpage">1420</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1812840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1056%2FNEJMoa1812840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=30970186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotFehtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=1408-1420&issue=15&author=M.+F.+Eganauthor=J.+Kostauthor=T.+Vossauthor=Y.+Mukaiauthor=P.+S.+Aisenauthor=J.+L.+Cummingsauthor=P.+N.+Tariotauthor=B.+Vellasauthor=C.+H.+van+Dyckauthor=M.+Boadaauthor=Y.+Zhangauthor=W.+Liauthor=C.+Furtekauthor=E.+Mahoneyauthor=L.+Harper+Mozleyauthor=Y.+Moauthor=C.+Surauthor=D.+Michelson&title=Randomized+Trial+of+Verubecestat+for+Prodromal+Alzheimer%E2%80%99s+Disease&doi=10.1056%2FNEJMoa1812840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of verubecestat for prodromal Alzheimer's disease</span></div><div class="casAuthors">Egan, Michael F.; Kost, James; Voss, Tiffini; Mukai, Yuki; Aisen, Paul S.; Cummings, Jeffrey L.; Tariot, Pierre N.; Vellas, Bruno; van Dyck, Christopher H.; Boada, Merce; Zhang, Ying; Li, Wen; Furtek, Christine; Mahoney, Erin; Mozley, Lyn Harper; Mo, Yi; Sur, Cyrille; Michelson, David</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1408-1420</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Prodromal Alzheimer's disease offers an opportunity to test the effect of drugs that modify the deposition of amyloid in the brain before the onset of dementia.  Verubecestat is an orally administered β-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) inhibitor that blocks prodn. of amyloid-beta (Aβ).  The drug did not prevent clin. progression in a trial involving patients with mild-to-moderate dementia due to Alzheimer's disease.  We conducted a randomized, double-blind, placebo-controlled, 104-wk trial to evaluate verubecestat at doses of 12 mg and 40 mg per day, as compared with placebo, in patients who had memory impairment and elevated brain amyloid levels but whose condition did not meet the case definition of dementia.  The primary outcome was the change from baseline to week 104 in the score on the Clin. Dementia Rating Scale-Sum of Boxes (CDR-SB; scores range from 0 to 18, with higher scores indicating worse cognition and daily function).  Secondary outcomes included other assessments of cognition and daily function.  The trial was terminated for futility after 1454 patients had been enrolled; 485 had been assigned to receive verubecestat at a dose of 12 mg per day (the 12-mg group), 484 to receive verubecestat at a dose of 40 mg per day (the 40-mg group), and 485 to receive placebo.  A total of 234 patients, 231 patients, and 239 patients per group, resp., completed 104 wk of the trial regimen.  The estd. mean change from baseline to week 104 in the CDR-SB score was 1.65 in the 12-mg group, 2.02 in the 40-mg group, and 1.58 in the placebo group (P = 0.67 for the comparison between the 12-mg group and the placebo group and P = 0.01 for the comparison between the 40-mg group and the placebo group), suggesting a worse outcome in the higher-dose group than in the placebo group.  The estd. rate of progression to dementia due to Alzheimer's disease was 24.5, 25.5, and 19.3 events per 100 patient-years in the 12-mg group, the 40-mg group, and the placebo group, resp. (hazard ratio for 40 mg vs. placebo, 1.38; 97.51% confidence interval, 1.07 to 1.79, not adjusted for multiple comparisons), favoring placebo.  Adverse events were more common in the verubecestat groups than in the placebo group. conclusions Verubecestat did not improve clin. ratings of dementia among patients with prodromal Alzheimer's disease, and some measures suggested that cognition and daily function were worse among patients who received verubecestat than among those who received placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2_0d9EBVvSrVg90H21EOLACvtfcHk0ljYRGe-ydp3Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotFehtrY%253D&md5=4f46fb485bfbd366eca939d40a7ee873</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1812840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1812840%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DM.%2BF.%26aulast%3DKost%26aufirst%3DJ.%26aulast%3DVoss%26aufirst%3DT.%26aulast%3DMukai%26aufirst%3DY.%26aulast%3DAisen%26aufirst%3DP.%2BS.%26aulast%3DCummings%26aufirst%3DJ.%2BL.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26aulast%3DVellas%26aufirst%3DB.%26aulast%3Dvan%2BDyck%26aufirst%3DC.%2BH.%26aulast%3DBoada%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DFurtek%26aufirst%3DC.%26aulast%3DMahoney%26aufirst%3DE.%26aulast%3DHarper%2BMozley%26aufirst%3DL.%26aulast%3DMo%26aufirst%3DY.%26aulast%3DSur%26aufirst%3DC.%26aulast%3DMichelson%26aufirst%3DD.%26atitle%3DRandomized%2520Trial%2520of%2520Verubecestat%2520for%2520Prodromal%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26issue%3D15%26spage%3D1408%26epage%3D1420%26doi%3D10.1056%2FNEJMoa1812840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moechars, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenthaler, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span> <span> </span><span class="NLM_article-title">BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer’s Disease</span>. <i>Trends Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1016/j.tins.2016.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1016%2Fj.tins.2016.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=26833257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2016&pages=158-169&issue=3&author=S.+Baraoauthor=D.+Moecharsauthor=S.+F.+Lichtenthalerauthor=B.+De+Strooper&title=BACE1+Physiological+Functions+May+Limit+Its+Use+as+Therapeutic+Target+for+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.tins.2016.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease</span></div><div class="casAuthors">Barao, Soraia; Moechars, Diederik; Lichtenthaler, Stefan F.; De Strooper, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Neurosciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">158-169</span>CODEN:
                <span class="NLM_cas:coden">TNSCDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-2236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The protease β-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) is required for the prodn. of the amyloid-β (Aβ) peptide, which is central to the pathogenesis of Alzheimer's disease (AD).  Chronic inhibition of this protease may temper amyloid prodn. and cure or prevent AD.  However, while BACE1 inhibitors are being pushed forward as drug candidates, a remarkable gap in knowledge on the physiol. functions of BACE1 and its close homolog BACE2 becomes apparent.  Here we discuss the major discoveries of the past 3 years concerning BACE1 biol. and to what extent these could limit the use of BACE1 inhibitors in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtIpCCZlND1LVg90H21EOLACvtfcHk0ljYRGe-ydp3Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaksb4%253D&md5=2f85406ce8d4a917de49e26f0ae1ea87</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.tins.2016.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tins.2016.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DBarao%26aufirst%3DS.%26aulast%3DMoechars%26aufirst%3DD.%26aulast%3DLichtenthaler%26aufirst%3DS.%2BF.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26atitle%3DBACE1%2520Physiological%2520Functions%2520May%2520Limit%2520Its%2520Use%2520as%2520Therapeutic%2520Target%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DTrends%2520Neurosci.%26date%3D2016%26volume%3D39%26issue%3D3%26spage%3D158%26epage%3D169%26doi%3D10.1016%2Fj.tins.2016.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wessels, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariot, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selzler, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bragg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krull, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downing, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shcherbinin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shering, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacSweeney, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, J. R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials</span>. <i>JAMA Neurol</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.1001/jamaneurol.2019.3988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1001%2Fjamaneurol.2019.3988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=31764959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A280%3ADC%252BB3MfivFehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2020&pages=199-209&issue=2&author=A.+M.+Wesselsauthor=P.+N.+Tariotauthor=J.+A.+Zimmerauthor=K.+J.+Selzlerauthor=S.+M.+Braggauthor=S.+W.+Andersenauthor=J.+Landryauthor=J.+H.+Krullauthor=A.+M.+Downingauthor=B.+A.+Willisauthor=S.+Shcherbininauthor=J.+Mullenauthor=P.+Barkerauthor=J.+Schumiauthor=C.+Sheringauthor=B.+R.+Matthewsauthor=R.+A.+Sternauthor=B.+Vellasauthor=S.+Cohenauthor=E.+MacSweeneyauthor=M.+Boadaauthor=J.+R.+Sims&title=Efficacy+and+Safety+of+Lanabecestat+for+Treatment+of+Early+and+Mild+Alzheimer+Disease%3A+The+AMARANTH+and+DAYBREAK-ALZ+Randomized+Clinical+Trials&doi=10.1001%2Fjamaneurol.2019.3988"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials</span></div><div class="casAuthors">Wessels Alette M; Zimmer Jennifer A; Selzler Katherine J; Bragg Sonja M; Andersen Scott W; Landry John; Krull James H; Downing AnnCatherine M; Willis Brian A; Shcherbinin Sergey; Matthews Brandy R; Sims John R; Tariot Pierre N; Mullen Jamie; Barker Peter; Schumi Jennifer; Shering Craig; Mullen Jamie; Stern Robert A; Vellas Bruno; Cohen Sharon; MacSweeney Emer; Boada Merce; Boada Merce</div><div class="citationInfo"><span class="NLM_cas:title">JAMA neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-209</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Alzheimer disease (AD) is a neurodegenerative disorder characterized by cognitive deterioration and impaired activities of daily living.  Current treatments provide only minor symptomatic improvements with limited benefit duration.  Lanabecestat, a brain-permeable inhibitor of human beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1/β-secretase), was developed to modify the clinical course of AD by slowing disease progression.  Objective:  To assess whether lanabecestat slows the progression of AD compared with placebo in patients with early AD (mild cognitive impairment) and mild AD dementia.  Design, Setting, and Participants:  AMARANTH (first patient visit on September 30, 2014; last patient visit on October 4, 2018) and DAYBREAK-ALZ (first patient visit on July 1, 2016; last patient visit on September 28, 2018) were randomized, placebo-controlled, phase 2/3 and phase 3 clinical trials lasting 104 weeks and 78 weeks, respectively.  AMARANTH and DAYBREAK-ALZ were multicenter, global, double-blind studies conducted at 257 and 251 centers, respectively, located in 15 and 18 countries or territories, respectively.  A population-based sample of men and women aged 55 to 85 years who met National Institute on Aging-Alzheimer's Association criteria for early AD or mild AD dementia was screened using cognitive assessments, and the presence of amyloid was confirmed.  Patients were excluded for unstable medical conditions or medication use, significant cerebrovascular pathologic findings, or a history of vitiligo and/or current evidence of postinflammatory hypopigmentation.  AMARANTH screened 6871 patients; 2218 (32.3%) were randomized, and 539 patients completed the study.  DAYBREAK-ALZ screened 5706 patients; 1722 (30.2%) were randomized, and 76 patients completed the study.  Interventions:  Patients were randomized (1:1:1) to once-daily oral doses of lanabecestat (20 mg), lanabecestat (50 mg), or placebo.  Main Outcomes and Measures:  The primary outcome measure was change from baseline on the 13-item Alzheimer Disease Assessment Scale-cognitive subscale.  Secondary outcomes included Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Inventory, Clinical Dementia Rating, Functional Activities Questionnaire, Mini-Mental State Examination, and Neuropsychiatric Inventory.  Efficacy analyses were conducted on the intent-to-treat population.  Results:  Among 2218 AMARANTH patients, the mean (SD) age was 71.3 (7.1) years, and 1177 of 2218 (53.1%) were women.  Among 1722 DAYBREAK-ALZ patients, the mean (SD) age was 72.3 (7.0) years, and 1023 of 1722 (59.4%) were women.  Both studies were terminated early after futility analysis.  There were no consistent, reproducible dose-related findings on primary or secondary efficacy measures.  Psychiatric adverse events, weight loss, and hair color changes were reported in a higher percentage of patients receiving lanabecestat than placebo.  Conclusions and Relevance:  Treatment with lanabecestat was well tolerated and did not slow cognitive or functional decline.  Trial Registration:  ClinicalTrials.gov identifiers: NCT02245737 and NCT02783573.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWiVGh1IBjdC86Js-BCLiifW6udTcc2eb82AbKrDeAzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MfivFehug%253D%253D&md5=af37918a3575efef243bd58895bcdb78</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1001%2Fjamaneurol.2019.3988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaneurol.2019.3988%26sid%3Dliteratum%253Aachs%26aulast%3DWessels%26aufirst%3DA.%2BM.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26aulast%3DZimmer%26aufirst%3DJ.%2BA.%26aulast%3DSelzler%26aufirst%3DK.%2BJ.%26aulast%3DBragg%26aufirst%3DS.%2BM.%26aulast%3DAndersen%26aufirst%3DS.%2BW.%26aulast%3DLandry%26aufirst%3DJ.%26aulast%3DKrull%26aufirst%3DJ.%2BH.%26aulast%3DDowning%26aufirst%3DA.%2BM.%26aulast%3DWillis%26aufirst%3DB.%2BA.%26aulast%3DShcherbinin%26aufirst%3DS.%26aulast%3DMullen%26aufirst%3DJ.%26aulast%3DBarker%26aufirst%3DP.%26aulast%3DSchumi%26aufirst%3DJ.%26aulast%3DShering%26aufirst%3DC.%26aulast%3DMatthews%26aufirst%3DB.%2BR.%26aulast%3DStern%26aufirst%3DR.%2BA.%26aulast%3DVellas%26aufirst%3DB.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DMacSweeney%26aufirst%3DE.%26aulast%3DBoada%26aufirst%3DM.%26aulast%3DSims%26aufirst%3DJ.%2BR.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Lanabecestat%2520for%2520Treatment%2520of%2520Early%2520and%2520Mild%2520Alzheimer%2520Disease%253A%2520The%2520AMARANTH%2520and%2520DAYBREAK-ALZ%2520Randomized%2520Clinical%2520Trials%26jtitle%3DJAMA%2520Neurol%26date%3D2020%26volume%3D77%26issue%3D2%26spage%3D199%26epage%3D209%26doi%3D10.1001%2Fjamaneurol.2019.3988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span> <span> </span><span class="NLM_article-title">Physiological Functions of the beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">97</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2017.00097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.3389%2Ffnmol.2017.00097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=28469554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A280%3ADC%252BC1crjvVWksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=97&author=R.+Yan&title=Physiological+Functions+of+the+beta-Site+Amyloid+Precursor+Protein+Cleaving+Enzyme+1+and+2&doi=10.3389%2Ffnmol.2017.00097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Physiological Functions of the β-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2</span></div><div class="casAuthors">Yan Riqiang</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in molecular neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">97</span>
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    </div><div class="casAbstract">BACE1 was discovered as the β-secretase for initiating the cleavage of amyloid precursor protein (APP) at the β-secretase site, while its close homology BACE2 cleaves APP within the β-amyloid (Aβ) domain region and shows distinct cleavage preferences in vivo.  Inhibition of BACE1 proteolytic activity has been confirmed to decrease Aβ generation and amyloid deposition, and thus specific inhibition of BACE1 by small molecules is a current focus for Alzheimer's disease therapy.  While BACE1 inhibitors are being tested in advanced clinical trials, knowledge regarding the properties and physiological functions of BACE is highly important and this review summarizes advancements in BACE1 research over the past several years.  We and others have shown that BACE1 is not only a critical enzyme for testing the "Amyloid Hypothesis" associated with Alzheimer's pathogenesis, but also important for various functions such as axon growth and pathfinding, astrogenesis, neurogenesis, hyperexcitation, and synaptic plasticity.  BACE2 appears to play different roles such as glucose homeostasis and pigmentation.  This knowledge regarding BACE1 functions is critical for monitoring the safe use of BACE1 inhibitors in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbYoN5Bm7IDcScOqQTSkOffW6udTcc2eb82AbKrDeAzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crjvVWksQ%253D%253D&md5=b8e9ffa2007cebb2ae68c0074b7dea06</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2017.00097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2017.00097%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DR.%26atitle%3DPhysiological%2520Functions%2520of%2520the%2520beta-Site%2520Amyloid%2520Precursor%2520Protein%2520Cleaving%2520Enzyme%25201%2520and%25202%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2017%26volume%3D10%26spage%3D97%26doi%3D10.3389%2Ffnmol.2017.00097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atwal, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snaedal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulem, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudbjartsson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyte, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhangale, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huttenlocher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsdottir, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreassen, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palotie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrens, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsteinsdottir, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, K.</span></span> <span> </span><span class="NLM_article-title">A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>488</i></span> (<span class="NLM_issue">7409</span>),  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1038/nature11283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1038%2Fnature11283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=22801501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWmt73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=488&publication_year=2012&pages=96-9&issue=7409&author=T.+Jonssonauthor=J.+K.+Atwalauthor=S.+Steinbergauthor=J.+Snaedalauthor=P.+V.+Jonssonauthor=S.+Bjornssonauthor=H.+Stefanssonauthor=P.+Sulemauthor=D.+Gudbjartssonauthor=J.+Maloneyauthor=K.+Hoyteauthor=A.+Gustafsonauthor=Y.+Liuauthor=Y.+Luauthor=T.+Bhangaleauthor=R.+R.+Grahamauthor=J.+Huttenlocherauthor=G.+Bjornsdottirauthor=O.+A.+Andreassenauthor=E.+G.+Jonssonauthor=A.+Palotieauthor=T.+W.+Behrensauthor=O.+T.+Magnussonauthor=A.+Kongauthor=U.+Thorsteinsdottirauthor=R.+J.+Wattsauthor=K.+Stefansson&title=A+mutation+in+APP+protects+against+Alzheimer%E2%80%99s+disease+and+age-related+cognitive+decline&doi=10.1038%2Fnature11283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A mutation in APP protects against Alzheimer's disease and age-related cognitive decline</span></div><div class="casAuthors">Jonsson, Thorlakur; Atwal, Jasvinder K.; Steinberg, Stacy; Snaedal, Jon; Jonsson, Palmi V.; Bjornsson, Sigurbjorn; Stefansson, Hreinn; Sulem, Patrick; Gudbjartsson, Daniel; Maloney, Janice; Hoyte, Kwame; Gustafson, Amy; Liu, Yichin; Lu, Yanmei; Bhangale, Tushar; Graham, Robert R.; Huttenlocher, Johanna; Bjornsdottir, Gyda; Andreassen, Ole A.; Joensson, Erik G.; Palotie, Aarno; Behrens, Timothy W.; Magnusson, Olafur T.; Kong, Augustine; Thorsteinsdottir, Unnur; Watts, Ryan J.; Stefansson, Kari</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">488</span>
        (<span class="NLM_cas:issue">7409</span>),
    <span class="NLM_cas:pages">96-99</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The prevalence of dementia in the Western world in people over the age of 60 has been estd. to be greater than 5%, about two-thirds of which are due to Alzheimer's disease.  The age-specific prevalence of Alzheimer's disease nearly doubles every 5 years after age 65, leading to a prevalence of greater than 25% in those over the age of 90 (ref. 3).  Here, to search for low-frequency variants in the amyloid-β precursor protein (APP) gene with a significant effect on the risk of Alzheimer's disease, we studied coding variants in APP in a set of whole-genome sequence data from 1795 Icelanders.  We found a coding mutation (A673T) in the APP gene that protects against Alzheimer's disease and cognitive decline in the elderly without Alzheimer's disease.  This substitution is adjacent to the aspartyl protease β-site in APP, and results in an approx. 40% redn. in the formation of amyloidogenic peptides in vitro.  The strong protective effect of the A673T substitution against Alzheimer's disease provides proof of principle for the hypothesis that reducing the β-cleavage of APP may protect against the disease.  Furthermore, as the A673T allele also protects against cognitive decline in the elderly without Alzheimer's disease, the two may be mediated through the same or similar mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4AFwQCLRQOLVg90H21EOLACvtfcHk0lhr1in_FtGXFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWmt73M&md5=4db9cb2e3842d5a9d4af4ce102249b70</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnature11283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11283%26sid%3Dliteratum%253Aachs%26aulast%3DJonsson%26aufirst%3DT.%26aulast%3DAtwal%26aufirst%3DJ.%2BK.%26aulast%3DSteinberg%26aufirst%3DS.%26aulast%3DSnaedal%26aufirst%3DJ.%26aulast%3DJonsson%26aufirst%3DP.%2BV.%26aulast%3DBjornsson%26aufirst%3DS.%26aulast%3DStefansson%26aufirst%3DH.%26aulast%3DSulem%26aufirst%3DP.%26aulast%3DGudbjartsson%26aufirst%3DD.%26aulast%3DMaloney%26aufirst%3DJ.%26aulast%3DHoyte%26aufirst%3DK.%26aulast%3DGustafson%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DBhangale%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DR.%2BR.%26aulast%3DHuttenlocher%26aufirst%3DJ.%26aulast%3DBjornsdottir%26aufirst%3DG.%26aulast%3DAndreassen%26aufirst%3DO.%2BA.%26aulast%3DJonsson%26aufirst%3DE.%2BG.%26aulast%3DPalotie%26aufirst%3DA.%26aulast%3DBehrens%26aufirst%3DT.%2BW.%26aulast%3DMagnusson%26aufirst%3DO.%2BT.%26aulast%3DKong%26aufirst%3DA.%26aulast%3DThorsteinsdottir%26aufirst%3DU.%26aulast%3DWatts%26aufirst%3DR.%2BJ.%26aulast%3DStefansson%26aufirst%3DK.%26atitle%3DA%2520mutation%2520in%2520APP%2520protects%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520age-related%2520cognitive%2520decline%26jtitle%3DNature%26date%3D2012%26volume%3D488%26issue%3D7409%26spage%3D96%26epage%3D9%26doi%3D10.1038%2Fnature11283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martiskainen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herukka, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stancakova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paananen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soininen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuusisto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laakso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiltunen, M.</span></span> <span> </span><span class="NLM_article-title">Decreased plasma beta-amyloid in the Alzheimer’s disease APP A673T variant carriers</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>82</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1002/ana.24969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1002%2Fana.24969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=28556232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1WrsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2017&pages=128-132&issue=1&author=H.+Martiskainenauthor=S.+K.+Herukkaauthor=A.+Stancakovaauthor=J.+Paananenauthor=H.+Soininenauthor=J.+Kuusistoauthor=M.+Laaksoauthor=M.+Hiltunen&title=Decreased+plasma+beta-amyloid+in+the+Alzheimer%E2%80%99s+disease+APP+A673T+variant+carriers&doi=10.1002%2Fana.24969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Decreased plasma β-amyloid in the Alzheimer's disease APP A673T variant carriers</span></div><div class="casAuthors">Martiskainen, Henna; Herukka, Sanna-Kaisa; Stancakova, Alena; Paananen, Jussi; Soininen, Hilkka; Kuusisto, Johanna; Laakso, Markku; Hiltunen, Mikko</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-132</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">We investigated the assocn. of Alzheimer's disease (AD)-related rare variants APP A673T and ABCA7 rs200538373-C with the levels of β-amyloid (Aβ) and parameters of metabolic and cardiovascular health in a population-based cohort of healthy middle-aged and elderly men.  Carriers of protective APP A673T variant had, on av., 28% lower levels of Aβ40 and Aβ42 in plasma as compared to the controls and the carriers of ABCA7 rs200538373-C.  This is the first report to show decreased Aβ levels in plasma in APP A673T carriers and thus provides evidence that lower Aβ levels throughout life may be protective against AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_Xdy_-kVupLVg90H21EOLACvtfcHk0ljSdYedD0_mJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1WrsL3L&md5=54fe8da37f480b062ac27548c47893c8</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fana.24969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.24969%26sid%3Dliteratum%253Aachs%26aulast%3DMartiskainen%26aufirst%3DH.%26aulast%3DHerukka%26aufirst%3DS.%2BK.%26aulast%3DStancakova%26aufirst%3DA.%26aulast%3DPaananen%26aufirst%3DJ.%26aulast%3DSoininen%26aufirst%3DH.%26aulast%3DKuusisto%26aufirst%3DJ.%26aulast%3DLaakso%26aufirst%3DM.%26aulast%3DHiltunen%26aufirst%3DM.%26atitle%3DDecreased%2520plasma%2520beta-amyloid%2520in%2520the%2520Alzheimer%25E2%2580%2599s%2520disease%2520APP%2520A673T%2520variant%2520carriers%26jtitle%3DAnn.%2520Neurol.%26date%3D2017%26volume%3D82%26issue%3D1%26spage%3D128%26epage%3D132%26doi%3D10.1002%2Fana.24969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span> <span> </span><span class="NLM_article-title">Editorial: Implications for BACE1 Inhibitor Clinical Trials: Adult Conditional BACE1 Knockout Mice Exhibit Axonal Organization Defects in the Hippocampus</span>. <i>J. Prev Alzheimers Dis</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.14283/jpad.2019.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.14283%2Fjpad.2019.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=30756113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A280%3ADC%252BB3cfis1Kmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=78-84&issue=2&author=R.+Vassar&title=Editorial%3A+Implications+for+BACE1+Inhibitor+Clinical+Trials%3A+Adult+Conditional+BACE1+Knockout+Mice+Exhibit+Axonal+Organization+Defects+in+the+Hippocampus&doi=10.14283%2Fjpad.2019.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Editorial: Implications for BACE1 Inhibitor Clinical Trials: Adult Conditional BACE1 Knockout Mice Exhibit Axonal Organization Defects in the Hippocampus</span></div><div class="casAuthors">Vassar R</div><div class="citationInfo"><span class="NLM_cas:title">The journal of prevention of Alzheimer's disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">78-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACE1 is the rate-limiting enzyme for the production of the Aβ peptide that forms amyloid plaques in Alzheimer's disease (AD).  Small molecule inhibitors of BACE1 are being tested in clinical trials for AD, but the safety and efficacy of BACE1 inhibition has yet to be fully explored.  Knockout of the Bace1 gene in the germline of mice causes multiple neurological phenotypes, suggesting that BACE1 inhibition could be toxic.  However, these phenotypes could be the result of BACE1 deficiency during development rather than due to the lack of BACE1 function in the adult.  To address this problem, we generated tamoxifen-inducible conditional BACE1 knockout mice in which the Bace1 gene may be deleted in the whole body of the adult at will.  Importantly, the adult conditional BACE1 knockout mice largely lack phenotypes, indicating that many BACE1 functions are not required in the adult organism.  However, a germline phenotype was observed after BACE1 knockout in the adult: reduced length and disorganization of the hippocampal mossy fiber infrapyramidal bundle comprised of axons of dentate gyrus granule cells.  The infrapyramidal bundle abnormality correlated with reduced proteolytic processing of the neural cell adhesion protein CHL1 that is involved in axonal guidance.  We conclude that BACE1 inhibition in the adult mouse brain does not lead to the phenotypes associated with BACE1 deficiency during embryonic and postnatal development.  However, adult conditional BACE1 knockout mice also suggest that BACE1 inhibitor drugs may disrupt the organization of an axonal pathway in the hippocampus, an important structure for learning and memory.  Here, I review the adult conditional BACE1 knockout results and consider their implications for BACE1 inhibitor clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcjPd2J9N9MMzK395ZObgVfW6udTcc2easNy9Jr3VMXbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfis1Kmug%253D%253D&md5=35c7251ad1415ebbdd30df3ea32c1b29</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.14283%2Fjpad.2019.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14283%252Fjpad.2019.3%26sid%3Dliteratum%253Aachs%26aulast%3DVassar%26aufirst%3DR.%26atitle%3DEditorial%253A%2520Implications%2520for%2520BACE1%2520Inhibitor%2520Clinical%2520Trials%253A%2520Adult%2520Conditional%2520BACE1%2520Knockout%2520Mice%2520Exhibit%2520Axonal%2520Organization%2520Defects%2520in%2520the%2520Hippocampus%26jtitle%3DJ.%2520Prev%2520Alzheimers%2520Dis%26date%3D2019%26volume%3D6%26issue%3D2%26spage%3D78%26epage%3D84%26doi%3D10.14283%2Fjpad.2019.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosior, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-DeWhitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueno, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, P. C.</span></span> <span> </span><span class="NLM_article-title">Biochemical and kinetic characterization of BACE1: investigation into the putative species-specificity for beta- and beta’-cleavage sites by human and murine BACE1</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1249</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2004.02764.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1111%2Fj.1471-4159.2004.02764.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=15584902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmslah" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2004&pages=1249-59&issue=6&author=H.+C.+Yangauthor=X.+Chaiauthor=M.+Mosiorauthor=W.+Kohnauthor=L.+N.+Boggsauthor=J.+A.+Ericksonauthor=D.+B.+McClureauthor=W.+K.+Yehauthor=L.+Zhangauthor=P.+Gonzalez-DeWhittauthor=J.+P.+Mayerauthor=J.+A.+Martinauthor=J.+Huauthor=S.+H.+Chenauthor=A.+B.+Buenoauthor=S.+P.+Littleauthor=J.+R.+McCarthyauthor=P.+C.+May&title=Biochemical+and+kinetic+characterization+of+BACE1%3A+investigation+into+the+putative+species-specificity+for+beta-+and+beta%E2%80%99-cleavage+sites+by+human+and+murine+BACE1&doi=10.1111%2Fj.1471-4159.2004.02764.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical and kinetic characterization of BACE1: Investigation into the putative species-specificity for β- and β'-cleavage sites by human and murine BACE1</span></div><div class="casAuthors">Yang, Hsiu-Chiung; Chai, Xiyun; Mosior, Marian; Kohn, Wayne; Boggs, Leonard N.; Erickson, Jon A.; McClure, Don B.; Yeh, Wu-Kuang; Zhang, Lianshen; Gonzalez-DeWhitt, Patricia; Mayer, John P.; Martin, Jose Alfredo; Hu, Jingdan; Chen, Shu-hui; Bueno, Ana Belen; Little, Sheila P.; McCarthy, James R.; May, Patrick C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1249-1259</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">β-Amyloid peptides (Aβ) are produced by a sequential cleavage of amyloid precursor protein (APP) by β- and γ-secretases.  The lack of Aβ prodn. in beta-APP cleaving enzyme (BACE1)-/- mice suggests that BACE1 is the principal β-secretase in mammalian neurons.  Transfection of human APP and BACE1 into neurons derived from wild-type and BACE1-/- mice supports cleavage of APP at the canonical β-secretase site.  However, these studies also revealed an alternative BACE1 cleavage site in APP, designated as β', resulting in Aβ peptides starting at Glu11.  The apparent inability of human BACE1 to make this β'-cleavage in murine APP, and vice versa, led to the hypothesis that this alternative cleavage was species-specific.  In contrast, the results from human BACE1 transgenic mice demonstrated that the human BACE1 is able to cleave the endogenous murine APP at the β'-cleavage site.  To address this discrepancy, we designed fluorescent resonance energy transfer peptide substrates contg. the β- and β'-cleavage sites within human and murine APP to compare:.  (i) the enzymic efficiency; (ii) binding kinetics of a BACE1 active site inhibitor LY2039911; and (ii) the pharmacol. profiles for human and murine recombinant BACE1.  Both BACE1 orthologs were able to cleave APP at the β- and β'-sites, although with different efficiencies.  Moreover, the inhibitory potency of LY2039911 toward recombinant human and native BACE1 from mouse or guinea pig was indistinguishable.  In summary, we have demonstrated, for the first time, that recombinant BACE1 can recognize and cleave APP peptide substrates at the postulated β'-cleavage site.  It does not appear to be a significant species specificity to this cleavage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj_CAuH6Gw07Vg90H21EOLACvtfcHk0lik8-mnw-Cz-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmslah&md5=77cf9dbc8e90ec9e128cdf97ac9b6d07</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2004.02764.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2004.02764.x%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%2BC.%26aulast%3DChai%26aufirst%3DX.%26aulast%3DMosior%26aufirst%3DM.%26aulast%3DKohn%26aufirst%3DW.%26aulast%3DBoggs%26aufirst%3DL.%2BN.%26aulast%3DErickson%26aufirst%3DJ.%2BA.%26aulast%3DMcClure%26aufirst%3DD.%2BB.%26aulast%3DYeh%26aufirst%3DW.%2BK.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DGonzalez-DeWhitt%26aufirst%3DP.%26aulast%3DMayer%26aufirst%3DJ.%2BP.%26aulast%3DMartin%26aufirst%3DJ.%2BA.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%2BH.%26aulast%3DBueno%26aufirst%3DA.%2BB.%26aulast%3DLittle%26aufirst%3DS.%2BP.%26aulast%3DMcCarthy%26aufirst%3DJ.%2BR.%26aulast%3DMay%26aufirst%3DP.%2BC.%26atitle%3DBiochemical%2520and%2520kinetic%2520characterization%2520of%2520BACE1%253A%2520investigation%2520into%2520the%2520putative%2520species-specificity%2520for%2520beta-%2520and%2520beta%25E2%2580%2599-cleavage%2520sites%2520by%2520human%2520and%2520murine%2520BACE1%26jtitle%3DJ.%2520Neurochem.%26date%3D2004%26volume%3D91%26issue%3D6%26spage%3D1249%26epage%3D59%26doi%3D10.1111%2Fj.1471-4159.2004.02764.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zamek-Gliszczynski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruterbories, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajamie, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickremsinhe, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pothuri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basavanakatti, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinjari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, A. K.</span></span> <span> </span><span class="NLM_article-title">Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>100</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2498</span>– <span class="NLM_lpage">507</span>, <span class="refDoi"> DOI: 10.1002/jps.22452</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1002%2Fjps.22452" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=21213309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC3MXks1Wlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=2498-507&issue=6&author=M.+J.+Zamek-Gliszczynskiauthor=K.+J.+Ruterboriesauthor=R.+T.+Ajamieauthor=E.+R.+Wickremsinheauthor=L.+Pothuriauthor=M.+V.+Raoauthor=V.+N.+Basavanakattiauthor=J.+Pinjariauthor=V.+K.+Ramanathanauthor=A.+K.+Chaudhary&title=Validation+of+96-well+equilibrium+dialysis+with+non-radiolabeled+drug+for+definitive+measurement+of+protein+binding+and+application+to+clinical+development+of+highly-bound+drugs&doi=10.1002%2Fjps.22452"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs</span></div><div class="casAuthors">Zamek-Gliszczynski, Maciej J.; Ruterbories, Kenneth J.; Ajamie, Rose T.; Wickremsinhe, Enaksha R.; Pothuri, Lavanya; Rao, Mukkavilli V. S.; Basavanakatti, Vinay N.; Pinjari, Jakir; Ramanathan, Vikram K.; Chaudhary, Ajai K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2498-2507</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Definitive plasma protein binding (PB) studies in drug development are routinely conducted with radiolabeled material, where the radiochem. purity limits quant. PB measurement.  Recent and emerging regulatory guidances increasingly expect quant. detn. of the fraction unbound (Fu) for key decision making.  In the present study, PB of 11 structurally- and therapeutically-diverse drugs spanning the full range of plasma binding was detd. by equil. dialysis of non-radiolabeled compd. and was validated against the resp. definitive values obtained by accepted radiolabeled protocols.  The extent of plasma binding was in agreement with the radiolabeled studies; however, the methodol. reported herein enables reliable quantification of fraction unbound (Fu) values for highly-bound drugs and is not limited by the radiochem. purity.  In order to meet the rigor of a development study, equil. dialysis of unlabeled drug must be supported by an appropriately validated bioanal. method along with studies to det. compd. soly. and stability in matrix and dialysis buffer, nonspecific binding to the dialysis device, and ability to achieve equil. in the absence of protein.  The presented methodol. establishes an exptl. protocol for definitive PB measurement, which enables quant. detn. of low Fu values, necessary for navigation of new regulatory guidances in clin. drug development. © 2011 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci 100:2498-2507, 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM32vmmYFDz7Vg90H21EOLACvtfcHk0lik8-mnw-Cz-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXks1Wlsrk%253D&md5=f4fc7251d5220a0474f4eefb2c7692a8</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Fjps.22452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22452%26sid%3Dliteratum%253Aachs%26aulast%3DZamek-Gliszczynski%26aufirst%3DM.%2BJ.%26aulast%3DRuterbories%26aufirst%3DK.%2BJ.%26aulast%3DAjamie%26aufirst%3DR.%2BT.%26aulast%3DWickremsinhe%26aufirst%3DE.%2BR.%26aulast%3DPothuri%26aufirst%3DL.%26aulast%3DRao%26aufirst%3DM.%2BV.%26aulast%3DBasavanakatti%26aufirst%3DV.%2BN.%26aulast%3DPinjari%26aufirst%3DJ.%26aulast%3DRamanathan%26aufirst%3DV.%2BK.%26aulast%3DChaudhary%26aufirst%3DA.%2BK.%26atitle%3DValidation%2520of%252096-well%2520equilibrium%2520dialysis%2520with%2520non-radiolabeled%2520drug%2520for%2520definitive%2520measurement%2520of%2520protein%2520binding%2520and%2520application%2520to%2520clinical%2520development%2520of%2520highly-bound%2520drugs%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26issue%3D6%26spage%3D2498%26epage%3D507%26doi%3D10.1002%2Fjps.22452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawada, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raub, T. J.</span></span> <span> </span><span class="NLM_article-title">Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1249</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1021/mp300555n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp300555n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1aju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=1249-61&issue=4&author=P.+V.+Desaiauthor=G.+A.+Sawadaauthor=I.+A.+Watsonauthor=T.+J.+Raub&title=Integration+of+in+silico+and+in+vitro+tools+for+scaffold+optimization+during+drug+discovery%3A+predicting+P-glycoprotein+efflux&doi=10.1021%2Fmp300555n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Integration of in Silico and in Vitro Tools for Scaffold Optimization during Drug Discovery: Predicting P-Glycoprotein Efflux</span></div><div class="casAuthors">Desai, Prashant V.; Sawada, Geri A.; Watson, Ian A.; Raub, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1249-1261</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In silico tools are regularly utilized for designing and prioritizing compds. to address challenges related to drug metab. and pharmacokinetics (DMPK) during the process of drug discovery.  P-Glycoprotein (P-gp) is a member of the ATP-binding cassette (ABC) transporters with broad substrate specificity that plays a significant role in absorption and distribution of drugs that are P-gp substrates.  As a result, screening for P-gp transport has now become routine in the drug discovery process.  Typically, bidirectional permeability assays are employed to assess in vitro P-gp efflux.  In this article, we use P-gp as an example to illustrate a well-validated methodol. to effectively integrate in silico and in vitro tools to identify and resolve key barriers during the early stages of drug discovery.  A detailed account of development and application of in silico tools such as simple guidelines based on physicochem. properties and more complex quant. structure-activity relationship (QSAR) models is provided.  The tools were developed based on structurally diverse data for more than 2000 compds. generated using a robust P-gp substrate assay over the past several years.  Anal. of physicochem. properties revealed a significantly lower proportion (<10%) of P-gp substrates among the compds. with topol. polar surface area (TPSA) <60 Å2 and the most basic cpKa <8.  In contrast, this proportion of substrates was greater than 75% for compds. with TPSA >60 Å2 and the most basic cpKa >8.  Among the various QSAR models evaluated to predict P-gp efflux, the Bagging model provided optimum prediction performance for prospective validation based on chronol. test sets.  Four sequential versions of the model were built with increasing nos. of compds. to train the models as new data became available.  Except for the first version with the smallest training set, the QSAR models exhibited robust prediction profiles with pos. prediction values (PPV) and neg. prediction values (NPV) exceeding 80%.  The QSAR model demonstrated better concordance with the manual P-gp substrate assay than an automated P-gp substrate screen.  The in silico and the in vitro tools have been effectively integrated during early stages of drug discovery to resolve P-gp-related challenges exemplified by several case studies.  Key learning based on our experience with P-gp can be widely applicable across other DMPK-related challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Q5Y8HssxH7Vg90H21EOLACvtfcHk0lik8-mnw-Cz-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1aju7o%253D&md5=3bd5239b80270c0f4ed85dffb86704ed</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fmp300555n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp300555n%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DP.%2BV.%26aulast%3DSawada%26aufirst%3DG.%2BA.%26aulast%3DWatson%26aufirst%3DI.%2BA.%26aulast%3DRaub%26aufirst%3DT.%2BJ.%26atitle%3DIntegration%2520of%2520in%2520silico%2520and%2520in%2520vitro%2520tools%2520for%2520scaffold%2520optimization%2520during%2520drug%2520discovery%253A%2520predicting%2520P-glycoprotein%2520efflux%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2013%26volume%3D10%26issue%3D4%26spage%3D1249%26epage%3D61%26doi%3D10.1021%2Fmp300555n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raub, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawada, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasper, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacon, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, G. M.</span></span> <span> </span><span class="NLM_article-title">Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1251</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.025064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=10.1124%2Fdmd.108.025064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=19273529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmslamu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1251-8&issue=6&author=R.+Zhaoauthor=T.+J.+Raubauthor=G.+A.+Sawadaauthor=S.+C.+Kasperauthor=J.+A.+Baconauthor=A.+S.+Bridgesauthor=G.+M.+Pollack&title=Breast+cancer+resistance+protein+interacts+with+various+compounds+in+vitro%2C+but+plays+a+minor+role+in+substrate+efflux+at+the+blood-brain+barrier&doi=10.1124%2Fdmd.108.025064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier</span></div><div class="casAuthors">Zhao, Rong; Raub, Thomas J.; Sawada, Geri A.; Kasper, Steven C.; Bacon, James A.; Bridges, Arlene S.; Pollack, Gary M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1251-1258</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Expression of breast cancer resistance protein (Bcrp) at the blood-brain barrier (BBB) has been revealed recently.  To investigate comprehensively the potential role of Bcrp at the murine BBB, a chem. diverse set of model compds. (cimetidine, alfuzosin, dipyridamole, and LY2228820) was evaluated using a multiexperimental design.  Bcrp1 stably transfected MDCKII cell monolayer transport studies demonstrated that each compd. had affinity for Bcrp and that polarized transport by Bcrp was abolished completely by the Bcrp inhibitor chrysin.  However, none of the compds. differed in brain uptake between Bcrp wild-type and knockout mice under either an in situ brain perfusion or a 24-h s.c. osmotic minipump continuous infusion exptl. paradigm.  In addn., alfuzosin and dipyridamole were shown to undergo transport by P-glycoprotein (P-gp) in an MDCKII-MDR1 cell monolayer model.  Alfuzosin brain uptake was 4-fold higher in mdr1a(-/-) mice than in mdr1a(+/+) mice in in situ and in vivo studies, demonstrating for the first time that it undergoes P-gp-mediated efflux at the BBB.  In contrast, P-gp had no effect on dipyridamole brain penetration in situ or in vivo.  In fact, in situ BBB permeability of these solutes appeared to be primarily dependent on their lipophilicity in the absence of efflux transport, and in situ brain uptake clearance correlated with the intrinsic transcellular passive permeability from in vitro transport and cellular accumulation studies.  In summary, Bcrp mediates in vitro transport of various compds., but seems to play a minimal role at the BBB in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO3WJxNsYgobVg90H21EOLACvtfcHk0lglN17JbHRTWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmslamu7g%253D&md5=3c274c38a03cbe512c471d826b2ce9e4</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.025064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.025064%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DRaub%26aufirst%3DT.%2BJ.%26aulast%3DSawada%26aufirst%3DG.%2BA.%26aulast%3DKasper%26aufirst%3DS.%2BC.%26aulast%3DBacon%26aufirst%3DJ.%2BA.%26aulast%3DBridges%26aufirst%3DA.%2BS.%26aulast%3DPollack%26aufirst%3DG.%2BM.%26atitle%3DBreast%2520cancer%2520resistance%2520protein%2520interacts%2520with%2520various%2520compounds%2520in%2520vitro%252C%2520but%2520plays%2520a%2520minor%2520role%2520in%2520substrate%2520efflux%2520at%2520the%2520blood-brain%2520barrier%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26issue%3D6%26spage%3D1251%26epage%3D8%26doi%3D10.1124%2Fdmd.108.025064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, N. F. H.</span>; <span class="NLM_string-name">Raub, T. J.</span>; <span class="NLM_string-name">Burton, P. S.</span>; <span class="NLM_string-name">Barsuhn, C. L.</span></span> <span> </span><span class="NLM_article-title">Quantitative Approaches to Delineate Passive Transport Mechanisms in Cell Culture Monolayers</span>. In  <i>Transport Processes in Pharmaceutical Systems</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, G. L.</span>, <span class="NLM_string-name">Lee, P. I.</span>, <span class="NLM_string-name">Topp, E. M.</span></span>, Eds.; <span class="NLM_publisher-name">Marcel Dekker</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2000</span>; pp  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">316</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=219-316&author=N.+F.+H.+Ho&author=T.+J.+Raub&author=P.+S.+Burton&author=C.+L.+Barsuhnauthor=G.+L.+Gordon&author=P.+I.+Lee&author=E.+M.+Topp&title=Transport+Processes+in+Pharmaceutical+Systems"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DN.%2BF.%2BH.%26atitle%3DQuantitative%2520Approaches%2520to%2520Delineate%2520Passive%2520Transport%2520Mechanisms%2520in%2520Cell%2520Culture%2520Monolayers%26btitle%3DTransport%2520Processes%2520in%2520Pharmaceutical%2520Systems%26aulast%3DGordon%26aufirst%3DG.%2BL.%26pub%3DMarcel%2520Dekker%26date%3D2000%26spage%3D219%26epage%3D316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UWV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UWV','PDB','6UWV'); return false;">PDB: 6UWV</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UVV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UVV','PDB','6UVV'); return false;">PDB: 6UVV</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7MYI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7MYI','PDB','7MYI'); return false;">PDB: 7MYI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7MYR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7MYR','PDB','7MYR'); return false;">PDB: 7MYR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7MYU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7MYU','PDB','7MYU'); return false;">PDB: 7MYU</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-6"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i88"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00489">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_01806"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00489?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00489</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">LCMS data for compounds <b>6</b>, <b>15</b>–<b>18</b>, and <b>20</b>–<b>22</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00489/suppl_file/jm1c00489_si_001.pdf">PDF</a>)</p></li><li><p class="inline">LY3202626 molecular string formulas (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00489/suppl_file/jm1c00489_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00489/suppl_file/jm1c00489_si_001.pdf">jm1c00489_si_001.pdf (729.92 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00489/suppl_file/jm1c00489_si_002.csv">jm1c00489_si_002.csv (1.28 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00489&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00489%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-12%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00489" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67990922488f3de3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
